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Relative bioavailability of terbutaline to the lungs following inhalation using different 
methods 
Abstract 
Keys words: terbutaline, urine, MMAD, FPD, relative lung bioavailability, Turbuhaler, 
spacers, nebulisers. 
The primary aim was to validate and implement a urinary pharmacokinetic method for 
terbutaline to determine the relative lung and systemic bioavailability following inhalation 
and to measure the in-vitro characteristics of the emitted dose by these inhalation methods.   
Two new robust, accurate and sensitive high performance liquid chromatography methods for 
the determination of terbutaline in aqueous and urine samples were validated in accordance 
with the FDA and ICH guidelines. Terbutaline was extracted using solid phase extraction with 
salbutamol and bamethane as internal standards. The accuracy, precision, lower limit of 
detection and recovery for both methods were within recognized limits. 
The in-vitro characteristics of terbutaline sulphate inhalers were measured according to 
standard compendial methodology as well as adaptation of this methodology to simulate 
routine patient use. The dose emission of terbutaline sulphate from a Bricanyl Turbuhaler was 
determined using an inhalation volume of 4 L at inhalation flows of 10-60 L min-1. The 
particle size distribution was measured using an Anderson Cascade Impactor (ACI) with a 
mixing inlet valve to allow measurement at different flows. A steady increase in total emitted 
dose (TED) and the fine particle dose (FPD) was observed as the inhalation flow increased 
thereby highlighting the flow dependent dose emission characteristics of the Turbuhaler. 
The in-vitro dose emission characteristics of terbutaline sulphate from Bricanyl MDIs were 
measured according to the standard compendial methodology at a flow of 28.3 L min-1 using a 
4 L inhalation volume. The TED and particle size distribution of terbutaline sulphate from the 
Bricanyl MDI were determined alone and with different spacers [AeroChamber Max 
(AMAX), AeroChamber Plus (APLUS), Fisonair and Nebuhaler]. The TED from the MDI 
alone was significantly higher than all MDI+spacers (p<0.001). The MDI with APLUS 
resulted in the smallest mass median aerodynamic diameter (MMAD) and the highest fine 
particle fraction (FPF). The MDI with AMAX resulted in the highest FPD. 
The in-vitro characteristics of terbutaline sulphate from Bricanyl respules using the Aeroneb 
Pro (vibrating mesh) and Sidestream jet nebulisers were determined by the CEN methodology 
and the Next Generation Impactor (NGI) methodology. The Aeroneb Pro was found to have 
significantly better aerodynamic properties than the Sidestream. The results from the NGI 
method were significantly different from the CEN method suggesting further evaluation of 
both methods. Cooling the NGI decreased the evaporation effect. 
Twelve healthy volunteers (6 females) completed in-vivo urinary terbutaline pharmacokinetic 
studies to determine the relative bioavailability following inhalation. The differences between 
the amounts excreted 0.5, 1, 2, 4, 6 and 24 hour post inhalation from a Bricanyl MDI (I) and 
oral (O) dosing of 500 µg terbutaline sulphate and with the co-administration of oral charcoal 
(IC and OC, respectively) were studied. No terbutaline was found in OC samples. The amount 
of terbutaline excreted 30 minutes post I and IC were significantly (p<0.001) higher than post 
O suggesting that the amount of terbutaline excreted 30 minutes post dosing can be used as an 
index of the lung deposition. The amount of terbutaline excreted 24 hour post I was 
significantly (p<0.01) higher than post O suggesting that the amount of terbutaline excreted 
24 hour post dosing can be used as an index of the relative systemic bioavailability. The dose 
response relationships and the low inter and intra-subject variability studies confirm the 
feasibility of this method. 
To demonstrate the application of the method the effect of inhalation technique on the lung 
and systemic bioavailability following inhalation from a dry powder inhaler was evaluated. 
The effect of different spacers on the dose emitted from the Bricanyl MDI and the effect of 
different nebulisers on the dose emitted were also studied using twelve healthy volunteers (6 
females) for each study. 
A fast inhalation flow using the Bricanyl Turbuhaler resulted in significantly higher amounts 
of terbutaline excreted 0.5 and 24 hour post dosing (2 doses of 500µg terbutaline sulphate 
from Bricanyl Turbuhaler) than slow inhalation flow (p<0.001). The Bricanyl MDI alone 
resulted in a significantly higher amount of terbutaline excreted 24 hour post dosing (2 doses 
of 250µg terbutaline sulphate from Bricanyl MDI) and significantly lower amounts excreted 
30 minutes post dosing than the MDI+Spacers. The AMAX provided a greater amount of 
urinary terbutaline excreted 30 minutes post dosing than the APLUS and Nebuhaler. The 
Aeroneb Pro resulted in significantly higher amounts of terbutaline excreted 0.5 and 24 hour 
post dosing (1 dose of 5mg/2ml terbutaline sulphate from Bricanyl respule) than a Sidestream 
Jet nebuliser (p<0.001).  
Further application of the method was demonstrated by 12 (6 female) COPD non-invasive 
mechanically ventilated patients. One dose of 2mg in 0.8ml terbutaline sulphate respiratory 
solution from Aeroneb Pro and one dose of 5mg in 2ml terbutaline sulphate respiratory 
solution from Sidestream jet nebuliser resulted in a similar amounts of urinary terbutaline 
excreted 0.5 and 24 hour post dosing. The results were consistent with the results of the ex-
vivo study performed on the same patients. 
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The thesis highlights extension of the urinary pharmacokinetic method following inhalation to 
terbutaline and its application in volunteer and patient studies. 
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 1 
1.1 Introduction 
Short acting β2-agonists (Salbutamol and Terbutaline) are widely used in the management 
of asthma and COPD. In the British Thoracic Society (BTS) / Scottish Intercollegiate 
Guidelines Network (SIGN) guidelines short acting β2 agonists are recommended as a first 
line treatment for the management of asthma. Short acting β2 agonists are also 
recommended by the National Institute for Health and Clinical Excellence (NICE) 
guidelines for the management of COPD as a first line option. NICE recommend to treat 
breathlessness and exercise limitation initially with short-acting bronchodilators (β2-
agonists or anticholinergics) when required. Salbutamol and terbutaline have been widely 
prescribed in the treatment of asthma and COPD and have been shown to be of benefit in 
both cases. 
Terbutaline sulphate, introduced in 1970 after salbutamol by AstraZeneca (Brand name-
Bricanyl), is available for inhalation as a metered dose inhaler (MDI), dry powder inhaler 
(DPI) and Respules for inhalation. The aerosol emitted from these inhalation methods has 
different characteristics. Part of the emitted dose contains particles that have an 
aerodynamic diameter of less than 5 µm. This portion of the dose has the greatest potential 
for deposition in the lungs and is referred to as the fine particle dose (FPD). Particles with 
an aerodynamic diameter more than 5 µm mostly deposit in the oropharyngeal area. 
Following an inhalation drug is deposited in the lungs, the mouth and the throat 
(oropharyngeal region) then it is absorbed into the systemic circulation where it faces 
metabolism and excretion. The swallowed portion can be metabolised in the stomach and 
the liver before it enters the systemic circulation. There is a lag time before the swallowed 
fraction enters the systemic circulation. Whereas that deposited into the lungs enters the 
body very quickly. 
Several in-vitro and in-vivo methods have been described to predict lung deposition. In-
vitro studies using compendial methods mostly use cascade impactors that have been 
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designed for a set of inhalation conditions. In-vitro methods are used as a quality 
assurance procedure to identify the quality of the inhaled product such as the total emitted 
dose, uniformity of dose and the aerodynamic characteristics. Further, they are often 
extrapolated to give an estimation of in-vivo deposition. The most commonly used 
techniques are inertial separation methods and laser diffraction. 
 In-vivo studies mostly use gamma scintigraphy, pharmacodynamic methods and 
pharmacokinetic methods to provide an insight into the lung deposition. The application 
of traditional pharmacokinetic methods to lung deposition studies is difficult, because the 
doses administered are small and the volume of distribution is large. Thus the resulting 
systemic drug concentrations are low and thus require sensitive assay methods (Newman 
et al., 1981). 
Pharmacokinetic methods to evaluate the relative lung bioavailability of an inhaled drug 
have used plasma and urine concentrations of the drug. A plasma pharmacokinetic method 
has been reported for salbutamol by drawing blood samples in the absorption lag time of 
the orally swallowed portion of the drug. Hence the concentration of these samples would 
account mainly for the drug deposited in the lung after inhalation. The proposed times for 
plasma samples are 5, 10, 20 minutes post inhalation (Anhoj et al., 1999; Lipworth and 
Clark, 1997; Mobley and Hochhaus, 2001). However due to the low concentration many 
doses are required instead of those routinely inhaled.  
The first urinary pharmacokinetic method used to evaluate the fate of an inhaled drug used 
urinary excretion with the co-administration of oral charcoal to block gastrointestinal 
absorption of the swallowed fraction of the inhaled dose. Later the methodology was 
extended to the lag time of the gastrointestinal absorption phase without the need to 
administer oral charcoal. 
The charcoal block urinary pharmacokinetic method original reported by Borgstrom and 
Nilsson (1992) highlighted the value of this method to determine the relative amount of 
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drug delivered to the lung. In this study terbutaline sulphate was given to healthy 
volunteers by inhalation from a metered dose inhaler (MDI) with the oral administration 
of a charcoal slurry (5 gm before the inhalations, 5 gm after inhalation and 10 gm after 1, 
2, 3 hours). Subjects provided urine samples at 0-12 hours, 12-24 hours, 24-36 hours and 
36-48 hours interval post dosing. The drug excreted in urine was measured. Since the 
charcoal slurry adsorbed 97% of an oral dose then the oral contribution to the overall 
systemic bioavailability after inhalation, when charcoal was co-administered, could thus 
be neglected. The use of a charcoal dose taken before and after an inhalation prevents any 
oral absorption hence for patients with concomitant use of other drugs then the use of 
charcoal is not possible. 
Using the lag time of the gastrointestinal absorption phase Hindle and Chrystyn (1992) 
developed a urinary pharmacokinetic method to determine the lung and systemic 
bioavailability of inhaled salbutamol. Their study demonstrated that following the oral 
administration of salbutamol, negligible amounts of salbutamol are excreted in the urine 
during the first 30 minutes post dose, and that significantly greater amounts (p<0.001) are 
excreted 30 minutes post inhalation. They showed that the salbutamol excreted in the 
urine 30 minutes post dosing was an index of the lung bioavailability and that the urinary 
salbutamol excreted 24 hours post dosing was an index of the systemic bioavailability. In 
this thesis application of this method has been investigated for terbutaline with extension 
to the in-vivo assessments together with in-vitro evaluations of the emitted dose. 
1.2 Aim and objectives 
1.2.1 Aim 
To use in-vitro and in-vivo methods to determine the respective dose emission properties 
and relative lung deposition of terbutaline from inhaled products using different inhalation 
techniques. 
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1.2.2 Objectives 
1. To modify and validate a previously reported salbutamol HPLC assays for 
terbutaline in aqueous and urine samples. 
2. To determine the aerodynamic characteristics of the emitted dose of terbutaline 
sulphate from a dry powder inhaler (Turbuhaler), a MDI with different spacers and 
from nebulisers. 
3. To optimise the in-vitro methodology for nebulised products to limit evaporation 
effects. 
4. To validate the Hindle and Chrystyn urinary salbutamol pharmacokinetic method to 
measure the relative lung and systemic bioavailability of terbutaline to the lung 
following inhalation. 
5. To consolidate the potential of the urinary terbutaline pharmacokinetic method by 
assessing its dose response relationship and intra- and inter-subject variability.  
6. To demonstrate the application of the method by evaluating the effect of inhalation 
technique and inhalation methods on the lung and systemic bioavailability 
following inhalation from a dry powder inhaler (Bricanyl Turbuhaler), Bricanyl 
MDI alone and with spacers and from nebulisers (using healthy volunteers and 
non-invasive positive pressure ventilated patients). 
1.3 Summary of the work 
To achieve the aim and objectives the work in this research has been divided into three 
parts: 
a. High performance liquid chromatography (HPLC) method validation for the 
determination of terbutaline in aqueous and urine samples. 
b. In-vitro studies to determine the dose emission properties of terbutaline sulphate 
from different inhalation methods and when using different inhalation techniques. 
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c. In-vivo studies to determine the relative lung bioavailability of terbutaline 
following inhalation. 
Terbutaline sulphate is a synthetic resorcinol derivative β2-adrenergic agonist that is used 
as a bronchodilator in the treatment of bronchial asthma. Terbutaline like most other 
sympathomematics exists as a racemic mixture.  
Aqueous and urine samples of terbutaline for in-vitro and in-vivo studies need an accurate 
and sensitive chromatographic method to analyse and separate them. Two sensitive and 
easy to perform assays to quantify salbutamol in aqueous and urine samples were 
developed and validated by Mazhar and Chrystyn (submitted for publication). The initial 
work was to adapt and validate similar assays for the quantification of terbutaline in 
aqueous and urine samples collected after in-vitro dose emission and in-vivo inhalation of 
the drug, respectively. Solid phase extraction (SPE) was used to isolate terbutaline from 
urine samples. The validated method for aqueous and urine samples used a C18 reversed 
phase column for HPLC separation and quantification using a fluorescence detector, set 
with an excitation/emission of 267/313 nm. 
The in-vitro studies have been divided into three parts, the first part has focussed on the 
determination of the aerodynamic characteristics of the emitted dose, from a Bricanyl 
Turbuhaler at different inhalation flows (10-60 L min-1). Previously dose emission below 
30 L min-1 through a DPI has not been determined and is not a compendial method. 
However during routine use some patients do not achieve an inhalation flow of 30 L min-1 
(Pedersen et al., 1990). Therefore, the Pharmacopoeia Methods were modified to 
determine dose emission characteristics to include low inhalation flows from a terbutaline 
sulphate Turbuhaler (Bricanyl, AstraZeneca, UK). To achieve this, a novel adaptation 
methodology using a mixing inlet valve has been incorporated into the compendial 
methods to enable the measurement of the particle size distribution at low inhalation 
flows. 
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The second part has focussed on the effect of different spacers on the dose emitted from a 
Bricanyl MDI at 28.3 L min-1 inhalation flow. The third part has focussed on the 
optimisation of methodology for the in-vitro assessment of the dose emitted from 
nebulised systems. The NGI and the CEN methods were used to determine the 
aerodynamic characteristics of the nebulised aerosol from two different nebulisers with 
optimisation of the NGI method to limit evaporation effects. 
The in-vivo study of this research work commenced with the validation of a urinary 
terbutaline pharmacokinetic method to determine the relative lung and systemic 
bioavailability of terbutaline following inhalation in healthy volunteers. This method has 
then been used to study: 
a. The effect of different inhalation flows on the relative lung and systemic bioavailability 
of terbutaline when using the Bricanyl Turbuhaler.  
b. The effect of different spacers on the relative lung and systemic bioavailability 
following inhalation from a Bricanyl MDI.  
c. The effect of different nebulisers on the lung and the systemic bioavailability of 
nebulised terbutaline on healthy volunteers and non-invasivly positive pressure ventilated 
patients. 
1.4 Thesis structure 
The work in this thesis is as follow: - 
Chapter 1 is a general introduction with a brief summary of the research work. 
Chapter 2 provides an overview of literature related to the areas of study. 
Chapter 3 describes the validation of a HPLC assay to determine terbutaline in aqueous 
and urine samples. Terbutaline and its internal standard bamethane or salbutamol, as 
appropriate, were extracted from urine samples using a solid phase extraction method and 
then quantified using high-performance liquid chromatography (HPLC). The intra-day 
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and inter-day accuracy, precision, limit of detection and lower limit of quantification of 
terbutaline by the extraction method and the HPLC assay method have been determined.  
Chapter 4 details the in-vitro studies to characterise the dose emission properties of the 
dose emitted from a terbutaline sulphate dry powder inhaler (Bricanyl Turbuhaler) at 
different inhalation flows (10-60 L min-1).  
Chapter 5 extends the in-vitro studies to characterise the dose emission properties of 
terbutaline sulphate emitted from a metered dose inhaler (Bricanyl MDI) alone and when 
it was attached to four different spacers. 
Chapter 6 completes the in-vitro studies by detailing the characteristics of the dose 
emitted from terbutaline sulphate Respules (Bricanyl Respules) using two different 
nebulisers measured by two different in-vitro methods. The methodology includes 
optimisation of the NGI method to limit evaporation effects. A comparison has been made 
of the two different in-vitro (CEN and NGI) methods. 
 Chapter 7 describes an extension of the urinary salbutamol pharmacokinetic method to 
measure terbutaline. A validation of this method to the relative bioavailability of 
terbutaline to the lung following inhalation by healthy volunteers is provided. It is divided 
into three parts 
a. Urinary excretion profiles following oral, oral with charcoal, inhalation (Bricanyl MDI) 
and inhalation (Bricanyl MDI) with charcoal administration. 
b. Dose dependant kinetics of terbutaline excretion 30 minutes and 24 hours post 
inhalation.  
c. Investigation of the intra- and inter-subject variability in the urinary terbutaline 
excretion 30 minutes post inhalation. 
Chapter 8 describes applications of the urinary terbutaline pharmacokinetic method. 
 a. Relative lung and systemic bioavailability of terbutaline inhaled from a dry powder 
inhaler at different inhalation flows. 
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b. Relative lung and systemic bioavailability of terbutaline inhaled from a metered dose 
inhaler alone and when it was attached to different spacers. 
c. Relative lung and systemic bioavailability of terbutaline inhaled from two different 
nebulisers (Aeroneb Pro and Sidestream Jet Nebuliser). 
Chapter 9 details an application of the urinary terbutaline pharmacokinetic method and ex-
vivo method to non-invasive positive pressure ventilated patients. Relative lung and 
systemic bioavailability of nebulised terbutaline using urinary drug excretion post 
inhalation has been determined. 
Finally a general conclusion from these studies and suggestion for future work are 
described in chapter 10.  
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2.1. Respiratory tract 
Studying, sleeping, and even exercising all have one common feature in that they all 
involve breathing. It is one of the first things that is checked to determine if the 
unconscious person is alive. Respiratory tract development in the embryo starts in the 
cephalcaudal (head-to-tail) direction with more turnovers till by the 28th week when the 
respiratory system develops sufficiently to sustain life (Nicpon-Marieb, 2004; Tortora, 
2003). 
Respiration includes the following processes:  
(1) Ventilation, which is the movement of air into and out of the lung. 
(2) Gas exchange between the air in the lungs and the blood, sometimes called external 
respiration. 
(3) Transport of oxygen and carbon dioxide in blood and tissues, sometimes called 
internal respiration. 
2.1.1. The respiratory system: 
The respiratory system, described in Figure 2.1, consists of the upper respiratory tract 
which is the nasal cavity and the pharynx and the lower respiratory tract which is the 
larynx, the trachea, the bronchi and the lungs. The diaphragm and the muscles of the 
thoracic wall are required for respiratory movements. In the mouth, nose and throat the air 
is heated to 37 °C and moistened to 99% relative humidity. The pharynx is the common 
opening of both the digestive system and the respiratory system. It receives air from the 
nasal cavity and air, food and water from the mouth. Inferiorly the pharynx connects the 
respiratory system at the larynx and the digestive system at the oesophagus.  
The larynx consists of an outer casing of nine cartilages that are connected to each other 
by muscles and two pairs of ligaments. The epiglottis prevents food and liquid from 
entering the larynx and air from leaving the lung.  
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Figure 2.1 Schematic diagram of the respiratory system. [Reproduced from Berico et al., 
(1997)] 
 
The trachea or windpipe is a membranous tube that consists of dense regular connective 
tissue that is reinforced with 15 to 20 C-shaped cartilages. The cartilages form the anterior 
and the lateral sides of the trachea. They protect the trachea and maintain an open 
passageway for the air. The posterior wall of the trachea is devoid of cartilage and consists 
of a ligamentous membrane and smooth muscle, because the oesophagus lies immediately 
posterior to the trachea (the cartilage free part).  
The trachea divides into left and right bronchi. Like the trachea these two branches are 
supported by C-shaped cartilage rings. The rest of the bronchial tree is supported by 
numerous small cartilage plates embedded in the walls of the airways rather than the C-
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shaped cartilage rings. Further down the respiratory tree the cartilages become smaller and 
smooth muscle becomes more abundant.  
As shown in Figure 2.2 the point of entry of the bronchi to the lung is called the hilum or 
root. The lungs are the principle organs of respiration and on a volume base they are 
among the largest organs in the body. Each lung is conical in shape, with a base resting on 
the diaphragm and its apex extending superiorly. The right lung is larger (weight about 
620 gm) than the left lung (weight about 560 gm). The right lung has three lobes and the 
left lung has two lobes. Between each two lobes a fissure is present. Each lobe is divided 
into lobules separated by connective tissue partitions and no blood or nerve supply passes 
it. Hence individual diseased lobules can be surgically removed. There are nine lobules in 
the left lung and ten lobules in the right lung. 
The basic architecture of the tracheobronchial region is theoretically a series of 
dichotomous branches (Hillery et al., 2001). Every branching of the tracheobronchial tree 
leads to a new generation (G) of airways, for example, the trachea (G0) branches into two 
main bronchi (G1) and then following sequential branching into secondary bronchi (G2), 
tertiary bronchi, bronchioles, and ultimately the terminal bronchioles (G16), then the 
alveolar region (G17 to 23) as shown in Figure 2.2. Progression from the trachea to the 
extremities of the respiratory tree is characterized by a decrease in the diameter and length 
of the tubules with each branching and an increase in number of airways which results in 
an increase of the surface area. 
The alveolar sac is composed of two or more alveoli that share a common opening. There 
are about 300 million alveoli in the lung. The average diameter of the alveolus is about 
0.25 mm and its wall is extremely thin. They are surrounded by a network of capillaries as 
shown in Figure 2.3. In a normal adult the total surface area of the respiratory membrane 
is about 70 m2 about half the size of a tennis court (Tortora, 2003). 
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In the alveolar region the lining is devoid of mucous and consists of simple squamous 
epithelium. There are two principal types, type I pneumocytes are thin cells for the 
diffusion of gas and drug molecules and type II pneumocytes are cuboidal cells that store, 
secret and re-use pulmonary surfactant. The surfactant decreases the surface tension and 
thereby maintains the morphology and function of the alveoli that is critical for 
respiration. In a newborn infant, a deficiency of surfactant is known as respiratory distress 
syndrome (RDS) and in adults as adult respiratory distress syndrome (ARDS). β2-
adrenergic agonists treat this type of respiratory distress by increasing the surfactant 
secretion from the type II pneumocytes (Isohama et al., 2001; Kresch et al., 1996; Singh et 
al., 2004). Macrophages are also present on the surface of the alveolar epithelium. 
 
Figure 2.2 Diagram representing airway branching in human lung. 
 
Figure 2.3 The alveolar duct, showing the blood supply to the alveoli. 
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2.1.2. Ventilation: 
The lungs are very elastic and when inflated they are capable of expelling air and return to 
their original uninflated state, however, even when uninflated the lungs retain some air, 
which give them their spongy texture. The lungs are contained in the thoracic cavity. Each 
lung is surrounded by a separate pleural cavity formed by the pleural serous membranes.  
The ventilatory apparatus consists of the lungs and surrounding chest wall. The chest wall 
includes not only the rib cages but also the diaphragm and abdominal wall (Figure 2.4). 
 
  
 
Figure 2.4 Forces and pressures during inspiration [Reproduced from Netter FH (1979)]. 
 
The muscles for inspiration include the diaphragm and those muscles that elevate the ribs, 
and the muscles of expiration consist of those that depress the ribs and sternum each 
contraction causing inspiration and expiration respectively.  
Movement of air into and out of the lungs is driven by pressure differentials or gradients 
across the lungs. At the end of expiration the atmospheric pressure and the alveolar 
pressure are equal. Therefore, no movement of air into or out of the lungs takes place. 
Interpleural pressure (increasingly 
subatmospheric) 
Elastic recoil of chest wall (interpleural pressure minus 
pressure at surface of chest) 
Force of muscular contraction (rib cage) 
Elastic recoil of lung (alveolar pressure minus interpleural 
pressure) 
Alveolar pressure (subatmospheric) 
Force of muscular contraction (diaphragm) 
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When inspiratory muscles (diaphragm and intercostal muscles) contract to expand the 
thoracic cavity, a force is applied to the lung surface, which causes expansion of the lungs. 
Lung expansion occurs because the lungs are compliant and distensible. By expanding, a 
negative pressure (approximately -1 cm H2O) is created within the lungs, specifically in 
the airways and alveoli. This results in airflow movement in the direction from high to 
low pressure, which is in the direction of the alveoli. At the end of inspiration the thorax, 
the lung and the alveoli stop expanding. The atmospheric pressure and the alveolar 
pressure are now equal and no movements of air into or out of the lungs take place but the 
volume of the lung is larger than at the end of expiration. During expiration the volume of 
the thorax decreases as the diaphragm relaxes, and the thorax and the lung recoil. The 
decreased thoracic volume results in a decrease in the alveolar volume. This causes an 
increase in the alveolar pressure over the atmospheric pressure of approximately 1 cm 
H2O. Hence air flows out of the lungs. As expiration ends, the decrease in the thoracic 
volume stops, the alveoli stop changing size and the inspiration process starts again. 
The flow of air decreases when the resistance to airflow is increased by conditions that 
reduce the radius of the respiratory passageways. The resistance to airflow is proportional 
to the radius [r] of the tube raised to the fourth power [r4] (Seeley, 2000). Hence a small 
change in the radius results in a large change in the resistance, which in turn decreases 
airflow. For example, asthma results in the release of inflammatory chemicals such as 
leukotrienes that cause severe constriction of the bronchioles. Emphysema produces 
increased airway resistance because the bronchioles are constricted. 
2.1.3. Pulmonary volumes, capacity and indices: 
Spirometry is the process of measuring volumes of air that move into and out of the 
respiratory system and it is measured by a spirometer. The different parameters describing 
pulmonary ventilation are shown in Figure 2.5. 
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Figure 2.5 Spirometric tracing demonstrating different measures for lung volumes and 
capacities.  
 
The pulmonary volumes are:  
1. Tidal Volume (TV): The volume of air inspired or expired during normal breathing. 
2. Inspiratory Reserve Volume (IRV): The amount of air that can be forcefully inspired 
after inspiration of a normal volume. 
3. Expiratory Reserve Volume (ERV): The amount of air that can be forcefully expired 
after expiration of a normal volume. 
4.  Reserve Volume (RV): also known as the residual volume. The volume of air still 
remaining in the respiratory passages and lungs after the most forceful expiration. 
Pulmonary capacities are the sum of two or more pulmonary volumes: 
1. Inspiratory Capacity (IC): The sum of the TV and the IRV, which is the amount of 
air that the person can inspire maximally after a normal expiration. 
2. Functional Residual Capacity (FRC): The sum of ERV and RV, which is the amount 
of air remaining in the lung at the end of normal expiration. 
3. Vital Capacity (VC): The sum of IRV, TV, and ERV, which is the maximum 
volume of air that a person can expel from their respiratory tract after a maximum 
inspiration. 
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4. Total Lung Capacity (TLC): The sum of IRV, TV, ERV, and RV. 
Furthermore performing a vital capacity manoeuvre with as much force as possible 
provides useful data. These spirometric measurements are the Forced Expiratory Volume 
in one second (FEV1), the Peak Expiratory Flow (PEF) and the Forced Expiratory Vital 
Capacity (FVC). 
1. The forced expiratory volume in one second (FEV1) is the volume of air that is 
exhaled during the first second of a forced expiratory manoeuvre starting from the level of 
total lung capacity. FEV1 is by far the most frequently used index for assessing airway 
obstruction, bronchoconstriction or bronchodilatation. FEV1 can be expressed as a 
percentage of the Forced Vital Capacity (FVC) and as a percentage of predicted. It is the 
standard index for assessing and quantifying airflow limitation. In adults, but not in 
children and adolescents, FEV1% declines with age. 
2. Expiratory peak flow (PEF) which is the maximum flow generated during an 
expiration performed with maximal force and started after a full inspiration. 
3. Forced expiratory vital capacity (FVC): The volume change of the lung between a 
full inspiration to total lung capacity and a maximal expiration to residual volume (RV). 
The measurement is performed during forceful exhalation. The manoeuvre is almost 
invariably performed in conjunction with the assessment of the FEV1 and PEF. 
2.1.4. Minute respiratory volume and alveolar ventilation rate: 
The minute respiratory volume is the total amount of air moved into and out of the 
respiratory system each minute, and it is equal to the product of TV and the respiratory 
rate. Since resting TV is about 500 ml and the respiratory rate is about 12 breaths per 
minute, the minute respiratory volume average is about 6 L min-1. The minute respiratory 
volume is not a measure of the amount of air available for gas exchange, which takes 
place in the alveoli, the alveolar duct, and the respiratory bronchioles. The volume of air 
 17 
available for gas exchange is called the alveolar ventilation rate (AVR) and it is calculated 
as follow: 
AVR=RR (TV-DAS) 
   AVR= Alveolar Ventilation Rate (ml/min) 
   RR = Respiratory Rate (Respiration/min) 
   TV = Tidal Volume (ml/ respiration) 
   DAS = Dead Air Space (ml/respiration) 
The Dead Air Space is about 150 ml (Nasal cavity, pharynx, larynx, trachea, bronchi, 
bronchioles and terminal bronchioles) so the alveolar ventilation rate is 4.2 L min-1. 
2.2. Diseases of the Respiratory tract:  
2.2.1 Asthma 
Asthma (reversible airway obstruction) is a disease characterised by an increase in the 
constriction of the bronchi in response to various stimuli, resulting in a narrowing of the 
air passageways and decreased ventilation efficiency followed by inflammatory changes. 
Symptoms include dyspnea, wheezing, coughing, shortness of breath, a tight feeling in the 
chest and poor exercise tolerance. A cough producing sticky mucus can also be a 
symptom of asthma. The aetiology of asthma is poorly understood, but asthma is 
described as extrinsic when it is associated with exposure to a specific allergen, such as 
pollen, dust, or non-specific stimulus such as chemical irritant or exercise. It may be 
described as intrinsic when no external precipitating factor is identified. These triggers can 
cause the asthmatic's lungs to release chemical mediators such as histamine and 
leukotrienes released from the mast cells. These chemical mediators cause inflammation 
to the bronchial lining, constriction, and bronchial spasms. If the effect on the bronchi 
becomes severe enough to obstruct exhalation, carbon dioxide could build up in the lungs 
and might lead to unconsciousness or death. 
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In contrast to many other respiratory disorders, the symptoms of asthma typically reverse 
either spontaneously or with therapy. The exact cause of asthma is unknown. There are no 
definitive pathological features or diagnostic tests for asthma, but the three important 
features of the disease are chronic airway inflammation, airway hyperreactivity and 
airway obstruction.  
Asthma is a form of hypersensitivity in which the bronchioles in the lungs are narrowed 
by inflammation and spasm of the lining of the airway wall. Inflammation occurs when 
irritated tissues swell and produce extra mucus, creating a condition known as 
bronchoconstriction as shown in Figure 2.6 (British Thoracic Society, 2007). Constriction 
or complete blockage of the airways can initiate symptoms of an asthma attack. During 
normal breathing, air is taken in through the nose and mouth. It goes down the windpipe, 
through the airways and into the air sacs. When breathing out, air is expelled from the 
lungs in the reverse order. During an asthma attack, the muscles around the airways 
tighten thereby making the opening in the airways smaller. The lining of the airways 
swells due to inflammation and oedema together with an increase in mucus that blocks the 
airways. Because it is more difficult to breathe out than to breathe in during acute 
bronchospasm then more air is retained in the air sacs in of lungs with each breath. It is 
this (the air- trapping phenomena) that requires emergency treatment because during an 
acute exacerbation this could lead to death. 
 
Figure 2.6 Normal bronchiole and asthmatic bronchioles (reproduced from WebMD 
medical reference 2005, www.mywebmd.com). 
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The changes that take place in the lungs of an asthmatic make the airways (bronchi and 
the smaller bronchioles) hyperreactive to many different types of stimuli that do not affect 
healthy lungs. In an asthma attack, the muscle tissues in the walls of the bronchi go into 
spasm, and the cells lining the airways swell and secrete mucus into the air spaces. 
Many patients with asthma are prone to react to such foreign substances as pollen, house 
dust mites, or animal dander; these are called allergens. On the other hand, asthma affects 
many patients who are not allergic in this way. Asthmatic symptoms are usually quite 
variable; someone with asthma may go for periods of time without symptoms, and then 
suddenly have severe episodes for days. The most common symptom recognized by both 
physicians and patients is wheezing. Wheezing is a whistling or rumbling sound that 
comes from the chest expiration. It may be very loud or barely audible. Asthma can be 
classified as mild, moderate and severe according to the degree of obstruction and its 
severity. Asthma usually begins in childhood or adolescence, but it also may first appear 
during the adult years. While the symptoms may be similar, certain important aspects of 
asthma are different in children and adults. Children born to families with a history of 
allergies or asthma are more likely to have asthma. Asthma could also be occupational if 
the worker is exposed to a substance that causes narrowing or spasm of the windpipe. The 
term ‘Brittle Asthma’ is used when the asthma can change from being apparently well 
controlled to poorly controlled in a short space of time. 
During an acute attack, the respiratory rate is rapid and tachycardia is common. The peak 
expiratory flow (PEF) and forced expiratory volume in one second (FEV1) decrease to less 
than 50% of the subject’s predicted values. Life threatening features include exhaustion, 
cyanosis, bradycardia, hypotension, confusion, and coma. 
2.2.2 Chronic Obstructive Pulmonary Disease (COPD) 
Chronic obstructive pulmonary disease (COPD) is a major cause of ill health and 
mortality world wide, and is the only leading cause of death that is predicted to increase 
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over the coming years. Survey findings have shown that primary care physicians wrongly 
diagnose COPD and asthma (Pauwels et al., 2001). Chronic obstructive pulmonary 
disease (COPD) is characterized by airflow obstruction. The airflow obstruction is usually 
progressive, not fully reversible and does not change markedly over several months. The 
disease is predominantly caused by smoking (National Institute for Health and Clinical 
Excellence (NICE), 2004; Global Initiative for Chronic Obstructive Lung Disease 
(GOLD), 2007). The defining feature of chronic obstructive pulmonary disease (COPD) is 
irreversible airflow limitation measured during forced expiration (Global Initiative for 
Chronic Obstructive Lung Disease (GOLD), 2007) which is the result of a prolonged time 
constant for lung emptying caused by either an increase in the resistance of the small 
conducting airways (Yanai et al., 1992), an increase in lung compliance due to 
emphysematous lung destruction, (Mead et al., 1967) or both. Hence COPD includes a 
number of different disease processes, which result in airflow obstruction due to a 
combination of damage to the airways and lung tissue. Irritants like cigarette smoke, air 
pollution, or infection can produce a chronic inflammation of the bronchi (Jensen et al., 
2000). The inflammation results in swelling of the mucous membrane lining the bronchi, 
an increase in the mucous production and a decrease in the movement of mucous by the 
cilia. If the irritant persist then the diameter of the bronchi decreases and ventilation is 
impaired causing bronchitis. Also emphysema results in the destruction of the alveolar 
walls. Loss of the alveolar walls decreases the respiratory membrane surface area, 
decreasing the gas exchange and loss of elastic fibers that decrease the ability of the lung 
to expel air out. Bronchitis and emphysema result in COPD.  
Figure 2.7 reproduces classic data from a study by Fletcher et al (1977) showing the 
different rates of decline in FEV1 with age for non-smokers and smokers who either do or 
do not develop COPD. The horizontal lines have been added to show the boundaries of 
COPD severity recommended by a global initiative on obstructive lung disease (GOLD) 
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(Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2007). Fletcher et al 
(1977) showed that the rate of decline in the FEV1 of many people who smoke is similar 
to that of non-smokers. These investigators also showed that in a susceptible minority of 
tobacco smokers (estimated at 15–20% of the total), lung function declines rapidly to 
levels consistent with moderate (GOLD 2), severe (GOLD 3), and very severe (GOLD 4) 
COPD. Their data also showed that stopping smoking had a beneficial effect on stopping 
the fast rate of decline at any age.  
 
Figure 2.7 Natural history of chronic obstructive pulmonary disease at varying age 
population [Reproduced from Fletcher and Peto (1977)]. 
 
Although this shows rate of loss of FEV1 for one particular susceptible smoker, other 
susceptible smokers will have different rates of loss, thus reaching disability at different 
ages (Fletcher and Peto, 1977) as the lung inflammation is present in everyone with a 
tobacco smoking habit (Hogg, 2004). The reason why only a minority of smokers 
experience an excessive decline in FEV1 is unknown, but preliminary evidence suggests 
that the lung inflammatory response is amplified in the susceptible group (Retamales et 
al., 2001). Figure 2.7 highlights why smoking cessation is the first intervention for COPD 
patients as recommended by the NICE guidelines, whereas long-term oxygen therapy is 
able only to prolong survival in severe COPD patients (Gorecka et al., 1997). 
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Pharmacological therapies are aimed at relieving symptoms and reducing exacerbations of 
the disease. 
COPD is a slow progressive disease usually following many years of smoking, although 
other risk factors, usually secondary, may also be responsible as shown in Table 2.1. 
COPD is not common in someone who has never smoked. Those non-smokers that 
develop COPD usually have a deficiency of alpha-antitrypsin. 
 
Table 2.1 Associated risk factors for COPD. 
• Tobacco exposure. 
• Alpha-1 antitrypsin deficiency. 
• Occupational exposure e.g. cadmium, silica or dusty 
environments. 
• Low social class. 
• Diet deficient in vitamin C. 
• Pre-existing bronchial hyper-responsiveness. 
• Low birth weight. 
• Childhood respiratory infections. 
 
However, there are some smokers that are not at risk, for reasons that are not fully 
understood, it may be relate to an individual’s genetic profile that give rise to α1 
antitrypsin deficiency with resultant low levels of protease inhibitors in those smoker who 
develop COPD (Figure 2.8). 
There has been an alarming increase in the hospital admissions in the past few years and 
this has created excess pressure on the hospitals as shown in Figure 2.9. 
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Figure 2.8 Disease processes in chronic obstructive pulmonary disease [Reproduced from 
Barnes (2000)]. 
 
Figure 2.9 Increase in the death of patients suffering from chronic obstructive pulmonary 
disease (reproduced from Gold Guidelines http://www.goldcopd.com). 
 
2.2.4 Difference between COPD and asthma 
Although COPD and asthma have similar characteristics such as the signs of coughing and 
wheezing, they are two different conditions in terms of cause, disease onset, frequency of 
symptoms and reversibility of airway obstruction.  
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1. The onset of asthma typically occurs during childhood or adolescence (British Thoracic 
Society, 2007). COPD most often develops in smokers and former smokers who are in 
their mid-50s (Petty, 1995; Hogg, 2004). 
2. Exacerbations of asthma - characterized by recurrent wheezing, shortness of breath, 
chest tightness and cough - often have identifiable triggers such as allergens, cold air, 
exercise, viral infection or bacterial infection (British Thoracic Society, 2007). However, 
exacerbations in COPD patients are commonly caused by respiratory tract infections 
(Pauwels et al., 2001).  
3. With treatment the aim is for asthma patients to have near-normal lung function and be 
symptom-free between exacerbations (British Thoracic Society, 2007). COPD patients 
rarely experience a day without symptoms. Airflow obstruction in COPD sufferers is only 
partially reversible (National Institute for Health and Clinical Excellence (NICE), 2004).  
4. In COPD patients there are more neutrophils compared to patients suffering from 
asthma. In asthmatic patients the percentage of eosinophils is more compared to patients 
suffering from COPD. Since glucocorticoids are effective against inflammation caused by 
eosinophils (Altman et al., 1981) then these agents are useful in asthma. Inflammation that 
is mediated by the neutrophils is more resistant to the effect of glucocorticoids agents. 
Smoking cessation decreases the accelerated downward progression of lung function and 
breathlessness whilst bronchodilator use provides symptom relief (British Thoracic 
Society, 2007). Despite these differences, COPD is often misdiagnosed, and persons with 
COPD are treated instead for asthma (British Thoracic Society, 2007). In fact, a survey of 
75 primary care physicians revealed that they prescribe similar medications for COPD and 
asthma even though the treatments differ (Kesten and Chapman, 1993).  
The maintenance therapy for most patients with asthma is an inhaled corticosteroid to 
control inflammation, with the addition of a bronchodilator, when required to control 
symptoms (British Thoracic Society, 2007). However, the reverse is true for the treatment 
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of COPD. Bronchodilators are the first line maintenance treatment for COPD. Treatment 
with inhaled corticosteroids is reserved only for selected patients whose COPD is not 
adequately managed with bronchodilators (British Thoracic Society, 2007) that have 
moderate or severe COPD (FEV1 50% predicted) and have frequent exacerbations 
(National Institute for Health and Clinical Excellence (NICE), 2004) A summary of the 
differences between COPD and asthma are shown in Table 2.2. 
 
Table 2.2 Differential diagnosis for chronic obstructive pulmonary disease and asthma. 
 COPD Asthma 
• Smoker or ex-smoker Nearly all Possibly 
• Symptoms under age 45 Rare Often 
• Chronic productive cough Common Uncommon 
• Breathlessness Persistent and progressive Variable 
• Night time waking with 
breathlessness and or wheeze Uncommon Common 
• Significant diurnal or day to 
day variability of symptoms Uncommon Common 
 
2.2.5. Asthma Management 
The treatment of asthma involves avoiding the causative stimulus if it is of the extrinsic 
type and administrating drug therapy (including prophylactic measures to reduce 
inflammation and airway resistance and to maintain flow with specific treatment for the 
acute attacks). Corticosteroids, leukotriene inhibitors and mast cell stabilizer, which 
prevent the release of chemical mediators from the mast cells, are used to reduce airway 
inflammation. Xanthines (e.g. theophylline), antimuscarinics (e.g. ipratropium and 
tiotropium) and β2-adrenergic agents (e.g. salbutamol, Terbutaline) are commonly used to 
provide bronchodilatation.  
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The British Thoracic Society (BTS) has set step guidelines for the treatment of asthma. A 
summary of these guidelines are shown in Figure 2.10. 
Step 1 of the BTS guidelines (British Thoracic Society, 2007) state that initially a short 
acting β2-agonist (e.g. salbutamol, terbutaline) should be inhaled when required for 
symptomatic relief to open up the airways. There is no consistent evidence of any benefit 
from the regular (four times daily) use of short acting β2-agonists compared with as 
required use (Dennis et al., 2000; Walters et al., 2003). Unless individual patients are 
shown to benefit from the regular use of inhaled short acting β2-agonists then as required 
use is recommended. Using two or more canisters of β2-agonists per month or >10-12 
puffs per day is a marker of poorly controlled asthma (Scottish Intercollegiate Guidelines 
(SIGN), 2002b). If the patient is using a short acting β2-agonist on a regular use,  basis 
anti-inflammatory therapy is recommended. 
 
Figure 2.10 Proposed BTS / SIGN guidelines for the treatment of asthma (www.brit-
thoracic.org.uk). 
 
Step 2 has been judged on the ability to improve symptoms, improve lung function, and 
prevent exacerbations, with an acceptable safety profile. Inhaled steroids are the most 
effective therapy for asthmatic patients to achieve overall treatment goals (Scottish 
Intercollegiate Guidelines (SIGN), 2002d; Adams et al., 2005). The exact threshold for the 
STEP 1 
Inhaled short-acting β2-agonist (or other bronchodilator)  
 
STEP 2  
Add inhaled corticosteroid: ≤ 800 µg/day adult ≤ 400 µg/day children 
 
STEP 3  
Add long-acting β2-agonist from 200µg per day  
STEP 4  
Add any or all of the following as determined by empirical 
trial: increase inhaled corticosteroid up to ≤ 2000 µg/day, 
oral β2-agonist, leukotriene receptor antagonist, 
theophylline, cromone 
STEP 5  
Add daily oral steroid or regular booster 
courses of oral steroid 
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introduction of inhaled steroids has never been firmly established. Two recent studies 
have shown a benefit from the regular use of inhaled steroids in patients with mild asthma 
(O'Byrne et al., 2001; Pauwels, 2003). Benefit in these studies was seen even with an 
FEV1 of 90% of predicted. Inhaled steroids should be considered for patients with any of 
the following (British Thoracic Society, 2007): 
• Exacerbations of asthma in the last two years 
• Using inhaled short acting β2-agonist three times a week or more 
• Symptomatic three times a week or more, or waking one night a week. 
The lowest dose of inhaled steroids should be initiated at which effective control of 
asthma is maintained. Literatures also suggest the use of twice daily dosing is more 
effective than single dose (Scottish Intercollegiate Guidelines (SIGN), 2002c). However 
some inhaled steroids that have recently been introduced are once daily regiment (e.g. 
ciclesonide) 
Step 3 focuses on add on therapy along with steroids. The use of high doses of steroids 
causes frequent side effects in patients. The BTS guidelines recommend a trial with add-
on medications before stepping up the dose of steroids.  
The first recommended choice is the use of a long acting β2-agonist like formoterol or 
salmeterol to improve lung functions and symptoms and to decrease exacerbations 
(Scottish Intercollegiate Guidelines (SIGN), 2002a). Long acting β2-agonist should always 
be used with an inhaled steroid and not alone in the management of asthma.  
Step 4 recommends an increase in the dose of steroids if there is poor control when 
prescribed a moderate dose of inhaled steroid and add-on therapy. If there is a response to 
long acting β2-agonist but control remains poor then the dose of the inhaled steroid should 
be increased and long acting β2-agonist should be continued. If the add-on therapy still 
remains inadequate the use of leukotriene receptor antagonists, theophyllines, slow release 
β2-agonist tablets are recommended in step 4 (Scottish Intercollegiate Guidelines (SIGN), 
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2002a). The maximum steroid dose that is recommended is equivalent to beclomethasone 
2000 µg per day. 
Step 5 recommends the use of oral steroids using the lowest dose that provides adequate 
control. A high dose of inhaled steroid at 2000 µg per day is advised. Consideration for 
other treatments to minimise the use of steroid tablets are also suggested.  
It should be noted that the guidelines stated that before stepping up the patient treatments 
the patient’s inhalation technique should be checked and compliance assessed. 
2.2.6. Management of COPD 
The diagnostic label COPD includes emphysema and chronic bronchitis with many 
patients presenting with both. 
The goals of management of COPD are to: 
• Enable early and accurate diagnosis 
• Control symptoms 
• Prevent deterioration 
• Prevent complications 
• Improve quality of life 
2.2.6.1. Diagnosis and assessment  
COPD produces a decrease in the peak expiratory flow (PEF) and forced expiratory 
volume in one second (FEV1). The BTS/NICE guidelines have staged the disease severity 
as mild, moderate and severe (Table 2.3) on the basis of spirometry measurements, using 
the FEV1. 
Although by definition COPD is an irreversible disease, reversibility testing is important 
in assessing both diagnosis, prognosis of COPD and determining treatment choice. Hence 
the results of reversibility tests are important for future management, they should be 
clearly documented and be easily available for future reference. There are patients with an 
element of reversibility and those do respond to inhaled corticosteroids. Whether or not 
there is an association with asthma is difficult to identify. 
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Reversibility should be assessed in all COPD patients to detect those whose FEV1 
increases substantially after bronchodilator use. FEV1 should be measured either before 
and 15 minutes post nebulised salbutamol (2.5-5 mg) or terbutaline (5-10 mg) or before 
and 30 minutes post nebulised ipratropium bromide (500 µg). These tests should be done 
when patients are clinically stable and free from infection. Patients should not take short 
acting bronchodilators within the previous six hours, long acting β2-agonists in the 
previous twelve hours and sustained release theophylline within the previous 24 hours. 
Significant reversibility is present if the FEV1 increases by more than 200 ml or by 15% 
over the pre-bronchodilator value.  
 
Table 2.3 Recommendations for staging disease severity in chronic obstructive pulmonary 
disease. 
Disease 
Severity 
FEV1 % 
predicted Symptoms and signs 
Mild 80 
No abnormal signs 
Smoker's cough 
Little or no breathlessness 
Moderate <50 
Breathlessness with or without wheeze on moderate 
exertion. 
Cough with or without sputum. 
Variable abnormal signs (general reduction in 
breath sounds, presence of wheezes) 
Severe <30 
Breathlessness on any exertion/at rest 
Wheeze and cough often prominent 
Lung overinflation usual with cyanosis, peripheral 
oedema and polycythaemia in advanced disease, 
especially during acute exacerbations 
 
2.2.6.2. Treatment of stable COPD 
A summary of National Institute for Clinical Excellence (NICE) therapeutic 
recommendation gives a broad outline to treat and stabilise COPD. A schematic design of 
the NICE guidelines recommendation for the therapeutic management of patients with 
stable COPD is described in Table 2.4. 
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Table 2.4 Summary of the recommended managements of stable COPD [reproduced from (National Institute for Health and Clinical Excellence 
(NICE), 2004)] 
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2.2.6.2.1 Smoking cessation 
All COPD patients should be encouraged to stop smoking as this is the most effective way 
to improve outcomes and prevent further accelerated airway obstruction (Fletcher and 
Peto, 1977; National Institute for Health and Clinical Excellence (NICE), 2004). If 
patients continue to smoke, lung function will deteriorate at an accelerated rate which 
cannot be prevented by drug therapy. While stopping smoking may not improve lung 
function, it will stop the progress of the accelerated decline and, in 90% of cases, excess 
sputum production may cease (Fletcher and Peto, 1977; Hogg, 2004). 
2.2.6.2.2 Bronchodilators 
Even if the bronchodilator reversibility test does not show an objective improvement in 
lung function (i.e. the test is negative), inhaled bronchodilators may still reduce 
symptoms. Therefore all COPD patients should be given an inhaled bronchodilator to 
provide relief of symptoms (Celli et al., 2004). If they help the patient to perform normal 
daily activities or to improve exercise tolerance, it is worthwhile continuing this treatment 
(National Institute for Health and Clinical Excellence (NICE), 2004). 
Inhaled short-acting β2-agonists (e.g. salbutamol, terbutaline) have a relatively rapid onset 
of action and are often used as required to relieve symptoms (National Institute for Health 
and Clinical Excellence (NICE), 2004). Inhaled antimuscarinics (e.g. ipratropium 
bromide) are as efficacious as short-acting β2-agonists in COPD and may provide a 
greater and longer bronchodilator response. However, due to their slower onset of action, 
antimuscarinics may be less suitable for symptom relief than β2-agonists. 
Antimuscarinics may be added or substituted for short-acting β2-agonists where adequate 
control of symptoms is not seen or where regular maintenance therapy is required. The 
concurrent use of short-acting β2-agonists with an antimuscarinic is not recommended 
unless the single drugs do not provide adequate symptom relief. Clinical trial evidence 
also recommends the use of long-acting β2-agonists (e.g. salmeterol and formoterol) in 
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COPD. Long-acting β2-agonists have a prolonged duration of action from 12-14 hours. In 
addition to their bronchodilator action, long-acting β2-agonists also inhibit mast cell 
mediator release, plasma exudation and may reduce sensory nerve activation (Nials et al., 
1994). 
Long-acting antimuscarinic bronchodilators show muscarinic M1 and M3 receptor subtype 
selectivity. Tiotropium bromide, the first of a new class of selective and long-acting 
antimuscarinic agents was introduced for once daily maintenance treatment of COPD 
patients. The combination of long-acting β2-agonists and tiotropium bromide exhibited 
additive effects in terms of daytime lung function improvements and sustained 
improvements during the night compared with the single components, despite the once 
daily dosing (Cazzola et al., 2004; Cazzola et al., 2005; van Noord et al., 2005). The NICE 
/ BTS guidelines recommend that the combination of two long-acting bronchodilators 
with different pharmacological mechanisms of action should be considered in all patients 
with moderate to severe chronic obstructive pulmonary disease. The rational for using 
both of the anticholinergics and the β2-agonist is that the anticholinergics will inhibit the 
vagal tone that exists in COPD. This will h elp  th e airways to  relax so  wh en  th e β2-
receptors are stimulated the bronchodilatation should be enhanced. A combination 
treatment of tiotropium and formetrol was more effective than the single agents with 
respect to bronchodilation in COPD patients (Cazzola et al., 2004; Cazzola et al., 2005). 
These two studies highlighted the value of using a long acting β2-agonist together with a 
long acting anticholinergic agent. When a long-acting antimuscarinic agent like tiotropium 
bromide is used then the patient should not use a short-acting antimuscarinic agent like 
ipatropium bromide. 
There is limited evidence showing the benefit of theophylline in COPD. In addition, 
theophylline may cause serious side effects which may occur within the normal dosage 
range. Such effects may be potentiated by concomitant drug therapy (e.g. erythromycin, 
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quinolone antibiotics). The common side effects of theophylline when the peak serum 
concentration reaches >20 mg L-1 are nausea, vomiting, headache and insomnia. As the 
peak serum concentration levels increase the side effects increase e.g. nausea, vomiting, 
stomach irritation, headache, cardiac arrhythmias and intractable seizures are produced. 
The use of theophyllines is therefore not strongly recommended and limited to those in 
whom other treatments have failed to control symptoms. Mucolytic therapies have 
recently had a lot of interest and should be considered in patients with a chronic 
productive cough. The aim of treatment is to reduce the frequency of cough and sputum 
production. A meta- analysis of such agents reveal that when used for more than two 
months there is a reduction in exacerbations by 29% correspond to placebo (Poole and 
Black, 2001). 
2.2.6.2.3 Corticosteroids 
The pathogenesis of airway obstruction in COPD is multifactorial, involving neutrophilic 
airway inflammation (Stanescu et al., 1996), protease-antiprotease imbalance (Tetley, 
1993), oxidative stress (Repine et al., 1997), and recurrent infection. These mechanisms 
are interrelated such that reducing one factor may also reduce the stimulus to others.  
An increased number of neutrophils are present in the lungs of cigarette smokers 
compared with that in nonsmokers. Cigarette smoke may attract neutrophils to the lung by 
stimulating alveolar macrophages to release a potent chemotactic factor for neutrophils 
(Hunninghake and Crystal, 1983). These increased neutrophils are associated with a rapid 
decline in the FEV1 (Stanescu et al., 1996). Furthermore, neutrophil activation markers are 
elevated in the sputum supernatants of subjects with COPD (Keatings and Barnes, 1997), 
suggesting that neutrophils are active participants in airway inflammation. There is still an 
ongoing debate about the benefit of inhaled or oral corticosteroids in patients with stable 
COPD. While corticosteroids have no effect on neutrophilic inflammation they may also 
influence the cyctokine level (Keatings et al., 1996). 
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Inhaled budesonide was found to be of no clinical benefit in COPD patients recruited from 
the general population by screening (Vestbo et al., 1999). Although the ISOLDE study 
(Burge et al., 2000) showed benefits from inhaled fluticasone the TORCH study 
(Calverley et al., 2003) did not. Only those COPD patients with a positive response to a 
corticosteroid reversibility test should be considered for inhaled steroid therapy without 
long-acting β2-agonists. It has also been noted that the combination of corticosteroid and 
long-acting β2-agonists in a single inhaler improved lung function and severity of 
dyspnoea in patients with COPD (Cazzola and Dahl, 2004). The TORCH (Towards a 
revolution in COPD Health) has also been published and consolidated these findings 
(Calverley et al., 2003). A similar study by Szafranski et al (2003) has shown the benefit 
of budesonide in combination with formoterol (Szafranski et al., 2003). The NICE 
guidelines suggest that if a patient is prescribed a long-acting β2-agonists and has a FEV1 
<50% with two or more exacerbations per year than a high dose of inhaled corticosteroid 
with a long-acting β2-agonists should be considered. Recently, from the results of the 
TORCH study, the prescription licence for Seretide (Fluticasone and Salmeterol) has been 
changed to allow those with a FEV1 <60% to be prescribed this inhaled combination. 
Also the benefit of the combination of long acting β2-agonist and an inhaled corticosteroid 
in a MDI was demonstrated in a study by Theophilus et al (2006). They demonstrated that 
there is a significant co-association of salmeterol and fluticasone propionate particles, 
leading to increased co-deposition when they are administered from the same inhaler. This 
provides a greater opportunity for a synergistic interaction between the two drugs to occur 
in the airways (Barnes et al., 2006) and may possibly be a significant factor contributing 
to the enhanced clinical effect seen in comparison with that observed when the drugs are 
administered separately from two inhalers (Theophilus et al., 2006). 
Furthermore, COPD patients may develop Cor Pulmonale (a secondary heart disease) with 
pulmonary hypertension, right ventricular hypertrophy and right heart failure. Patients 
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with COPD frequently suffer acute exacerbations of their symptoms, and may require 
hospitalization (Vestbo et al., 1999). Treatment options include antibacterial agents and 
oxygen as necessary, together with appropriate managements of any associated 
cardiovascular disorder (Hogg, 2004; Martindale, 2002; Vestbo et al., 1999). 
2.2.6.2.4 Supplemental long-term oxygen therapy (LTOT) 
Supplemental long-term oxygen therapy (LTOT) improves survival, exercise, sleep and 
cognitive performance in hypoxaemic patients (Eaton et al., 2004; Global Initiative for 
Chronic Obstructive Lung Disease (GOLD), 2007). Arterial blood gas (ABG) assessment 
is the preferred method to determine oxygen need because it includes acid-base 
information. Arterial oxygen saturation as measured by pulse oximetry (SpO2) is used as 
well in determining oxygen need. Physiological indications for oxygen include an arterial 
oxygen tension (PaO2) <7.3 kPa (55 mmHg). The therapeutic goal is to maintain 
SpO2>90% during rest, sleep and exertion. As a general principle, prevention of tissue 
hypoxia displaces CO2 retention concerns. If CO2 retention occurs, it is suggested to 
monitor for acidemia. If acidemia occurs, mechanical ventilation is essential for the 
survival of the patient.  
Mechanical ventilation can be administered via non-invasive or invasive ventilation. Non-
invasive is preferred whenever possible. Mechanical ventilation, either "invasive" or "non-
invasive", is not a therapy but it is a form of life support until the cause underlying the 
acute respiratory failure is reversed with medical therapy (British Thoracic Society, 2007) 
Patients considered for mechanical ventilation should have a measurement of ABGs. 
The institution of mechanical ventilation should be considered when, despite optimal 
medical therapy and oxygen administration, there is acidosis (pH<7.35), hypercapnia 
[PaCO2>6–8 kPa (45–60 mmHg)] and respiratory frequency >24 breaths min-1.  
Non-invasive mechanical ventilation (NIV) can be instituted by two methods: non-
invasive positive pressure ventilation (NPPV) by nasal or face masks; or negative pressure 
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ventilation (e.g. iron lung, not recommended). NPPV is by far the most popular mode of 
providing non-invasive ventilation. It is typically administered as a combination of 
continuous positive airway pressure [CPAP] plus pressure support ventilation [PSV] 
(Elliott et al., 1990; Ambrosino et al., 1995; Brochard et al., 1995; Lightowler et al., 2003; 
British Thoracic Society, 2007). The combination of some CPAP (e.g. 4–8 cmH2O) and 
PSV (e.g. 10–15 cmH2O) provides the most effective mode of NPPV. In the first hours, 
NPPV requires the same level of supervision as conventional mechanical ventilation. 
Contraindications for NPPV include the following: respiratory arrest; cardiovascular 
instability (hypotension, arrhythmias, myocardial infarction); impaired mental status, 
somnolence, inability to cooperate; copious and/or viscous secretions with high aspiration 
risk; recent facial or gastrooesophageal surgery; facial trauma and/or fixed 
nasopharyngeal abnormality; burns; and extreme obesity (Plant and Elliott, 1998). NPPV 
can be considered successful when ABGs and pH improve, dyspnoea is relieved, the acute 
episode resolves without the need of endotracheal intubation, mechanical ventilation can 
be discontinued and the patient is discharged from the hospital. 
2.3 Pulmonary drug delivery: 
Pulmonary drug delivery by inhalation is primarily used to treat conditions of the airways 
by delivering locally acting drugs to their site of action thereby reducing the dose needed 
to produce a pharmacological effect with minimal systemic effects (Dhand, 2000; Hillery 
et al., 2001; Kondili and Georgopoulos, 2002). Direct delivery of drug to the airways 
enables a rapid onset of action, avoids the gastrointestinal upset of oral therapy, and 
avoids the first pass effect in the intestine and the liver if this occurs (Barnes, 2004b; 
Dhand, 2000; Kondili and Georgopoulos, 2002; Witek, 2000). The lung may additionally 
be employed as a route for delivery of drugs into the systemic circulation. The type of 
drug and device used are very important factors in targeting drug to the respiratory tract 
(Barnes, 2004b; Bisgaard, 1998). 
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2.3.1. Mechanism of particle deposition in the airways: 
There are three principal deposition mechanisms operating within the lower respiratory 
tract. The first mechanism is inertial impaction which is the dominant deposition 
mechanism for particles in the upper respiratory tract (mouth, pharynx, larynx, and 
tracheobronchial region). A particle with a large momentum (the product of velocity and 
mass) is unable to follow the changing direction of the inspired air as it passes the bending 
and branching of the upper respiratory tract. This large momentum leads to impaction on 
the airway walls. The probability of impaction is dependent upon the momentum, thus 
particles with a large diameter or high density travelling in the airstreams at higher 
velocity will show greater impaction. The airflow velocity in the main bronchi is 
estimated to be 100-fold higher than that in the terminal bronchioles, and 1,000 fold 
higher than in the alveolar region (Hillery et al., 2001).  
The second mechanism of deposition is sedimentation. When the airstream velocity is 
low the particles will settle down under the effect of gravity. This occurs in the 
bronchioles and the alveolar region where the airflow is low. The fraction of particles 
deposited by this mechanism will be dependent upon the time the particles spend in these 
regions. Holding the breath after an inhalation increases the time the particles spend in 
these regions thus increases deposition by this mechanism (Hillery et al., 2001). 
The third principle mechanism of deposition is Brownian diffusion. This usually occurs 
for particles with a particle size lower than 1μm, as particles below this size are displaced 
by random bombardment of gas molecules, which results in particle collision with the 
airway walls. The probability of particle deposition by diffusion increases as the particle 
size deceases and it is also more prevalent in regions where airflow is very low or absent, 
e.g. in the alveoli. Holding the breath after an inhalation increases deposition by this 
mechanism. Figure 2.11 shows a diagram of the above mentioned three mechanisms 
(Hillery et al., 2001). 
 38 
 
 
Figure 2.11 Particle deposition mechanisms at airway branching site. 
 
From the above three mechanisms it is obvious that the lung morphology affects the 
particle deposition as the particles with large size are forced to deposit in the upper 
airways rather than stay airborne. To stay airborne particles must passes through a 
successive series of branching tubes of constantly decreasing size and must continually 
change directions. The increase in the inspiratory flow will also affect the particle 
deposition, as it will enhance deposition by impaction in the first few generations of the 
tracheobronchial region and also increase turbulence, particularly in the larynx and 
trachea, which itself will enhance impaction. The effect of the inspiratory flow on 
deposition from devices that use the energy of inspiration to generate the drug aerosol, e.g. 
dry powder inhalers (DPIs), are more complex, because the increase in the inspiratory 
flow will in most cases lead to the production of aerosol of smaller particle size.  
An increase in inspiratory volume increases the penetration of the aerosol particles deeper 
into the lung thereby increasing the chance of deposition within the alveolar region. 
Breath holding also increases sedimentation and diffusion as it increases the time that 
particles stay in the lung and is used to optimize the pulmonary drug delivery (Dhand and 
Fink, 1999). 
Pharmaceutical factors such as the aerosol velocity, particle size distribution generated 
from the aerosol, shape of the particle, density and its physical stability may also affect the 
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deposition. In general, for effective particle deposition in the lower airways, the 
aerodynamic diameter of particles should be <5 µm, however, particularly for patients 
with obstructive lung disease, all particles should ideally be within the 2–3 µm range 
(Terzano, 2001). 
2.4. Inhalation devices: 
Although there are several new treatments for asthma, which may be given orally (more 
specific drugs) or via injection (monoclonal antibodies), it is unlikely that these will be as 
effective as inhaled β2-agonists or corticosteroids. Hence, inhaled therapy is likely to 
predominate for asthma treatment (Barnes, 2004a). 
From a pharmaceutical perspective, an ideal inhaler would have the following 
characteristics; ease of manufacture, no propellant (i.e. environmentally friendly), uniform 
dosing throughout inhaler life, low potential of contamination and long shelf life (Hillery 
et al., 2001). However, these ideal characteristics are very much device-driven, rather than 
patient focused (Kohler, 2004). From a clinical perspective, to provide consistent clinical 
control, an appropriate inhaler should satisfy the criteria that are described in Figure 2.12. 
Perhaps, the most important characteristic from a patient and physician point of view is 
successful delivery of the therapeutic agent to the lungs and easy to use. 
Most of the inhalation devices are more concerned with the local delivery of the drugs, 
such as the anti-asthmatics, directly to their site of action. An aerosol can be considered as 
colloidal, consisting of finely divided condensed matter in a gaseous container that on 
atomization produces a spray with small size drug loaded droplets suitable for inhalation. 
For maximum efficiency, these drug loaded droplets need to be less than 5μm in diameter. 
The principal categories of aerosol generator used for inhalation therapy are nebulisers, 
pressurized metered dose inhalers (MDIs) and dry powder inhalers (DPIs).  
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Figure 2.12 Criteria for an ideal inhaler. [reproduced from Chrystyn (2007)] 
 
2.4.1. Nebulisers: 
Nebulisers are devices that convert a solution or a micronized suspension of drug into an 
aerosol suitable for inhalation. Nebulisers have the potential to deliver relatively large 
amounts of drug to the patient, so they are frequently used for drugs that cannot be 
conveniently formulated into a MDI or a DPI or where the therapeutic dose is too large for 
delivery using an alternative system (McCallion et al., 1996; Taylor and McCallion, 
1997). Energy is generated in the nebuliser by one of the following principal mechanisms; 
high velocity air stream dispersion (air-jet nebulisers), ultrasonic energy dispersion 
(ultrasonic nebulisers) and vibration energy dispersion (vibrating mesh nebulisers). 
Nebuliser solutions are concentrated solutions from which aliquots are withdrawn and 
diluted before administration. Some concentrated solutions contain preservatives and 
antioxidants which sometime cause bronchospasm, and hence the standard practice is to 
use small unit dose isotonic solutions (Respules) free from preservatives and antioxidants. 
The physicochemical properties, e.g. viscosity and surface tension, of a nebulised solution 
significantly affect the nebuliser performance (McCallion and Patel, 1996; Taylor and 
McCallion, 1997). 
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2.4.1.1. Air-jet nebuliser: 
Jet Nebulisers use compressed gas (air or oxygen) from a compressed gas cylinder, 
hospital air-line or electrical compressor to convert a liquid (respiratory solution) into a 
spray (Mercer, 1981). The jet of high velocity gas is passed either tangentially (concentric 
Nebulisers, e.g. Turret, Respirgard II) or co-axially (Inspiron Mini-neb) through a narrow 
Venturi nozzle, typically 0.3-0.7 mm in diameter. An area of negative pressure, where the 
air jet emerges, results in liquid being drawn from a fluid reservoir up a feed tube as 
shown in Figure 2.13. A proportion of the resultant (primary) aerosol leaves the nebuliser 
directly carried in the airstream. The remaining, large, non-respirable droplets impact on 
baffles or the walls of the nebuliser chamber and are recycled into the reservoir fluid. The 
aerosol leaving the nebuliser is diluted by atmospheric air and inhaled through a face-
mask or mouth-piece. The droplet size of this aerosol is significantly modified within the 
nebuliser by the 'filtering' effect of the baffles in the jet nabuliser and due to droplet 
aggregation, solvent evaporation and condensation. The nebuliser has a tendency to 
concentrate the solution (Dhand and Tobin, 1997; McCallion et al., 1996). During 
nebulization from a jet nebuliser cooling of the reservoir solution occurs which together 
with the vapour loss, results in concentration of the drug solution. This can lead to 
crystallization with subsequent blockage within the device, or variation of the aerosol 
particle size (Taylor and McCallion, 1997; Hillery et al., 2001). The aerosol output from a 
jet nebuliser is a mixture of drug solution and solvent vapour which saturate the outgoing 
air (Ferron et al., 1976). This causes solute concentration to increase with time (Ferron et 
al., 1976) and results in a rapid decrease in the temperature of the liquid being nebulised 
by approximately 10-15°C (Taylor et al., 1992; Clay et al., 1983). The air-jet nebuliser is 
used more often in hospitals.  
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Nebulisers are operated continuously and since the inspiratory phase of breathing 
constitutes approximately 1/3 of the breathing cycle (McCallion et al., 1996), a large 
proportion of the emitted aerosol is not inhaled.  
The rate of gas flow driving atomization is the major determinant of the aerosol droplet 
size produced by a jet nebuliser. Clay et al (1983) in a laser diffraction analysis of four jet 
nebulisers showed that a 50% reduction in the MMAD was produced when the flow was 
increased from 4 to 8 L min-1. This was accompanied by a linear increase in the fine 
particle dose (containing droplet less than 5µm) and an increase in the polydispersity of 
the aerosol (Clay et al., 1983). Increasing the flow increases the shearing forces to which 
the fluid filaments and the surface of droplets are exposed, resulting in smaller droplets. 
Viscosity and surface tension might be expected to affect the output characteristics of 
nebulisers, since energy is required to overcome viscous forces and to create a new 
surface. Atomization theory suggests that the mean diameter of aerosol droplets will 
increase as viscosity increases (Mercer, 1973). McCallion et al. (1996) studied the 
viscosity effects on nebulization of aqueous solutions. They found that the low viscosity 
solutions offered less resistance to the essential aerosol disintegration process, thereby 
producing smaller droplets and higher outputs (McCallion and Patel, 1996). 
 
Figure 2.13 (a) Sidestream jet nebuliser as an example of air-jet nebuliser. (b) Schematic 
diagram of the jet nebuliser. [Reproduced from McCallion et al. (1996)]. 
(a) 
(b) 
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This type of nebuliser is the one recommended for suspensions such as corticosteroid 
formulations, e.g. Pulmicort Respules, AstraZeneca (McCallion et al., 1996). Jet 
nebulisers have been used successfully to atomize recombinant human deoxyribonuclease 
(Cipolla et al., 1994). The activity and structural integrity of the enzyme was maintained, 
when jet nebulisers were employed, although ultrasonic nebulization caused denaturation 
of the protein, probably as a result of the elevated temperatures. However, studies with 
lactate dehydrogenase have suggested that during aerosolization in jet nebulisers there was 
an irreversible time-dependant loss of enzyme activity (Niven and Brain, 1994). Many 
different models of nebuliser and compressors are commercially available. Such devices 
cannot be considered equivalent. For instance, in a study of 18 different commercially 
available jet nebulisers, operated according to the manufacturer’s guidelines, aerosols 
were produced with MMADs ranging from 0.9 to 7.2 µm (Waldrep et al., 1994). Clearly, 
the regional deposition within the lung of aerosols generated from such devices will vary 
enormously. Variability may not only exist between different nebulisers but also between 
individual nebulisers of the same type (Alvine et al., 1992) whilst repeated use of a single 
nebuliser may cause variability due to baffle wear and non-uniformity of assembly 
(Massey et al., 1982). In addition to factors relating to the design of nebulisers, gas flow 
rate, fill volume and the physicochemical properties of the fluid must be considered, 
alongside patient-related factors, when considering both the size of the aerosols produced 
and drug output. 
2.4.1.2. Ultrasonic nebuliser: 
The ultrasonic nebuliser uses a transducer made from a piezo-electric crystal to produce 
high frequency sound waves in the liquid in the nebulizing unit to produce vertical 
capillaries of liquid. When the amplitude of energy applied is sufficient the vertical 
capillaries break up to provide an aerosol, as shown in Figure 2.14. Ultrasonic nebuliser 
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causes a rise in the temperature of the nebulised solution so decrease its use with 
thermolabile drugs, e.g. proteins. They are less used than the jet nebuliser despite their 
compactness which makes them easy to be carried. 
  
Figure 2.14 (a) An example of ultrasonic nebuliser. (b) Schematic diagram of an 
ultrasonic nebuliser [Rreproduced from Fink et al. (2001a)]. 
 
2.4.1.3. Vibrating mesh nebuliser: 
Vibrating mesh nebulisers have recently been introduced. The drawbacks of conventional 
nebulisers are their lack of portability (an electrical or compressed gas source is needed 
for operation), poor efficiency and variability in performance between nebulisers of 
different brands (Smith et al., 1995). Recent technological advancements have led to the 
development of devices that can overcome many of the disadvantages of conventional 
nebulisers. The vibrating mesh nebulisers have much greater efficiency, precision and 
consistency of drug delivery to the lung than conventional jet or ultrasonic nebulisers. 
This new generation of nebulisers use a vibrating mesh or plate with multiple apertures to 
generate a liquid aerosol. Several manufacturers have developed aerosol devices that use a 
vibrating mesh or plate with multiple apertures to produce a liquid aerosol. These include 
Aerogen’s Aerosol Generator (Aeroneb Portable Nebuliser System, Aeroneb Professional 
Nebuliser System, Aerodose Inhaler), Omron’s Vibrating Mesh (NE-U03, NE-U22), 
(a) (b) 
 45 
ODEM’s TouchSpray Technology (TouchSpray inhaler devices) and Pari’s device (the e-
Flow). Some of them are shown in Figure 2.15. 
Some vibrating mesh nebulisers have been designed for use during mechanical ventilation 
(Dhand, 2002). These generate aerosol continuously, though it can be adapted to generate 
aerosol only during inspiration. When it is connected to the inspiratory limb of the 
ventilator circuit, the aerosol that is generated is entrained in the airflow from the 
ventilator. The Aeroneb Pro has a three to five fold higher efficiency for delivering drug 
to the lungs than conventional jet or ultrasonic nebulisers (Fink et al., 2001; Fink and 
Schmidt, 2002; Kristin et al., 2003). Hence, similar clinical effects should be obtained 
with lower nominal doses of drugs with vibrating mesh nebuliser compared with 
conventional nebulisers.  
 
Figure 2.15 Three examples of the vibrating mesh nebulisers a) e-flow (Pari’s), 
b)Aeroneb Pro (Aerogen) and c) NE-U22 (Omron). 
 
The aerosol generator, which is powered by alternating current or a rechargeable battery 
pack, consists of a vibrational element and a domed aperture plate as shown in Figure 
2.16. The aperture plate has about 1,000 tapered holes that are electroformed in a sheet. 
The wider portion of the hole is toward the medication, and the narrower end is toward the 
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atmosphere. The medication is placed in a reservoir above (e.g. Aeroneb Pro) or against 
(e.g. e-flow) the domed aperture plate. When electric current is applied, the ceramic 
vibrational element expands and contracts, causing the domed aperture plate to move 
upward and downward by a few micrometers, which creates a micro-pump action that 
extrudes medication through the apertures to produce an aerosol (Dhand, 2002). 
 
Figure 2.16 a) Picture of Aerogen’s aerosol generator, b) A microscopic view of an 
aperture plate X 250 magnification and c) diagram of the aerosol generator components. 
 
The aerosol particle size and the flow are determined by the exit diameter of the aperture 
hole. These can be modified for specific clinical applications. These nebulisers nebulise at 
a rate ranging from 0.3 to 0.6 ml min-1 and generally the nebulisation time is shorter 
compared with conventional nebulisers (Fink et al., 2001b). These devices are relatively 
quiet because they do not require any compressed gas flow or high vibration energy for 
aerosol generation. Moreover, the volume of solution remaining in these devices at the 
end of treatment (residual volume) is minimal. The energy required for nebulisation is 
applied to the vibrational element in the aerosol generator rather than to the nebulised 
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solution, hence the increase in temperature of the solution during operation is minimised 
(Fink et al., 2001a). There is, therefore a negligible risk of denaturing proteins or peptides 
and of reducing the activity of antibiotics during aerosolisation. 
Blockage of the minute apertures with drug particles, especially when suspensions are 
aerosolised can occur. These devices, therefore, must be cleaned regularly to prevent build-
up of deposit in the apertures. 
A study by Fink et al (2001) compared the ability of the Aeroneb Pro and two small 
volume jet nebulisers, MistyNeb (Allegiance) and Vix One (Westmed), to deliver 2.5 mg 
of salbutamol sulphate to a simulated pediatric patient during mechanical ventilation with 
high frequency oscillation. The Aeroneb Pro delivered more salbutamol (582 ± 89 µg) to 
the end of the endotracheal tube than the MistyNeb (201 ± 87 µg) or the Vix One (197 ± 
50 µg) (p<0.02). Operation of the Aeroneb Pro did not alter any of the monitored ventilator 
parameters. In contrast, both of the jet nebulisers increased mean airway pressure during 
operation by >5 cmH2O and required adjustment of ventilator flow settings during 
operation to maintain ventilator parameters with initiation and discontinuation of 
nebulization. Opening the medication reservoir to refill the Aeroneb Pro did not result in 
any change of the ventilator parameters. In contrast, both of the jet nebulisers required 
interruption of ventilation in order to refill. This level of aerosol delivery without changes 
in airway pressure may make aerosol delivery during mechanical ventilation with high 
frequency oscillation more practical. 
2.4.2. Pressurized metered dose inhalers (MDIs) and Add-no devices:  
MDIs are effective and easily accessible when patients are away from home. They are the 
gold standard for the treatment of airflow obstruction since they provide reliable, 
reproducible, effort-independent dosing, protection of their contents from environmental 
humidity and bacterial infection and at the same time are the most readily pocketable, 
efficient and least expensive aerosol therapy devices available. When combined with add-
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on devices they are also the most flexible delivery system because they are well suited to a 
variety of patients. 
2.4.2.1 Pressurized metered dose inhalers (MDIs) 
MDIs were introduced in the 1950s, and in the UK have remained the most popular 
method for achieving inhalation therapy (Crompton, 2004; Vaswani and Creticos, 1998). 
The pressurized metered dose inhaler (MDI) is the most widely used device for aerosol 
therapy. Over 70 million patients in the world use one, either alone or with a spacer fitted. 
The MDI has changed little since it was first developed (Terzano, 2001). 
The MDI, as shown in Figure 2.17, is a remarkable small spray that repeatedly provides 
almost identical aerosol doses from the beginning to the end of the canister charge. 
 
Figure 2.17 Pressurized metered dose inhalers (MDIs). [Reproduced from Daniel et al. 
(2003)] 
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The MDI consists of a canister with a metering valve containing a drug in suspension or in 
solution with surfactants, lubricants and a propellant at a pressure. The canister is lodged 
upside down in a plastic support called the actuator. By pressing the bottom of the canister, 
a pre-metered drug dose is released. When the canister is depressed, liquid propellant 
containing the drug substance is forced into the actuator where flashing occurs. The 
resulting gas under high pressure forces the propellant together with the excipient and the 
drug substance as particles or droplets of drug solution exit through the actuator orifice, 
thus creating the aerosol cloud. The aerosol cloud consists of a so-called heterodisperse 
aerosol consisting of a variety of particle sizes from approximately 1 µm to 35 µm. These 
emerge at a very high speed. The large particles have considerable inertia resulting in their 
deposition on the tongue and in the oropharynx. From 100 µg of a drug such as salbutamol 
in the Ventolin CFC formulation leaving the actuator orifice, approximately 10 µg remains 
in the actuator and mouthpiece, 75–80 µg is deposited in the mouth and throat and only 
about 10–15 µg reaches the lungs. Newman et al (1981) had reported a Controlled 
inhalations study by eight patients with obstructive airways disease showed that on average 
8.8% of the dose was deposited in the lungs (3.0% in the alveoli and 5.8% on the 
conducting airways) and 80% in the mouth. The remainder of the dose was either expired 
[1.0%] or deposited in the aerosol actuator [9.8%] (Newman et al., 1981). While the MDI 
delivery system is quite inefficient overall, this dose is sufficient to provide maximum 
bronchodilatation in stable mild–moderate asthmatics (Ruffin et al., 1978). 
The size of the particles delivered by MDIs is influenced by a variety of factors, including: 
(1) the pressure inside the canister; (2) the physical and chemical properties of the 
propellant and of the other additives; (3) the drug used, its concentration and the delivered 
volume; (4) the metering valve and delivery outlet design; (5) mouthpiece and delivery 
outlet cleanness (Terzano, 2001). 
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The particle size depends on the propellant evaporation time and on the distance to travel 
from the delivery outlet. For effective particle deposition in the lower airways, the 
aerodynamic diameter of particles should be <5 µm (Heyder et al., 1986). However, 
particularly for patients with obstructive lung disease, all particles should ideally be within 
the 2–3 µm range (Patel et al., 1990; Zanen et al., 1994; Zanen et al., 1996; Bisgaard, 
1997b). 
Until recently the MDIs were formulated using chlorofluorocarbons (CFC) propellants. In 
1974 Molina and Rowland reported that CFCs were being added to the environment in 
steadily increasing amounts and were causing the destruction of the atmospheric ozone 
layer (Molina and Rowland, 1974). In 1987 the Montreal Protocol banned the use of all 
CFC propellant gases, this included MDIs, to protect the ozone layer from further 
depletion (Montreal, 2000). Pharmaceutical companies have reformulated MDIs with 
hydrofluorocarbons (HFAs) propellants which are 2000 times more potent greenhouse 
gases than CFCs but do not damage the ozone layer (Crompton, 2004).  
The major limitation of a MDI is the patient’s inability to use the correct inhalation 
technique, especially good co-ordination between aerosol discharge and inhalation. A 
number of studies have shown that between 25% of patients who have been taught how to 
use MDIs in a chest clinic (Crompton, 1982) and 75% of elderly patients (Allen and Prior, 
1986) may not perform the inhalation manoeuvre very efficiently. A recent study of 
asthmatics revealed that only 7.5% used the correct technique (Al-Showair et al., 2007). 
Table 2.5 Shows the main problems connected with the use of MDIs. 
Previously, MDI technique assessment has heavily focussed on co-ordinating the dose 
release with the start of an inhalation. However studies have shown that co-ordination of 
dose actuation and inhalation is not important as long as the patient is inhaling when the 
dose is released (Tomlinson et al., 2005) and a slow inhalation flow is used. Also a slow 
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inhalation flow through the MDI provides better lung deposition than a fast inhalation flow 
(Newman et al., 1982; Terzano and Mannino, 1999; Tomlinson et al., 2005).  
 
Table 2.5 Main problems connected with the use of MDIs. 
Canister not shaken energetically before delivery 
Mouthpiece cap not removed 
Patient breathes in before or after delivery or through the nose 
Patient breathes out during delivery or before inhalation is complete 
Patient delivers multiple doses during the same breath 
Drug delivery and inhalation are not simultaneous 
The inhalation flow is too fast 
Inhalation is interrupted due to ‘Freon effect’ (early breath cut-off  caused by a cold sensation 
provoked by CFCs in the mouth and the pharynx) 
 
A new training aid, the 2Tone Trainer, which looks like a MDI but without a canister has 
been introduced to help training and maintaining a slow inhalation flow. In a clinical study 
using adult asthmatics the 2Tone Trainer helped patients to maintain the recommended 
MDI technique post verbal inhalation technique training with a resultant improvement in 
Asthma Quality of Life (Al-Showair et al., 2007).  
 In an effort to preclude the need for patients to co-ordinate device actuation with 
inhalation, breath-actuated MDIs were introduced in 1989. In the UK these are available as 
the Autohaler (Teva, UK) and the Easi-Breathe (Teva, UK). The Autohaler system is a 
metered aerosol equipped with a spring device which once loaded, is actuated by a 
moderate inspiratory flow (about 30 L min-1), consequently delivering the drug dose in the 
form of an aerosol. The Easi-Breathe inhaler is primed when the mouthpiece cover is 
opened. When the patient breathes in, the mechanism is triggered and a dose is 
automatically released into the airstream. It has an integral mouthpiece cover and can be 
actuated at airflows of approximately 20 L min-1. 
Breath-actuated inhalers are likely to increase lung deposition in patients with a poor 
inhalation technique (Terzano and Mannino, 1996; Barry and O'Callaghan, 2003). They 
are much easier and more efficacious for patients with poor inhalation technique. It has 
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been shown that the Autohaler can be used easily by children over 7 years old (Pedersen 
and Mortensen, 1990). These devices can help to achieve a satisfactory level of lung 
deposition in poor co-ordinators, but may not deposit additional drug in patients who can 
use the MDI with the correct inhalation technique (Newman et al., 1991c). A small volume 
spacer, the Optimiser, has been evaluated for use with the Easi-Breathe inhaler. 
Oropharyngeal deposition in healthy subjects was reduced by 80% by the use of the spacer 
(Hardy et al., 1996). The Optimiser spacer removes most of the non-respirable drug, 
without compromising the fine particle dose delivered from the Easi-Breathe inhaler 
(Hardy et al., 1996). At present there is no evidence that a breath actuated MDI helps to 
overcome the ‘cold Freon’ effect, as the spray is fired direct into the oropharynx just like a 
standard MDI.  
One marketed MDI actuator, the Neohaler, and another in development, Tempo, use novel 
technologies to slow the aerosol cloud before it leaves the actuator (Newman and Clarke, 
1993; Shrewsbury et al., 2006). The Neohaler device was formerly known as the 
Gentlehaler and Spacehaler. This device has been shown to reduce oropharyngeal 
deposition because it removes most of the non-respirable drug, while lung deposition is 
either increased (Newnham et al., 1993) or unchanged (Newman and Clarke, 1993). The 
Neohaler device is similar to the MDI but has a slightly elongated mouthpiece as show in 
Figure 2.18. The Tempo device also includes a breath-actuation mechanism, and markedly 
increases lung deposition compared with a conventional actuator (Shrewsbury et al., 2006). 
 
Figure 2.18 Diagram of Spacehaler MDI 
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2.4.2.2. Spacer: 
Spacers were first introduced in the 1970s as an extension tube attached to the MDI 
mouthpiece to eliminate patient MDI co-ordination problem, A spacer device, as shown in 
Figure 2.19, is a tube extension to a MDI or a holding chamber with a port at one end to 
which the MDI is attached, a mask or mouthpiece being fitted at the other end. Patients 
dispense a dose (one puff at a time) into the spacer and inhale by breathing normally 
through the mask or mouthpiece. As mentioned before, approximately 25% of adult 
patients and, in practice, all children have difficulty synchronizing actuation of the MDI 
with inhalation of the aerosol (Crompton, 1982). Spacer devices attached to the MDI can 
help to overcome this difficulty and improve inhalation technique. The use of a spacer 
reduces both the velocity and the size of the aerosol particles and decreases the need for 
patient co-ordination between actuation of the MDI and inhalation of the aerosol.  
 
Figure 2.19 Four examples of spacer, (a) Babyhaler (b) Volumatic, (c) Aerochamber with 
mask and (d) Optimiser used with a breath-actusted MDI. 
 
An in-vitro study by Terzano and Mannino (1999) compared the MDI alone to the MDI 
plus a large-volume holding chamber (Volumatic). They estimated the particle 
characteristics of fluticasone propionate, flunisolide and beclomethasone dipropionate, at 
(a) (b) 
(c) (d) 
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inhalation flows of 30 L min-1 from the MDI alone and the MDI attached to the Volumatic 
spacer (GlaxoSmithKline, Ware, UK). A significant reduction of the MMAD and increase 
of the fine particles dose was obtained for all three drugs with the MDI plus Volumatic 
spacer (Terzano and Mannino, 1999).  
Moreover spacers have a size selective function, retaining the non-breathable particles, 
reducing the ‘cold-Freon effect’ and drug deposition in the oropharynx. Furthermore 
valved holding chambers reduce drug loss associated with poor hand-breath co-ordination 
(Aswania and Chrystyn, 2001; Fink, 2000; Terzano, 2001; Vaswani and Creticos, 1998). 
Spacers may not improve the clinical effect in patients able to use a MDI properly, but may 
reduce the systemic bioavailability of the inhaled drug (Newman, 2004).  
Recent guidelines (British Thoracic Society, 2007) indicate that a MDI plus spacer is the 
preferred method for the delivery of β2-agonists and inhaled corticosteroids in children 
below 5 years of age.  
Almost all spacer devices are constructed of plastic and so unless specially treated the 
surfaces can accumulate static charge, especially when handled by the patient. Drug 
delivery from a spacer may be increased by placing an antistatic lining on the inner walls 
of the device (O'Callaghan et al., 1993). It has been found that washing a plastic spacer in 
detergent without subsequent rinsing in tap water and then allowing it to air dry (Kenyon et 
al., 1998; Pierart et al., 1999; Wildhaber et al., 2000), priming by using the spacer several 
times (Bisgaard et al., 1995) or using a spacer made of metal [Figure 2.20] (Bisgaard, 
1995) can decrease the electrostatic charges on the spacer surface which decrease drug 
output from plastic spacers. Rubbing the spacer with a cloth increases the electrostatic 
charge. In a metal spacer the aerosol half life is about 30 seconds compared with about 10 
seconds in a new plastic spacer (Bisgaard, 1997a); a short half-life increases the need for 
co-ordination between actuation and inhalation. Therefore non-electrostatic spacers deliver 
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a significantly higher dose than plastic spacers. Similarly, using a large volume spacer 
increases the lung dose in adults by approximately 50% (Bisgaard, 1997a). 
Several spacers and holding chambers are available. Dose delivery varies considerably 
depending on design. Some devices can be used to deliver aerosols from MDIs to intubated 
or tracheotomised patients (Cates, 2003) and the mechanically ventilated patient (Dhand 
and Tobin, 1996; Manthous et al., 1995).  
 
Figure 2.20 Nebuchamber a metal spacer (AstraZeneca, Sweden) 250 ml 
 
Inhalation from the spacer must be slow and multiple actuations should be avoided because 
this will reduce drug output from the spacer (Barry and O'Callaghan, 1994). 
Certain spacers (Volumatic, Nebuhaler) are designed to fit only a single type of MDI, 
whereas others can be used with all types (AeroChamber). The right kind of spacer must be 
used, choosing the most suitable kind, ideally after testing a number of different devices 
for the individual patient. The disadvantages of spacers are that they are bulky, and 
difficult to carry around; in addition, the valves sometimes stick or become otherwise 
faulty. 
During an acute attack the use of a high dose (10–15 puffs) of short-acting β2-agonist via a 
MDI and a large volume spacer was found to be an effective alternative to its use via a 
nebuliser (Cates et al., 2003; Cates, 2003; Duarte et al., 2000; Marik et al., 1999). In 
addition, cost analysis studies indicate that for hospitalized adult patients with asthma 
exacerbations, treatment with either MDIs plus spacers or nebulisers produce equivalent 
 56 
responses, and MDI plus spacer use is not associated with longer periods of hospitalization 
(Chou et al., 1995).  
There are many types of spacer, ranging from large volume spacer e.g. Nebuhaler, 
Volumatic and Fisonair to small volume e.g. Aerochamber and Inhalet. 
The spacers are classified into three categories, simple tube spacer, holding chambers 
devices and reverse-flow devices. The simple tube spacer is an extension to the inhaler 
mouthpiece. Holding chamber devices usually contain a one-way valve in the mouthpiece. 
A reverse-flow device is a device in which the spray is fired away from the patient into a 
bag or chamber, from which the patient then inhales. The three categories are shown in 
Table 2.6 (Newman and Newhouse, 1996; Newman, 2004). 
 
Table 2.6 Types of spacer device for pressurised metered dose inhalers [reproduced from 
Newman and Newhouse (1996)]. 
Device (manufacturer) Volume in ml 
Simple tube spacer  
MicroSpacer (Respiratory Delivery System) 20 
Optimiser (Norton Healthcare) 50 
Inhalet (AstraZeneca) 80 
Azmacort spacer (Aventis) 110 
Syncroner (Aventis) 150 
Holding Chambers  
Jet spacer (Chiesi) 100 
AeroChamber (Trudell Medical) 149 
Space Chamber (Orthopaedic Appliances) 200 
Inhacort spacer (Boehringer Ingelheim) 250 
Nebuchamber (AstraZeneca) 250 
Babyspacer (AstraZeneca) 260 
Rondo (Leiras) 270 
Integra (GlaxoWellcome) 312 
Babyhaler (GlaxoWellcome) 350 
Nebuhaler (AstraZeneca) 750 
Volumatic (GlaxoWellcome) 750 
Fisonair (Fisons) 750 
Reverse-flow devices  
Optihaler (Respironics) 70 
Aerosol Cloud Enhancer (DHD Corporation) 170 
InspirEase (Schering-Plough) 600 
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An example of a large volume spacer, the Nebuhaler is based on a design from 1976 
(Barry and O'Callaghan, 2003). It is 750 ml in size. Its shape was intended to replicate the 
shape of the aerosol cloud emitted from the MDI, and early versions of the Nebuhaler were 
described as the pear-shaped extension tube. 
Another large volume spacer, the Volumatic, is a 750 ml diamond-shaped valved spacer 
that increases fine particle delivery of drug in-vitro (Barry and O'Callaghan, 1996), 
increases lung deposition of drug compared to the MDI alone (Newman, 2004) and reduces 
oropharyngeal deposition.  
The Fisonair is another large volume spacer that has been shown to be as effective as the 
properly used sodium cromoglycate MDI in the prevention of exercise induced asthma in 
children (Comis et al., 1993).  
It had been found that, taking multiple tidal breaths from a large volume spacer may be 
more practical than taking single deep breaths, especially in children, and fortunately this 
appears to result in a satisfactory bronchodilator response (Castro-Rodriguez and Rodrigo, 
2004; Gleeson and Price, 1988). 
The Aerochamber was first described as a ‘portable, breath actuated particle size selective 
medical aerosol spacer (Barry and O'Callaghan, 2003). The Aerochamber has undergone a 
number of modifications in design and construction from the original design. Aerochamber 
is available in 3 sizes; adult (with and without a mask), child (with mask) and infant (with 
mask). The size of the Aerochamber is 149ml with the difference for the patient group 
being in the mouthpiece and the size of the mask. 
A device developed specifically for the treatment of babies and young children (Kraemer, 
1995), the Babyhaler, is a polycarbonate tube of only 350 ml volume which could be easier 
for a child to empty than larger devices (Newman, 2004). Inspiratory and expiratory valves 
are fitted in an exhalation area of 36 ml. Also the addition of a facemask to the spacers 
helps with the management of infants and young children (O'Callaghan and Barry, 2000). 
 58 
The facemask is a useful alternative to the nebulisers in infants and small children (Fok et 
al., 1998; British Thoracic Society, 2007).  
2.4.4. Dry powder inhalation devices (DPIs): 
Dry powder inhalers basically contain four functional elements; the powder container, the 
metering system, the disintegration principle and a mouthpiece. Based on these functional 
elements, dry powder inhalers can be divided into two major groups, single dose and multi-
dose inhalers (Table 2.7).  
 
Table 2.7 Dry powder inhalers available in the market. 
Inhaler device (manufacturer) 
Single dose inhalers 
Spinhaler (Aventis) 
Cyclohaler (Pharmachemie) 
Rotahaler (GlaxoWellcome) 
Aerolizer (Novartis Pharma) 
Inhalator (Boehringer Ingelheim) 
Handihaler (Boehringer Ingelheim) 
Multi-dose inhalers 
Multiple unit-dose inhalers 
Diskhaler (GlaxoWellcome) 
Aerohaler (Boehringer Ingelheim) 
Diskus / Accuhaler (GlaxoWellcome) 
Reservoir systems 
Turbuhaler (AstraZeneca) 
Clickhaler (Innovata Biomed/ML labs celltech) 
Easyhaler (Orion Pharma) 
Pulvinal (Chiesi) 
Novolizer (Viatris) 
 
The multi-dose inhalers are divided in two different types of design: the reservoir systems 
and the multiple unit-dose inhalers. An example for the reservoir system is Turbuhaler, 
Clickhaler, Pulvinal, Novolizer and Easyhaler. In this type of inhaler, the powder 
formulation is stored in a reservoir from which single doses are measured volumetrically 
and dispensed with a special dose metering unit. Accurate dose metering for this type of 
inhaler requires careful manipulation of the device by the patient. In the multiple unit-dose 
inhalers, single doses are filled by the manufacturer into suitable dose compartments, such 
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as blisters. Examples are Diskhaler, having the blisters on a disk (Rotadisk), and Diskus 
(know as Accuhaler in UK) with the blisters on a long strip. 
The early DPIs were all unit dose systems such as the Spinhaler which was introduced in 
1969 (Figure 2.21), and the Rotahaler in 1977. As single dose inhalers, both utilize 
premetered doses dispensed into hard gelatine capsules with a different mechanism of 
powder delivery. The capsule cap and body must be separated before inhalation (Rotacaps 
for Rotahaler) or the capsule has to be pierced at both ends; as for the capsules for the 
Aerolizer, the Spincaps for the Spinhaler, and the Spiriva Handihaler.  
The Diskhaler, introduced in 1980, (Figure 2.21) has individual doses contained within a 
blister on a disk. The dose is released by piercing the upper and the lower surfaces of one 
of the blisters before an inhalation. 
 The Diskus/Accuhaler (GlaxoSmithKline) was launched in 1994. It contains 60 discrete 
dispensed doses packed on a strip which is coiled within the inhaler. 
The multiple dosing reservoir devices contain 100-200 doses with each dose metered 
immediately before an inhalation. The Turbuhaler was introduced in 1988, (Figure 2.21) 
and was designed to deliver 500μg per dose of terbutaline sulphate devoid of carrier, and 
then it was used for other drugs. It is the most frequently prescribed DPI that produces 
good deposition of drug in the lungs provided that a sufficient inspiratory flow has been 
achieved by the patients [i.e. 60 L min-1] (Dhand and Fink, 1999). Patients with reduced 
inspiratory capacity may not get the full benefit from the Turbuhaler (Barry and 
O'Callaghan, 2003).  
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Figure 2.21 A schematic diagram of different types of inhalers available in the market. 
[Reproduced from de Boer et al. (1996)].  
 
Recently many multiple dosing reservoir DPI devices have been introduced e.g. Clickhaler, 
Pulvinal and Easyhaler which give a fairly consistent emitted dose irrespective of the 
inhalation technique used by patients of all age groups (Chrystyn, 2006). In 2001 the 
Novolizer (Viatris, Germany) entered the market (Crompton, 2004). It is a multiple dosing 
reservoir device with a refillable cartridge system. The dose has to be inhaled at a flow 
more than 35 L min-1 to release the dose (Kohler, 2004; Richter, 2004). No dose is released 
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when the patient inhalation flow is less than 35 L min-1. A study to assess whether 
asthmatic children may generate sufficient peak inspiratory flow through the Novolizer 
was done by Vogelberg et al (2004). They found out that the medium to low intrinsic 
resistance of the Novolizers permits a relatively high PIF [mena (SD) of 69.0 (18.0) L min-
1] through this device. Together with the feedback mechanisms, this makes the Novolizer 
particularly valuable for inhalation therapy in asthmatic children with drugs such as 
salbutamol, formoterol or budesonide (Vogelberg et al., 2004). 
For the marketed dry powder inhalers, only two different types of powder formulations are 
currently used; spherical pellets and adhesive mixture. Spherical pellets are used in the 
Turbuhaler. In this type of formulation, the micronized drug particles are agglomerated 
into much larger spherical units without a binding agent, behaving as a free flowing 
powder. Some micronized diluents such as lactose or glucose may be added to the active 
component when the dose is low (e.g. Formoterol 6 and 12µg), but the formulation does 
not contain coarser carrier crystals. Spherical pellets have to disintegrate nearly completely 
during inhalation into much smaller agglomerates or even primary particles that have the 
required size-range for deep penetration into the respiratory tract. 
All other DPIs are filled with adhesive mixtures. This type of formulation consists of 
relatively large carrier crystals, mostly α-lactose monohydrate, carrying the micronized 
drug particles distributed over their surface. During inhalation, the drug particles have to 
be released from the carrier crystals to generate the aerosol with particles of the desired 
particle size, which are able to enter the lower respiratory tract. The fraction of drug not 
detached may cause local side effects, such as candidiasis with inhaled corticosteroids, in 
the upper respiratory tract (mouth and throat) where the carrier crystals, and other larger 
particles, are deposited. 
All currently available DPIs are breath actuated, thus a dose capable of delivery to the 
lungs is produced in response to the patient’s inspiratory effort. The principle of operation 
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for a DPI is to use the patient generated inspiratory flow as an energy source for the release 
of the dose and the delivery of fine drug particles into the respiratory tract. The particle 
size of the adhesive mixtures or the spherical pellets is far too large for lung deposition. 
Therefore, the pellet or mixture has to be disintegrated to make an aerosol cloud, which 
contains a high fraction of non-agglomerated drug particles with the desired particle size 
(<5 µm). Many different disintegration principles exist. They may vary from a simple 
screen (Rotahaler, Diskhaler), to twisted powder channels (Turbuhaler). The applied 
disintegration concept in the design of a dry powder inhaler largely determines the 
resistance to airflow of the inhaler device.  
Inhalers without a recognisable disintegration principle Figure 2.22, for example Diskhaler 
and Accuhaler, often have a low resistance to airflow. Due to the low resistance to airflow, 
larger variations in peak inspiratory flow are found. However, the fine particle output is 
more or less constant over a broad range of inspiratory flows at a low level (de Boer et al., 
1996), although there is a tendency for this to increase slightly as the PIF increases. 
 
Figure 2.22 Schematic diagram of the disintegration of micronized drug particles from 
carrier crystals through a non-specific disintegration system. 
 
More specific disintegration systems like the Turbuhaler use inspiratory flow more 
optimally as the energy source for disintegration and delivery of fine particles into the 
Carrier / drug 
powder bed 
Carrier / drug 
aerosol 
Disintegration 
mechanism 
Airflow 
Carrier and drug 
aerosol after 
disintegration 
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airflow (Figure 2.23). This usually results in an increased resistance to airflow through the 
inhaler. Due to the inhaler design, the fine particle output depends more strongly on the 
patient’s inspiratory performance. As a result, the fine particle output is more or less flow 
dependent. The optimum aerosol dispersion threshold for the high internal resistance 
Turbuhaler occurs at a peak inhalation flow (PIF) of at least 60 L min-1. Patients who 
cannot achieve the recommended optimal PIF through the Turbuhaler may not obtain the 
maximum benefit from their medication (Cegla, 2004; Chrystyn, 1999). The peak 
inspiratory flow achieved by a patient through a powder inhaler depends upon the specific 
resistance to flow of the device and the patient inspiratory capability for a set of inspiratory 
effort. The lower the specific resistance in the DPI the higher will be the peak inspiratory 
flow (Clark and Hollingworth, 1993). Therefore, resistance to airflow is one of the design 
parameters for DPIs that could be used to control the inspiratory flow profile and optimize 
particle deposition in the airways (de Koning et al., 2002). 
 
Figure 2.23 Schematic diagram of the disintegration of spherical pellets through a specific 
disintegration mechanism [Reproduced from Chrystyn (2003)]. 
 
The performance of DPIs will depend upon the peak inspiratory flow (PIF) generated 
through the device. The relationship between inhalation rate and the resistance in an 
inhaler is described by the relationship 
F= P∆ / R (Clark and Hollingworth, 1993) 
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F= flow through the inhaler (L min-1) 
∆P= pressure difference developed across the device (cm H2O) 
R= Resistance in the inhaler device resistance in (cm H2O)0.5 / L min-1 
Thus the more resistance there is inside the inhaler then the lower will be the inhalation 
flow for a set inspiratory effort.  
The high resistance to airflow limits the range of possible inhalation flows. However, due 
to the higher disintegration efficiency, the fine particle output is higher compared to the 
non-specific disintegration systems (de Koning et al., 2002; Srichana et al., 1998; 
Hawksworth et al., 2000). The mouthpiece may be used to control the resistance to airflow 
of the inhaler and the direction of the aerosol cloud in the mouth and throat, in order to 
reduce drug deposition in the oropharyngeal cavities (de Boer et al., 1997). The most 
important factors affecting the dose delivered are the peak inspiratory flow of the patient, 
inspiration time, resistant to flow of the device, acceleration rate and type of drug in the 
inhaler (de Boer et al., 1996).  
The total emitted dose and fine particle fraction released by some DPIs have been shown to 
vary considerably and be affected by differences in inspiratory flow (Chrystyn, 2007). The 
inhalation profile employed may affect both drug delivery and particle size distribution 
(Miller et al., 2000). A study was conducted to compare the emitted dose and the fine 
particle fraction of salbutamol from Easyhaler, Turbuhaler and Diskus (Palander et al., 
2000). They concluded that the emitted dose and the fine particle fraction showed less flow 
dependency with Easyhaler and Diskus than with Turbuhaler. Hence patients cannot use all 
DPIs equally well (Gustafsson et al., 2005). A study by Tarsin et al (2006) have measured 
the aerodynamic characteristics of the emitted dose for both active constituents from 
Seretide Diskus (salmeterol xinafoate 50 µg; fluticasone propionate 500 µg) and Symbicort 
Turbuhaler (formoterol 6 µg; budesonide 200 µg). They found that the Turbuhaler dose 
characteristics were more dependent on the patient’s inhalation flow (Tarsin et al., 2006). 
Sometime patients are not able to achieve the required energy. This energy requirement 
differs from one DPI to another. Patients using the Turbuhaler have to use a significantly 
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higher inspiratory effort compared to other DPIs in order to achieve the same inspiratory 
flow inside the device (Cegla, 2004; Chrystyn, 1999). Hence, patients when using DPIs for 
the relief of symptoms during acute exacerbations of asthma may have problems (Dhand 
and Fink, 1999). Also changing a delivery device can have adverse effects on both the 
safety and efficacy of an inhaled drug. Hence DPIs should not be regarded as 
interchangeable (Chrystyn, 2005; Williams and Chrystyn, 2007). Some of the recent DPIs 
incorporate an additional energy source to supplement airflow to the inspiratory force of 
the patient, in order to aerosolize the drug particles into the inhaled air stream, but not quite 
used yet and will have the patient co-ordination problems.  
Comparative studies assess different DPIs at the constant pressure drop across the device 
(Clark and Hollingworth, 1993). This concept is used by all the compendial methods 
(European Pharmacopeia, 2001; British Pharmacopoeia, 2005a; United States 
Pharmacopeia, 2005). However these conditions are quality control indications and do not 
reflect patient use. Patients with COPD have been reported to have a lower inhalation flow 
than adult asthmatics when they use a dry powder inhaler (Tarsin et al., 2001). This study 
also showed that asthmatic children (aged 5-6 years) achieved the highest inhalation flows 
and that the more severe the airway obstruction the lower was the inhalation flow through 
a variety of dry powder inhalers (Tarsin et al., 2001). Another study has also recommended 
that the Turbuhaler device was not suitable for pre-school children because of the low flow 
achieved by this group (Pedersen et al., 1990) 
Some advantages and disadvantages of dry powder inhalers are summarised in Table 2.8.  
2.5. Methods of determination of the bioequivalence of inhaled products: 
Two products may be pharmaceutically equivalent if they have the same composition and 
in-vitro performance. They may be bioequivalent if they have the same pharmacokinetic 
and lung deposition profiles. They may be clinically equivalent if they have the same 
therapeutic effects and side effects (Barry and O'Callaghan, 2003). 
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Table 2.8 Advantages and disadvantages for dry powder inhalers versus metered dose 
inhalers (Ashurst et al., 2000). 
Advantages of dry powder inhalers Disadvantages of dry powder inhalers 
• Propellant free • Performance depends on the patients inspiratory flow profile 
• Less need for patient co-ordination • Resistance to airflow of the device 
• Less potential for formulation 
problems 
• Potential difficulties to obtain 
dose uniformity 
• Less potential problems with drug 
stability 
• Less protection from 
environmental effects and patient 
abuse 
• Less potential for extractables from 
device components • More expensive 
 
The assessment of pulmonary drug absorption and deposition is becoming increasingly 
important in drug development. Several methods are available to investigate pulmonary 
drug absorption and deposition. The methods include pharmacokinetic and 
pharmacodynamic studies, gamma scintigraphy method and in-vitro studies (Witek, 2000; 
Pauwels et al., 1997). In combination, these methods can indicate the fate of an inhaled 
drug, as the pulmonary fate of the aerosolized drug is influenced by where the aerosol 
particle is deposited in the lung (Chrystyn, 2000; Chrystyn, 2001; Mobley and Hochhaus, 
2001).  
2.5.1. Pharmacokinetic methods (using plasma or urine samples): 
As shown in Figure 2.24, the inhaled drug will be deposited in the lung and ingested into 
the gastrointestinal tract, then into the systemic circulation where it faces metabolism and 
excretion. 
The ingested portion may undergo the first pass effect (e.g. fluticasone propionate) and is 
absorbed after a lag time. The pharmacokinetic methods to evaluate the inhaled drug use 
either urinary excretion or blood concentrations of the drug. 
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Figure 2.24 Pharmacokinetics of inhaled drug [Reproduced from Chrystyn (2001).] 
 
Pharmacokinetic methods (using plasma or urine samples) can be used to identify the 
relative lung deposition of the drug (the effective lung dose) and total systemic delivery. 
The plasma or the urine concentration of the drug accounts for the total absorption from 
lung and gastrointestinal tract of the inhaled drug. The identification of the relative lung 
deposition using pharmacokinetic method, for a drug with an extensive first pass effect in 
the gastrointestinal tract (e.g. fluticasone) is easy as the oral absorption of it would be 
negligible. Hence sampling of urine or plasma after inhalation would be accurate to 
measure the relative lung deposition. The use of oral charcoal doses taken before and after 
the inhalation to block the gastrointestinal absorption of the oral ingested portion has been 
demonstrated (Borgstrom and Nilsson, 1990). The original study by Borgstrom and 
Nilsson (1990), as shown in Figure 2.25 highlighted the value of charcoal blockage of the 
gastrointestinal absorption to determine the relative amount of drug delivered to the lung. 
However, because this method uses oral charcoal it would be unethical to extend this 
method to patient studies due to their concomitant oral therapy (Chrystyn, 2000). 
Systemic 
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Figure 2.25 Mean amount of urinary terbutaline excreted 36 hours post dose with and 
without the administration of charcoal (Borgstrom and Nilsson, 1990). 
 
The measurement of either plasma concentration or amount excreted in urine post 
inhalation during the absorption lag time of the orally swallowed portion represents the 
drug deposited in the lungs. The proposed time for the plasma sampling method is 5, 10 
and 20 minutes post inhalation (Anhoj et al., 1999; Lipworth and Clark, 1997; Mobley and 
Hochhaus, 2001) and for urine it is 30 minutes after the start of an inhalation (Hindle and 
Chrystyn, 1992).  
The drug concentrations in plasma or serum are very low because the inhaled dose is small 
and the volume of distribution of the drug is very large, specially for polar or basic drugs 
which are cleared from the blood very fast (Chrystyn, 1994). 
Using the lag time of the gastrointestinal absorption Hindle and Chrystyn (1992) developed 
a urinary pharmacokinetic method to determine the relative lung and systemic 
bioavailability of inhaled salbutamol. They showed that the urinary salbutamol excreted 30 
minutes post dosing was an index of the lung bioavailability and that the urinary 
salbutamol excreted 24 hours post dosing was an index of the systemic bioavailability. The 
amount excreted 30 minutes post inhalation was significantly different from that after oral 
dosing (p<0.001) as shown in Figure 2.26. The method is very simple and non-invasive. 
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The method has been extended to assess the relative lung bioavailability of inhaled sodium 
cromoglycate (Aswania and Chrystyn, 2001; Aswania and Chrystyn, 2002; Aswania et al., 
1997; Aswania et al., 1999), nedocromil (Aswania et al., 1998), gentamicin (Al-Amoud et 
al., 2002), tobramycin (Barber, 2002) and formoterol (Nadarassan et al., 2007). 
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Figure 2.26 Mean and individual amounts of urinary salbutamol excreted 30 minutes post 
inhalation and oral dosing (Hindle and Chrystyn, 1992).  
 
The use of this pharmacokinetic method provides useful information about the relative 
lung deposition and the relative systemic delivery to compare different methods, devices or 
technique and allows the use of the original products. The disadvantages of the 
pharmacokinetic methods are the need to differentiate between the swallowed and inhaled 
fraction of the inhaled dose. They do not identify dose deposition into different zones of 
the lungs and some assays do not have the sensitivity to measure the low concentrations 
(Chrystyn, 2001). 
2.5.2. Gamma scintigraphy: 
There are two types of gamma scintigraphy, two dimensional and three-dimensional 
imaging methods (Chrystyn, 2000; Newman and Wilding, 1999).  
The two dimensional gamma scintigraphy (planer imaging) method usually uses 99m 
Technetium adhered to either the formulation or the drug molecules in the dosage form 
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(physical attachment). The subjects inhale the combination and then use rapid imaging of a 
radionuclide to identify the drug deposition in the lung following inhalation (Bondesson et 
al., 2003; Borgstrom and Newman, 1993; Newman and Wilding, 1999). The planar images 
obtained with this method may be insensitive to the relative deposition in the different 
zones of the lungs.  
Three-dimensional imaging methods (SPECT and PET) have recently been introduced to 
overcome the disadvantage of planner imaging. SPECT (single photon emission computed 
tomography) is similar to two-dimensional gamma scintigraphy (physical attachment of the 
radiolabelling of the drug) except that the gamma camera rotates through 360oC. This 
increases the data collection time. Hence, a very large dose is required. The dose may be 
40 times larger than that required for the planar imaging and thus introduces formulation 
and preparation problems (Newman and Wilding, 1999).  
PET (Positron emission tomography) is a direct incorporation of a radiolabel into the drug 
molecule (chemical attachment). The ones recently used are positron emitters such as 11C 
(short half life) or 18F (long half life). The positron emitters used so far have short half-
lives and the method is very expensive. 11C has been introduced into triamcinolone 
acetonide and studies have highlighted the greater peripheral deposition when a spacer is 
attached to an MDI (Heald et al., 1997). This was mainly due to a substantial increase in 
the total amount of drug deposited in the lungs (13.6% with and 4.9% without the spacer). 
This technique has also been used for fluticasone (Berridge et al., 1998). 
Gamma scintigraphy produces data of the total lung dose that is absorbed through the 
airways and cleared by mucociliary clearance. Since the former is the part of the dose that 
is responsible for the therapeutic action in the airways then gamma scintigraphy will 
overestimate the effective dose reaching the lung. The charcoal block method using urinary 
excretion of terbutaline (Borgstrom and Nilsson, 1990) has been compared with total lung 
deposition measured by gamma scintigraphy (Borgstrom et al., 1992). The mean (SD) 
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terbutaline excreted in the urine post inhalation with concurrent charcoal administration 
was 21.1 (3.2) % of the nominal dose whilst gamma scintigraphy showed the total lung 
deposition to be 26.9 (3.8) %. The difference obtained is because part of the inhaled dose is 
cleared by mucociliary clearance. This fraction of the dose delivered to the lungs is 
identified by gamma scintigraphy but not by pharmacokinetic methods.  
The long term safety and the expensive study costs are considered disadvantages of gamma 
scintigraphy (Chrystyn, 2001). In addition, the labelling procedure involves manipulations 
of the formulations. Consequently, the radiolabelled formulation is different from the 
formulation in the original product although in-vitro tests are carried out to confirm 
similarity (Snell and Ganderton, 1999). However, a previous report has shown that when 
using the Andersen Cascade Impactor the mass median aerodynamic diameter (MMAD) of 
a labelled drug was larger than the original product and that there was a difference in the 
homogeneity of the size distribution (Newman et al., 1982). Furthermore, particle size 
ranges should be quoted as amounts emitted rather than a percentage, and in-vitro 
determinations should use the same number of doses that were used in the scintigraphic 
study. Agencies such as the FDA are very cautious in using results from imaging studies 
for assessing bioequivalence (Mobley and Hochhaus, 2001).  
There are also non-radioactive assessment methods such as nuclear magnetic resonance 
imaging (MRI) and magnetic marker monitoring (MMM) but their use is not well 
established yet (Newman and Wilding, 1999). 
2.5.2. Clinical studies: 
Clinical studies using spirometry or bronchoprovocation challenge have been used to 
identify the bioequivalence between two inhaled products (Eiser et al., 2001; Rodriguez-
Carballeira et al., 2001). 
A method often used in the evaluation of the efficacy of inhaled drugs is the protective 
effect on methacholine or histamine induced bronchoconstriction (Tattersfield, 1987; 
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Britton et al., 1988). The inhalation of a short-acting β2-agonist increases the provocative 
dose of inhaled methacholine or histamine from 1.1 to 3.9 times (Casterline et al., 1976; 
Cockcroft et al., 1977). More recent studies have demonstrated that salbutamol increases 
the provocative dose of methacholine by 2.8 to 3.1 times (Wong et al., 1997; Seppälä et al., 
1998). 
Most clinical studies are carried out using measurements at the flat (plateau) portion of the 
dose-response relationship. For instance, a doubling of the therapeutic fluticasone inhaled 
dose has been shown to increase the peak expiratory flow rate (PEFR) by only 4.3 L min-1 
from a baseline of almost 200 L min-1 (Dahl et al., 1993). Also for beclomethasone the 
FEV1 (forced expiratory volume in the first second) increased by 0.18 L above baseline 
after 200 mg inhaled twice daily and by 0.21 L after 400 mg twice daily (Raphael et al., 
1999). For the β2-agonists the maximum response from therapeutic inhaled doses has been 
studied (Barnes and Pride, 1983). It has been found that in normal subjects a maximum 
airway response to inhaled salbutamol was achieved with a cumulative dose of 110 µg. By 
contrast the dose required to produce a maximal bronchodilator response in asthmatic 
subjects was significantly higher and increased as the severity of bronchoconstriction 
increased (Barnes and Pride, 1983). Newman et al. (1991) also demonstrated this in 
asthmatic subjects except that they also measured lung deposition using gamma 
scintigraphy. When these subjects inhaled radiolabelled salbutamol from a MDI and a MDI 
attached to a large volume spacer the total lung deposition was 12.3 and 23.1% (of the 
dose), respectively, but there was no difference in spirometry measurements (Newman et 
al., 1991b). Also bronchoprovocation challenge cannot differential between different 
inhalation techniques due to the large variability of the method (Tomlinson et al., 2005). 
The inter-patient variability in clinical studies is high. Thus sensitivity to detect a 
difference is low and so a large number of subjects need to be studied (Barry and 
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O'Callaghan, 2003). Furthermore the bronchoprovocation agents may stimulate different 
receptors to those of the drug studied causing deterioration of lung function. 
2.5.3. In-vitro methods: 
In-vitro methods are used as a quality assurance procedure to identify the quality of the 
inhaled product such as the total emitted dose, uniformity of dose and the aerodynamic 
particle size distribution. Further, they are often extrapolated to give an estimation of in-
vivo deposition. The most used techniques are inertial separation methods and laser 
diffraction. Microscopic methods have also been used. 
Aerosol particles are not perfectly spherical, instead they are of an uneven shape, weight 
and surface area that would be impossible to be described accurately by any one variable. 
Instead, such particles are generally described by their aerodynamic diameter. This is the 
diameter of a unit density sphere that has the same settling velocity in air as the particle. 
This aerodynamic diameter takes into account particle density, shape and size (Hickey, 
1992). The mass median aerodynamic diameter (MMAD) of an aerosol is the diameter that 
separates the mass of the particles equally by 50% and is the term along with the geometric 
standard deviation (GSD) that is often used to describe an aerosol. The GSD is a measure 
of the polydispersity, or spread, of an aerosol. A monodisperse aerosol has a GSD of 1 and 
heterodisperse aerosol has a GSD greater than 1.2. The amount of an aerosol contained in 
particles with an aerodynamic diameter less than 5µm, is generally referred to as the fine 
particle dose [FPD] (Newman, 1991). This is the quantity of drug in the prescribed dose of 
an inhaled product that is generally considered to be of a size capable of penetrating the 
lung during inhalation i.e. respirable amount. The FPD expressed as a percentage of the 
emitted dose is the fine particle fraction (FPF). Although the respirable fraction does not 
equal the amount of aerosol deposition in the lung, it provides an estimate of the fraction of 
the dose that has the potential to be deposited into the lungs (Barry and O'Callaghan, 2003; 
Dhand and Fink, 1999). 
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2.5.3.1 Total emitted dose: 
(a) MDI dose emission unit: 
The delivered dose is the total amount of drug emitted from the drug device and hence 
available to the user. Its uniformity is critical to the safety and efficacy of all orally inhaled 
drug products. Based on an original design by Charles Thiel (a chemist who is credited 
with producing the first MDI, 1956) in the laboratories of 3M Healthcare, the MDI dose 
emission unit, as shown in Figure 2.27, has been designed specifically for the sampling and 
testing of MDIs. It is used to perform those tests specified by the relevant compendial 
standards (European Pharmacopeia, 2001; United States Pharmacopeia, 2005; British 
Pharmacopoeia, 2005a), namely ‘Delivered Dose Uniformity’ and in the case of multidose 
inhalers, ‘Delivered Dose Uniformity over the Entire Contents’. 
The sample collection tube is fitted with a 25 mm glass fibre filter, with 99.98% aerosol 
retention and a pore size of 1 micron. It has a volume of approximately 50 ml, which 
approximates to that of the human oropharynx. 
 
Figure 2.27 Parts and fitting of the MDI dose emission unit (Reproduced from Copley 
2008). 
 
(b) DPI dose emission unit:  
A second and larger version of the MDI dose emission unit capable of sampling at a 
variety of flows up to 100 L min-1 is available for use with Dry Powder Inhalers (DPIs). 
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Like the MDI dose emission unit, the DPI dose emission unit, as shown in Figure 2.28, is 
used to perform those tests specified by the Pharmacopoeia (European Pharmacopeia, 
2001; United States Pharmacopeia, 2005; British Pharmacopoeia, 2005a) that relate to 
content uniformity namely ‘Delivered Dose Uniformity’ and in the case of a multi-dose 
DPI, ‘Dose Uniformity over the Entire Contents’. In the case of DPIs, both the emitted and 
fine particle dose is affected by the strength and duration of the patient’s inspiration 
(Newman et al., 1991a; Ross and Schultz, 1996). Furthermore, different inhalers provide 
varying degrees of resistance to flow (Clark and Hollingworth, 1993). For these reasons, 
according to the compendial methods, it is essential, particularly when testing DPIs of 
intermediate to high flow resistance, to determine the appropriate test flow and duration 
based on the pressure drop developed over the specific inhaler under test (European 
Pharmacopeia, 2001; United States Pharmacopeia, 2005; British Pharmacopoeia, 2005a). 
Assuming this is done, it is then important to ensure that critical (sonic) flow occurs in the 
flow regulating valve employed in the system. This ensures that the flow through the dose 
emission unit is set as required and that it is unaffected by minor fluctuations in the pump. 
The resulting airflow that produces a drop of 4.0 kPa over the inhaler to be tested, should 
then be used for the determination of the delivered dose and particle size distributions as 
recommended by the compendial methods (European Pharmacopeia, 2001; United States 
Pharmacopeia, 2005; British Pharmacopoeia, 2005a). 
The only exception to this criterion is for those low resistances DPI that produce a flow in 
excess of 100 L min-1. In this case, a flow of 100 L min-1 should be used. 
When using the DPI dose emission unit, it is necessary to use a critical flow controller to 
determine the pressure drop over the inhaler, to ensure critical (sonic) flow conditions and 
to set the duration, and hence volume of inspiration. 
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Figure 2.28 Parts and fitting of the DPI dose emission unit (Reproduced from Copley 
2008) 
 
2.5.3.2 Characterisation of the emitted dose: 
Inertial impaction as a size separation factor by cascade impaction methods has been 
widely used as the ‘gold standard’ to determine the aerodynamic characteristics of the 
emitted dose from aerosols (European Pharmacopeia, 2001; United States Pharmacopeia, 
2005; British Pharmacopoeia, 2005a). The application of this class of particle size analysis 
to the assessment of medical aerosols has recently been extensively reviewed, focusing on 
the types of impactor that are in current use together with their strengths and limitations for 
measurements with the different classes of inhalers (Mitchell and Nagel, 2003).  
(a) Twin Stage Impinger: 
 The Twin Stage Impinger shown in Figure 2.29 (United States Pharmacopeia, 2005) can 
be operated using inhalation flows of 30 and 90 L min-1. It has been retained in the 
Pharmacopeias because of its value as a simple and inexpensive quality control tool. 
However, it is generally accepted that an impactor or impinger should have a minimum of 
five stages, and preferably more, if it is to provide detailed particle size distribution data. 
The Twin Impinger is likely to be withdrawn from compendial methods. Although they are 
useful for rapid quantification of the FPF, it provides insufficient rapid resolution in the 
critical aerodynamical diameter range of 0.5 to 5.0 µm (Newman and Kenyon, 1994). 
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Figure 2.29 The Twin Stage Impinger (Reproduced from Copley, 2008). 
 
(b) Multistage Liquid Impinger: 
The Multistage Liquid Impinger [MSLI] (United States Pharmacopeia, 2005) consists of a 
metal throat, impaction stages and a final filter. The MSLI operates at 60 L min-1 and has 
cut-off diameter of 25, 13, 6.8, 3.1 and 1.7 µm, thus giving a much more detailed particle 
size distribution then the Twin Stage Impactor (Figure 2.30). However the number of cut-
off  diameters is limited. 
 
Figure 2.30 Multistage Liquid Impinger (Reproduced from Copley, 2008). 
 
(c) Anderson Cascade Impactor: 
As shown in Figure 2.31 the Anderson Cascade Impactor (ACI) consists of a stack of eight 
plates, each containing a series of precision drilled holes, and a final filter stage (European 
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Pharmacopeia, 2001; United States Pharmacopeia, 2005; British Pharmacopoeia, 2005a). 
The diameter of the holes decreases progressively in each succeeding stage. Therefore, the 
jet velocity increases as a particle travels through the impactor. The ACI operates at a flow 
of 28.3 L min-1 with cut-off diameters of 9, 5.8, 4.7, 3.3, 2.1, 1.1, 0.65 and 0.43 µm, 
respectively. This method allows a more detailed description of the particle size 
distribution than either the MSLI or the Twin Impinger. Although the ACI is designed to 
be used at inhalation flows of 28.3 L min-1, modifications are available for the use at high 
flows 60 and 90 L min-1. For an inhalation flow of 60 L min-1 stages 0 and 7 are removed 
and replaced by stages -1 and -0 on the top of the ACI. For an inhalation flow of 90 L min-
1 stages 0, 6 and 7 are removed and replaced by stages -2, -1, and -0 on the top of the ACI. 
Alternatively the standard ACI can be operated at different flows with the cut-off stages 
altered according to the following equation (ECDF2 = ECD28.3 (28.3/F2)0.5). Where ECDF2 
= the Effective Cut-Off Diameters at the other flow; ECD28.3 is the ECD at the 
manufacturers flow (28.3 L min-1) and F2 is the other flow rate in L min-1 (Van Oort, 
1995). 
When sampling DPI aerosols, a pre-separator with a small amount of solvent is added to 
the ACI to prevent those particles greater than 10µm from bouncing into the ACI stages 
(Figure 2.31). 
The high flows these devices operate at may result in the extensive evaporation of aqueous 
particles such as nebulised aerosols, thus underestimating the particles size (O’Callaghan 
and Barry, 1997). The respiratory tract has a highly complex anatomy along with the 
effects of temperature, humidity and pathological changes. Hence such in-vitro methods 
cannot accurately predict lung deposition. Differences in relative humidity and temperature 
within the respiratory tract may also lead to a change in the size of particles. 
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Figure 2.31 (a) Anderson Cascade Impactor set for MDI. (b) Anderson Cascade Impactor 
set for DPI (Reproduced from Copley, 2008). 
 
(d) Next Generation Impactors: 
The Next Generation Impactor has been designed specifically for pharmaceutical inhaler 
testing (Figure 2.32). This impactor has seven stages and is intended to operate at any 
inhalation flow between 30 and 100 L min-1. 
The cut-off size ranges from 0.54 µm to 11.7 µm aerodynamic diameter at 30 L min-1 and 
0.24 µm to 6.12 µm at 100 L min-1. The NGI has several features to enhance its utility for 
inhaler testing: 
1. Particles deposited on collection cups are held in a tray from the impactor as a single 
unit, facilitating quick sample turn-around times if multiple trays are used.  
2. The user can add up to approximately 40 ml of an appropriate solvent directly to the 
cups for more efficient drug recovery.  
3. The Micro-orifice Collector (MOC) captures, in its collection cup, extremely small 
particles normally collected on the final filter of other impactors. The particles captured in 
the MOC cup can be analyzed in the same manner as the particles collected in the other 
impactor stage cups.  
(a) (b) 
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Figure 2.32 Next Generation Impactor (Reproduced from Copley, 2008). (a) NGI 
including preseparator and induction port. (b) NGI (open view) showing nozzles & 
collection cups. (c) NGI (open view) showing cup tray removed. (d) Collection cups 
showing typical deposition pattern.  
 
2.5.3.3 Principles of operation of the cascade impactors: 
Cascade impactors operate on the principle of inertial impaction. Each stage of the 
impactor comprises a single or series of nozzles or jets, as shown in Figure 2.33, through 
which the sample laden air stream is drawn directing any airborne particles towards the 
surface of the collection plate for that particular stage. Whether a particular particle 
impacts on that stage is dependent on its aerodynamic particle size. Particles having 
sufficient inertia will impact on that particular stage collection plate, whilst smaller 
particles with insufficient inertia will remain entrained in the air stream and pass to the 
next stage where the process is repeated. 
(a) 
(b) 
(c) (d) 
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Figure 2.33 Principal of Cascade impactors operation (Reproduced from Copley, 2008). 
 
The stages are assembled in a stack, in order of decreasing particle size. As the jets get 
smaller, the air velocity increases and finer particles are collected. Any remaining particles 
are collected on a final filter. At the end of the test, the particle mass relating to each stage 
collection plate is recovered using a suitable solvent and then analysed usually using 
HPLC to determine the amount of active drug actually present. 
By analysing the amount of drug deposited on the various stages in this manner, it is then 
possible to calculate the Fine Particle Dose (FPD) and Fine Particle Fraction (FPF) and 
following further manipulation, the Mass Median Aerodynamic Distribution (MMAD) and 
Geometric Standard Deviation (GSD) of the active drug particles collected. 
The term ‘impactor’ is generally used for an instrument where the particles ‘impact’ on a 
dry impaction plate or cup. If the collection surface is liquid, as in the case of the multi 
stage liquid impinger, then the term ‘impinger’ is used. The general principles of inertial 
impaction apply to both ‘impactors’ and ‘impingers’ 
In some instances, particles may bounce in response to impact when they contact the 
collection plate, in which case they are normally re-entrained into the air stream and 
carried to a lower stage. This can be a particular problem with a DPI and certain MDIs 
(where measurements are based on a limited number of actuations from the inhaler). This 
tendency may be avoided by coating the collection plate with a suitable surface coating 
 82 
(Allen, 1990). Also particle deposition on impactor parts other than the collection plates is 
called ‘Inter-stage Losses’ (Kamiya et al., 2004). 
2.5.3.4 In-vitro characterisation of the dose emitted from a Nebuliser: 
For the in-vitro characterisation of the dose emitted from a nebuliser, the European 
Respiratory Society Nebuliser Guidelines were published to standardise nebuliser 
performance and therapy (Boe et al., 2001). These guidelines recommend the Comité 
Européen Normalisation (CEN) method to measure the aerodynamic particle size of the 
dose emitted from a nebuliser (Boe et al., 2001; Comité-Européen-Normalisation., 2001). 
This in-vitro method uses the Marple 298X Cascade Impactor, which is shown in Figure 
2.34, because it is operated at low flows that correspond close to that of a normal sinus 
breathing inhalation flow. However the sampling of a limited fraction of the emitted dose 
due to the limited loading capacity of the cascade stages, filter fitting (and availability), 
desorption problems and its suitability for operation with drug formulations may each 
affect assessments (Jauernig et al., 2002; Jauernig et al., 2004). Also it has been shown that 
when using the Marple Impactor only 13% of the aerosol emitted is sampled (Jauernig et 
al., 2004). This impactor has 8 stages and a final filter. The stages have effective cut-off 
diameters of 21.3, 14.8, 9.8, 6.0, 3.5, 1.55, 0.93 and 0.52 µm respectively, at the 
recommended flow of 2 L min-1.  
 
Figure 2.34 The Marple 298X Cascade. 
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As previously described; the NGI has been introduced for the determination of the 
aerodynamic particle size distribution of the dose emitted from metered dose and dry 
powder inhalers using compendial procedures (United States Pharmacopeia, 2005; British 
Pharmacopoeia, 2005a). The methodology was calibrated to work with a flow range of 30-
100 L min-1 and later at 15 L min-1 for nebulisers (Marple et al., 2004b). The cut-off 
diameters of the stages at 15 L min-1 flow were 14.1, 8.61, 5.39, 3.3, 2.08, 1.36 and 0.98. 
Studies have assessed the use of the NGI without the preseparator, with a filter in or after 
the Micro-Orifice Collector (MOC) [Figure 2.35] to collect any extra-fine particles that 
would bypass this component (Marple et al., 2004a; Berg et al., 2007) and with cooling the 
NGI either in a water bath (Jauernig et al., 2003) or refrigerator at 5oC for 90 minutes 
before use (Berg and Asking, 2004; Berg et al., 2007). A consortium of pharmaceutical 
companies was formed in 2002 (the EPAG group–European Pharmaceutical Aerosol 
Group) to investigate the NGI at a flow of 15 L min-1 in compliance with the CEN 
recommendations for nebulisers, and sampling the whole air stream leaving the Nebuliser. 
 
Figure 2.35 (a) Electrostatic filter holder placed after the MOC. (b) MOC with the internal 
filter holder. (Reproduced from Copley, 2008) 
 
2.5 β2-adrenergic drugs: 
The β-receptor is a glycoprotein embedded in the plasma membranes of a number of cell 
types. Three distinct subtypes of β-receptors are now known, β1, β2, and β3, found 
predominately in cardiac muscle, airway smooth muscle and adipose tissue, respectively 
(a) (b) 
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(Sears and Lotvall, 2005). Following β2-adrenoceptor activation, the β2-receptor induces 
cyclic AMP to produce an intracellular signaling which mainly produces airway relaxation 
through phosphorylation of muscle regulatory proteins and modification of cellular Ca2+ 
concentrations (Johnson, 2001; Sears and Lotvall, 2005; Thirstrup et al., 1997). As shown 
in Figure 2.36; β2-agonists have been categorized into those which directly activate the 
receptor (salbutamol and terbutaline), those, which are taken up into a membrane depot 
(formoterol) from which it is thought they progressively leach out to interact with the β2-
receptors and those, which interact with a receptor-specific, auxiliary binding site and 
remains in the outermost monolayer, and slowly diffuses from the membrane (salmeterol) 
(Sears and Lotvall, 2005; Waldeck, 2002). These differences in mechanism of action are 
reflected in the kinetics of airway smooth muscle relaxation and bronchodilatation in 
asthmatic patients. A number of polymorphisms of the β2-receptor have been described 
which appear to alter the behavior of the receptor, including a degree of downregulation 
(which produce tolerance to the β2-agonists) and response to β2-agonists (Brodde et al., 
2002; Johnson, 2001; Sears and Lotvall, 2005). 
 
Figure 2.36 Diagrammatic representation of the diffusion microkinetic hypothesis. 
[reproduced from Anderson (1993)] 
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β2-agonists and corticosteroids are the standard drugs routinely used in the management of 
asthma. β2-agonists have been shown to be effective for the protection against exercise-
induced bronchoconstriction (Vilsvik et al., 2001) and preferably administered by 
inhalation to deliver the drug directly to the desired site of action. Short acting inhaled β2-
agonists such as salbutamol and terbutaline are the initial drug of choice for acute 
bronchospasm because of their immediate bronchodilatation effect.  
The first β-agonist introduced to treat the symptoms of asthma was isoprenaline 
(isoproternol), which was a non selective β-agonist. Its use was subsequently discontinued 
in favour of more selective β2-agonists because of the epidemic morbidity and mortality in 
asthmatic patients associated with the use of non selective β-agonists such as isoprenaline 
in the 1960s (Pearce et al., 1991). But even the selective β2-agonists had a second epidemic 
morbidity (Crane et al., 1989; Pearce et al., 1990; Grainger et al., 1991; Pearce et al., 1991; 
Pearce et al., 1995). It occurred in New Zealand and Canada in the late 1970s to 1980s 
associated with the use of the long acting β2-agonist fenoterol (Pearce et al., 1995) and the 
same results in Canada and Japan for salbutamol (Spitzer et al., 1992; Beasley et al., 1998). 
However, an analysis of the deaths in the New Zealand study could not identify such a risk 
of using β2-agonists other than fenoterol (Pearce et al., 1995). The meta-analysis of the 
accumulated data to 1992 concluded that the increase in morbidity due to β2-agonists was 
slight and doubtful (Mullen et al., 1993). Since the last epidemic, the doses of β2-agonists 
have fallen, selective short acting agonists have became more preferred, and even the 
frequency of administration has changed especially for the long acting β2-agonists whilst 
regular administration of the majority has changed to administration as required. 
2.5.1. Terbutaline Sulphate: 
Terbutaline sulphate is a synthetic resorcinol derivative β2-adrenergic agonist that is used 
as a bronchodilator in the treatment of asthma. It was first introduced in 1970s (Sears and 
Lotvall, 2005; Waldeck, 2002). 
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Its Molecular Weight is 548.658 and its empirical formula is (C12H19NO3)2.H2SO4. Its 
chemical name is [(1RS)-1-(3,5-Dihydroxyphynyl)-2-(tert-butylamino)-ethanol] sulphate 
(2:1 salt) (British Pharmacopoeia, 2005b). Figure 2.37 shows the molecular structure of 
terbutaline sulphate. 
N
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Tebutaline Sulphate M.W.548.658 C24H40N2O10S
 
Figure 2.37 Molecular structure of terbutaline sulphate. 
 
It is a hydrophilic white to grey-white crystalline powder, odourless or with a faint odour 
of acetic acid, soluble in water and 0.1N-hydrochloric acid, insoluble in chloroform, 
slightly soluble in methanol (United States Pharmacopeia, 2002).  
The commercially available terbutaline sulphate is a racemic mixture. Its melting point 
range differs according to the crystal type, as there are two types of the crystal form. 
Crystal form A has a melting point range from 268 oC to 271 oC, and the crystal form B has 
a melting point range from 258 oC to 260 oC (Analytical Profiles, 1990).  
Terbutaline sulphate is present in many dosage forms (inhalation, oral solution, injection 
and tablet) for prophylactic and acute bronchodilator treatment. Many methods have been 
established to determine terbutaline in these dosage forms (Daraghmeh et al., 2002; Henze 
et al., 2001; Lv et al., 2003). 
Terbutaline Sulphate is a direct selective β2-agonist, administered as the sulphate salt for its 
bronchodilating properties in reversible airways obstruction diseases and in patients with 
COPD. It also decreases uterine contractility by relaxing the uterus smooth muscles hence 
may be used to arrest premature labour in several dosage form, even as a vaginally applied 
gel (Bulletti et al., 1997; de Moustier et al., 1997; Elliott et al., 1999; Elliott et al., 2002; 
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Smigaj et al., 1996; Sophie Thayer, 1996). However in most cases it causes pulmonary 
oedema and other cardiovascular effects to the mother. The British National Formulary 
(BNF) does not recommend its prolonged use as a maintenance treatment in premature 
labour (Martindale, 2002) because of the risk to the mother increases after 48 hours and 
there is a lack of evidence of benefit from further treatment. 
After inhalation, the bronchodilating effect of terbutaline usually begins within 5 minutes 
and last for about 3 to 4 hours. In regular use it should be inhaled as one or two doses of a 
250μg terbutaline sulphate inhalation, every 4 to 6 hours upto a maximum of 8 inhalations 
in 24 hours (Martindale, 2002). Spacers may be used with terbutaline MDIs for better lung 
deposition (Comis et al., 1993). A dry powder inhaler (DPI) delivering 500μg terbutaline 
sulphate per dose is also available, with a maximum of 4 inhalations in 24 hours. 
For oral administration the dose starts with 2.5 to 3 mg three times daily upto a maximum 
of to 5 to 6 mg three times daily, and in children the dose should be calculated with respect 
to body weight with a suggested dose of 75μg/kg. The onset of action of orally 
administrated terbutaline is about 30 minutes and its duration of action is up to 8 hours 
(Martindale, 2002). Modified release tablets are also available with a daily dose of 7.5mg 
twice daily. Severe unresponsive bronchospasm may require the administration of 
nebulised terbutaline sulphate which is available as 5 mg/2 ml terbutaline sulphate.  
2.5.2. Pharmacokinetics:  
Terbutaline sulphate is variably absorbed from the gastrointestinal tract. The resorcinol 
structure of terbutaline sulphate prevents it from being metabolised by the Catechol-O-
Methyltransferase or monoamine oxidase (Analytical Profiles, 1990; Sears and Lotvall, 
2005; Waldeck, 2002). About 60% of the absorbed dose undergoes first pass effect 
metabolism by conjugation with sulphuric acid, and some conjugation with glucuronic acid 
(in rate) in the liver and the gut wall (Martindale, 2002). Terbutaline like most other 
sympathomematics exists as a ± racemic mixture. The (-) enantiomer is the 
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pharmacologically active one. The oral bioavailability of the racemic mixture is 14.8%. 
Several studies have tried to separate the enantiomers from each other or determinate the 
concentration of each one of them in dosage forms and in biological samples (Desiderio 
and Fanali, 1995; Huynh et al., 1995; Boulton and Fawcett, 1996; Szeman et al., 1997; de 
Boer and Ensing, 1998; Lu and Cole, 1998; Kim et al., 2001a; Kim et al., 2001b; Roig et 
al., 2002; Lee and Jung, 2003). 
The Terbutaline sulphate volume of distribution is 1.6 L kg-1 (Nyberg, 1984) and it is 
excreted in the urine as an inactive conjugate and unchanged terbutaline. Its half-life is 3 to 
4 hours. There is some placental transfer and traces are delivered into the breast milk. 
Terbutaline plasma protein binding is low, 14 to 25% in contrast, binding to erythrocytes is 
more pronounced producing a erythrocyte: plasma concentration ratio of 2 to 2.5 
(Analytical Profiles, 1990). Several methods have been described for the extraction and the 
determination of terbutaline in biological samples (Borgstrom and Nilsson, 1990; Boyd D, 
1996; Croes et al., 1995; Herring and Johnson, 2000; Polettini et al., 1995; Van der Vlis et 
al., 1995; Van Vyncht et al., 1996).  
Terbutaline and other β-agonists, especially large doses, may cause fine tremors of skeletal 
muscles (particularly the hand), palpitations, tachycardia, nervous tension, headaches, 
peripheral vasodilatation and rarely muscle cramps (Waldeck, 2002). Potentially serious 
hypokalaemia has been reported after large doses especially after parental or nebulised 
administration and is potentiated by concomitant administration of corticosteroids, 
diuretics, or xanthines [e.g. theophylline] (Smith and Kendall, 1986). Potassium blood 
concentrations should therefore be monitored in severe asthma when administrating large 
doses, as hypokalaemia may lead to arrhythmias. The concomitant administration of 
terbutaline with an monoamineoxidase inhibitor (MAOIs), e.g. toloxatone, may cause a 
symptom resembling pheochromocytoma (A rare catecholamine secreting tumour of 
adrenal medulla, accompanied with hypertension, headache, palpitation, and excessive 
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sweating), and this interaction is more typical of the older, irreversible, less selective 
MAOIs (Martindale, 2002). Some inhaled powder formulation of bronchodilators 
(including terbutaline) have been found to cause tooth erosion due to their pH, which is 
below 5.5, and it was suggested that might contribute to the dissolution of the enamel 
surface of the teeth (O'Sullivan and Curzon, 1998). 
Some studies suggest that regular inhalation of a short acting β2-agonist, although it 
continues to produce bronchodilatation, increases the airway hyperresponsiveness and may 
reduce its protective effect against bronchoconstriction provoked by stimuli such as 
allergen due to tolerance and tachyphylaxis (Lipworth et al., 1998; Hancox et al., 2000). 
Also, it have been shown that enhancement of Interleukin-8 production is one of the 
pathways via which β2-adrenergic agonists can influence inflammatory responses 
(Kavelaars et al., 1997). Hence anti-inflammatory therapy such as corticosteroids is also 
required (Korn et al., 1998).  
There is an inactive prodrug of terbutaline called bambuterol (Terbutaline Bisdimethyl 
Carbamate). It is a long acting bronchodilator (at least 24 hours) because when 
administrated orally at bedtime it is slowly hydrolysed to terbutaline and carbamic acid in 
the systemic circulation. The Preliminary clinical studies have indicated that the mean 
terbutaline half-life after bambuterol ingestion is about 21 hours (Zeng et al., 1995). 
Bambuterol inhibits the plasma cholinesterase activity like salbutamol, which can be 
correlated with the prolonged action of bambuterol and its prolongation of activity of 
sympathomematics (e.g. Suxuamethonium) when co-administered with bambuterol (Staun 
et al., 1990). 
There is also another prodrug of terbutaline, which is ibuterol the diisobutyryl ester of the 
resorcinol function of terbutaline. After inhalation, ibuterol is 3-times as effective as 
terbutaline. In-vivo studies have shown that ibuterol is absorbed more rapidly than 
terbutaline, but both lung and serum terbutaline concentrations were lower after inhaled 
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ibuterol administration than those obtained after the administration of the free terbutaline, 
indicating that the prodrug acts as a reservoir releasing parent drug over a prolonged period 
(Andersson, 1976). 
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3.1 Introduction 
The use of pharmacokinetic methods to identify the relative lung and systemic 
bioavailability of inhaled drugs require a sensitive, reliable and robust assay for the drug in 
samples of any body fluid. Traditional high performance liquid chromatography is used 
with solid phase extraction to isolate the drug from a body fluid matrix. 
Recently, Mazhar and Chrystyn (submitted for publication) have modified the reversed-
phase ion-pair HPLC assay for salbutamol in the urine, previously published by Hindle and 
Chrystyn (1992). The aim of the work in this section was to adapt this recent method of 
Mazhar and Chrystyn to develop a sensitive, robust and reliable HPLC assay for the 
determination of terbutaline concentrations in aqueous samples for  in-vitro testing of 
inhaled products and urine samples collected from subjects following terbutaline inhalation 
and oral administration. 
3.2 Analysis of terbutaline sulphate in aqueous samples 
The reversed-phase HPLC method, for the terbutaline sulphate, was based on the assay 
developed by Mazhar and Chrystyn (submitted for publication) for the determination of 
salbutamol in aqueous samples. The mobile phase used was buffer : acetonitrile (75:25), 
the buffer was 5mM potassium dihydrogen orthophosphate buffer adjusted to pH 2.5, with 
orthophosphoric acid. A constant flow-rate of 1 ml min-1 was used with florescence 
detector was set at an excitation/emission of 267/313 nm. An operating temperature of 
30oC was used throughout the analysis using a column chiller model 7950 (Jones 
Chromatography, UK).  
3.2.1 Materials 
3.2.1.1 Standards   
Terbutaline sulphate: HPLC grade; Sigma (UK). 
Bamethane sulphate: HPLC grade; Sigma (UK). 
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3.2.1.2 Mobile phase 
Acetonitrile: HPLC grade; Fisher Scientific (UK). 
Water: Highly purified double distilled water 
Potassium dihydrogen orthophosphate: Analytical grade; BDH (Poole, UK). 
3.2.1.3 HPLC conditions 
Stationary phase: Spherisorb, ODS1, column 5µm 4.6 x 250mm, C-18 (Water 
Chromatography, UK). 
Mobile phase: Buffer : acetonitrile (75:25), the buffer was 5mM potassium 
dihydrogen orthophosphate buffer adjusted to pH 2.5, with 
orthophosphoric acid. The mobile phase was filtered through a 
45mm membrane filter (Millipore, Whatman Ltd, UK) and degassed 
under vacuum in an ultrasonic bath for 10 minutes prior to use. 
Internal standard: Bamethane sulphate 300μg L-1 
Flow rate: 1 ml min-1 
Pump: Gilson model 307 
Injector: Shimadzu Corporation SIL-9A Liquid Chromatography 
Automatic Sample Injector fitted with a 200µl loop 
Detector: Shimadzu RF-551 fluorescence detector, set at an 
excitation/emission of 267/313 nm. 
Integrator: Shimadzu C-R6A Chromoatopac 
Temperature: 30oC using a column chiller model 7950 (Jones Chromatography, 
UK). 
3.2.1.4 Standards 
Aqueous stock solutions of terbutaline sulphate 1000 mg L-1 (w/v) were prepared and 
stored below –20oC. From the terbutaline sulphate stock solution, working standards were 
prepared by serial dilution to yield nominal terbutaline sulphate concentrations of 10, 25, 
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50, 100, 200, 300, 400, 500, 600, 700 and 800μg L-1 (w/v). Working solutions were stored 
below –20oC in well closed, light resistant containers prior to analysis. Stability studies 
over 21 days of storage at –20oC, 15 days at room temperature and through three thawing 
cycles showed no significant change in the analyte concentration. 
3.2.2 Calibration 
Calibration curves were performed using eleven terbutaline sulphate standards between 
10µg L-1 and 800µg L-1 with 300μg L-1 bamethane as an internal standard. Three injections 
were performed for each terbutaline sulphate standard. The peak height ratio of terbutaline 
sulphate and bamethane was plotted against the concentration of the terbutaline sulphate 
standard. A straight line was fitted to the data using linear regression. A representative 
plot, described by the equation y = 0.012x + 0.0086 (r2=0.9989) is shown in Figure 3.1. 
Representative chromatograms are shown in Figure 3.2. The detector response was shown 
to be linear over the range of 10 to 800μg L-1 of terbutaline sulphate in aqueous samples 
containing 300μg L-1 of bamethane with correlation coefficients of 0.9995. 
R2 = 0.9989
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Figure 3.1 A representative calibration curve of the peak height ratio of terbutaline 
sulphate and bamethane against the concentration of terbutaline sulphate. 
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Figure 3.2 Chromatograms obtained from the analysis of the aqueous standard samples 
containing (a) 50, (b) 100 and (c) 200μg L-1 terbutaline sulphate, and 300μg L-1 bamethane 
represented as a, b and c, respectively. 
 
Representative chromatographic parameters are shown in Table 3.1. The results are 
expressed as the mean (SD) from 10 samples. 
 
Table 3.1 Chromatographic parameters for aqueous standards, (n=10) 
Parameter Mean (SD) 
Rt ter (min) 
Rt bam (min) 
6.0 (0.03) 
9.0 (0.06) 
k’ ter 
k’ bam 
2.8 (0.05) 
4.6 (0.07) 
α (ter/bam) 1.5 (0.03) 
R (ter/bam) 4.2(0.3) 
N 14270.1(235.5) 
 
Where Rt is retention time, k’ is capacity factor, α is the separation factor, R is resolution 
and N is number of theoretical plates. 
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3.2.3 Precision 
This is a measure of the distribution of individual measurements around the mean. This 
parameter is generally assessed by repeated analysis of the same solution and expressed as 
the Relative Standard Deviation (RSD) otherwise known as the Coefficient of Variation 
(CV). The lower the value the better is the assay performance. Three concentrations (low 
50, medium 300 and high 700μg L-1) within the linear range 10 - 800μg L-1 were used to 
examine the precision of the method. Twenty five chromatographs for each of the three 
selected terbutaline sulphate concentrations were obtained; five chromatographs each day 
for five days. Intra-day and inter-day variations, expressed as the coefficient of variation in 
peak height ratio, were calculated by dividing the standard deviation of the calculated 
concentrations by the mean concentration and multiplying by hundred. The mean (SD) 
intra-day assay variability, determined for the three standard concentrations of terbutaline 
sulphate on five occasions, was 2.8 (0.2) %. The inter-day assay variability, determined at 
the same three concentrations, using five replicate runs on different days was 4.5 (0.1) %. 
The results are shown in Table 3.2. 
 
Table 3.2 Precision of the assay. 
Nominal Concentration 
(µg L-1) 
Intra-day Coefficient of 
variation (%) 
Inter-day Coefficient of 
variation (%) 
50 (n=25) 2.6 4.5 
300 (n=25) 2.9 4.6 
700 (n=25) 2.9 4.4 
Mean±SD (n=75) 2.8 ± 0.2 4.5 ± 0.1 
 
3.2.4 Accuracy 
This is a measure of how close is the observed value to the actual value. The accuracy of 
the assay was calculated by comparison of the nominal terbutaline sulphate concentration 
to the actual concentration obtained from the linear regression line within the concentration 
range investigated (10 to 800μg L-1). Twenty five chromatographs for each of the three 
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selected terbutaline sulphate concentrations were preformed; five chromatographs each day 
for five days. The results are shown in Table 3.3. 
 
Table 3.3 Accuracy of the assay 
Nominal Concentration 
(µg L-1) 
Mean±SD µg L-1 of measured 
Concentration (n=5) 
Mean±SD % of measured 
Concentration (Accuracy, n=5) 
Intra-assay variation 
50 (n=25) 51.3 ± 0.3 97.5 ± 0.7 
300 (n=25) 285.8 ± 3.2 95.3 ± 1.1 
700 (n=25) 676.5 ± 8.2 96.7 ± 1.2 
Mean±SD (n=75) 96.5 ± 1.1  
Inter-assay variation 
50 (n=25) 50.1 ± 1.4 99.7 ± 2.8 
300 (n=25) 293.7 ± 9.2 97.9 ± 3.1 
700 (n=25) 660.9 ± 9.2 94.4 ± 1.3 
Mean±SD (n=75) 97.4 ± 2.7 
 
3.2.5 Detection and quantitation limits 
According to the ICH and FDA guidelines, to determine the lower limit of quantitation 
(LLOQ) and the limit of detection (LOD) a method based on the signal-to-noise approach 
and a method based on the standard deviation of the response and the slope (liner 
regression line method) are used.  
According to the method based on the signal-to-noise approach, the limit of detection 
(LOD) is the lowest concentration of analyte that can be detected but not quantified and it 
should be a value greater than 3:1 for the signal to noise ratio. The lower limit of 
quantitation (LLOQ) is the lowest concentration of analyte that can be measured with 
acceptable precision and accuracy by the assay and it should be a value greater than 10:1 
for the signal to noise ratio. The limit of detection (LOD) and the lower limit of 
quantitation (LLOQ) can be calculated from the mean of the slope and SD of the intercept 
of five calibration curves using the linear regression line method. The LOD is equal to 3.3 
multiplied by the SD of the intercept of the linear regression line divided by its slope. The 
LLOQ is equal to the 10 multiplied by SD of the intercept of the linear regression line 
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divided by its slope. The linear regression line method was used here to determine LOD 
and LLOQ. The LOD and LLOQ of terbutaline sulphate with a 50 μl injection volume 
were 10.9μg L-1 and 33.1μg L-1, respectively. 
3.2.6 Summary of the aqueous HPLC assays 
The reversed-phase HPLC assay developed by Mazhar and Chrystyn (submitted for 
publication) for the determination of salbutamol in aqueous samples may also be used to 
determine the concentration of terbutaline sulphate in aqueous samples. The assay has 
acceptable limits for both accuracy and precision and has been successfully used to analyze 
samples from this study, and other subsequent studies. This assay is simple, sensitive 
(LLOQ is 33.1μg L-1) and suitable for routine studies. Automatic injection allows up to 
120 samples to be analyzed in one day. 
3.3 Analysis of terbutaline in urine samples 
Recently, Mazhar and Chrystyn (submitted for publication) also developed a reversed-
phase ion-pair HPLC assay for salbutamol in urine, where terbutaline and bamethane were 
used as the internal standards. Bamethane and terbutaline have a similar chemical structure 
to salbutamol as shown in Figure 3.3. Bamethane does not have the CH2OH on carbon 
number 3 of the phenyl group of salbutamol and has a different aliphatic group linked to 
the nitrogen atom. Terbutaline has an OH in place of the CH2OH and the position of the 
other OH is different. These differences result in different retention times.  
 
Figure 3.3 The chemical structure of terbutaline, salbutamol and bamethane. 
 
The original method by Mazhar and Chrystyn has been used to develop a sensitive, robust 
and reliable HPLC assay for the determination of terbutaline concentrations in urine 
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samples following oral and inhaled administration. Hence, this determination could be 
used to study the relative deposition of terbutaline in the lung. The mobile phase was 
acetonitrile : methanol : tetrahydrofuran : ethyl acetate : buffer 5:5:5:5:80% v/v. The buffer 
was of 40mM phosphate buffer and 27.5mM sodium dodecyl sulphate adjusted to pH 6.75 
using 10mM KOH. The mobile phase was filtered through a 45 mm membrane filter 
(Millipore) and degassed under vacuum in an ultrasonic bath for 10 minutes prior to use. A 
constant flow-rate of 1 ml min-1 was used with florescence detector was set at an 
excitation/emission of 267/313 nm. An operating temperature of 30oC was used throughout 
the analysis using a column chiller model 7950 (Jones Chromatography, UK). 
3.3.1 Materials 
3.3.1.1 Standards 
Terbutaline sulphate: HPLC grade; Sigma (UK). 
Bamethane sulphate: HPLC grade; Sigma (UK). 
Salbutamol sulphate: HPLC grade; Sigma (UK). 
3.3.1.2 Mobile phase 
Acetonitrile: HPLC grade; Fisher Scientific (UK). 
Water: Highly purified double distilled water 
Methanol: HPLC grade; Fisher Scientific (UK). 
Tetrahydrofuran: HPLC grade; Fisher Scientific (UK). 
Ethyl acetate: HPLC grade; Fisher Scientific (UK). 
Potassium hydroxide: Analytical grade; Sigma (UK). 
sodium dodecyl sulphate: Analytical grade; BDH (Poole, UK). 
Potassium dihydrogen orthophosphate: Analytical grade; BDH (Poole, UK). 
3.3.1.3 HPLC conditions 
Column: ODS 5μm, 4.6 x 250mm, Zorbax C-18 (Agilent Technology, 
Phenomenex, UK). 
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Pre-column:  4mm x 3 mm; C-18 ODS (Phenomenex, UK) 
Mobile phase: acetonitrile : methanol : tetrahydrofuran : ethyl acetate : buffer 
5:5:5:5:80% v/v. The buffer was of 40mM phosphate buffer and 
27.5mM sodium dodecyl sulphate adjusted to pH 6.75 using 
10mM KOH. The mobile phase was filtered through a 45mm 
membrane filter with a pore size of 0.45µm (Nylaflo, Pall 
corporation, UK) and degassed under vacuum in an ultrasonic 
bath for 10 minutes prior to use. 
Flow rate: 1 ml min-1 
Pump: Gilson model 307 
Injector: Shimadzu Corporation SIL-9A Liquid Chromatography 
Automatic Sample Injector fitted with a 200µl loop 
Detector: Shimadzu RF-551 fluorescence detector, set at an 
excitation/emission of 267/313 nm. 
Integrator: Shimadzu C-R6A Chromoatopac 
Temperature: 30oC using a column chiller model 7950 (Jones Chromatography, 
UK). 
3.3.1.4 Standards 
Aqueous stock solutions of terbutaline 1000 mg L-1 (w/v) equivalent to 1217.7 mg L-1 
terbutaline sulphate were prepared and stored below -20oC. From the terbutaline stock 
solution, working standards were prepared by serial dilution using pooled urine collected 
from five (two female) volunteers to yield nominal terbutaline concentrations of 10, 25, 50, 
100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 and 1200μg L-1 (w/v). Working 
solutions were stored below –20oC prior to analysis. Stability studies over 15 days at room 
temperature, 21 days of storage at –20oC, and through three thawing cycles showed no 
significant change in analyte concentration.  
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3.3.4 Solid phase extraction 
HPLC is a good separation and quantification method, however urine cannot be directly 
injected into the HPLC column because it contains many endogenous compounds that can 
either block the column or may interfere with the chromatogram of the analytes. A pre 
treatment step is therefore required to remove these endogenous compounds. Solid Phase 
extraction (SPE) is a technique in which the biological liquid sample is passed through a 
sorbent bed to retain the analyte followed by flushing with different solvents to remove any 
interfering compounds. The method used is optimized so that the analyte remains on the 
column until the end when it is eluted free of endogenous compounds.  
3.3.4.1 Extraction of unchanged terbutaline from urine samples - pre hydrolysis 
extraction 
A solid-phase extraction method using Isolute HCX Cartridges (International Sorbent 
technology, U.K.) was developed by Mazhar and Chrystyn (submitted for publication) to 
extract salbutamol, terbutaline and bamethane from urine. The amino group of these three 
compounds is linked to the sulphonic acid group on the sorbent bed. A pretreated sample 
was prepared by adding 1 ml of urine, 1 ml of aqueous solution of 500μg L-1 (w/v) 
bamethane and/or 300μg L-1 (w/v) salbutamol as internal standards as appropriate and 2 ml 
of 30mM potassium dihydrogen phosphate. This was adjusted (if necessary) to pH 7 (using 
10mM KOH) and mixed well for 30 seconds. Each Isolute Cartridge was conditioned with 
1 ml methanol followed by 1 ml of 15mM potassium dihydrogen phosphate (pH 7). The 
pretreated sample was then applied to the cartridges followed by the addition of 1 ml of 
15mM potassium dihydrogen phosphate (pH 7). The cartridge was then washed with 2 ml 
of 0.00001 N hydrochloric acid (pH 5) followed by a vacuum for 2 minutes, then 1 ml of 
0.005 N hydrochloric acid (pH 2.5) was eluted through each cartridge using low vacuum 
(less than 3 bar) followed by drying for 5 minutes using vacuum drying. The cartridge was 
washed with 1.5 ml of 75% methanol and again dried by applying a full vacuum for 5 
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minutes. The interaction between the analytes and the sorbent bed was then broken by 
increasing the pH of the column. Hence, the analyte was eluted from the cartridge into a 
sample tube using 1 ml of 0.54 % (v/v) ammonia in methanol with the application of a low 
vacuum (less than 3 bars). After evaporation to dryness using a sample concentrator 
(Techne, USA) set at 65oC with a stream of nitrogen for 15 min, the residue was 
reconstituted in 1 ml mobile phase and 100μl was injected into the HPLC system. 
3.3.4.1.1 Pre hydrolysis sample extraction 
Solid phase extraction cartridge:  Isolute HCX 130mg 10ml XL cartridge, 
International Sorbent Technology, UK. 
Nitrogen cylinder BOC gases, UK 
Extraction station VAC-ELUT 10 manifold (Varian Limited, UK) 
Sample concentrator DRI-BLOCK DB-3A, Temperature range ambient 5°C to 
200°C. (Techne, USA). 
Water: Highly purified double distilled water 
Potassium dihydrogen orthophosphate: Analytical grade; BDH (Poole, UK). 
Methanol: HPLC grade; Fisher Scientific (UK). 
Hydrochloric acid: Analytical grade; BDH (Poole, UK). 
Ammonia solution 33%: Analytical grade; BDH (Poole, UK). 
Potassium hydroxide: Analytical grade; Sigma (UK). 
3.3.4.2 Extraction of unchanged terbutaline and the terbutaline sulphate ester 
metabolite from urine samples - post hydrolysis extraction 
Terbutaline is excreted in the urine as an unchanged molecule and its sulphate ester. The 
latter is not extracted by the solid phase method described above. To quantify the sulphate 
ester the conversion to terbutaline base by acid hydrolysis is required. 
A solid-phase extraction method using Oasis HLB 30mg cartridges (Water 
Chromatography, UK) has been developed by Mazhar and Chrystyn (submitted for 
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publication) to extract salbutamol, terbutaline and bamethane from urine. A pretreated 
sample was prepared by adding 1 ml of urine, 1 ml of aqueous solution of 500μg L-1 (w/v) 
bamethane and/or 300μg L-1 (w/v) salbutamol as internal standards as appropriate and 8ml 
of 0.1N HCl in a test tube. The mixture was vortexed, covered with aluminium foil, boiled 
in a water bath at 100oC for 1 hour and then cooled. 1 ml of 0.5M potassium dihydrogen 
phosphate pH 13.0 was then added to the mixture. This was adjusted (if necessary) to pH 
6.5-7.2 using 10mM KOH. The final solution was mixed well for 30 seconds. Each HLB 
cartridge was conditioned with 2 ml methanol followed by 2 ml of 45mM potassium 
dihydrogen phosphate solution (pH 7). The pretreated sample was then applied to the 
cartridges followed by the addition of 2 ml of 15mM potassium dihydrogen phosphate (pH 
7) followed by a vacuum drying for 2 minutes. The cartridge was then washed with 1 ml of 
5% (v/v) methanol followed by vacuum drying for 1 minute, then 1 ml of 2% (v/v) 
acetonitrile followed by vacuum drying for another 1 minutes. The cartridge was then 
washed with 1 ml of 0.25% (v/v) tetrahydrofuran followed by vacuum drying for 1 minute. 
The analyte was then eluted from the cartridge into a sample tube using 2 ml of acetic acid 
2% (v/v) with a low vacuum (less than 3 bars). After evaporation to dryness using a sample 
concentrator (Techne, USA) set at 125oC with a stream of nitrogen for 30 min, the residue 
was reconstituted in 1 ml mobile phase and 100μl was injected into the HPLC system. 
3.3.4.2.1 Post hydrolysis sample extraction 
Solid phase extraction cartridge: Oasis HLB 30mg, Water Chromatography, UK. 
Column reservoir: 25 ml column reservoir, IST Ltd., Wales, UK. 
Sample concentrator DRI-BLOCK DB-3A, Temperature range ambient 5°C to 
200°C. (Techne, USA). 
Nitrogen cylinder BOC gases, UK 
Extraction station VAC-ELUT 10 manifold (Varian Limited, UK) 
Potassium dihydrogen orthophosphate: Analytical grade; BDH (Poole, UK). 
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Methanol: HPLC grade; Fisher Scientific (UK). 
Tetrahydrofuran: HPLC grade; Fisher Scientific (UK). 
Hydrochloric acid: Analytical grade; BDH (Poole, UK). 
Acetic acid: Analytical grade; BDH (Poole, UK). 
Acetonitrile: HPLC grade; Fisher Scientific (UK). 
Water: Highly purified double distilled water 
3.3.4.2.2 Acid hydrolysis of sulphate ester conjugates 
Potassium hydroxide: Analytical grade; Sigma (UK). 
Hydrochloric acid: Analytical grade; BDH (Poole, UK). 
3.3.5 Calibration 
Calibration curves were performed using fourteen urine standard samples containing 
terbutaline standards between 10µg L-1 and 1200µg L-1 with 300μg L-1 salbutamol and 
500μg L-1 bamethane as the internal standards. Three injections were performed for each 
terbutaline standard. The peak height ratios of terbutaline and bamethane or salbutamol 
(internal standards) were plotted against the concentration of the terbutaline standards. A 
straight line was fitted to the data using linear regression. A representative plot, described 
by the equation y = 0.003x + 0.1031 (r2=0.9983) was obtained using bamethane as the 
internal standard and y = 0.0031x + 0.0643 (r2=0.9994) using salbutamol. The calibration 
curves are presented in Figure 3.4 and 3.5, respectively and representative chromatograms 
are shown in Figure 3.6 and 3.7. The detector response was shown to be linear over the 
urinary terbutaline concentration range of 50 to 1200μg L-1 using bamethane and 
salbutamol as internal standards with correlation coefficients of 0.9992 and 0.9997, 
respectively. 
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Figure 3.4 A representative calibration curve of the peak height ratio of terbutaline and 
bamethane against the concentration of terbutaline. 
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Figure 3.5 A representative calibration curve of the peak height ratio of terbutaline and 
salbutamol against the concentration of terbutaline. 
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Figure 3.6 Pre-hydrolysis chromatograms obtained from the analysis of (a) an extracted 
blank urine sample (b) a standard urine sample containing 400μg L-1 terbutaline, 300μg L-1 
salbutamol and 500μg L-1 bamethane (c) a volunteer urine sample 0–0.5 hour post 
inhalation of 2 doses of 250 µg terbutaline sulphate from Bricanyl MDI and (d) the same 
volunteers urine sample 0–0.5 hour post oral dose of 500 µg terbutaline sulphate using pre-
hydrolysis sample extraction method. 
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Figure 3.7 Post-hydrolysis chromatograms obtained from the analysis of (a) an extracted 
blank urine sample (b) a standard urine sample containing 400μg L -1 terbutaline, 300μg L-1 
salbutamol and 500μg L-1 bamethane (c) a volunteer urine sample 0–0.5 hour post 
inhalation of 2 doses of 250 µg terbutaline sulphate from Bricanyl MDI and (d) the same 
volunteers urine sample 0–0.5 hour post oral dose of 500 µg terbutaline sulphate using 
post-hydrolysis sample extraction method. 
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Representative chromatographic parameters are shown in Table 3.4. The results are 
expressed as mean (SD) from 10 samples. 
 
Table 3.4 Chromatographic parameters for the HPLC method, (n=10). 
Parameter Mean (SD) 
Rt sal (min) 
Rt ter (min) 
Rt bam (min) 
11.0 (0.1) 
14.0 (0.11) 
34.0 (0.2) 
k’ ter 
k’ ter 
k’ bam 
5.3 (0.04) 
7.0 (0.13) 
18.3 (0.36) 
α (ter/sal) 
α (ter/bam) 
1.3 (0.1) 
2.4 (0.2) 
R (ter/sal) 
R (ter/bam) 
2.0 (0.2) 
10.5 (0.5) 
N 5302.4(125.5) 
 
Where Rt is retention time, k’ is capacity factor, α is the separation factor, R is resolution 
and N is number of theoretical plates. 
3.3.6 Recovery 
The recovery was calculated by comparing the peak height of the extracted urine standards 
with the peak height of blank urine spiked with aqueous standards of terbutaline. Three 
concentrations (low 100, medium 500 and high 1000μg L-1) over the linear range 50 - 
1200μg L-1 were used to examine the recovery of the method. Four extractions from urine 
containing the above concentration of terbutaline provided a mean (SD) recovery of 
92.7(1.5), 95.9(1.4) and 94.4(1.6) %, respectively. Overall combining all results the mean 
(SD) absolute recovery of terbutaline from urine, using this method, was 94.3 (1.6) %. 
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3.3.7 Precision 
The same three concentration levels (low 100, medium 500 and high 1000μg L-1) over the 
linear range 50 - 1200μg L-1 were used to examine the precision of the method. Twenty 
five chromatographs for each of the three selected terbutaline concentrations were 
preformed. Five chromatographs each day for five days. The intra-day and inter-day 
variation, expressed as the coefficient of variation in peak height ratio, were calculated by 
dividing the standard deviation of the calculated concentrations by the mean concentration 
and multiplying by hundred. The overall mean (SD) intra-day assay variability, determined 
for the three standard concentrations of terbutaline on five occasions using bamethane as 
the internal standard, was 7.1 (4.0) %. The inter-day assay variability, determined at the 
same three concentrations using five replicate runs on different days, was 12.0 (5.2) %. 
With salbutamol as the internal standard intra and inter-day assay variability was 6.0 (2.3) 
% and 9.9 (2.5) %, respectively. The results are shown in Table 3.5. 
 
Table 3.5 Precision of the assay, (n=75). 
Nominal 
Concentration 
(µg L-1) 
Bamethane as internal standard Salbutamol as internal standard 
Intra-day 
Coefficient of 
variation (%)  
Inter-day 
Coefficient of 
variation (%) 
Intra-day 
Coefficient of 
variation (%) 
Inter-day 
Coefficient of 
variation (%) 
100 (n=25) 11.5 12.4 8.6 8.0 
500 (n=25) 5.9 6.5 4.6 9.1 
1000 (n=25) 3.8 16.9 4.7 12.7 
Mean±SD 
(n=75) 
7.1 ± 4.0 12.0±5.2 6.0±2.3 9.9±2.5 
 
3.3.8 Accuracy 
The accuracy of the assay was calculated by comparison of the nominal terbutaline 
concentration to the actual concentration obtained from the linear regression line over the 
concentration range investigated (50 to 1200μg L-1). The results are shown in Table 3.6. 
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Table 3.6 Accuracy of the assay, (n=75). 
Nominal 
Concentration 
(µg L-1) 
Bamethane as internal standard Salbutamol as internal standard 
Mean±SD µg L-1 
of measured 
Concentration 
Mean±SD % of 
measured 
Concentration 
(Accuracy) 
Mean±SD µg L-1 
of measured 
Concentration  
Mean±SD % of 
measured 
Concentration 
(Accuracy) 
Intra-assay variation 
100 (n=25) 107.0 ± 3.5 93.0 ± 3.5 103.2 ± 2.9 96.8 ± 2.9 
500 (n=25) 490.3 ± 11.4 98.1 ± 2.3 493.7 ± 7.3 98.7 ± 1.5 
1000 (n=25) 1049.9 ± 27 95.0 ± 2.7 1028.3 ± 26.3 97.2 ± 2.6 
Mean±SD (n=75) 95.4 ± 2.5  97.6 ± 1.0 
Inter-assay variation 
100 (n=25) 108.2 ± 8.2 91.8 ± 8.2 99.3 ± 6 99.3 ± 6 
500 (n=25) 515.9 ± 37.5 96.8 ± 7.5 511.3 ± 27.3 97.8 ± 5.5 
1000 (n=25) 968.4 ± 48 96.8 ± 4.8 1044.9 ± 29.5 95.5 ± 3 
Mean±SD (n=75) 95.1 ± 3.0  97.5 ± 1.9 
 
3.3.9 Detection and quantitation limits 
The limit of detection (LOD) and the lower limit of quantitation (LLOQ) were calculated 
from the mean of the slope and SD of the intercept of five calibration curves. The LOD and 
LLOQ for urine sample using bamethane as the internal standard were 24.2μg L-1 and 
73.4μg L-1, respectively and 20μg L-1 and 60.3μg L-1, respectively, when salbutamol was 
used as the internal standard. 
3.3.10 Summary of the urine HPLC assays 
The reversed-phase ion-pair HPLC assay that was developed by Mazhar and Chrystyn 
(submitted for publication), for the determination of urinary salbutamol may also be used 
to determine the concentration of terbutaline in urine samples post dose. The clean-up 
stage using Isolute or HLB cartridges isolated terbutaline, salbutamol and bamethane from 
urinary endogenous substances that might interfere with the assay and gave a highly, 
reproducible absolute recovery of the three compounds. The assay has good accuracy and 
precision and has been successfully used to analyze samples from this study, and other 
subsequent clinical studies. Compared with other published methods (Polettini et al., 1995; 
Roig et al., 2002), this assay is simple, sensitive (LOD is 24.2μg L-1) and suitable for 
routine clinical studies. Automatic injection allows up to 41 samples to be analyzed in one 
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day. Salbutamol can be used as the internal standard for all the volunteer samples, as it has 
shorter retention time than bamethane. For patient samples bamethane can be used as the 
internal standard as salbutamol is routinely inhaled by them. This enables routine therapy 
to be maintained when studying patients  
3.3.10 Conclusions of the urine HPLC assays 
The reversed-phase ion-pair HPLC assay developed by Mazhar and Chrystyn (submitted 
for publication), for the determination of urinary salbutamol may also be used to determine 
the concentration of terbutaline in urine samples post dose from both volunteers using 
salbutamol as the internal standard and patients using bamethane as the internal standard. 
The assay has acceptable limits for both accuracy and precision and has been successfully 
used to analyze samples from this study, and other subsequent clinical studies. The assay is 
simple, sensitive (LOD is 24.2μg L-1) and suitable for routine clinical studies. Automatic 
injection allows up to 41 samples to be analyzed in one day. 
 
 
 
 
 
 (Hindle and Chrystyn, 1992) 
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4.1 Introduction 
Consistent and reliable dosage emission from an inhaler is essential for the management of 
patients (Tarsin et al., 2004), with respect to the aerodynamic particle size distribution, the 
fine particle dose and the emitted dose. These parameters are useful to provide some 
indication of therapeutic use (Weda et al., 2004). 
The variation of the emitted dose is a very important factor that could affect the clinical 
response and side effects. The lung deposition for short acting β2 agonist and budesonide 
dry powder inhalers can vary with the inhalation flow (Newman et al., 1991; Borgstrom et 
al., 1994). Gamma scintigraphy using radiolabelled drug in an inhalation device has shown 
different total lung deposition with inhalation flows that is consistent with separate in-vitro 
analysis of the emitted dose at different flows (Newman et al., 1991; Borgstrom et al., 
1994). The Turbuhaler has previously been shown to be a device of high resistance, which 
also demonstrates in-vitro flow dependent dose emission (Ross and Schultz, 1996). Studies 
focus on inhalation flow of greater than 30 L min-1 through a DPI. However during routine 
use some patients do not achieve a minimum inhalation flow of less than 30 L min-1 
required for the delivery of the dose (Pedersen et al., 1990; Calverley et al., 2003). 
Therefore, the aim of this study was to investigate the in-vitro emitted dose and 
aerodynamic characteristics from the Bricanyl Turbuhaler at different inhalation flow from 
10 to 60 L min-1. Hence data below 30 L min-1 will be generated. 
4.2 Methods 
4.2.1 Equipment and inhalation devices 
Equipment: 
DPI sampling apparatus: Copley Scientific Ltd, UK 
Andersen MKII Cascade Impactor:  Copley Scientific Ltd, UK 
A/E fibre glass filter discs: 47mm; Pall Corporation, USA 
GF 50 filter: Copley Scientific Ltd, UK 
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GAST pump : Brook Crompton, UK 
An electronic digital flow meter: MKS Instruments, USA 
Parafilm M laboratory film: Pechiney Plastic Packaging, USA 
Silicone fluid spray:  Releasil B silicone spray, Dow Corning Limited, Barry, 
Glamorgan, UK. 
Critical flow controller model TPK: Copley Scientific Ltd, UK 
HPLC system: Previously described in section 3.2 in this thesis 
Inhaler devices: 
Bricanyl Turbuhaler: Labelled as a nominal dose of 500μg terbutaline sulphate per 
shot, AstraZeneca, UK 
4.2.2 Procedure 
4.2.2.1 Total Emitted Dose 
The emitted dose from the Bricanyl Turbuhaler (labelled as a nominal dose of 500μg 
terbutaline sulphate per shot, AstraZeneca, UK) was measured using a DPI sampling 
apparatus with a critical flow controller model TPK (Copley Scientific Ltd, UK). The basic 
methodology is described in Appendix XII F of the British Pharmacopoeia (2005), 2.9.18 
of the European Pharmacopeia (2001) and 601 of the United States Pharmacopeia (2005). 
The final filter was a 47 mm A/E fibre glass filter discs (Pall Corporation, USA). Vacuum 
flow through the apparatus was provided by a GAST pump (Brook Crompton, UK). The 
standard compendial methodology of the USP at an inhalation volume of 4 L and at 
pressure drop of 4 kPa was modified to allow determination at different flows and 
volumes. The inhalation flow through the mouthpiece of the Turbuhaler was set at 10, 20, 
30, 40, 50 and 60 L min-1 with flow-duration of 24, 12, 8, 6, 4.8 and 4 sec. respectively to 
allow an inhaled volume of 4 L of air to be drawn through the inhaler (British 
Pharmacopoeia, 2005; United States Pharmacopeia, 2005). The flow was measured by an 
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electronic digital flow meter (MKS Instruments, USA). Parafilm M laboratory film 
(Pechiney Plastic Packaging, USA) was used to seal the apparatus. 
Each inhaler was inserted tightly into the mouthpiece and aligned along the horizontal axis. 
The emitted dose from the Bricanyl Turbuhaler was measured by collecting one individual 
dose at different inhalation flows of 10, 20, 30, 40, 50 and 60 L min-1. For each 
determination the Turbuhaler was loaded to deliver a dose, according to the instructions in 
the patient information leaflet. For each inhalation flow, the emitted dose of 10 separate, 
single doses, throughout the life of each inhaler, were determined. The randomisation 
schedule used is shown in Table 4.1. Doses not required were discharged to waste using a 
flow of 90 L min-1 for a 16 second vacuum period to clean the Turbuhaler.  
 
Table 4.1 The randomization schedule for the dose numbers from the Turbuhaler inhaler 
for the dose emission determination (100 doses in the inhaler). 
Flow (L min-1) Dose Number from the inhaler 
60 2, 10, 15, 24, 38, 47, 56, 72, 78, 95 
50 13, 20, 23, 32, 40, 46, 55, 58, 73, 91, 
40 3, 14, 31, 36, 48, 57, 64, 67, 77, 92 
30 8, 16, 35, 42, 49, 59, 66, 71, 79, 93 
20 5, 21, 30, 43, 53, 60, 68, 76, 80, 90 
10 7, 17, 28, 39, 44, 54, 69, 74, 81, 89 
 
For this procedure a switching system was used to produce sonic flow conditions, as 
recommended by the Pharmacopoeial Methods, (European Pharmacopeia, 2001; British 
Pharmacopoeia, 2005; United States Pharmacopeia, 2005). For each determination only 
one dose was discharged in the DPI sampling apparatus. For each flow ten separate 
determinations were made (n=10). Following dose emission into the apparatus, the 
sampling unit was washed with 25% acetonitrile and the filter was completely submerged 
in 25% acetonitrile and then sonicated for 3 minutes (preliminary analysis revealed that 
this procedure removes all drug entrained on the filter). All the solutions were collected 
and made up to a volume of 100, 250, 250, 250, 500 and 500ml, for the flow of 10, 20, 30, 
 114 
40, 50 and 60 L min-1, respectively. The amount of drug was determined by high 
performance liquid chromatography using the previously validated method described in 
section 3.2. The total dose emitted was the amount deposited in the plastic dose sampling 
apparatus and the final filter.  
4.2.2.2 The Aerodynamic Particle Size Characterization 
All the parts of the Andersen MKII Cascade Impactor (including the preseparator) were 
washed in methanol and allowed to dry. The ACI was assembled with the modification 
plates for a flow of 60 L min-1 hence stages 0 and 7 were replaced by -0 and -1 on the top 
of the impactor. The collection plates were then sprayed with silicone fluid (Releasil B 
silicone spray, Dow Corning Limited, Barry, Glamorgan, UK) and then allowed to dry for 
at least one hour prior to analysis. The cascade impactor was assembled with 10 ml of 25% 
acetonitrile placed in the preseparator and the final filter was a GF 50 (Copley Scientific 
Ltd, UK). The ACI was assembled with the mixing inlet as described in Figure 4.1. The 
mixing inlet allows the flow through the inhaler to be varied upto 60 L min-1 while a 
constant flow of 60 L min-1 is maintained through the ACI. That is achieved by 
supplementary air pumped through the side arm of the mixing inlet as shown in Figure 4.1. 
Figure 4.1 (b) describes how the air flow through the DPI is 10 L min-1 with 50 L min-1 air 
provided via the sidearm. 
The flow through the mouthpiece of the Turbuhaler was set at 10, 20, 30, 40, 50 and 60 L 
min-1 with a flow-duration of 24, 12, 8, 6, 4.8 and 4 seconds respectively (corresponding 
for 4L through the inhaler) with a constant flow through the ACI of 60 L min-1. The flow 
was measured using an electronic digital flow meter (MKS Instruments, USA) and a 
critical flow controller model TPK (Copley Scientific Ltd, UK). Parafilm M laboratory 
film (Pechiney Plastic Packaging, USA) was used to seal the apparatus.  
Five determinations from each inhalation flow were made, according to the randomization 
procedure shown in Table 4.2.  
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Figure 4.1 (a) The mixing inlet in the ACI with the preseparator. (b) Inhalation flow set up 
using the mixing inlet valve with S referring to stage. 
 
For each determination, the inhaler was loaded to deliver one dose, according to the 
instructions in the patient information leaflet. It was placed into the mouthpiece. The pump 
(set for the required flow) was switched on for the previously mentioned inhalation time to 
allow a volume of 4 L of air, as recommended in Pharmacopoeial Methods, (European 
Pharmacopeia, 2001; British Pharmacopoeia, 2005; United States Pharmacopeia, 2005) to 
be withdrawn through the inhaler during each determination. For each determination only 
one dose was discharged into the ACI. For each flow five separate determinations were 
made (n=5). Each stage of the Cascade Impactor was rinsed with 25% acetonitrile and 
made up to the volume as described in Table 4.3. The washing procedure was the same as 
that described for the total dose emission. The amounts deposited on each stage were 
determined by high performance liquid chromatography using the previously validated 
method described in section 3.2. 
(a) (b) 
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Table 4.2 The randomization schedule for the dose numbers from the Turbuhaler inhaler 
for the aerodymanic charcteristics determination (100 doses in the inhaler). 
Flow Dose Number from the inhaler 
60 9, 18, 33, 45, 85 
50 4, 25, 52, 83, 94 
40 6, 26, 61, 70, 96 
30 12, 29, 50, 62, 86 
20 11, 34, 41, 82, 97 
10 13, 22, 65, 87, 98 
 
Table 4.3 The washing volume of 25% acetonitrile for ACI stages in the Aerodynamic 
Characterization. 
Stage Volume of washing (ml) 10 L min-1 20 L min-1 30 L min-1 40 L min-1 50 L min-1 60 L min-1 
Induction port 50 50 100 100 100 100 
Preseparator 50 50 100 100 100 100 
-1 10 10 10 10 10 10 
-0 10 10 10 10 25 25 
1 10 10 25 25 50 50 
2 10 10 25 25 25 25 
3 10 10 25 25 25 25 
4 10 10 10 10 25 25 
5 10 10 10 10 25 25 
6 10 10 10 10 10 10 
Filter 10 10 10 10 10 10 
 
4.2.3. Data Analysis  
The total dose emission was determined as the total amount of drug ex-mouthpiece. This 
has been reported with respect to the nominal emitted dose. Using the ACI with a flow of 
60 L min-1 (after the mixing inlet unit) for the DPI, the effective cut-off diameter of each 
stage was fixed to 60 L min-1 flow (Copley, 2007; Van Oort, 1995). The fine particle dose 
(FPD) was the amount with particles that correspond to a size less than 5µm. The fine 
particle fraction % (FPF) was the FPD expressed as a percentage of the total amount 
deposited into the throat and stages of the cascade impactor (this is the dose exiting the 
mouthpiece). The mass median aerodynamic diameter (MMAD) was obtained from a plot 
of the logarithm of the percentage less than a stated size on a probability scale against the 
logarithm of the effective cut-off diameter of the stage (United States Pharmacopeia, 2005) 
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and this was done using Copley Inhaler Testing Data Analysis Software (CITDAS). The 
MMAD was the diameter corresponding to 50% undersize. The geometric standard 
deviation (GSD) was the square root for the size corresponding to 84.13% less than the 
stated size divided by the square root of the size for 15.87% (United States Pharmacopeia, 
2005). 
4.2.4 Statistical analysis  
A two-way analysis of variance (ANOVA) test was used to compare the total emitted dose 
and aerodynamic particle size characterization at different flows using SPSS V15.0 (SPSS 
Inc., Chicago, USA). 
4.3 Results 
4.3.1 Total Emitted Dose 
The individual doses and the mean (SD) emitted dose of terbutaline sulphate from the 
Turbuhaler are shown in Table 4.4 and Figures 4.1 and 4.2. These values are for each dose 
for which the nominal dose is 500μg terbutaline sulphate. The overall mean (SD) % of the 
nominal emitted dose (n = 10 doses), from the Turbuhaler at 10, 20, 30, 40, 50 and 60 L 
min-1 inhalation flows were 34.0(7.4), 48.0(8.3), 56.0(7.8), 64.8(5.7), 72.5(8.6) and 
76.6(6.5) % of the emitted dose respectively.  
The comparison of the dose emission results at different flows showed that the amount 
emitted increased significantly (p< 0.001) with the increase of the inhalation flow.  
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Table 4.4 Terbutaline sulphate emitted dose (µg) from the Turbuhaler (500 μg nominal 
dose) determined at different flows. 
Dose 
Inhalation flow rate (L min-1) 
10  20  30  40 50 60 
1 114.2 231.6 308.1 340.8 415.7 368.7 
2 208.8 255.4 241.3 341.7 405.6 367.3 
3 211.5 268.1 255.8 299.2 316.3 401.1 
4 110.3 222.8 274.2 334.2 316.8 410.6 
5 152.4 173.9 345.7 322.2 347.1 417.0 
6 174.5 270.9 216.9 301.1 357.2 437.6 
7 172.0 214.7 304.8 375.2 309.7 354.1 
8 182.0 229.7 250.6 274.2 349.9 377.7 
9 160.4 209.2 304.3 338.6 428.6 334.0 
10 212.5 323.8 297.7 311.0 428.6 362.6 
Mean 169.8 240.0 279.9 323.8 362.2 383.1 
SD 37.0 41.4 38.9 28.5 43 32.2 
RSD 21.8 17.3 13.9 8.8 11.9 8.4 
% of nominal 
dose 
34.0 
(7.4) 
48.0 
(8.3) 
56.0 
(7.8) 
64.8 
(5.7) 
72.4 
(8.6) 
76.6 
(6.4) 
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Figure 4.2 Terbutaline sulphate total emitted dose from the Turbuhaler, expressed as a 
percent of the nominal dose, at flows of 10, 20, 30, 40, 50 and 60 L min-1 (n=10 separate 
doses). 
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Figure 4.3 The mean (SD) total emitted dose of terbutaline sulphate from the Turbuhaler, 
expressed as a percent of the nominal dose, at each inhalation flow (n=10 separate doses). 
 
4.3.2 The Aerodynamic Particle Size Characterization 
A summary of the data obtained from the Andersen Cascade Impactor is shown in Table 
4.5 together with Figures 4.4-4.6. 
The majority of the emitted dose from the Turbuhaler is deposited in the induction port and 
the preseparator of the ACI. As the flow increases the deposition onto the induction port 
decreases while it increases in the preseparator. However, after 30 L min-1 the deposition 
increases in the induction port and decreases in the preseparator.  
The comparison of the aerodynamic particle size characterization results for different flow 
showed that the total dose per shot, FPD and FPF significantly increases with the increase 
of the inhalation flow (p< 0.001). 
4.3.3 Statistical analysis 
A summary of the statistical comparison between flow 60 L min-1 and the other flows to 
highlight the differences is presented in Table 4.6.  
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Table 4.5 A summary of the data obtained from the ACI for the Turbuhaler (500 μg nominal dose). Mean values in µg are quoted except those in bold 
which are mean (SD). 
 
Stage 
Cut-off  
  
Amount in µg 
10 L min-1  20 L min-1 30 L min-1 40 L min-1 50 L min-1 60 L min-1 
Induction port  
 
91.4 68.5 38.9 91.6 105.4 146.8 
Preseparator 2.8 110.1 130.3 109.5 104.7 81.4 
-1 9.0 1.2 3.2 1.7 1.9 3.4 3.6 
- 0 5.8 1.4 1.0 3.3 6.7 5.3 6.4 
1 4.7 1.0 2.1 6.3 12.2 17.8 22.7 
2 3.3 1.0 2.1 6.6 12.4 21.6 27.8 
3 2.1 1.2 2.9 9.0 20.4 35.4 57.9 
4 1.1 1.3 1.3 5.0 11.5 26.9 39.4 
5 0.7 2.0 0.3 2.4 5.7 12.0 25.0 
6 0.4 1.1 0.4 0.0 0.7 3.1 5.3 
Filter 0.0 0.6 0.3 0.4 1.3 4.2 4.6 
Total emitted dose (μg) 
  
105.0(7.5) 192.1(73.1) 203.9(15.4) 273.9(59.9) 339.8(72.7) 420.7(26.8) 
Total emitted dose (% of nominal dose) 21.0(1.5) 38(20.7) 40.8(6.2) 54.8(13.8) 68.0(14.5) 84.1(5.4) 
FPD (μg) 7.5(3.5) 7.9(0.4) 25.6(0.8) 56.4(14.3) 109.8(8.8) 168.6(23.3) 
FPF (% of nominal dose) 1.5(0.7) 1.6(0.1) 5.1(0.3) 11.3(3.3) 22.0(1.8) 33.7(4.7) 
FPF% of the emitted dose 7.0(3.1) 5.9(3.5) 12.8(1.3) 20.9(5.1) 33.2(5.6) 40.1(5.4) 
MMAD (μm) 2.8(1.6) 4.4(0.8) 3.4(0.05) 3.2(0.3) 2.6(0.2) 2.5(0.03) 
GSD 3.6(1.2) 2.3(0.6) 1.7(0.05) 1.8(0.1) 1.9(0.1) 1.9(0.03) 
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Table 4.6 Mean difference (95% confidence interval) for the inhalation flow of 60 L min-1 compared to the other flows.  
Comparator FPD (µg) FPF (%) MMAD (µm) Emitted dose (µg) 
50 L min-1 58.8 (43.0, 74.6)** 6.9 (1.3, 12.5)* -0.1 (-1.2, 0.9) 20.8 (-13.5, 55.2) 
40 L min-1 112.1 (96.4, 127.9)** 19.2 (10.4, 28.0)** -0.7 (-1.7, 0.4) 59.2 (24.9, 93.6)** 
30 L min-1 142.9 (127.2, 158.7)** 27.3 (18.5, 36.2)** -0.9 (-2.0, 0.2) 103.1 (68.8, 137.5)** 
20 L min-1 160.7 (144.9, 176.4)** 34.2 (25.4, 43.0)** -1.9 (-3.0, -0.9)** 143.1 (108.9, 177.4)** 
10 L min-1 161.0 (145.3, 176.8)** 33.1 (24.3, 41.9)** -0.3 (-1.4, 0.8) 213.2 (178.9, 247.6)** 
 
* p<0.05, ** <0.001 otherwise no significant difference. 
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Figure 4.4 The mean (SD) fine particle dose of terbutaline sulphate from Turbuhaler, 
expressed as percent of nominal dose, at different flows (n=5). 
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Figure 4.5 Mean (n=5) terbutaline sulphate (µg) deposited on each stage at each inhalation 
flow. 
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Figure 4.6 The mean (n=5) aerodynamic distribution of the dose emitted from the 
Turbuhaler at each inhalation flow.  
 
4.4 Discussion 
Total dose and fine particle dose emission together with the determination of the 
aerodynamic particle size distribution provide useful data about the inhalation method 
tested. Ross and Schultz (1996) and Palander et al. (2000) have demonstrated the property 
of flow dependent dose emission from dry powder devices. They showed that for some dry 
powder devices such as the Accuhaler and Easyhaler the effect of the inhalation flow is 
low whilst it is greater for the Turbuhaler. Hence an optimal inhalation flow may have to 
be achieved through DPIs to be used effectively. 
Previous study have shown that children (Pedersen et al., 1990), adult asthmatic (Brown et 
al., 1995; Van der Palen, 2003) and COPD (Broeders et al., 2003; Tarsin et al., 2001) 
patients have problems achieving the recommended optimal (Borgstrom et al., 1994) 
inhalation flow of 60 L min-1 through a Turbuhaler.  
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Flow dependent fine particle dose characteristics have been reported from the Turbuhaler 
containing budesonide (Ross and Schultz, 1996; Hill and Slater, 1998), salbutamol (Prime 
et al., 1999), terbutaline (Meakin et al., 1995b; Meakin et al., 1995a) and a combination of 
budesonide and formoterol (Tarsin et al., 2004). However those studies were done using an 
inhalation flow above 30 L min-1.  
The results in this chapter show that the terbutaline sulphate from Turbuhaler has a flow 
dependent dose emission property and flow dependent fine particle dose characteristic. The 
dose emitted, FPD and FPF were significantly increased with the increase of the flow 
(p<0.001). The flow had a more pronounced effect on the FPD than the emitted dose, thus, 
a faster inhalation increases the respirable amount more than it increases the emitted dose. 
That might be due to the increase of the break down of the small particles to fine particles 
as the flow increase is higher than the increase of the ability of the air stream to carry large 
particles present in the mouthpiece of the Turbuhaler. 
The results are consistent with the most desirable inhalation flow for use with the 
Turbuhaler which has been reported to be 60 L min-1 (Newman et al., 1991; Borgstrom et 
al., 1996) and the patient information leaflet which instructs the patients to inhale as deep 
and hard as they can during inhalation. All dry powder inhalers are designed with a 
resistance to airflow to facilitate particle de-aggregation during inhalation. When patients 
use the recommended inhalation technique for a Turbuhaler and inhale as deep and hard as 
they can, then their inhalation flow through this device will determine the amount 
deposited in their lung.  
Tarsin et al. (2004) also measured the in-vitro dosage emission and the fine particle dose 
(FPD) from the 100/6 and 200/6 Symbicort Turbuhaler (budesonide and formoterol) at 
different flow rates (30, 60 and 90 L min-1). The data also confirmed that the amounts of 
budesonide and formoterol emitted from the Symbicort 100/6 and Symbicort 200/6 
inhalers were affected by the increased inhalation flow. Also the results demonstrated that 
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the average total dose emissions at 90 L min-1 were all greater than 100% (Tarsin et al., 
2004). Each determination at 90 L min-1 was carried out after doses had been discharged to 
waste using a flow rate of 60 L min-1. The data obtained suggest that at 60 L min-1 the total 
dose emission is not 100%. Thus total dose emission of >100% at 90 L min-1 suggests that 
at the higher flow some residual dose from the previous inhalation may also be inhaled 
(Tarsin et al., 2004). For this reason in this study doses were discharged to waste at 90 L 
min-1. 
Ross and Schultz (1996) compared the emitted dose delivery from a Diskhaler (Ventodisk 
200µg), Rotahaler (Beclotide 100µg), and Turbuhaler (Pulmicort 200µg) at two different 
flows (30 and 60 L min-1). The relative standard deviation (RSD) of the delivered dose for 
the DPI products ranged from 10% to 44%. In addition, the dose delivered from these DPI 
inhalers was generally less than the labelled amount and was dependent on the inhalation 
flow (Ross and Schultz, 1996). 
The data represented in this chapter suggests that below 30 L min-1 although the MMAD 
increases it is still below 5µm. However the FPD falls off very sharply below this flow. 
This is the first data to study dose emission below 30 L min-1 and suggests that this is the 
minimum flow that should be used through the terbutaline Turbuhaler. Recently 
Nadarassan et al have shown that the pressure drop across the inhaler is the same with and 
without mixing valve at flows 10-60 L min-1 (Nadarassan et al., 2007). 
The results in this chapter also showed that the inhalation flow has an effect on the amount 
deposited on the induction port and the preseparator, as seen in Table 3.5. The amount 
deposited on the induction port decreases and the amount deposited on the preseparator 
increase as the inhalation flow increase till the flow of 30 L min-1. That might be because 
at an inhalation flow of 10 L min-1 the de-aggregation of the powder is low. This produces 
very big aggregates that are too heavy to be carried with the airstream through the bending 
of the induction port so they deposit more within the induction port. It is very unlikely that 
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patients will inhale as slow as this. However during acute exacerbation of severe asthma or 
COPD this could occur (Broeders et al., 2003). As the inhalation flow increases the ability 
to de-aggregate the powder increases hence decreasing the particle size, decreasing the 
amount deposited on the induction port and increasing the amount deposited on the 
preseparator till reaching an inhalation flow of 30 L min-1. As the inhalation flow increases 
above more than 30 L min-1 the amount deposited on the induction port increases and the 
amount deposited on the preseparator decreases. This could be due to the increase of the 
velocity of the inhaled particles which increases the inertial impaction which is the 
dominant deposition mechanism for particle with large momentum [the product of velocity 
and mass] (Hillery et al., 2001).  
4.5 Conclusions 
 In-vitro flow dependent dose emission has been demonstrated for terbutaline sulphate in 
the Turbuhaler. The effect of this was more pronounced for the fine particle dose 
especially below 30 L min-1. The emitted dose at the higher flow was greater than at lower 
flows. The flow dependent dose emission results highlight the need for the 
Pharmacopoeias to use a variety of inhalation flows for in-vitro tests rather than one that is 
determined according to the resistance of the dry powder inhaler. The clinical relevance of 
the flow dependent and inconsistent dosage characteristics of terbutaline sulphate in the 
Turbuhaler requires investigation. The date suggests that the minimum inhalation flow 
through a terbutaline sulphate Turbuhaler is 30 L min-1. 
 
 127 
5.1 Introduction 
Many patients have problems using their MDI with the recommended inhalation technique. 
Problems include not being able to co-ordinate the actuation of a dose with the start of an 
inhalation and the cold-freon effect which causes patients to stop inhaling (Crompton, 
1982; Al-Showair et al., 2007). Another problem is that most of the MDI dose is deposited 
on the throat even if the patient has good co-ordination between the dose actuation and 
inhalation (Aswania and Chrystyn, 2001). Spacers are used to decrease oropharyngeal 
deposition and overcome the co-ordination problem (Aswania and Chrystyn, 2001; Fink, 
2000; Terzano, 2001; Vaswani and Creticos, 1998). Also because the patient inhales from 
a static cloud and the dose has had some time to evaporate in the spacer then lung 
deposition is greater when using a spacer (Hirst et al., 2001; Richards et al., 2001). 
Different spacers are commercially available for patient use. Some of them are prone to 
static charges (Newman, 2004). This static charge in addition to the shape and the type of 
material the spacer is formed of, can affect the amount inhaled by the patient. Some 
spacers have been designed to be antistatic (e.g. Nebuchamber, AstraZeneca; 
AeroChamber Max and Plus, Trudell Medical). 
The use of in-vitro testing methodology for inhalation methods can give some information 
about the potential to deliver a dose to the lungs. The Dose Emission Unit gives 
information about the amount emitted from the inhaler while cascade impactors give 
information about the aerodynamic characteristics of the emitted dose. 
Therefore, the aim of this study was to investigate the in-vitro emitted dose and 
aerodynamic characteristics from a Bricanyl MDI with and without different spacers. 
5.2 Methods 
5.2.1 Equipment and inhalation devices 
Equipment: 
MDI sampling apparatus: Copley Scientific Ltd, UK 
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Andersen MKII Cascade Impactor : Copley Scientific Ltd, UK 
A/E fibre glass filter discs: 25 mm; Pall Corporation, USA 
GF 50 filter: Copley Scientific Ltd, UK 
GAST pump:  Brook Crompton, UK 
An electronic digital flow meter: MKS Instruments, USA 
Parafilm M laboratory film: Pechiney Plastic Packaging, USA 
Silicone fluid spray:  Releasil B silicone spray, Dow Corning Limited, Barry, 
Glamorgan, U.K. 
Critical flow controller model TPK: Copley Scientific Ltd, UK 
HPLC system: Previously described in section 3.2 in this thesis 
Inhaler and spacer devices: 
Bricanyl Metered Dose Inhaler: Labelled as a nominal dose of 250μg terbutaline 
sulphate per puff, AstraZeneca, UK 
Fisonair spacer: Fisons plc-Pharmaceuticals Division, UK 
AeroChamber MAX spacer: Valved Holding Chambers; Trudell Medical 
International Europe Ltd, UK 
AeroChamber Plus spacer: Valved Holding Chambers; Trudell Medical 
International Europe Ltd, UK 
Nebuhaler: Valved Holding Chambers; AstraZeneca, UK 
5.2.2 Procedure 
5.2.2.1 Total Emitted Dose 
The emitted dose from a Bricanyl MDI (labelled as a nominal dose of 250μg terbutaline 
sulphate per puff, AstraZeneca, UK) was determined. Determinations were made for the 
MDI and when the MDI was attached to each of the four different spacers. The spacers 
were the Fisonair spacer (Fisons plc-Pharmaceuticals Division, UK), the AeroChamber 
MAX [AMAX] and the AeroChamber Plus [APLUS] Valved Holding Chambers (Trudell 
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Medical International Europe Ltd, UK) and Nebuhaler (AstraZeneca, UK). The Fisonair 
was also washed with water and left to air dry [FISONAIRW]. The Fisonair without 
washing was primed using several single puffs from the MDI and was not washed after use 
[FISONAIR]. Also the AeroChamber MAX spacer was used with one puff with one 
inhalation volume [AMAX] and one puff with three inhalation volumes [AMAX3] through 
the spacer. 
The MDI sampling apparatus (Copley Scientific Ltd, UK) with a critical flow controller 
model TPK (Copley Scientific Ltd, UK) was used. The final filter was a 25 mm A/E fibre 
glass filter (Pall Corporation, USA). Vacuum flow through the apparatus was provided by 
a GAST pump (Brook Crompton, UK). The flow through the MDI / MDI+Spacer was 28.3 
L min-1 with a flow-duration of 8.5 sec such that the inhalation volume was 4 L. The flow 
was measured by an electronic digital flow meter (MKS Instruments, USA). Parafilm M 
laboratory film (Pechiney Plastic Packaging, USA) was used to seal the apparatus. 
Each inhaler / spacer mouthpiece was inserted tightly into the mouthpiece adaptor of the 
dose sampling unit and aligned along the horizontal axis. The emitted dose from the MDI / 
MDI+Spacer was measured by collecting one individual dose at 28.3 L min-1 with an 
inhaled volume of 4 L. Ten determination were made for each dose emission (n=10). The 
MDI was shaken and primed by firing two doses to waste before use (Barry and 
O'Callaghan, 2003). The discharge of the dose was done in co-ordination with the 
switching on of the pump in case of the MDI without spacer. When using the spacer, the 
dose was discharged into the spacer and with the switching on of the pump within 1 
second.  
For each dose emission procedure the critical flow controller system was used to produce 
sonic flow conditions, as recommended by the Pharmacopoeial Methods, (European 
Pharmacopeia, 2001; British Pharmacopoeia, 2005; United States Pharmacopeia, 2005). 
Following dose emission into the apparatus, the sampling unit was washed with 25% 
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acetonitrile and the filter was completely submerged in 25% acetonitrile and then sonicated 
for 3 min (preliminary analysis revealed that this procedure removes all drug entrained on 
the filter). All the solutions were collected and made up to a volume of 250 ml for the MDI 
without spacer and 50 and 100 ml for MDI with a spacer (Dose emission unit and spacer, 
respectively). The amount of drug was determined by high performance liquid 
chromatography using the previously validated method descried in section 3.2. The total 
dose emitted was the amount deposited in the plastic dose sampling apparatus and the final 
filter.  
5.2.2.2 The Aerodynamic Particle Size Characterization 
All the parts of the Andersen MKII Cascade Impactor were washed in methanol and 
allowed to dry. The collection plates were then sprayed with silicone fluid (Releasil B 
silicone spray, Dow Corning Limited, Barry, Glamorgan, UK.) and allowed to dry for at 
least one hour prior to analysis. The cascade impactor was assembled and the final filter 
was a GF 50 (Copley Scientific Ltd, UK). The flow through the mouthpiece of the inhaler 
was 28.3 L min-1 with a flow-duration of 8.5 seconds (equivalent to 4 L inhalation 
volume). The flow was measured using an electronic digital flow meter (MKS Instruments, 
USA) and a critical flow controller model TPK (Copley Scientific Ltd, UK). Parafilm M 
laboratory film (Pechiney Plastic Packaging, USA) was used to seal the apparatus.  
Five determinations from each spacer were made. For each determination, the discharge of 
the dose was done in co-ordination with the switching on of the pump in case of the MDI 
without spacer. When using the spacer, the dose was discharged into the spacer and with 
the switching on of the pump within 1 second. Each stage of the Cascade Impactor was 
rinsed with 25% acetonitrile and made up to the volume as described in Table 5.1.  
The washing procedure of the filter was the same as that described for the total dose 
emission. The amounts deposited on each stage were determined by high performance 
liquid chromatography of the previously validated method described in section 3.2. 
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Table 5.1 The washing volume of 25% acetonitrile for ACI stages. 
Stage Volume of washing (ml) MDI MDI with spacers 
Spacer - 100 
Induction port 100 25 
0 10 10 
1 25 25 
2 25 25 
3 25 25 
4 25 25 
5 10 10 
6 10 10 
7 10 10 
Filter 10 10 
 
5.2.3 Data Analysis  
The total dose emission was determined as the total amount of drug ex-mouthpiece. This 
has been reported with respect to the nominal dose. Using the ACI at a flow of 28.3 L min-
1 for the MDI the standard effective cut-off diameter of each stage at a flow 28.3 L min-1 
was used (Copley, 2007). The fine particle dose (FPD) was the amount with particles that 
correspond to a size less than 5µm. The fine particle fraction % (FPF) was the FPD 
expressed as a percentage of the total amount deposited into the throat and stages of the 
cascade impactor (this is the dose exiting the mouthpiece). The mass median aerodynamic 
diameter (MMAD) was obtained from a plot of the logarithm of the percentage less than a 
stated size on a probability scale against the logarithm of the effective cut-off diameter of 
the stage (United States Pharmacopeia, 2005) and this was done using Copley Inhaler 
Testing Data Analysis Software (CITDAS). The MMAD was the diameter corresponding 
to 50% undersize. The geometric standard deviation (GSD) was the square root for the size 
corresponding to 84.13% less than the stated size divided by the square root of the size for 
15.87% (United States Pharmacopeia, 2005). 
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5.2.4 Statistical analysis  
A two-way analysis of variance (ANOVA) test was used to compare the total emitted dose 
and aerodynamic particle size characterization of the different spacer with the MDI using 
SPSS V15.0 (SPSS Inc., Chicago, USA). 
5.3 Results 
5.3.1 Total Emitted Dose 
The individual doses and the mean (SD) emitted dose of terbutaline sulphate are shown in 
Table 5.2 and Figures 5.1-5.3. 
The overall means (SD) amount of terbutaline sulphate (n=10 doses) when using the 
AeroChamber MAX spacer with three inhalations (AMAX3) were 91.7(8.9) and 
107.4(15.9) µg for the dose emission unit and spacer. These correspond to a mean (SD) % 
of 36.7 (3.6) and 43.0 (6.4) % of the nominal dose (n = 10 doses), respectively for the total 
emitted dose and the spacer. These are similar to that of one inhalation with the 
AeroChamber MAX as shown in table 5.2 and Figures 5.1-5.3. 
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Table 5.2 Terbutaline sulphate emitted dose (µg) from the MDI (250μg nominal dose) determined at a flow 28.3 L min-1. 
Dose Amount in µg 
MDI *FISONAIRW FISONAIR AMAX APLUS Nebuhaler 
ED ED Spacer ED ED Spacer ED Spacer ED Spacer 
1 208.8 46.4 130.7 107.8 84.3 108.4 80.9 184.3 72.1 140.2 
2 204.2 56.2 163.2 73.6 91.4 97.1 87.5 122.2 62.4 186.3 
3 213.1 47.8 127.0 90.7 99.0 121.3 81.5 153.2 67.1 140.0 
4 173.9 58.3 166.4 98.3 95.9 129.1 65.8 139.0 71.1 120.8 
5 144.4 50.6 136.2 112.9 98.5 128.1 89.3 121.5 72.6 155.6 
6 152.8 58.9 156.4 84.1 88.0 100.9 65.1 158.0 65.8 156.2 
7 216.3 63.7 162.6 99.2 98.6 94.0 69.2 112.1 75.8 157.3 
8 212.1 40.8 104.1 100.0 82.5 93.9 91.2 124.3 75.4 135.3 
9 206.9 45.4 116.3 95.5 82.7 89.7 73.0 116.2 74.9 165.9 
10 194.8 53.9 119.9 90.8 79.9 95.8 67.8 146.4 74.3 161.9 
Mean 192.7 52.2 138.3 95.3 90.1 105.8 77.1 137.7 71.1 151.9 
STD 26.3 7.2 22.4 11.3 7.5 15.0 10.1 22.9 4.6 18.4 
RSD 13.6 13.8 16.2 11.9 8.4 14.2 13.1 16.6 6.4 12.1 
% of nominal dose 77.1(10.5) 20.9(2.9) 55.3(8.9) 38.0(4.5) 35.1(3.0) 41.1(6.0) 30.9(4.1) 55.1(9.1) 28.5(1.8) 60.8(7.4) 
* Fisonair spacer with washing of the spacer with water after use (FISONAIRW), Fisonair spacer without washing the spacer prior to use 
(FISONAIR), AeroChamber MAX spacer (AMAX), AeroChamber Plus spacer (APLUS), Emitted Dose (ED) and amount Left in Spacer (Spacer).  
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Figure 5.1 Terbutaline sulphate total emitted dose expressed as a percent of the nominal 
dose from the MDI at flow of 28.3 L min-1 (n=10 separate doses). 
 
Figure 5.2 Terbutaline sulphate deposited in each spacer expressed as a percent of the 
nominal dose from the MDI at flow of 28.3 L min-1 (n=10 separate doses). 
 135 
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
AMAX AMAX3 APLUS NH FISONAIR FISONAIRW MDI
M
ea
n 
E
m
itt
ed
 D
os
e 
(%
 n
om
in
al
 d
os
e)
ED
Spacer
 
Figure 5.3 The mean (SD) total emitted dose (ED) and amount deposited in each spacer of 
terbutaline sulphate expressed as a percent of the nominal dose (n=10 separate doses). 
 
5.3.2 The Aerodynamic Particle Size Characterization 
A summary of the data obtained from the Andersen Cascade Impactor is shown in Table 
5.3 and Figures 5.4-5.6.  
The majority of the emitted dose is deposited in the induction port of the ACI, but when 
using the spacer the majority of the emitted dose is deposited in the spacer.  
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Table 5.3 A summary of the data obtained from the ACI for MDI (250 μg nominal dose). Mean values in µg are quoted except those bold which are 
mean (SD). 
 
Stage 
Cut-off  
Amount in µg 
MDI FISONAIRW FISONAIR AMAX AMAX3 APLUS Nebuhaler 
Spacer 
 
-- 104.5 -- 96.3 86.4 140 158.3 
Induction port 114.6 7.4 16.1 24.7 15.2 8.5 8.7 
0 10 4.7 5 8.3 3.4 4.7 2.6 6.6 
1 9 8.5 10 17.2 9.4 15.3 6.2 15.6 
2 5.8 10.1 12.2 18.8 12.6 21.2 13.6 15.8 
3 4.7 19 21 29.6 48.2 39.6 30.9 23.5 
4 3.3 13.4 10.6 12.5 11.9 14.3 20.3 13.5 
5 2.1 5.4 4.2 3.3 4 4.9 3 5 
6 1.1 0 0 0 0 0 1.5 1.5 
7 0.7 0 0 0 0 0 2.2 1.5 
Filter 0.4 0 0 0 0 0 1.9 2.8 
Total emitted dose (μg)* 
 
 
175.7(15.9) 70.4(10.9) 104.1(13.6) 114.1(10.4) 115.3(33.1) 90.6(9.0) 94.5(13.8) 
Total emitted dose (% of nominal dose) 70.3(6.4) 28.2(4.4) 41.6(5.4) 45.6(4.2) 46.1(13.2) 36.2(3.6) 37.8(5.5) 
FPD (μg) 41.1(7.9) 39.7(5.4) 39.7(5.4) 68.2(7.9) 65.9(19.1) 64.7(7.8) 52.9(9.6) 
FPF (of nominal dose) 16.4(3.2) 15.9(2.2) 15.9(2.2) 27.3(3.2) 26.4(7.6) 25.9(2.1) 21.2(3.8) 
FPF% of the emitted dose 23.4(3.9) 56.7(2.9) 48.7(5.9) 59.7(2.3) 57.0(2.7) 71.3(4.1) 55.8(3.6) 
MMAD (μm) 4.1(0.2) 4.4(0.2) 4.7(0.3) 4.1(0.2) 4.3(0.2) 3.8(0.1) 4.4(0.2) 
GSD 1.6(0.1) 1.6(0.05) 1.6(0.1) 1.4(0.2) 1.5(0.03) 1.4(0.05) 1.6(0.02) 
*Total is the total amount of terbutaline sulphate deposited in the ACI. 
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Figure 5.4 The mean (SD) fine particle dose of terbutaline sulphate expressed in µg (n=5) 
for each inhalation method. 
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Figure 5.5 Mean terbutaline sulphate (µg) deposited on each stage of the ACI using an 
inhalation flow of 28.3 L min-1. 
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Figure 5.6 The mean (n=5) aerodynamic distribution of the dose emitted from the Bricanyl 
MDI with different spacers.  
 
5.3.3 Statistical analysis 
The comparison of the dose emission results from the MDI alone and the MDI with 
different spacers showed that the amount emitted from the MDI alone is significantly 
higher than with any of the MDI+spacers (p>0.001). The amount emitted increased in the 
following order, FISONAIRW, Nebuhaler, APLUS, AMAX, FISONAIR and MDI without 
spacer. However when statistically comparing the MDI+spacers with each other it was 
found that there was no significant difference between the Nebuhaler emitted dose and the 
APLUS emitted dose. Also, there was no significant difference between the AMAX and 
FISONAIR. 
The amount deposited on wall of AMAX spacer is significantly lower than all other 
spacers (p<0.001) 
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The comparison of the aerodynamic particle size characterization results from the MDI 
alone and the MDI with different spacers showed that the FPD from the MDI alone was 
significantly lower than that from the AMAX and APLUS (p< 0.01). However, the total 
dose per shot was significantly higher than that of all MDI+Spacers (p<0.001). The FPD 
increased in the following order, FISONAIRW, MDI without spacer, FISONAIR, NH, 
APLUS and AMAX (p< 0.05). When comparing the MDI+spacers with each other it was 
found that there was no significant difference between them. However the FPD from 
FISONAIRW was significantly lower than that from the AMAX and APLUS (p< 0.005). 
When comparing the FPF (of the emitted dose), it was found that the APLUS had a 
significantly higher FPF than any of the other methods (p<0.001). The FPF from the MDI 
alone was significantly lower than all the methods (p<0.001). 
Regarding the MMAD it was found that the APLUS had the smallest MMAD (p<0.05) and 
FISONAIR had the biggest MMAD (p<0.05). 
A summary of the statistical comparison between the MDI and the MDI+Spacers to 
highlight the differences is presented in Table 5.4. Also a summary of the statistical 
comparison between the APLUS (as the gold standard) and the other MDI+Spacers 
combinations to highlight the differences is presented in Table 5.5.  
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Table 5.4 Mean difference (95% confidence interval) for MDI compared to the MDI+Spacers.  
Comparator FPD (µg) FPF (%) MMAD (µm) Emitted dose (µg) 
Nebuhaler -11.7 (-27.4, 3.9) -32.3 (-37.9, -26.8)*** -0.3 (-0.6, -0.02)* 121.6 (110.1, 133.1)*** 
APLUS -23.6 (-39.2, -7.9)* -47.9 (-53.4, -42.4)*** 0.3 (0.004, 0.6)* 115.6 (104.1, 127.1)*** 
AMAX -24.8 (-40.4, -9.5)* -33.6 (-39.1, -28.1)*** -0.2 (-0.5, -0.04) 102.7 (91.2, 114.1)*** 
FISONAIRW 1.4(-14.2, 17.0) -33.3 (-38.8, -27.7)*** -0.3 (-0.6, -0.003)* 140.6 (129.1, 152.0)*** 
FISONAIR -9.7(-25.3, 6.0) -25.3 (-30.8, -19.8)*** -0.6 (-0.9, -0.3)*** 97.4 (86.0, 108.9)*** 
 
Table 5.5 Mean difference (95% confidence interval) for APLUS compared to the rest of MDI+Spacers.  
Comparator FPD (µg) FPF (%) MMAD (µm) Emitted dose (µg) Amount deposited in spacer (µg) 
Nebuhaler 11.8 (-3.8, 27.5) 15.6 (10.0, 21.18)*** -0.6 (-0.9, -0.3)*** 6.0 (-5.5, 17.5) -14.2 (-31.2, 2.8) 
AMAX -1.2 (-16.8, 14.4) 14.3 (8.8, 19.8)*** -0.5 (-0.8, -0.2)*** -12.9 (-24.4, -1.5) * 31.9 (14.9, 48.9)*** 
FISONAIRW 25.0 (10.6, 41.8)** 14.6 (9.1, 20.2)*** -0.6 (-0.8, -0.3)*** 25.0 (13.5, 36.4)*** 30.4 (-17.5, 16.4)*** 
FISONAIR 13.9 (-0.5, 30.7) 22.6 (17.1, 28.1)*** -0.9 (-1.1, -0.6)*** -18.2 (-29.6, -6.7)*** NA 
 
For both tables * p<0.05, ** <0.01, ***<0.001 otherwise no significant difference 
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5.4 Discussion 
The results show that the total amount of terbutaline sulphate emitted from the MDI as 
well as the FPF from the same dose were significantly affected by the type of the spacer 
used (p< 0.001). The significantly higher emitted dose from the MDI alone (p<0.001) was 
due to the spacer which decreases the amount of large particles reaching the dose sampling 
unit. Therefore, as expected, the MDI without a spacer had the largest total emitted dose.  
The AeroChamber Max is coated with an antistatic lining. The amount deposited on the 
walls of the AMAX spacer, therefore, is significantly lower than all other spacers 
(p<0.001). Also, there was no significant difference between the emitted dose from the 
FISONAIR and the AMAX spacer which is an antistatic spacer. This may account for the 
decrease of the static charge in the Fisonair spacer when used unwashed. 
The static charge of polycarbonate spacers has been reported to vary greatly depending on 
the washing procedure (Wildhaber et al., 1996; Pierart et al., 1999). Also it have been 
reported that washing with light anionic detergent solution (most of the household 
detergents) decreases static charge (O'Callaghan and Barry, 2000; Chuffart et al., 2001). 
Static charge is produced from washing the Fisonair spacer with only water without 
detergent. It decreases the emitted dose as it increases the amount deposited in the spacer 
itself. The results here were consistent with the results reported by Kenyon et al (1998) and 
Wildhaber et al (2000). They had concluded that in-vivo lung deposition from plastic 
spacer devices will vary according to the electrostatic charge on the spacer walls (Kenyon 
et al., 1998; Wildhaber et al., 2000). The static charge can also account for the significantly 
lower amount deposited on walls of AMAX spacer (p<0.001). 
The significantly lower FPF from the MDI alone (p<0.001) was consistent with the in-vivo 
studies by Hindle et al (1994) and Silkstone et al (2002). Both studies showed that the 
spacer significantly increased the relative lung bioavailability compared to the MDI alone 
(p<0.01). The result was also consistent with many in-vivo studies that have shown that the 
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spacers significantly increase lung bioavailability (Comis et al, 1993; Newman et al, 1998; 
Aswania and Chrystyn, 2001). This result might be due to the fact that patients inhaled 
from a static cloud because the spacer decreases the velocity of the aerosol particles and 
allows some evaporation of the droplets. This allows the propellant to evaporate thereby 
decreasing the particle size, hence decreasing the amount deposited on the induction port. 
In case of the MDI used alone, the aerosol particles travel at a high speed which enhances 
their deposition in the induction port and therefore, decreases the FPF.  
It was also found that the FPF of the emitted dose from the Fisonair spacer without 
washing (FISONAIR) is higher than the FPF from the Fisonair spacer with washing 
(FISONAIRW). A study by Bisgaard et al (1995) have shown that priming the plastic 
spacers with repeated puffs from a budesonide MDI to minimise the electrostatic charge on 
the plastic prolonged the half life (t1/2) of the aerosol in the Nebuhaler from nine to 32 
seconds. A normal cleaning procedure reduced the aerosol t1/2 back to baseline (Bisgaard et 
al., 1995). A short half-life increases the need for co-ordination between actuation and 
inhalation. Therefore non-electrostatic spacers deliver a significantly higher dose than 
plastic spacers. 
Another study by Pierart et al (1999) showed that there was a three-fold increase in lung 
deposition from detergent-coated spacers [45.6(2.2) %] compared to static spacers 
[11.5(3.5) %]. The mean (range) gastrointestinal deposition was 2.4% (1.0±3.9) through a 
static spacer and 8.8% (4.1±11.2) through a non-static spacer (p<0.001). The mean (range) 
amount of salbutamol remaining in the static spacers was 76.7% (71.8±81.4) compared to 
33.1% (26.0±40.8) in the detergent-coated spacers (p<0.001). Typical deposition patterns 
are shown in Figure 5.7. 
There are many deposition studies involving the use of a plastic spacer, and the results are 
highly variable (Newman et al., 1989; Tal et al., 1996; Melchor et al., 1993). As the 
question of electrostatic charge affecting drug delivery from plastic spacers has not been 
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adequately addressed prior to the work of O'Callaghan et al. (1993) and Barry and 
O'Callaghan (1995), there is a strong possibility that a substantial part of the variability 
between studies using similar spacer devices and breathing patterns is due to differences in 
electrostatic charge. The effect of reducing electrostatic charge on the lung deposition from 
a spacer, highlighted in Figure 5.7, has not been adequately quantified. 
 
Figure 5.7 Typical deposition patterns of radioaerosol in the same subject after inhalation 
through a new and a detergent-coated spacer (posteroanterior view) [reproduced from 
Pierart et al. (1999)]. 
 
The static charge greatly affects the output from spacer. It was found that the drug output 
from a spacer lined with an antistatic agent may be increased by a factor of three or more 
(O'Callaghan and Barry, 2000). This was consistant with the result of the comparison 
between the FISONAIR and AeroChamber MAX spacer, the FPD for AeroChamber MAX 
spacer is higher than for FISONAIR, even though the emitted doses form FISONAIR and 
AeroChamber MAX spacers was not significantly different. This might be due to the 
AeroChamber MAX spacer, as antistatic spacer, having more ability to produce particles 
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with a smaller particle size than the FISONAIR spacer (as a primed spacer with repeatd 
puffs). This was also seen from the MMAD statistical comparison as the FISONAIR has a 
significantly higher MMAD than the AMAX (p<0.02).  
When using the MDI without a spacer, the majority of the emitted dose is deposited in the 
induction port of the ACI, but when using the spacer the majority of the emitted dose is 
deposited in the spacer. Thus, the use of the spacer would decreases the amount deposited 
in the mouth. 
For the AeroChamber MAX one inhalation and AeroChamber MAX three inhalations the 
emitted dose and  FPD did not differ significantly, thus the use of the spacer with one 
inhalation or three inhalations does not affect the respirable fraction and the emitted dose. 
However the insignificant difference between 1 and 3 inhalations may be due to the large 
inhaled volume (4 L) used per inhalation. 
The FPF of the AeroChamber Plus (small volume spacer) was significantly higher than all 
the other methods (p<0.001) and the MMAD was significantly lower than all the other 
methods (p<0.05).  However the AeroChamber MAX have the largest emitted dose and 
FPD of all the used spacers. Which are more important FPF and MMAD or emitted dose 
and FPD, needs further investigation. 
5.5 Conclusions 
 When the MDI is attached to a spacer there is an increase in the FPD and FPF and a 
decrease in the amount deposited in the induction port. The dose emitted and the FPD from 
plastic spacer devices will vary according to the electrostatic charge on the spacer walls. 
Thus, using a spacer theoretically increases the amount that reaches the respiratory tract 
and decreases the amount deposited in the mouth. The AeroChamber MAX had the largest 
FPD. However the AeroChamber Plus has the best FPF and MMAD. 
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6.1 Introduction  
The choice of a nebulisation system for a patient usually depends on the equipment 
available as there is only limited guidance on the selection and use of a nebuliser. In-vitro 
determination of the droplet size distribution, the fine particle dose and the emitted dose 
are necessary to compare nebulisers because they are important parameters that have the 
potential to indicate differences in the clinical response and side effects. Hence the 
European Respiratory Society Nebuliser Guidelines were published to standardise 
nebuliser performance and therapy (Boe et al., 2001). These guidelines recommend the 
Comité Européen Normalisation (CEN) method for the in-vitro measurement of the 
aerodynamic particle size of nebulisers (Boe et al., 2001; Comité-Européen-
Normalisation., 2001). This method uses the Marple 298X Cascade Impactor. The 
volumetric flow leaving the nebuliser is set at a constant flow of 15 L min-1 with 2 L min-1, 
of this flow, drawn through the impactor. The 15 L min-1 flow was chosen for the CEN 
standard to represent a typical (adult) mid-point flow for tidal breathing (Dennis and 
Pieron, 2004). The aerosol is sampled anisokinetically by the low flow impactor from the 
main flow exiting the nebuliser. This could be a significant limitation of the CEN 
methodology as anisokinetic sampling may introduce size-related bias that thus far has not 
been quantified. Furthermore the sampling of a limited fraction of the emitted dose (2/15), 
the limited loading capacity of the cascade stages, filter fitting (and availability plus their 
cost), desorption problems and its suitability for operation with drug formulations may 
each affect the accuracy and precision of assessments (Jauernig et al., 2002; Jauernig et al., 
2004) .  
The Next Generation Impactor (NGI) was originally introduced for the determination of 
the aerodynamic particle size distribution of the dose emitted from metered dose and dry 
powder inhalers using compendial procedures (British Pharmacopoeia, 2005; United States 
Pharmacopeia, 2005) and calibrated within the flow range of 30–100 L min-1. Later, this 
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archival NGI was calibrated at 15 L min-1 for use in the evaluation of nebulisers. Unlike 
the CEN approach the NGI allows sampling of all of the flow from the nebuliser by the 
impactor (Marple et al., 2004b). Several studies have since assessed the use of the NGI 
without the preseparator, with a filter in or after the Micro-Orifice Collector (MOC) to 
collect any extra-fine particles that would bypass this component (Marple et al., 2004a; 
Berg et al., 2007b) and with cooling the NGI either in water bath (Jauernig et al., 2003) or 
refrigerator at 5oC for 90 minutes before use (Berg and Asking, 2004; Berg et al., 2007b). 
A consortium of pharmaceutical companies ‘The NGI Consortium’ was formed in 2002 to 
investigate the NGI at a flow of 15 L min-1 in compliance with the CEN recommendations 
for nebulisers, and sampling the whole air stream leaving the nebuliser. In 2003 the EPAG 
(European Pharmaceutical Aerosol Group) took over technical management of the NGI. Its 
Nebuliser Sub-Team was formed in 2005 to evaluate specific aspects of nebuliser testing in 
relation to the development of a new monograph, 2.9.44 “Preparations for Nebulisation”, 
proposed for the European Pharmacopeia. One of the tasks of this group has been an inter-
laboratory evaluation of the need to chill the NGI to avoid heat transfer-related evaporation 
of aqueous droplets from nebulisers (Berg et al., 2007b; Dennis et al., 2008). 
Recently evaporation effects during aerodynamic characterisation of the aerosolised dose 
from nebulised salbutamol (5mg/ml) solutions has been noted with cooling the NGI for 90 
minutes in a refrigerator immediately before use when using a flow of 15 L min-1 (Berg et 
al., 2007b).  
The aim of this Chapter was to further investigate the aerodynamic characteristics of 
aerosolised doses from nebuliser systems using different operating conditions with the NGI 
and to determine similar properties using the CEN methodology to identify if evaporation 
effects occur. To address this aim the NGI has been operated at inhalation flows of 15 and 
30 L min-1 with and without cooling. The CEN method was modified to analyse the drug 
rather than alter the formulation by adding a fluoride tracer (Silkstone et al., 2002). Two 
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different nebulisers operate by different principles have been used in this chapter to 
examine the robustness of the new approach. The Sidestream is a jet nebuliser and 
therefore the aerosolised dose will be cooler than ambient room conditions (Fink et al., 
2001). The Aeroneb Professional is a vibrating mesh nebuliser and thus the aerosolised 
dose that is emitted will be similar to ambient room temperature (Fink et al., 2001). 
6.2. Material and Method  
6.2.1 Equipment and inhalation devices 
Equipment: 
Next Generation Impactor (NGI): Copley Scientific Ltd, UK 
Cascade Impactor  Marple Series 298X, Low flow cascade impactor 
(Graseby Ltd., UK) 
Breathing simulation machine: Compass breathing simulator, Pari GmbH, 
Germany 
GAST pump : Brook Crompton, UK 
An electronic digital flow meter: MKS Instruments, USA 
Parafilm M laboratory film: Pechiney Plastic Packaging, USA 
Critical flow controller model TPK: Copley Scientific Ltd, UK 
Electrostatic filter: An electrostatic filter (Pari GmbH, Germany) enclosed 
in filter holder (Pari GmbH, Germany) 
Marple stages filters Glass fibre filters with radial slits for Marple Impactor, 
Diameter 34mm, (SKC Inc., USA) 
Marple back filters Glass fibre filters for the bottom stage of  Marple Impactor, 
without radial slits, Diameter 34mm (SKC Inc., USA) 
Data analysis software : Copley Inhaler Testing Data Analysis Software 
(CITDAS), Copley Scientific Ltd, UK 
HPLC system: Previously described in section 3.2 in this thesis 
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Inhalation devices: 
Normal saline: Sodium chloride 0.9% respiratory solution, Teva, UK 
Sidestream jet nebuliser: Intersurgical Ltd, UK; attached to a Porta Neb 
compressor, Respironics, UK 
Porta Neb compressor: Respironics, UK 
The Aeroneb Professional Nebuliser: Vibrational mesh nebuliser system; 
Aerogen,Inc,USA 
Inhalation solution: Bricanyl Respules labelled as a nominal dose of 5mg 
terbutaline sulphate 2.5mg/ml, AstraZeneca, UK 
6.2.2 Procedure 
6.2.2.1 The Aerodynamic Particle Size Characterization using the NGI 
The NGI method was identical to that described by Berg et al (Berg et al., 2007b) except a 
standard T-mouthpiece, routinely used with each nebulised system, was fitted tightly to the 
USP/Ph.Eur induction port of the NGI using a standard rubber mouthpiece adapter. Any 
remaining air flow not delivered from the nebulised system was thus provided through the 
open (inlet) end of the T-mouthpiece as shown in Figure 6.1. 
 
Figure 6.1 Schematic of NGI methodology to measure nebulised aerosol droplet size. A 
constant inhalation of 15 L min-1 is drawn over (and through) the nebuliser to the NGI. 
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All the parts of the Next Generation Impactor were washed in methanol and allowed to 
dry. The NGI collection cups were not pre-coated with an agent to provide a tacky surface. 
It has been recommended recently by the European Pharmaceutical Aerosol Group 
(EPAG) that the NGI collection cups do not require coating for nebuliser aerosol 
assessments (Berg et al., 2007a; Berg et al., 2008). The micro orifice collector (MOC) is 
ineffective to hold the very small aerosol droplets when the NGI is operated at 15 L min-1 
(Marple et al., 2004a) therefore a back-up filter (Pari GmbH, Germany) was placed after 
the MOC. The vacuum flow through the apparatus was provided by a GAST pump (Brook 
Crompton, UK). The flow was measured using an electronic digital flow meter (MKS 
Instruments, USA) and a critical flow controller model TPK (Copley Scientific Ltd, UK). 
Parafilm M laboratory film (Pechiney Plastic Packaging, USA) was used to seal the 
apparatus.  
Determinations were made using an inhalation flows of 15 and 30 L min-1 through the 
system at room ambient conditions; temperature=25oC and relative humidity=55% 
(ROOM). Also these experiments were repeated after the NGI (with its collection plate in 
place) and the throat had been placed in a refrigerator set at 5oC for 90 minutes (COLD). 
For this procedure nebulisation of the dose started within 5 minutes of removal from the 
fridge and the nebulisation process was <5 minutes in accordance with the published 
recommendations (Finlay and Stapleton, 1999; Marple et al., 2004a; Berg et al., 2007b; 
Berg et al., 2008; Dennis et al., 2008). For each determination the dose was nebulised to 
dryness when using the Aeroneb Pro and to sputtering with the Sidestream.  
For each set of operating conditions five separate determinations were made for each 
nebulised system. Following dosage emission the pump was switched off. Each plate of the 
NGI was rinsed with 25% acetonitrile and made up to fixed pre-determined volumes for 
optimal assay sensitivity. Similarly amounts left in the nebuliser system (chamber and 
tubing) were also recovered by rinsing. The amounts of terbutaline sulphate deposited on 
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each plate and remaining in the nebuliser system were determined by high performance 
liquid chromatography of the previously validated method described in section 3.2.  
6.2.2.2 CEN (prEN13544-1) methodology 
6.2.2.2.1 Aerosol output according to (prEN13544-1) –CEN 
The total output of each system was determined according to the draft European Standard 
(Boe et al., 2001; Comité-Européen-Normalisation., 2001) except that amounts of 
terbutaline sulphate were determined rather than the use of a fluoride tracer (Silkstone et 
al., 2002). Each of the two nebuliser systems (described above) was assembled according 
to Figure 6.2. 
 
Figure 6.2 Schematic of Comité European de Normalisation methodology to measure 
nebulised aerosol output. Reproduced from Boe et al (2001). 
 
Two ml of terbutaline sulphate solution (2.5mg/ml; Bricanyl respiratory solution) was 
added to the chamber of each nebuliser. In case of the Sidestream jet nebuliser the 
determination was done twice with and without the addition of 2 ml normal saline to the 
terbutaline sulphate solution. A breathing simulation machine (Pari GmbH, Germany) was 
set at a sinus flow of 15 breaths per minute with an inspiration : expiration ratio of 1:1 and 
a tidal volume of 500 ml. An electrostatic filter (A) was attached between the mouthpiece 
of the nebuliser and the breathing machine. This filter, therefore, would collect all the 
aerosol produced during the inspiration phase of a breathing cycle and thus provides a 
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good measure of the total inhaled aerosol dose (referred to as the in-vitro emitted dose 
available for inspiration). Another electrostatic filter (B) was attached to the vacuum pump. 
The vacuum pump was set at a flow of 25 L min-1 to scavenge any exhaled aerosol that 
would be released into the immediate ambient environment during expiration. Preliminary 
analysis revealed that this gross flow of 25 L min-1 collect all exhaled aerosols from the 
exhalation phase and did not affect the collection of the aerosol output that was inhaled by 
the breathing machine. The B filter was positioned close to the open end (4 cm away) of 
the nebuliser mouthpiece of each system to entrain drug emitted during the expiration 
phase. The amount collected on this filter would be that which would be exhaled during the 
nebulisation process. The breathing machine and vacuum pump were switched on 30 
seconds before the nebuliser compressor. The Sidestream nebulisers were allowed to 
operate until sputtering occurred, consistent with the NGI-based determinations. Likewise 
the Aeroneb Pro devices were operated until dryness had been reached. For each nebuliser 
system ten determinations were made (n=10). Amounts trapped on the filters and left in the 
chamber and T-piece were determined by high performance liquid chromatography of the 
previously validated method described in section 3.2 in this thesis.  
6.2.2.2.2 Aerodynamic characterization of the respirable dose according to 
(prEN13544-1) –CEN 
A Marple Series 298 low flow cascade impactor (Graseby Ltd., UK) was used according to 
the draft European Standard (Boe et al., 2001; Comité-Européen-Normalisation., 2001) 
except that amounts of terbutaline sulphate were determined rather than the use of a 
fluoride tracer (Silkstone et al., 2002). This impactor has 8 stages and a final filter. A 
marple stage filter was placed on each stage except the final stage where it had a Marple 
back filter. The stages have effective cut-off diameters of 21.3, 14.8, 9.8, 6.0, 3.5, 1.55, 
0.93 and 0.52 µm respectively, at the recommended flow of 2 L min-1.  
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Figure 6.3 shows that the airflow through the Marple 298X was set at a continuous flow of 
2 L min-1 with a further 13 L min-1 drawn from a supplementary pump connected between 
the cascade impactor and the nebuliser. Hence a constant flow of 15 L min-1 was drawn 
across the outlet of the nebuliser. The vacuum pump operating the impactor was switched 
on 30 seconds before each nebuliser system. To prevent sample overload on the filter on 
each stage of the impactor, preliminary experimentation (using congo red dye added to 
each formulation) indicated that the optimal sampling time for the Sidestream was 130 
seconds and for the Aeroneb Pro system was 100 seconds. Amounts of terbutaline sulphate 
on each stage were obtained by desorption and determined by high performance liquid 
chromatography, the previously validated method described in section 3.2 in this thesis. 
Ten determinations were made (n=10) for each nebuliser system. 
 
Figure 6.3 Schematic diagram of the Comité European de Normalisation methodology to 
measure nebulised aerosol droplet size. A constant inhalation of 15 L min-1 is drawn over 
(or through) the nebuliser. Reproduced from Boe et al (2001). 
 
6.2.3 Data Analysis 
The fine particle dose (FPD) was the amount of terbutaline sulphate that contained droplets 
< 5 µm aerodynamic diameter. The fine particle fraction % (FPF) was the FPD divided by 
the total amount that deposited into the throat and onto the stages of the cascade impactor 
 153 
for the NGI (this is the dose exiting the mouthpiece). For the CEN method the total amount 
was that recovered from stage 0 to the final filter of the cascade impactor. The mass 
median aerodynamic diameter (MMAD) was obtained from a plot of the percentage less 
than a stated size on a probability scale against the logarithm of the effective cut-off 
diameter of the stage (United States Pharmacopeia, 2005). Copley Inhaler Testing Data 
Analysis Software (CITDAS, Copley Scientific, Nottingham, UK) impactor data analysis 
software was used for assessing the data. The MMAD was the diameter corresponding to 
50% undersize. The geometric standard deviation (GSD) was the square root for the size 
corresponding to 84.13% less than the stated size divided by the square root of the size for 
15.87 % (United States Pharmacopeia, 2005). 
6.2.4. Statistical analysis  
A Two Way analysis of variance (ANOVA) was used to compare the 5 different operating 
conditions (15COLD, 15ROOM, 30COLD, 30ROOM and CEN) with respect to the FPF, 
MMAD and GSD using SPSS V15.0 (SPSS Inc., Chicago, USA). From this analysis the 
mean difference (95% confidence limits) were obtained for each operating condition 
compared to 15COLD. This comparator was used as the benchmark because of the 
recommendation to cool the NGI for characterising nebulised doses. A paired T-test was 
used to compare the results of Sidestream jet nebuliser and Aeroneb Pro at different 
conditions. 
6.3 Results 
6.3.1 Aerodynamic Particle Size Characterization using the NGI 
A summary of the data obtained from the NGI methodology is shown in Tables 6.1 and 6.2 
and Figures 6.4-6.11. The amount remaining in the Aeroneb Pro chamber is about one 
third of the amount remaining in the Sidestream jet nebuliser chamber.  
The FPD when using the Aeroneb Pro is significantly higher then the FPD when using the 
Sidestream jet nebuliser at the different flows tested (p<0.001).  
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Table 6.1 A summary of the data obtained from the NGI for the terbutaline sulphate Respules (5 mg nominal dose) nebulised using Aeroneb Pro 
nebuliser. Mean values in µg are quoted except those bold which are mean (SD). 
 
Stage 
Cut-off  
 
Amount in µg 
15 ROOM 15 COLD 30 ROOM 30 COLD 
Remaining 
 
1220.1 1559.2 1344.2 1459.3 
Throat 75.2 113.7 135.7 194.4 
1 14.1 264.9 278.6 273.9 308.4 
2 8.61 444.7 637.0 520.3 702.5 
3 5.39 552.9 692.6 284.3 694.3 
4 3.3 650.8 859.9 431.8 776.6 
5 2.08 660.8 642.4 987.8 497.0 
6 1.36 413.9 232.7 627.3 77.3 
7 0.98 175.3 76.3 251.2 42.1 
MOC 0 100.2 33.4 136.3 26.0 
Total emitted dose (μg) 
 
3338.8(198.9) 3566.7(151.5) 3648.6(119.1) 3318.5(363.7) 
Total % of nominal dose 66.8(4.0) 71.1(3.4) 72.6(2.6) 67.6(7.8) 
FPD (μg) 1918.7 (151.0) 1716.0(109.7) 2572.7(123.2) 1758.5(143.2) 
FPF % of nominal dose 38.4(3.0) 34.5(2.5) 51.1(2.7) 35.6(3.1) 
FPF(% of the emitted dose) 57.5(2.7) 48.1 (1.5) 70.5 (3.4) 53.0 (1.9) 
MMAD (μm) 4.1(0.3) 5.0(0.1) 2.0(0.3) 4.4(0.2) 
GSD 2.5(0.1) 2.2(0.03) 4.0(0.4) 2.1(0.04) 
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Table 6.2 A summary of the data obtained from the NGI for the terbutaline sulphate Respules (5 mg nominal dose) nebulised using Sidestream jet 
nebuliser. Mean values in µg are quoted except those bold which are mean (SD). 
 
Stage 
Cut-off  
 
Amount in µg 
15 ROOM 15 COLD 30 ROOM 30 COLD 
Remaining 
 
3441.6 3282.1 3477.0 3433.6 
Throat 68.7 34.2 26.9 48.9 
1 14.1 61.9 73.3 52.8 112.2 
2 8.61 102.8 194.0 77.8 334.3 
3 5.39 160.3 304.6 59.1 330.5 
4 3.3 208.8 358.7 290.4 406.2 
5 2.08 290.6 285.2 451.6 299.3 
6 1.36 261.6 157.6 288.2 140.9 
7 0.98 156.9 80.2 153.9 73.9 
MOC 0 123.3 43.1 113.7 50.9 
Total emitted dose (μg) 
 
1434.9(155.1) 1530.8(255.9) 1514.4(302.3) 1797.1(103.8) 
Total % of nominal dose 28.0(3.1) 30.3(5.9) 29.8(6.9) 36.8(1.0) 
FPD (μg) 1009.4(74.7) 877.7(102.3) 1329.4(.4) 1138.9(80.0) 
FPF % of nominal dose 20.0(1.7) 17.1(2.0) 25.8(4.9) 23.4(0.8) 
FPF(% of the emitted dose) 70.3 (5.7) 57.3 (4.6) 87.8 (5.2) 63.4 (1.1) 
MMAD (μm) 2.6(0.4) 4.2(0.4) 1.7(0.1) 3.5(0.1) 
GSD 2.8(0.14) 2.2(0.05) 2.1(0.6) 2.3(0.1) 
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Figure 6.4 The mean (SD) fine particle dose of terbutaline sulphate, expressed in μg, 
determined using the NGI for Bricanyl Respules (5 mg nominal dose) nebulised using the 
Aeroneb Pro nebulisers. 
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Figure 6.5 The mean (SD) fine particle fraction of terbutaline sulphate, expressed as 
percent of the emitted dose, determined using the NGI for Bricanyl Respules (5 mg 
nominal dose using the Aeroneb Pro nebulisers. 
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Figure 6.6 The mean (SD) fine particle dose of terbutaline sulphate, expressed in μg, 
determined using NGI for Bricanyl Respules (5 mg nominal dose) nebulised using the 
Sidestream jet nebulisers. 
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Figure 6.7 The mean (SD) fine particle fraction of terbutaline sulphate, expressed as 
percent of the emitted dose, determined using the NGI for Bricanyl Respules (5 mg 
nominal dose using the Sidestream jet nebulisers. 
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Figure 6.8 The mean (n=5) amount of terbutaline sulphate captured on each stage of the 
NGI following the nebulisation of 5mg in 2ml by the Aeroneb Pro nebuliser using different 
NGI operating conditions. 
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Figure 6.9 The mean (n=5) amount of terbutaline sulphate captured on each stage of the 
NGI following the nebulisation of 5mg in 2ml by the Sidestream jet nebuliser using 
different NGI operating conditions. 
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Figure 6.10 The mean (n=5) aerodynamic distribution of the dose nebulised from the 
Aeroneb Pro using the different NGI operating conditions.  
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Figure 6.11 The mean (n=5) aerodynamic distribution of the dose nebulised from the 
Sidestream using the different NGI operating conditions.  
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The mean difference (95% confidence interval) for FPD between the Aeroneb Pro and the 
Sidestream jet nebuliser was 162.3 (637.8, 1040.8) µg for the 15COLD methodology. 
6.3.2 CEN (prEN13544-1) methodology 
6.3.2.1 Aerosol output according to (prEN13544-1) –CEN 
The individual doses and the mean (SD) total aerosol output using the CEN methodology 
for the Aeroneb Pro are presented in Tables 6.3 and Figure 6.12 whereas Table 6.4 and 
Figure 6.13 present the data for the Sidestream jet nebuliser. The data of the CEN 
methodology for the Sidestream jet nebuliser with the addition of 2 ml saline is presented 
in Table 6.5 and Figure 6.14. The mean (SD) emitted dose of terbutaline sulphate 
expressed as a percent of the nominal dose from the nebulisers is presented in Table 6.6 
and Figure 6.15. The data labeled ‘total’ in the previously mentioned Tables and Figure is 
the total amount deposited on the T-piece, the inhalation filter and the exhalation filter. 
 
Table 6.3 Terbutaline sulphate emitted dose (µg) for the 2 ml Bricanyl Respules (5 mg 
nominal dose of Terbutaline sulphate in 2 ml) nebulised using the Aeroneb Pro nebuliser. 
Dose 
Amount in µg 
Inhalation filter Exhalation Filter T-piece Nebuliser Total 
1 969.8 1389.5 949.3 870.5 3308.6 
2 849.9 1078.8 1284.5 638.4 3213.1 
3 861.5 1158.4 1226.4 976.7 3246.2 
4 836.2 1241.3 706.7 1068.4 2784.2 
5 876.2 1211.8 851.7 822.3 2939.6 
6 907.2 958.0 1048.3 773.6 2913.5 
7 938.5 1232.2 937.0 1037.1 3107.6 
8 986.1 1306.9 1016.8 841.8 3309.8 
9 1079.1 1379.1 936.1 911.6 3394.3 
10 1189.8 1257.3 1172.7 678.7 3619.8 
Mean 949.4 1221.3 1012.9 861.9 3183.7 
STD 112.6 131.7 176.9 142.3 251.4 
RSD 11.9 10.8 17.5 16.5 7.9 
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Table 6.4 Terbutaline sulphate emitted dose (µg) for the 2 ml Bricanyl Respules (5 mg 
nominal dose of Terbutaline sulphate in 2 ml) nebulised using the Sidestream jet nebuliser. 
Dose 
Amount in µg 
Inhalation filter Exhalation Filter T-piece Nebuliser Total 
1 384.8 291.0 59.9 2982.6 735.7 
2 206.0 167.2 54.4 3250.6 427.6 
3 439.6 149.6 69.7 1994.4 658.9 
4 196.3 127.1 48.8 3175.8 372.1 
5 192.6 262.2 49.2 3031.9 504.0 
6 347.3 324.4 59.1 2670.4 730.8 
7 320.3 277.6 50.9 2386.0 648.8 
8 230.6 200.5 58.0 3601.8 489.1 
9 350.4 224.7 55.2 3573.5 630.3 
10 391.7 240.4 61.8 3506.9 693.9 
Mean 306.0 219.3 56.3 3012.2 589.1 
STD 92.9 64.4 6.7 563.0 130.4 
RSD 30.4 29.6 11.5 18.7 22.14 
 
Table 6.5 Terbutaline sulphate emitted dose (µg) for the 2 ml Bricanyl Respules (5 mg 
nominal dose of Terbutaline sulphate in 2 ml) nebulised using the Sidestream jet nebuliser 
with the addition of 2 ml saline. 
Dose 
Amount in µg 
Inhalation filter Exhalation Filter T-piece Nebuliser Total 
1 781.2 523.1 61.9 2692.8 1366.2 
2 606.0 473.1 78.7 2726.8 1157.8 
3 515.9 449.1 69.0 2724.7 1034.1 
4 626.9 536.9 60.7 2372.4 1224.5 
5 565.4 376.9 58.9 2935.5 1001.3 
6 517.8 709.7 75.6 2862.7 1303.1 
7 622.1 562.0 72.6 1972.4 1256.7 
8 600.9 570.4 70.1 2887.9 1241.4 
9 587.3 547.8 51.1 2864.1 1186.2 
10 555.3 659.6 63.0 2702.6 1277.8 
Mean 597.9 540.9 66.2 2674.2 1204.9 
STD 75.4 96.7 8.5 293.6 114.8 
RSD 12.6 17.9 12.9 11.0 9.5 
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Table 6.6 The mean (SD) amount of terbutaline sulphate deposited on each part expressed 
as a percent of the nominal dose from different nebuliser (n=10 separate doses). 
 Inhalation filter Exhalation Filter T-piece Nebuliser Total 
▪ Aeroneb Pro 19.0(2.3) 24.4(2.6) 20.3(3.5) 17.2(2.8) 63.7(5.0) 
▪ Sidestream 
jet nebuliser  6.1(1.8) 4.4(1.3) 1.1(0.1) 60.4(10.6) 11.8(2.6) 
▪ Sidestream 
jet nebuliser 
with 2 ml 
saline 
 
12.0(1.5) 
 
10.8(1.9) 
 
1.3(0.2) 
 
53.5(5.9) 
 
24.1(2.3) 
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Figure 6.12 Terbutaline sulphate emitted dose, expressed as a percent of the nominal dose, 
when 2 ml Bricanyl respiratory solutions were nebulised using the Aeroneb Pro nebuliser 
(n=10 separate doses). 
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Figure 6.13 Terbutaline sulphate emitted dose, expressed as a percent of the nominal dose, 
when 2 ml Bricanyl respiratory solutions were nebulised using the Sidestream jet nebuliser 
(n=10 separate doses). 
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Figure 6.14 Terbutaline sulphate emitted dose, expressed as of the nominal dose, when 2 
ml Bricanyl respiratory solutions with the addition of 2 ml saline were nebulised using the 
Sidestream jet nebuliser (n=10 separate doses). 
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Figure 6.15 The mean emitted dose of terbutaline sulphate expressed as a percent of the 
nominal dose from different nebulisers (n=10 separate doses). 
 
The overall mean (SD) total output, the amount deposited on the inhalation filter, from the 
Aeroneb Pro and the Sidestream nebuliser with and without the addition of 2ml saline (n = 
10 doses), were 949.4(112.6), 597.9(75.4) and 306.0(92.9) µg respectively. The amount 
emitted from the Aeroneb Pro is significantly higher (p < 0.001) than from the amount 
emitted from the Sidestream jet nebuliser. The mean difference (95% confidence interval) 
for the amount emitted between Aeroneb Pro and Sidestream jet nebuliser was 351.6 
(255.1, 448.0). 
6.3.2.2 Aerodynamic characterization of the respirable dose according to 
(prEN13544-1) –CEN 
A summary of the data obtained from the Marple Series 298 low flow cascade impactor 
using the Aeroneb Pro and the Sidestream jet nebuliser is shown in Table 6.7 and Figures 
6.16 - 6.18. 
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Table 6.7 A summary of the data obtained from the CEN method for the 2 ml Bricanyl 
Respules (5 mg nominal dose of Terbutaline sulphate in 2 ml) nebulised using the two 
different nebuliser. Mean values in µg are quoted except those bold which are mean (SD). 
 
Amount of Terbutaline sulphate in µg 
 Aeroneb Pro Sidestream jet nebuliser 
Inhalation filter Stage 
Cut-off  
 
186.9 954.0 
Exhalation filter 0.3 0.3 
T-piece 150.8 37.7 
Top filter >50 0.5 1.4 
1 21.3 0.7 1.4 
2 14.8 1.1 2.6 
3 9.8 4.6 12.7 
4 6 4.6 18.0 
5 3.5 8.4 22.9 
6 1.55 26.1 37.9 
7 0.93 4.5 13.9 
8 0.52 3.1 10.7 
Filter 0.25 0.6 3.0 
Total amount emitted in the impactor(μg) 
 
54.2(1.6) 124.4(9.3) 
FPD(μg) 39.4(9.1) 79.2(6.8) 
FPF% of amount emitted in the impactor 72.5(15.7) 63.6(3.6) 
MMAD(μm) 3.0(0.5) 3.2(0.3) 
GSD 2.3(0.5) 2.9(0.4) 
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Figure 6.16 The mean (SD) fine particle fraction of terbutaline sulphate, expressed as 
percent of the emitted dose captured in the cascade impactor, using the CEN method for 
the Bricanyl Respules (5 mg in 2ml of terbutaline sulphate as nominal dose). 
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Figure 6.17 Terbutaline sulphate (µg) deposited on each stage of the cascade impactor 
using the CEN method for the Bricanyl Respules (5 mg in 2ml of terbutaline sulphate as 
nominal dose). 
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Figure 6.18 The mean (n=5) aerodynamic distribution of the dose nebulised from the 
Aeroneb Pro and the Sidestream measured using the Marple 298X cascade Impactor (CEN 
method). 
 
The aerodynamic particle size characterization of the emitted dose from the Sidestream jet 
nebuliser and Aeroneb Pro nebuliser (n=10 doses) revealed a mean fine particle fraction 
(FPF) of 63.6 (3.6) and 72.5 (15.7) % of the emitted dose respectively captured in the 
cascade impactor and MMADs of 3.0 (0.5) and 3.2 (0.3) μm, respectively. The majority of 
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the emitted dose is deposited on the inhalation filter as shown in Table 6.7. The FPF and 
the MMAD of the Aeroneb Pro and the Sidestream jet nebuliser were similars.  
The data in Table 6.7 highlight that the mean (SD) amount of terbutaline sulphate captured 
in the Marple 298X cascade impactor was 54.2 (1.6) µg from the Aeroneb pro and 124.4 
(9.3) µg from the Sidestream nebuliser. In addition to the total amount deposited in the 
cascade impactor a further 150.8 (111.8) µg was recovered from the T-mouthpiece and 
186.9 (56.5) µg on the filter fitted to the vacuum pump when using the Aeroneb Pro. For 
the Sidestream these amounts were 37.7 (8.0) and 945.0 (141.3) µg, respectively. This 
leads to a total 392.0 and 1116.4µg emitted from the Aeroneb Pro and the Sidestream 
nebulisers respectively. The amounts sampled in the Marple therefore represent 13.8 and 
11.2% of the amount emitted from the Aeroneb Pro and the Sidestream nebuliser and are 
much lesser than the amounts sampled in the total aerosol output using the CEN 
methodology. From the prievous section (6.3.2.2) it was found that the overall mean (SD) 
total output from the Aeroneb Pro and the Sidestream nebuliser systems captured on the 
inhalation filter were 949.4 (112.6) and 306.0 (92.9) µg respectively. Hence the amount 
captured in the Marple Cascade Impactor represents only 5.7% and 40.6% of the dose 
available to be inhaled (also equivalent to 1.1 and 2.5% of the nominal dose). 
6.3.2.3 Statistical analysis 
A summary of the statistical comparison between the Aeroneb Pro and the Sidestream 
using the NGI and the CEN methodology is shown in table 6.8. It shows that the Aeroneb 
Pro resulted in a significantly higher emitted dose, FPD (p<0.001) and MMAD (p<0.01) 
and a lower FPF (p<0.01) using NGI methodology. When using the CEN method there 
was no significant difference. 
A summary of the statistical comparison between 15COLD (as it is the benchmark 
condition) and the other operating conditions to highlight the very large differences is 
presented in Table 6.9. Statistical analysis revealed that there was a highly significant 
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difference (p<0.001) between the FPF and the MMAD for each nebuliser system with 
respect to the 4 operating conditions of the NGI and that of the CEN method. Similar 
statistical analysis of the GSD data between the operating conditions (including the CEN 
method) also revealed highly significant differences, (p<0.001) for the Aeroneb Pro and 
(p=0.002) for the Sidestream. 
 
Table 6.8 Mean difference (95% confidence interval) for Aeroneb Pro vs Sidestream. 
Comparator Aeroneb Pro vs Sidestream  
Input output 328.7 (230.8, 426.6; p<0.001)*** 
NGI 15 COLD  
FPD 839.3 (637.8, 1040.7; p<0.001)*** 
FPF -9.7 (-15.6, -3.8; p=0.01)** 
MMAD 0.8 (0.4, 1.3; p=0.008)** 
GSD 0.2 (-0.04, 0.07; p=0.445) 
CEN  
FPF 7.8 (-5.6, 21.4; p=0.181) 
MMAD -0.2 (-0.8, 0.4; p=0.408) 
GSD -0.5 (-1.1, 0.1; p=0.072) 
* p<0.05, ** <0.01, *** <0.001, otherwise N/S 
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Table 6.9 Mean difference (95% confidence interval) for 15COLD compared to the other operating conditions 
Comparator Aeroneb Pro Sidestream 
FPF (%) MMAD (µm) FPF (%) MMAD (µm) 
15ROOM -9.4 (-13.7, -5.0)** 1.0 (0.5, 1.4)** -13.0 (-18.3, -7.7)*** 1.6 (1.1, 2.1)*** 
30COLD -5.0 (-9.4, -0.7)* 0.6 (0.2, 1.1)** -5.6 (-10.8, -0.3)* 0.7 (0.2, 1.3)* 
30ROOM -22.4 (-26.8, -18.1)*** 3.0 (2.5, 3.4)*** -30.5 (-35.7, -25.2)*** 2.5 (2.0, 3.0)*** 
CEN -24.4 (-32.1, -16.8)*** 2.0 (1.4, 2.6)*** -6.9 (-12.2, -1.5)*** 1.1 (0.7, 1.5)*** 
 
* p<0.05, ** <0.01, *** <0.001, otherwise no significance difference 
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6.4 Discussion 
The results obtained using the NGI provide further evidence of the evaporation effects 
shown by Berg et al for a jet nebuliser (Berg et al., 2007b) and their finding that the NGI 
should be cooled prior to use with nebulisers using a low flow of 15 L min-1. The data 
presented for a flow of 30 L min-1 adds further evidence of evaporation and shows that at 
this flow even cooling does not prevent this effect. Although a slight modification has been 
made to the method of Berg et al (2007) in that the exit of the mouthpiece was a tight seal 
with the NGI throat using a standard rubber adapter the MMAD values for the two 
nebuliser systems are in line with those previously reported (Berg et al., 2007b; Berg et al., 
2008). 
Two different nebuliser systems were studied. Although the relative humidity of their 
aerosolised doses would be expected to be similar, the temperature would be different. The 
aerosolised dose emitted from the Sidestream (jet nebuliser) would be about 10oC cooler 
than ambient room temperature whilst that from the Aeroneb Pro will be similar to room 
temperature (Fink et al., 2001; Zhou et al., 2005). The magnitude of the different between 
15ROOM and 15 COLD NGI operating conditions, summarised in Table 6.9, for the two 
systems were comparable with those for the Sidestream being slightly bigger. This would 
be due to the lower temperature of the aerosol emitted from the Sidestream compared to 
ambient room conditions (Berg et al., 2007b; Berg et al., 2008). Hence evaporation of the 
aerosol solvent due to thermal transfer from the NGI (when operated at room temperature) 
will be greater with Sidestream. These evaporation effects in the NGI are comparable to 
those previously reported for the Andersen Cascade Impactor for nebulised salbutamol and 
budesonide (Finlay and Stapleton, 1999; Zhou et al., 2005). 
At higher flows more relatively warm and dry room air is entrained in the equipment used 
and this will cause the particles to evaporate and shrink. Evaporation effects will be offset 
when cooling the NGI because the lower temperatures will raise the relative humidity and 
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decrease the evaporation. Using lower flows and limiting the distance between the 
nebuliser output and the NGI would minimise evaporation effects. Therefore, the distance 
between the nebuliser output and NGI here was limited and a tight seal (akin to the mouth 
sealed round the mouthpiece) was used. Hence this mimicked the situation during normal 
patient use. Inhalation flows lower than 15 L min-1 were not used because the NGI has not 
been calibrated for flows below this value. The Marple 298X Cascade Impactor samples 
air at 2 L min-1 and thus, theoretically could minimise evaporation effects. For this method 
a constant flow of 15 L min-1 is drawn across the output of the nebuliser. Comparing the 
CEN results to the equivalent operating conditions of 15ROOM with the NGI suggest 
greater evaporation effects occur with the CEN method. Thus lowering the vacuum flow 
through the Marple 298X cascade impactor did not have any effect on minimising 
evaporation. 
The different results (very small MMAD and high FPF) using the CEN methodology 
warrant further investigation. 
Two abstract studies have previously compared the NGI and CEN methods. One 
concluded encouraging equivalence between the NGI and the Marple 298X impactor for 
the nebuliser system (Pieron et al., 2007b) when nebulising a commercially available 
budesonide suspension. The other indicated that the two impactors have poor equivalence 
when measuring the droplet size distributions from the same nebuliser system (Pieron et 
al., 2007a). For the later study they used the Omron VVT nebuliser and NE C30 
compressor with 2ml 2.5% w/v sodium fluoride and they placed the NGI in a fridge at 5oC 
for only 1 hour prior to sizing. The first study used budesonide suspension rather than a 
clear solution like that of all bronchodilator respiratory solutions. The equivalence between 
the CEN and the NGI methods in this study may be because the evaporation has less effect 
on the suspension than on the solution. Thus there was no significance difference between 
the NGI results and the CEN results. The results of the second study are consistent with the 
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data presented here in that the aerodynamic characteristics of the emitted dose from 
different nebuliser systems are not the same. 
Pieron et al (2007) reported that the standard CEN methods embodied in EN13544-1:2001 
to size nebulised aerosol using the Marple 298X impactor are highly robust, repeatable and 
easily adapt to sizing budesonide suspension. However the effect of evaporation is not 
addressed and, as described above, may be less for particles suspended rather than drug 
dissolved in the emitted droplets (Pieron et al., 2007c).  
Although these in-vitro methods have been introduced to provide a comparison between 
different nebuliser systems the clinical meaning of these results needs to be investigated. It 
has been shown that lung deposition and physiologic response was greater when using a 
nebuliser that emits small (MMAD 3.3µm) compared to large (MMAD 7.7µm) particles 
(Johnson et al., 1989). Further evidence of a link between fine particle dose and relative 
lung deposition has been reported as well as the total emitted dose and relative systemic 
delivery (Silkstone et al., 2002). Doubts have recently been raised about the clinical 
meaning of the CEN results for nebulised solutions in that the reported relative lung 
bioavailability of nebulised salbutamol in patients with asthma and COPD was less than 
that for a metered dose inhaler attached to a spacer yet the aerodynamic characteristics of 
the nebulised method indicated more favourable lung deposition (Mazhar et al., 2008). In 
this clinical study the relative lung bioavailability for the two inhalation methods was 
similar but the fine particle dose was thirteen times greater for the nebuliser method. The 
FPF of 80.1% for the nebulised method suggest that the CEN method may be producing 
misleading information due to an evaporation effect. The effect of evaporation with respect 
to the CEN method requires investigation. Hence further method validation of the CEN 
method and also for the NGI method is required so that meaningful data can be obtained 
especially when the differences in the aerodynamic characteristics of the nebulised doses 
for the different operating conditions were huge. Correlation to the clinical effect (efficacy 
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and safety) would also be required to highlight what the in-vitro results mean and help in 
the recommendation of the most appropriate operating conditions. 
No large scale robust attempt has been made to investigate in-vitro / in-vivo correlations. 
Although this is not easy it will help understand the clinical significance of different in-
vitro results. Conditions that mimic those present in the airways were not used so in the 
future aerodynamic studies should investigate such conditions. Without a robust in-vitro 
in-vivo examination the proposed ‘European Respiratory Society Guidelines on the use of 
nebulisers’ (Boe et al., 2001) will remain a meaningless issue. The results here and that of 
others comparing many more nebulising systems (Smith et al., 1995) confirm that their in-
vitro aerosolised dose properties are different. In clinical practice these differences become 
insignificant due to the use of very high doses that are above that required to reach the 
plateau of the dose response relationship (Smith et al., 1995). Although this provides the 
necessary clinical response the greater systemic availability should be considered during 
routine use in stable patients. 
One drawback of the cooled NGI method is that realistically the nebulisation process has to 
be completed within 5 minutes. This limits the volume of solution to be nebulised. 
However studies have shown that the aerodynamic properties of an aerosolised dose from a 
nebuliser are not affected by the fill volume (Clay et al., 1983a; Hess et al., 1996; Silkstone 
et al., 2002) with the only difference being a larger emitted dose and hence fine particle 
dose as the fill volume increases (Clay et al., 1983b; Hess et al., 1996). 
When using jet nebulisers due to the large residual volume (as shown in this chapter) in 
clinical practice the solution is diluted with an equal volume of saline nebuliser solution 
(Clay et al., 1983b; Clay and Clarke, 1987). To add 2ml saline nebuliser solution to the 
2ml terbutaline sulphate solution in the Sidestream would have prolonged the nebuliser 
time to over 5 minutes (Silkstone et al., 2002). The residual volumes were much higher and 
the emitted dose was lower than if 2ml saline had been added to the terbutaline nebuliser 
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solution. Hence the solution routinely used in clinical practice with these nebulisers cannot 
be characterised by the NGI method unless a cooling system or jacket is included or do the 
test for part of the solution instead of the whole volume. This problem did not appear with 
the Aeroneb Pro because it is recommended that the nebuliser solution is not diluted and 
only 0.3 ml is left in the nebulisation chamber as a residual volume (as mentioned in the 
Aeroneb Pro Data Sheet). 
The aerosol output results show that the amount of terbutaline sulphate deposited on the 
inhalation filter from the Aeroneb Pro is significantly higher then that from the Sidestream 
jet nebuliser (p< 0.001). This was as expected because as the results show the residual 
volume of Aeroneb Pro (Table 6.6) is much lower in accordance to previous results 
reported by Fink and Schmidt (2002). The Aeroneb Pro nebuliser system delivered greater 
than four times more drug than the other pneumatic small volume nebulisers when 
delivering 3 ml doses of salbutamol (Fink and Schmidt, 2002). 
The inhalation laboratory results also show that dilution with 2ml approximately doubles 
the output from the Sidestream. However even with this increased emitted dose when using 
saline with the Sidestream, the Aeroneb Pro emitted dose was still almost double that of 
the Sidestream. The fine particle dose mirrored the amount emitted but whether the higher 
MMAD, for the Aeroneb Pro, would have any effect on influencing the amount and 
distribution in the lung is not known. However the higher FPD from Aeroneb Pro does 
suggest a higher total lung deposition. The relatively high amounts that were deposited 
onto the T-mouthpiece of the Aeroneb Pro could be due to the downward delivery of the 
emitted dose. 
6.5 Conclusions 
The NGI method is an easy, reliable and reproducible method for the determination of the 
aerodynamic particle size distribution but evaporation of the droplets from the nebulised 
dose of a solution is possible. Using two different nebulising systems it has been shown 
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that the use of cooling and operation at an inhalation flow of 15 L min-1 is very important 
in limiting the evaporation effect when using the NGI method based on Berg et al (2007). 
The 5 minutes set up time and 5 minute nebulisation time of the cooled system do provide 
constraints and thus adaptations to introduce a cooling jacket may be necessary to 
characterise the doses routine used in clinical practice. The CEN method needs a more 
through validation to highlight the optimal operating conditions, the evaporation effect and 
the interpretations of the results. Whether the sampling of the emitted dose also introduces 
errors needs to be addressed. The large differences in the FPF, MMAD and GSD for the 
different methodologies highlight that a through validation is required with correlation 
linking to clinical effects so that an optimised method can be recommended that produces 
quality control and clinically relevant data. 
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7.1 Introduction 
Pulmonary drug delivery by inhalation is primarily used to treat conditions of the airway 
by delivering locally acting drugs to their site of action. This reduces the dose needed to 
produce a pharmacological effect in the lungs with minimal systemic effects (Dhand, 2000; 
Hillery et al., 2001; Kondili and Georgopoulos, 2002). Following inhalation, most of the 
dose is swallowed while less than 20% is deposited into the airways (Newman et al., 
1981). The pulmonary absorbed fraction is responsible for the pharmacological effect 
while the swallowed part is responsible for systemic side effects (Davies, 1975).  
The assessment of pulmonary drug deposition is becoming increasingly important (Mobley 
and Hochhaus, 2001). Lung deposition can be identified by gamma scintigraphy and 
pharmacokinetic methods. Gamma scintigraphy provides direct measurements of lung 
deposition and highlights the zones of the lungs where the deposition occurs. However the 
formulation has to be modified to incorporate a radio- isotope (Chrystyn, 2000; Chrystyn, 
2001). The application of traditional pharmacokinetic methods to lung deposition studies is 
difficult, because the doses administered are small and together with the volume of 
distribution means systemic concentrations are low. Thus these concentrations are difficult 
to assay accurately and reproducibly (Rogers and Ganderton, 1995). Also the resulting 
systemic drug concentrations are due to the swallowed and inhaled fractions (Newman et 
al., 1981). 
Pharmacokinetic methods to evaluate the relative lung bioavailability of inhaled drugs 
have used plasma or urine concentration of the drug in the absorption lag time phase of the 
orally swallowed portion. The amounts delivered to the systemic circulation that are 
cleared by the renal route during the lag phase will represent the drug absorbed from the 
lung after inhalation. The proposed sampling times for plasma are 5, 10, 20 minutes post 
inhalation (Anhoj et al., 1999; Lipworth and Clark, 1997b; Mobley and Hochhaus, 2001). 
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Urinary terbutaline excretion with the administration of oral charcoal to block oral 
absorption using 36 hours post dose collection periods (Borgstrom and Nilsson, 1990; 
Derom et al., 2001; Borgstrom et al., 2000) and the amount of salbutamol excreted in the 
urine in the first 30 minutes post inhalation (Hindle and Chrystyn, 1992) are as a urinary 
pharmacokinetic methods for inhaled drugs. The charcoal block method can identify total 
lung deposition but cannot be used with patients because it will block all the absorption of 
orally administered drugs. The urinary salbutamol pharmacokinetic method demonstrated 
that following oral administration of salbutamol, negligible amounts of salbutamol are 
excreted in the urine during the first 30 minutes post dose, and that significantly greater 
amounts (p<0.001) are excreted 30 minutes post inhalation. Thus, the urinary excretion of 
salbutamol during the 30 minutes post inhalation period is a representative of the amount 
delivered to the lungs. This study also demonstrated that urinary excretion of salbutamol 
over the 24 hours post dose period reflects the total systemic bioavailability. A dose 
response relationship and the reproducibility of the Hindle and Chrystyn method have been 
reported (Tomlinson et al., 2003). Another study has shown the method to be more 
sensitive to identify a difference between inhalation techniques than bronchoprovacation 
challenge testing using methacholine (Tomlinson et al., 2005). This urinary 
pharmacokinetic method has been used to compare different inhalation methods and 
products (Hindle et al., 1995; Hindle et al., 1994; Chege et al., 1996a; Chege and Chrystyn, 
1996), to determine an optimal inhalation technique for MDIs (Hindle et al., 1993), to 
determine the effect of inhalation flow and formulation (Chege and Chrystyn, 2000; Chege 
et al., 1996b), when administration is prolonged (Silkstone et al., 2000), to provide useful 
information on the use of large volume spacers (Chege and Chrystyn, 1994), and 
nebulisers (Silkstone et al., 2002). This technique has been extended to identify the relative 
lung deposition of sodium cromoglycate (Aswania et al., 1997; Aswania and Chrystyn, 
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2002), nedocromil (Aswania et al., 1998), gentamicin (Al-Amoud et al., 2002), tobramycin 
(Barber, 2002) and formoterol (Nadarassan et al., 2007).  
Similar to the principle of the urinary salbutamol pharmacokinetic method (Hindle and 
Chrystyn, 1992) the urinary excretion of terbutaline at 30 minutes following inhalation 
could be used to indicate the relative amount of drug reaching the respiratory tract and thus 
can be used to determine the relative bioavailability to the lungs following inhalation. Also 
the 24 hours renal excretion could be an index for the relative bioavailability of terbutaline 
to the body following an inhalation. A bioanalytical method to measure terbutaline from 
urine samples using a reversed phase ion-pair high performance liquid chromatography 
(HPLC) assay has been previously described in section 3.3 of this thesis. This analysis 
method will be used to determine the amount of terbutaline excreted in urine post 
administration. 
7.2 Validation of relative bioavailability of terbutaline to the lung following inhalation 
using urinary excretion 
7.2.1 Methods 
The aim of this section was to identify if the urinary pharmacokinetic method developed 
for the relative lung bioavailability of salbutamol post inhalation can be applied to 
terbutaline post inhalation.  
7.2.1.1 Equipment and inhalation devices 
Inhaler device: 
 
Bricanyl Metered Dose Inhaler labelled as a nominal dose of 
250μg terbutaline sulphate per shot (AstraZeneca, UK) 
Charcoal Carbomix, Meadon Laboraties Limited, UK 
HPLC condition: Previously described in section 3.3 in this thesis 
7.2.1.2 Subjects 
Ethical approval was obtained from the University of Bradford. Twelve healthy, non-
smoking volunteers (six females) with a FEV1>90% of predicted gave written informed 
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consent (University of Bradford Ethics Committee Approval obtained) to take part in this 
study. On separate occasions subjects received the following 
(a) The oral administration of 500μg terbutaline sulphate in 20 ml water [O]. 
(b) The oral administration of 500μg terbutaline sulphate in 20 ml water with 20g activated 
charcoal (10g in 50 ml water before and after dosing) [OC]. 
(c) Two 250μg doses inhaled from a terbutaline sulphate metered dose inhaler (Bricanyl, 
AstraZeneca, UK) [I]. 
(d) Two 250μg doses inhaled from a terbutaline sulphate metered dose inhaler with 20g 
activated charcoal (10g in 50 ml water before and after dosing) [IC].  
The use of charcoal in this dose has been proven to be enough to block the gastrointestinal 
absorption of the swallowed terbutaline sulphate (Borgstrom and Nilsson, 1990). All 
subjects were trained on how to use a MDI according to the patient information leaflet and 
the MDI was shaken and primed by firing two doses to waste before use (Barry and 
O'Callaghan, 2003). Subjects were trained to shake the MDI, remove the cap, exhale 
slowly as far as comfortable, put the MDI into their mouth and seal their lips round the 
mouthpiece. They were then instructed to start a slow inhalation through their mouth and 
activate the MDI immediately after the start of this slow inhalation. This slow inhalation 
continued until their lungs were full of air (total lung capacity). After inhalation they held 
their breath for 10 seconds and for the second dose this was repeated 30 seconds later 
(Hindle et al., 1993). Subjects voided their urine pre-dosing and provide urine samples at 0, 
0.5, 1, 2, 4, 6, 12, and 24 hours post study dose. The volume of urine excreted was 
recorded and aliquots of each sample were frozen at -20° C prior to analysis. The order of 
the four study doses was randomized with a 7-day washout period between 
administrations. The HPLC method with solid phase extraction developed and validated 
for the assay of terbutaline from urine samples (previously described in section 3.3 in this 
thesis) was used to identify urinary terbutaline concentration. 
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7.2.2 Statistical analysis 
The urine samples were compared using two way analysis of variance (ANOVA) using 
SPSS V15.0 (SPSS Inc., Chicago, USA). The mean differences with 95% confidence 
interval were calculated. 
7.2.4 Results 
Twelve healthy volunteers (six females), whose mean (SD) age, weight and height, were 
29.1(4.6) years, 65.6(12.7) kg and 166.8(5.1) cm, respectively, with a FEV1 of 96.1(3.7) % 
of predicted completed the study. Table 7.1 describe the demographic data of the subjects. 
No terbutaline was detected in all urine samples following oral dosing with concomitant 
administration of oral charcoal [OC]. Each individual’s and the mean (SD) urinary 
excretion post I, IC and O dosing is shown in Tables 7.2-7.7. A summary of the mean (SD) 
amounts excreted during each collection period is shown in Table 7.8. Table 7.9 and 
Figure 7.2 describe the cumulative urinary excretion of terbutaline post study dosing. The 
mean (SD) urinary terbutaline excretion rates post study doses are shown in Table 7.10 and 
Figure 7.1. These show that negligible amounts of terbutaline were excreted in the urine 
following oral administration during the first 0.5 hour urine collection period. There was 
no terbutaline detected from the urine samples of five subjects during the first 30 minutes 
post oral dosing. A mean (SD) of 0.2 (0.2) µg and 167.7 (68.1) µg of the oral dose was 
excreted, in the urine, during the 0.5 and 24 hours post dose collection periods, 
respectively. Following the inhaled dose, the terbutaline renal excretion during the 0.5 and 
24 hours post dose collection periods were 7.4 (2.2) µg and 230.0 (86.2) µg excreted, 
respectively. The terbutaline excreted at the 0.5 and 24 hours collection periods following 
IC dosing were 6.5 (2.1) µg and 65.8 (32.6) µg, respectively. 
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Table 7.1 Demographic data of the patients that participated in the study 
Patient code Gender Age Height Weight FEV1 
1 Female 25.0 161.0 50.0 99.0 
2 Male 25.0 168.0 68.0 95.0 
3 Male 31.0 163.0 95.0 98.0 
4 Male 36.0 163.0 65.0 90.0 
5 Male 32.0 170.0 80.0 99.0 
6 Female 32.0 165.0 54.0 98.0 
7 Female 36.0 175.0 57.0 97.0 
8 Female 24.0 172.0 62.0 92.0 
9 Female 24.0 160.0 54.0 99.0 
10 Female 25.0 162.0 60.0 89.0 
11 Male 32.0 169.0 70.0 99.0 
12 Male 27.0 173.0 72.0 98.0 
Mean  29.1 166.8 65.6 96.1 
SD  4.6 5.1 12.7 3.7 
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Table 7.2 Individual and mean (SD) urinary terbutaline excretion rates post inhaled 500µg terbutaline sulphate dosing via a MDI (I) expressed in 
µg/hour, (n=12). 
Mid Point 1 2 3 4 5 6 7 8 9 10 11 12 Mean SD 
0.25 14.7 19.3 7.0 14.7 18.0 21.0 11.9 14.8 8.3 15.3 19.5 12.5 14.7 4.3 
0.75 18.6 46.0 6.1 5.4 16.9 12.4 14.9 3.8 0.7 46.0 11.6 14.7 16.4 14.9 
1.5 37.9 45.2 17.8 0.0 41.4 18.8 47.2 0.4 19.0 44.7 18.7 49.9 28.4 18.1 
3 22.4 41.5 28.2 14.0 24.5 57.8 15.4 13.8 28.9 41.3 50.3 14.1 29.3 15.1 
5 23.9 31.3 22.4 11.9 24.8 26.3 19.1 10.5 17.9 34.6 32.2 23.8 23.2 7.5 
9 5.2 13.0 5.4 7.7 4.0 13.2 1.6 7.4 5.0 13.7 11.9 3.6 7.6 4.2 
18 9.2 0.2 1.5 0.9 9.5 4.5 0.0 0.7 1.3 0.4 3.9 3.8 3.0 3.3 
 
Table 7.3 Individual and mean (SD) urinary terbutaline excretion rates post inhaled with charcoal 500µg terbutaline sulphate dosing via a MDI (IC) 
expressed in µg/hour, (n=12). 
Mid Point 1 2 3 4 5 6 7 8 9 10 11 12 Mean SD 
0.25 8.3 6.5 10.2 9.6 9.3 18.3 14.6 12.8 14.5 14.3 20.4 16.6 13.0 4.3 
0.75 4.7 0.5 0.0 1.5 4.1 1.4 1.1 1.0 1.1 1.1 1.6 1.3 1.6 1.4 
1.5 0.9 1.2 0.6 8.7 0.5 0.0 0.0 2.5 0.0 2.9 0.0 0.0 1.4 2.5 
3 4.5 9.5 11.7 2.5 0.0 0.0 1.7 1.7 12.1 9.2 0.0 1.2 4.5 4.7 
5 4.7 8.0 0.0 0.5 3.1 6.4 4.4 10.2 0.0 10.7 1.2 9.3 4.9 4.0 
9 0.4 5.6 1.7 0.9 0.9 4.4 4.1 5.2 1.8 5.6 5.1 4.5 3.4 2.0 
18 0.8 0.0 0.0 1.9 0.1 2.2 1.3 3.2 0.0 0.0 7.9 0.8 1.5 2.3 
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Table 7.4 Individual and mean (SD) urinary terbutaline excretion rates post oral ingestion 500µg terbutaline sulphate dosing (O) expressed in µg/hour, 
(n=12). 
Mid Point 1 2 3 4 5 6 7 8 9 10 11 12 Mean SD 
0.25 0.0 0.9 0.4 0.6 0.0 0.0 0.6 0.5 0.4 0.0 0.0 0.7 0.3 0.3 
0.75 4.4 9.7 7.0 11.1 5.1 15.1 13.0 10.3 7.0 9.6 15.1 30.2 11.5 6.9 
1.5 9.5 7.7 37.8 10.2 12.7 45.7 14.5 10.8 18.6 7.1 43.8 14.3 19.4 14.4 
3 24.0 20.6 13.4 14.5 30.9 18.6 34.3 13.4 7.1 20.6 16.3 40.2 21.2 9.7 
5 30.3 13.1 15.1 3.6 38.3 25.7 15.1 5.1 8.1 12.4 20.1 13.6 16.7 10.3 
9 8.2 3.6 4.3 1.7 10.7 14.6 6.5 2.4 2.2 2.5 15.5 6.9 6.6 4.8 
18 1.0 0.0 2.6 4.5 1.6 4.2 0.5 5.5 1.4 0.0 5.1 0.7 2.3 2.0 
 
Table 7.5 Cumulative urinary excretion of terbutaline post inhaled 500µg terbutaline sulphate dosing via a MDI (I) expressed in µg, (n=12). 
Time 1 2 3 4 5 6 7 8 9 10 11 12 mean SD 
0.5 7.4 9.6 3.5 7.3 9.0 10.5 6.0 7.4 4.1 7.6 9.8 6.2 7.4 2.2 
1 16.6 32.6 6.5 10.0 17.5 16.7 13.4 9.3 4.5 30.6 15.5 13.6 15.6 8.6 
2 54.5 77.8 24.3 10.0 58.8 35.5 60.7 9.8 23.5 75.3 34.2 63.5 44.0 24.1 
4 99.4 160.8 80.7 38.1 107.8 151.1 91.4 37.4 81.3 157.9 134.8 91.6 102.7 42.1 
6 147.1 223.4 125.4 61.8 157.3 203.7 129.6 58.3 117.1 227.1 199.2 139.3 149.1 56.5 
12 178.3 301.3 157.7 108.3 181.1 282.6 139.1 102.5 147.4 309.3 270.3 160.9 194.9 75.2 
24 288.4 304.2 176.0 119.2 295.1 336.7 139.1 111.0 163.4 313.9 316.9 206.3 230.8 86.2 
 
 
 
 
 184 
Table 7.6 Cumulative urinary excretion of terbutaline post inhaled with charcoal 500µg terbutaline sulphate dosing via a MDI (IC) expressed in µg, 
(n=12). 
Time 1 2 3 4 5 6 7 8 9 10 11 12 mean SD 
0.5 4.2 3.2 5.1 4.8 4.7 9.2 7.3 6.4 7.3 7.2 10.2 8.3 6.5 2.1 
1 6.5 3.5 5.1 5.6 6.7 9.9 7.9 6.9 7.8 7.7 11.0 9.0 7.3 2.1 
2 7.4 4.7 5.7 14.3 7.2 9.9 7.9 9.4 7.8 10.6 11.0 9.0 8.7 2.6 
4 16.5 23.6 29.1 19.3 7.2 9.9 11.3 12.7 31.9 29.0 11.0 11.3 17.7 8.6 
6 25.8 39.7 29.1 20.3 13.4 22.6 20.1 33.2 31.9 50.3 13.5 29.9 27.5 10.7 
12 28.5 73.1 39.6 25.4 19.1 48.9 44.9 64.5 42.9 83.8 44.3 57.1 47.7 19.3 
24 37.8 73.1 39.6 48.3 19.8 75.7 60.2 103.2 42.9 83.8 138.8 66.6 65.8 32.6 
 
Table 7.7 Cumulative urinary excretion of terbutaline post oral ingestion of 500µg terbutaline sulphate dosing (O) expressed in µg, (n=12). 
Time 1 2 3 4 5 6 7 8 9 10 11 12 mean SD 
0.5 0 0.4 0.2 0.3 0 0 0.3 0.2 0.2 0 0 0.4 0.2 0.2 
1 2.2 5.3 3.7 5.9 2.6 7.6 6.8 5.4 3.7 4.8 7.5 15.5 5.9 3.5 
2 11.7 12.9 41.5 16.1 15.2 53.3 21.3 16.2 22.3 11.9 51.3 29.7 25.3 15.2 
4 59.7 54.2 68.3 45.1 77.1 90.5 89.9 43.1 36.4 53.1 83.9 110.2 67.6 22.8 
6 120.3 80.4 98.6 52.2 153.7 141.9 120.1 53.3 52.7 77.9 124.1 137.4 101.0 36.9 
12 169.2 102.3 124.2 62.6 217.7 229.7 158.9 67.4 66.0 93.0 216.9 178.8 140.6 62.8 
24 181.1 102.3 155.8 117.1 237.3 279.9 164.7 133.1 83.2 93.0 277.5 187.1 167.7 68.1 
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Table 7.8 The mean (SD) amounts of urinary terbutaline excreted, expressed in µg, during 
each collection period post 500µg terbutaline sulphate dosing via a MDI (I), a MDI with 
simultaneous oral administration of 20g activated charcoal (IC) and an oral solution of 
500µg terbutaline sulphate (O). 
Time in Hour I IC O 
0.0-0.5 7.4(2.2) 6.5(2.1) 0.2(0.2) 
0.5-1 8.2(7.4) 0.8(0.7) 5.7(3.4) 
1-2 28.4(18.1) 1.4(2.5) 19.4(14.4) 
2-4 58.4(30.2) 9.0(9.5) 42.3(19.4) 
4-6 46.4(15.1) 9.8(8.0) 33.4(20.6) 
6-12 45.8(25.5) 20.2(12.1) 39.5(28.8) 
12-24 35.9(40.0) 18.1(27.2) 27.1(24.5) 
 
Table 7.9 The mean (SD) cumulative urinary excretion of terbutaline excreted, expressed 
in µg, post 500µg terbutaline sulphate dosing via a MDI (I), a MDI with simultaneous oral 
administration of 20g activated charcoal (IC) and an oral solution of 500µg terbutaline 
sulphate (O). 
Time in Hour I IC O 
0.5 7.4(2.2) 6.5(2.1) 0.2(0.2) 
1 15.6(8.6) 7.3(2.1) 5.9(3.5) 
2 44.0(24.1) 8.7(2.6) 25.3(15.2) 
4 102.7(42.1) 17.7(8.6) 67.6(22.8) 
6 149.1(56.5) 27.5(10.7) 101.0(36.9) 
12 194.9(75.2) 47.7(19.3) 140.6(62.8) 
24 230.8(86.2) 65.8(32.6) 167.7(68.1) 
 
Table 7.10 Mean (SD) urinary terbutaline excretion rates post 500µg terbutaline sulphate 
dosing via a MDI (I), a MDI with simultaneous oral administration of 20g activated 
charcoal (IC) and an oral solution of 500µg terbutaline sulphate (O) expressed as µg/hour, 
(n=12). 
Mid Point I IC O 
0.25 14.7(4.3) 13.0(4.3) 0.3(0.3) 
0.75 16.4 (14.9) 1.6 (1.4) 11.5 (6.9) 
1.5 28.4 (18.1) 1.4 (2.5) 19.4 (14.4) 
3 29.3 (15.1) 4.5 (4.7) 21.2 (9.7) 
5 23.2 (7.5) 4.9 (4.0) 16.7 (10.3) 
9 7.6 (4.2) 3.4 (2.0) 6.6 (4.8) 
18 3.0 (3.3) 1.5 (2.3) 2.3 (2.0) 
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Figure 7.1 Mean (SD) urinary terbutaline excretion rates post study doses. 
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Figure 7.2 Mean (SD) cumulative urinary excretion of terbutaline, expressed in µg, post 
500µg terbutaline sulphate dosing via a MDI (Inhalation), a MDI with simultaneous oral 
administration of 20g activated charcoal and an oral solution of 500µg terbutaline. 
 
Figure 7.3 shows that, the amount of terbutaline recovered at 30 minutes post dose was 
significantly higher after inhaled and IC compared with oral (p<0.001). The mean 
difference (95% confidence intervals) for the 0.0–0.5 hour urinary drug excretion post 
inhaled and IC administration compared with oral administration were 7.2 (5.7, 8.7) µg and 
6.3 (4.9, 7.8) µg, respectively (p<0.001).  
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Figure 7.3 Individual (n=12) and mean (SD) amounts of terbutaline expressed in µg 
recovered post 500µg terbutaline sulphate dosing via (a) MDI [I] vs the oral solution [O], 
(b) a MDI and 20g oral activated charcoal [IC] vs the oral solution [O] and (c) MDI [I] vs a 
MDI and 20g oral activated charcoal [IC]. 
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A summary of the statistical comparison between I, IC and O is presented in Table 7.11.  
No significant difference was found between the amount of terbutaline excreted in the 
urine samples 0.0–0.5 hour post dose following inhaled and IC administration as shown in 
Figure 7.3c and Table 7.11.  
 
Table 7.11 Mean difference (95% confidence interval) between the cumulative amount (in 
µg) excreted post different times for I vs O, IC vs O and I vs IC.  
Time I vs O (µg) IC vs O (µg) I vs IC (µg) 
0.5 hour 7.2 (5.7, 8.7)*** 6.3 (4.9, 7.8)*** 0.9 (-0.7, 2.4) 
1 hour 9.7 (5.0, 14.3)*** 1.4 (-3.3, 6.0) 8.3 (3.6, 12.9)*** 
2 hours 18.7 (3.6, 33.8)** -16.6 (-31.7, -1.5)* 35.3 (20.2, 50.4)*** 
4 hours 35.1 (12.1, 58.0)*** -49.9 (-72.8, -27.0)*** 85.0 (62.0, 107.9)*** 
6 hours 48.1 (17.9, 78.3)** -73.6 (-103.8, -43.3)*** 121.6 (91.4, 151.8)*** 
12 hours 54.3 (10.6, 98.0)** -92.9 (-136.6, -103.5)*** 147.2 (103.5, 190.9)*** 
24 hours 69.3 (23.8, 114.7)** -101.9 (-147.3, -56.424)*** 171.1 (125.7, 216.6)*** 
* p<0.05, ** <0.01, ***<0.001 otherwise no significant difference. 
  
Table 7.11 shows that when comparing the cumulative amount excreted in the urine 
following inhaled and oral dosing, a significant difference (p<0.01) was found at 0.0-2, 
0.0-6, 0.0-12 and 0.0-24 hours urine collection intervals investigated and the difference 
was found more significant (p<0.001) at 0.0-0.5, 0.0-1 and 0.0-4 hours urine collection 
interval. When comparing the cumulative amount excreted in the urine following IC and 
oral dosing, a significant difference (p<0.001) was found at all time intervals investigated, 
except for the cumulative excretion over the first hour where no significant difference was 
found and (p<0.05) over the first 2 hours. 
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The mean (SD) urinary excretion of terbutaline over the 24 hours period post dosing of 
inhaled (I) dosing, inhaled plus charcoal (IC) and oral (O) as 230.0 (86.2), 65.8 (32.6) and 
167.0 (68.1)µg, respectively. The 0-24 hours urinary terbutaline excretion following IC 
was a mean (SD) of 16.0 (7.9) % of the nominal dose. This represents the total lung 
bioavailability for the MDI.  
7.2.5 Discussion 
Statistically significantly more amounts of terbutaline were excreted in the urine following 
inhalation compared with oral administration during the first 30 minutes post dose. The 
ratios of the amounts of terbutaline recovered in the urine following oral and inhaled 
administration were 1:43.1 and 1:1.37 for the 0.5 and 24 hours urinary collection periods 
post dose, respectively. The high 0.5 hour ratio is due to the rapid and complete absorption 
of the terbutaline fraction deposited in the lungs, and the slow and negligible early 
absorption from the gastrointestinal tract that highlights the lag time for drug absorption 
from the gastrointestinal tract. This is similar to the salbutamol urinary excretion data 
following inhaled and oral administration originally presented by Hindle & Chrystyn 
(Hindle and Chrystyn, 1992). In this original study the mean ratio (SD) of inhaled to oral 
excretion at 0.5 hour and 24 hours was 8.3 (2.2) and 0.92 (0.25) respectively. As expected 
since the activated charcoal effectively blocks the gastrointestinal absorption of terbutaline 
then the amount excreted in the urine following inhaled administration with oral charcoal 
did not differ significantly from that following inhaled dosing during the first 0.5 hour 
urine collection period. The significant difference between the amounts of urinary 
terbutaline in samples taken more than 0.5 hour post inhalation from the inhaled and IC 
highlights the contribution of the orally absorbed fraction.  
Thus the amount of terbutaline excreted in the urine during the first 0.5 h following 
inhalation can be used as an index of the relative bioavailability of terbutaline to the lungs 
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following inhalation. This index could be, therefore, used to compare the in-vivo lung 
deposition of inhaled terbutaline products or methods of inhalation.  
The low ratios (1:1.37) of the amounts of terbutaline recovered in the urine following oral 
and inhaled administration confirms that this index identifies the relative total systemic 
bioavailability of terbutaline post inhalation. Hence the amount of terbutaline delivered to 
the body and excreted in the urine over the 24 hours post inhalation period could be used to 
compare the systemic delivery following inhalation of different products or by different 
techniques. This index represents the relative bioavailability to the body following an 
inhalation. The 24 hours terbutaline excreted post oral dosing was relatively lower than 
that post inhalation even though the doses are the same. This might be due to the 
incomplete absorption of the oral dose compared to the inhaled dose. This was consistent 
with the previously reported relative bioavailability of oral terbutaline [14.8%] 
(Martindale, 2002) compared to the relative bioavailability of inhaled terbutaline [16.51%] 
(Borgstrom and Nilsson, 1990). Finally this 16.5% lung deposition for the MDI with oral 
charcoal reported by Borgstrom and Nilsson (1990) is very similar to the 16.0% reported in 
this study. 
7.3 Intra- and inter-subject variability 
7.3.1 Methods 
7.3.1.1 Equipment and inhalation devices 
Inhaler device: 
 
Bricanyl Metered Dose Inhaler labelled as a nominal dose of 
250μg terbutaline sulphate per shot (AstraZeneca, UK) 
HPLC condition: Previously described in section 3.3 in this thesis 
7.3.1.2 Procedure 
Ethical approval was obtained from the University of Bradford and all volunteers gave 
signed informed consent. Twelve non-smoking volunteers (six females), older than 18 
years with a FEV1> 90% of predicted, agreed to repeat the MDI inhalation study dose 
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(described as [I] in section 7.2) on five separate occasions to determine the reproducibility 
of the 30 minutes urinary terbutaline. They all received training on how to use a metered 
dose inhaler (MDI) and the MDI was shaken and primed by firing two doses to waste 
before use (Barry and O'Callaghan, 2003). Subjects were trained to shake the MDI, remove 
the cap, exhale slowly as far as comfortable, put the MDI into their mouth and seal their 
lips round the mouthpiece. They were then instructed to start a slow inhalation through 
their mouth and activate the MDI immediately after the start of this slow inhalation. This 
slow inhalation continued until total lung capacity. After inhalation they held their breath 
for 10 seconds and for the second dose this was repeated 30 seconds later (Hindle et al., 
1993). 
Following a light breakfast and no caffeine or alcohol containing drinks for at least 12 
hours, each subject inhaled two doses from a Bricanyl MDI (labelled 250µg terbutaline 
sulphate nominal dose, AstraZeneca, UK). Immediately before each study dose(s) each 
subject voided their urine and then provided a urine sample 30 minutes after the start of the 
first dose. The volume was measured and the urinary terbutaline assayed using the 
previously validated HPLC method described in section 3.3 in this thesis. 
7.3.2 Results 
Twelve (six females) healthy non-smoking subjects with a mean (SD) age, weight and 
height of 29.2(4.7) years, 66.8(13.3) kg and 168.2(6.2) cm, respectively and FEV1 
96.8(3.2) % of predicted completed the reproducibility study. Table 7.12 describe the 
demographic data of the subjects. The mean 30 minutes post inhalation urinary terbutaline 
excretion and coefficient of variation is shown in Table 7.13 The mean (SD) urinary 
terbutaline in the 30 minutes post inhalation was 10.4(2.9) µg following the two doses and 
the mean (SD) intra-subject coefficient of variation was 9.2 (2.1) %. The mean (SD) inter-
subject coefficient of variation was 28.8 (1.0) %. 
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Table 7.12 Demographic data of the patients that participated in the study 
Patient code Gender Age Height Weight FEV1 
1 Female 25.0 161.0 50.0 99.0 
2 Male 25.0 168.0 68.0 95.0 
3 Male 31.0 163.0 95.0 98.0 
4 Male 32.0 170.0 80.0 99.0 
5 Male 27.0 173.0 72.0 99.0 
6 Male 37.0 180.0 80.0 98.0 
7 Female 24.0 160.0 54.0 99.0 
8 Female 25.0 162.0 60.0 89.0 
9 Male 32.0 169.0 70.0 99.0 
10 Female 32.0 165.0 54.0 98.0 
11 Female 36.0 175.0 57.0 97.0 
12 Female 24.0 172.0 62.0 92.0 
Mean  29.2 168.2 66.8 96.8 
SD  4.7 6.2 13.3 3.2 
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Table 7.13 Urinary excretion of terbutaline 30 minutes post inhalation of two 250µg terbutaline sulphate doses from the MDI for the 12 individuals on 
five different occasions. 
Occasion 1 2 3 4 5 6 7 8 9 10 11 12 Mean SD inter-subject C.V.% 
1 10.3 8.5 5.1 13.9 10.0 7.7 9.2 12.7 7.1 12.6 9.7 15.8 10.2 3.1 30.0 
2 10.2 10.3 4.2 11.5 9.9 8.0 10.1 12.5 7.2 13.7 10.9 15.4 10.3 3.0 28.6 
3 8.6 8.2 5.8 12.2 10.2 9.7 9.4 15.9 8.2 14.6 9.9 12.4 10.4 2.9 27.5 
4 8.0 9.0 5.5 12.6 8.4 9.6 10.1 14.5 9.4 14.5 9.8 15.2 10.5 3.0 28.6 
5 9.5 9.1 5.3 13.4 8.4 9.5 10.0 14.8 7.8 12.7 8.7 15.5 10.4 3.1 29.4 
Mean 9.3 9.0 5.2 12.7 9.4 8.9 9.8 14.1 7.9 13.6 9.8 14.8 10.4 2.9 28.8 (1.0) 
SD 1.0 0.8 0.6 1.0 0.9 1.0 0.4 1.4 0.9 1.0 0.8 1.4    
intra-subject C.V.% 10.7 9.0 11.9 7.6 10.0 10.8 4.6 10.2 11.8 7.0 8.1 9.3 9.2 (2.1)  
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7.3.3 Discussion 
Healthy volunteers were used because lung deposition is affected by the airway calibre and 
the renal function and those should remain stable in healthy volunteers (Lipworth and 
Clark, 1997a). The inter-subject variability was high [28.8 (1.0) % after two dose] due to 
between subject variability of lung deposition together with their renal excretion. This 
variability between subjects is consistent with previous reports (Chege and Chrystyn, 1994; 
Hindle and Chrystyn, 1992; Hindle et al., 1995; Hindle et al., 1994; Tomlinson et al., 
2003). However the intra-subject variability was much [9.2 (2.1) %] lower and similar to 
that reported by Hindle and Chrystyn (1992) when volunteers inhaled four doses (Hindle 
and Chrystyn, 1992; Tomlinson et al., 2003). Hence the method is suitable for cross over 
studies. 
7.4 Dose response relationship 
7.4.1 Methods 
7.4.1.1 Equipment and inhalation devices 
As section 7.3.1.1 
7.4.1.2 Procedure 
Ethical approval was obtained from the University of Bradford and all volunteers gave 
signed informed consent. The twelve subjects (six females) were healthy, non-smoking 
volunteers older than 18 years with a FEV1> 90% of predicted. They all received training 
on how to use a metered dose inhaler (MDI). The MDI was shaken and primed by firing 
two doses to waste before use (Barry and O'Callaghan, 2003). Subjects were trained to 
shake the MDI, remove the cap, exhale slowly as far as comfortable, put the MDI into their 
mouth and seal their lips round the mouthpiece. They were then instructed to start a slow 
inhalation through their mouth and actuate the MDI immediately after the start of this slow 
inhalation. This slow inhalation continued until total lung capacity. After inhalation they 
held their breath for 10 seconds and if another dose was scheduled it was inhaled 30 
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seconds later (Hindle et al., 1993). On each of the four occasions, following a light 
breakfast and no caffeine or alcohol containing drinks for at least 12 hours, each subject 
randomly inhaled either one, two, three or four doses from a Bricanyl MDI (labelled 250µg 
terbutaline sulphate nominal dose, AstraZeneca, UK). Immediately before each study 
dose(s) each subject voided their urine and then provided a urine sample 30 minutes after 
the start of the first dose and cumulatively collected their urine for the rest of the 24 hours. 
The volume was measured and the urinary terbutaline assayed using the previously 
validated HPLC method described in section 3.3 in this thesis. 
Statistical analysis looked at the linear regression to identify correlation coefficient (r), 
intercept and slope for each subject together with an inspection to determine if there was a 
systematic deviation from the overall line of linear regression using the residuals. 
 7.4.2 Results 
Twelve (six females) healthy subjects with a mean (SD) age, weight and height of 
28.5(4.0) years 67.3(13.9) kg, 168.2(6.2) cm, respectively and FEV1 96.8(3.2) % predicted 
completed all four inhalations. Table 7.14 describe the demographic data of the subjects. 
Table 7.15 and Figure 7.4-7.7 show the mean (SD) and individual cumulative urinary 
excretion of terbutaline following inhaled one, two, three and four dose(s) of 250µg via a 
MDI expressed as µg, (n=12). 
Although there was an inter-subject variability the amount of terbutaline excreted in the 
urine during the first 30 minutes and 24 hours post dosing were linear (p< 0.002) with the 
dose. The mean (SD) for the r values was 0.9858(0.0202) with a range of 0.9255 to 0.9996. 
The regression slopes were significantly above zero. The mean (SD) terbutaline excreted 
after one, two, three and four doses during the 30 minutes post start of the inhalation was 
4.23(2.13), 8.94(2.74), 13.05(3.1) and 18.27(4.68) µg, respectively and the mean (SD) 24 
hours urinary terbutaline was 103.9(52.2), 219.6(67.4), 320.6(76.1) and 448.6(115) µg, 
respectively. 
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Table 7.14  Demographic data of the patients that participated in the study 
Patient code Gender Age Height Weight FEV1 
1 Female 25.0 161.0 50.0 99.0 
2 Male 25.0 168.0 68.0 95.0 
3 Male 31.0 163.0 95.0 98.0 
4 Male 29.0 180.0 85.0 98.0 
5 Male 32.0 170.0 80.0 99.0 
6 Female 32.0 165.0 54.0 98.0 
7 Male 32.0 169.0 70.0 99.0 
8 Male 27.0 173.0 72.0 98.0 
9 Female 36.0 175.0 57.0 97.0 
10 Female 24.0 172.0 62.0 92.0 
11 Female 24.0 160.0 54.0 99.0 
12 Female 25.0 162.0 60.0 89.0 
Mean  28.5 168.2 67.3 96.8 
SD  4.0 6.2 13.9 3.2 
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Table 7.15 Urinary excretion of terbutaline post MDI inhalation expressed in µg, (n=12). 
Number of doses Time 1 2 3 4 5 6 7 8 9 10 11 12 Mean SD 
One dose 0.5 3.6 3.5 2.3 4.0 2.3 5.4 4.6 1.7 3.0 4.0 7.5 8.8 4.2 2.1 
24 88.3 85.5 57.5 97.2 56.9 132.3 112.5 42.5 73.9 98.0 185.1 217.2 103.9 52.2 
Two doses 0.5 8.5 11.6 3.5 7.3 9.2 10.5 10.1 5.1 9.7 7.8 10.4 13.6 8.9 2.7 
24 209.9 285.5 85.8 180.2 225.3 257.4 248.4 126.2 237.0 192.0 254.5 332.8 219.6 67.4 
Three doses 0.5 12.9 14.7 6.3 10.4 15.0 15.3 13.1 12.4 11.0 13.6 13.0 19.1 13.1 3.1 
24 316.4 360.2 154.2 255.6 368.0 375.7 321.3 305.5 270.1 332.9 318.9 468.9 320.6 76.1 
Four doses 0.5 20.5 22.5 10.1 13.0 19.7 19.8 16.6 19.1 12.7 21.7 16.8 26.6 18.3 4.7 
24 504.5 553.4 247.9 318.4 484.0 486.5 408.9 468.0 311.6 534.1 412.9 653.4 448.6 114.9 
 One dose is 250µg terbutaline sulphate 
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Figure 7.4 The individual amounts of urinary terbutaline excreted 30 minutes post MDI 
dosing (n=12). 
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Figure 7.5 The mean (SD) [n=12] amounts of urinary terbutaline excreted 30 minutes post 
MDI dosing. 
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Figure 7.6 The individual amounts of urinary terbutaline excreted 24 hours post MDI 
dosing (n=12). 
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Figure 7.7 The mean (SD) [n=12] amounts of urinary terbutaline excreted 24 hours post 
MDI dosing. 
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7.4.3 Discussion 
The dose–response relationships for the 30 minute and 24 hours terbutaline urinary excretion 
post dosing were linear. This is consistent with the results of a similar study for salbutamol by 
Tomlinson et al. (2003). In this study Tomlinson and colleges concluded that the 30 minute 
salbutamol urinary excretion post inhalation pharmacokinetic method was linear with the 
inhaled dose (p<0.001) and reproducible.  
Regulatory Authorities favour the demonstration of clinical equivalence using the degree of 
protection to a bronchoprovocation agent together with in-vitro characterization of the emitted 
dose (Adams et al., 1994). Hence simultaneous measurements of 30 minute urinary salbutamol 
excretion and the dose of methacholine to reduce the FEV1 by 20% following one and two 
doses would support the pharmacokinity method as a positive link to the clinical bioassay. The 
study of salbutamol from an Easibreathe in 12 asthmatics had shown the two methods to be 
equal (Tomlinson et al., 2005). The study demonstrated a correlation between the 
pharmacokinetic and pharmacodynamic method. Twelve asthmatics inhaled 0, 1 and 2 doses 
of 100 mg salbutamol from a breath-activated MDI on separate study days. The mean (SD) 
salbutamol 30 minutes post dose was 0, 2.25 (0.65) and 5.18 (1.68) mg, respectively, with a 
ratio between 1 : 2 doses of 2.30. The mean (SD) PD20 was 0.21 (0.24), 0.74 (0.70) and 1.69 
(1.60) mg, respectively, with a ratio of 2.28 between 1 and 2 doses. This positive link to a 
clinical bioassay together with the reproducibility and dose–response properties highlight the 
potential of this 30 minute index of lung deposition in studies to compare different inhalation 
products and inhalation methods. 
7.5 General conclusions 
The amount excreted following an inhaled terbutaline sulphate dose taken together with an oral 
dose of activated charcoal represents the pulmonary absorbed fraction and because of the lack 
of difference between the inhaled and inhaled plus oral charcoal (IC) in the first 30 minutes 
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then the use of activated charcoal is not necessary when this method is used to compare 
between different products or techniques. In addition, the magnitude of the difference between 
the amount excreted in the first 30 minute following oral and inhaled dosing confirm that this 
30 minutes urinary excretion of terbutaline post inhalation is an index of the relative 
bioavailability of terbutaline to the lungs following inhalation. The similarity between the 24 
hours excretion post inhaled dosing (I) and the oral (O) dosing confirms that the 24 hours 
urinary excretion of terbutaline is an index that identifies the relative total systemic 
bioavailability of terbutaline post inhalation and can be used to compare the delivered dose to 
the body from two different inhalation products or methods. The method is linear and 
reproducible similar to that for urinary salbutamol method (Tomlinson et al., 2003). 
Thus the urinary drug excretion technique, which has already been considered to be the basis 
for a novel clinical equivalence test for inhalation products of salbutamol (Hindle and 
Chrystyn, 1992) and extended to sodium cromoglycate (Aswania et al., 1997; Aswania and 
Chrystyn, 2002), nedocromil (Aswania et al., 1998), gentamicin (Al-Amoud et al., 2005; Al-
Amoud et al., 2002), tobramycin. (Barber, 2002) and formoterol (Nadarassan et al., 2007), can 
also be used for other water-soluble inhaled drugs like terbutaline.  
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8.1 Introduction  
The bioequivalence of inhaled products is complicated because the therapeutic effect is 
influenced by the topical deposition of drug in the lungs and safety is determined by systemic 
delivery. For inhaled corticosteroids, oropharyngeal impaction is also considered with respect 
to safety because of the potent side effect of the corticosteroids in this area. Regulatory 
Authorities favour the demonstration of clinical equivalence using the degree of protection to 
a bronchoprovocation agent together with in-vitro characterization of the emitted dose (Adams 
et al., 1994). This method measures the amount of inhaled bronchoprovocation agent that is 
required to reduce the FEV1 by 20% following the inhalation of a placebo and active drug. 
Any method used in bioequivalence studies should be reproducible and have a dose response 
relationship. This has been reported for the bronchoprovocation method (Creticos et al., 2002). 
However, most clinical studies are carried out using measurements at the plateau portion of 
the dose response relationship (Chrystyn, 2000). 
Hindle and Chrystyn (1992) have shown that the amount of salbutamol excreted in the urine 
during the first 30 minutes post inhalation represents the amount of drug deposited in the 
lungs. This urinary salbutamol pharmacokinetic method has been used to compare metered 
dose inhalers when attached to a large volume spacer (Chege and Chrystyn, 1994) and dry 
powder inhalers (Hindle et al., 1995; Hindle et al., 1994). Another study by Tomlinson et al. 
(2005) has shown that this method is more sensitive to demonstrate a difference between 
inhalation techniques than bronchoprovacation challenge test using methacholine (Tomlinson 
et al., 2005). The validation of this method for terbutaline is described in chapter 7.  
To demonstrate the application of the urinary terbutaline pharmacokinetic method the aims of 
this chapter are 
1. To evaluate the effect of inhalation technique on the lung and systemic bioavailability 
following inhalation from a dry powder inhaler after slow and fast inhalation flow. 
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2. To detect the effect of different spacers on the lung and the systemic bioavailability of 
inhaled terbutaline from the MDI. 
3. To show the effect of different nebulisers on the lung and the systemic bioavailability of 
nebulised terbutaline. 
8.2 Relative lung and systemic bioavailability of terbutaline inhaled from a dry powder 
inhaler using different inhalation flow 
8.2.1 Methods 
8.2.1.1 Equipment and inhalation devices 
Inhaler device: 
 
Bricanyl Turbuhaler labelled as a nominal dose of 500μg 
terbutaline sulphate per inhalation (AstraZeneca, UK) 
In-Check Dial: Clement Clarke International, UK 
HPLC condition: Previously described in section 3.3 in this thesis 
8.2.1.2 Procedure 
Ethical approval was obtained from the University of Bradford and all volunteers gave signed 
informed consent. Twelve non-smoking volunteers (six females), older than 18 years with an 
average FEV1> 90% of predicted, agreed to inhale through a terbutaline sulphate Turbuhaler 
(Bricanyl, labelled 500µg terbutaline sulphate nominal dose, AstraZeneca, UK) using slow 
and fast inhalation flows. They were trained how to inhale using a slow inhalation flow (30 L 
min-1) and also a fast inhalation flow (60 L min-1) with aid of the In-Check Dial. They all 
received training on how to use a DPI. Doses were loaded for the subject before use according 
to the patient information leaflet. Subjects were trained to breathe out gently but not breathe 
out through the inhaler, prepare a dose for inhalation as recommended in the patient 
information leaflet, then place the mouthpiece between1their lips and inhale through their 
mouth, according to the inhalation flow to be used, inhalation continued till their lungs were 
full (total lung capacity) and they then removed the Turbuhaler from their mouth and held 
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their breath for 10 seconds before breathing out slowly followed by normal breathing. Each 
subject inhaled two doses from two separate Bricanyl Turbuhalers using either a slow or a fast 
inhalation flow in random order of slow and fast inhalation manoeuvres. 
The use of the two Turbuhalers was to avoid the inhalation of the residual part that would 
remain in the Turbuhaler from first dose. The residual part was later removed from the 
Turbuhaler by discharge to waste using a very high inhalation flow (over 90 L min-1) for 16 
seconds. This flow has been reported to clear the Turbuhaler from residue (Tarsin et al., 2004). 
On each study day subjects were allowed to have a light breakfast and no caffeine or alcohol 
containing drinks for at least 12 hours before dosing. Immediately before each study dose each 
subject voided their urine and then provided a urine sample 30 minutes after the start of the 
first dose and cumulatively collected their urine for 24 hours. The volume of urine samples 
was measured and the urinary terbutaline assayed using the previously validated HPLC 
method described in section 3.3 of this thesis. The urine samples at slow and fast inhalation 
flows were compared using a two way analysis of variance (ANOVA) test using SPSS V15.0 
(SPSS Inc., Chicago, USA).  
8.2.2 Results 
Twelve (six females) healthy non-smoking subjects with a mean (SD) age, weight and height 
of 29.2(4.8) years, 66.3(11.8) kg and 170.5(7.4) cm, respectively and FEV1 96.1 (3.7) % of 
predicted completed this DPI flow effect study. Table 8.1 describe the demographic data of the 
subjects. The individual and mean (SD) urinary excretion of terbutaline post inhalation of two 
doses of 500µg terbutaline sulphate from the Turbuhaler DPI at slow and fast inhalation flow 
are shown in Tables 8.2 and 8.3 and Figure 8.1 and 8.2. 
The mean (SD) terbutaline excreted after slow and fast inhalation flow during the 30 minutes 
post start of the inhalation was 5.1(4.3) and 18.3(12.4) µg, respectively as shown in Figure 
8.1. These values are equivalent to 0.6(0.5) and 2.2(1.5) %, respectively when calculated as a 
 205 
percentage of the nominal dose. The mean (SD) amount of terbutaline excreted in the urine 
over the first 24 hours post inhalation was 249.7(210.6) and 534.9(199.2) µg, respectively as 
shown in Figure 8.2. These values are equivalent to 30.4(25.6) and 65.1(24.3) %, respectively 
when calculated as a percentage of the nominal dose. Statistical analysis revealed that the 
mean difference (95%; confidence interval) between fast and slow inhalation flow for the 
terbutaline excreted in 0.0-0.5 hour interval was 13.2 (6.5, 19.9; p<0.001) µg and for the 
amounts of terbutaline excreted over the 24 hours period post inhalation was 285.1 (154.4, 
415.8; p<0.001) µg. 
 
Table 8.1 Demographic data of the patients that participated in the study 
Patient code Gender Age Height Weight FEV1 Sequence of flow* 
1 Female 25.0 161.0 50.0 99.0 A2 
2 Male 25.0 168.0 68.0 95.0 A1 
3 Male 32.0 170.0 80.0 99.0 A2 
4 Female 32.0 165.0 54.0 98.0 A1 
5 Male 34.0 180.0 74.0 90.0 A1 
6 Male 27.0 173.0 72.0 99.0 A2 
7 Male 37.0 180.0 80.0 98.0 A2 
8 Female 36.0 175.0 57.0 97.0 A2 
9 Female 24.0 172.0 62.0 92.0 A2 
10 Female 24.0 160.0 54.0 99.0 A1 
11 Female 25.0 162.0 60.0 89.0 A1 
12 Male 29.0 180.0 85.0 98.0 A1 
Mean  29.2 170.5 66.3 96.1  
SD  4.8 7.4 11.8 3.7  
*A1is fast flow first and A2 is slow flow first 
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Table 8.2 Mean (SD) and individual urinary excretion of terbutaline 0.5 hr. post inhalation of two 500µg terbutaline sulphate doses from the 
Turbuhaler using slow and fast inhalation flows [expressed in µg] (n=12). 
Flow 1 2 3 4 5 6 7 8 9 10 11 12 Mean SD 
Slow 1.3 4.8 2.4 0.9 6.4 3.3 3.2 5.0 0.8 10.8 7.3 15.0 5.1 4.3 
Fast 4.4 17.1 25.4 21.4 8.5 3.2 20.0 15.2 7.1 48.3 22.2 26.4 18.3 12.4 
 
 
Table 8.3 Mean (SD) and individual urinary excretion of terbutaline over the first 24 hr. post inhalation of two 500µg terbutaline sulphate 
doses from the Turbuhaler using slow and fast inhalation flows [expressed in µg] (n=12). 
Time 1 2 3 4 5 6 7 8 9 10 11 12 Mean SD 
Slow 66.0 233.6 117.6 42.2 313.3 160.4 156.1 244.4 39.0 529.9 356.2 737.7 249.7 210.6 
Fast 215.4 698.0 658.7 625.0 419.8 156.0 634.6 598.7 349.3 738.4 610.5 713.8 534.9 199.2 
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Figure 8.1 Mean (n=12) and the individual amounts of urinary terbutaline excreted 30 minutes 
post 500µg terbutaline sulphate dosing from the DPI after using a fast and slow inhalation 
flow. 
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Figure 8.2 Mean (n=12) and the individual amounts of urinary terbutaline excreted over the 
first 24 hours post 500µg terbutaline sulphate dosing from the DPI after using a fast and slow 
inhalation flow. 
 208 
8.2.3 Discussion 
The amount excreted 30 minutes and 24 hours post dosing using inhalation flows 30 and 60 L 
min-1 confirm the application of the urinary terbutaline pharmacokinetic method for inhaled 
terbutaline. 
The results indicates that the fast inhalation flow resulted in a significantly higher amount of 
urinary terbutaline excretion 30 minutes and 24 hours post dosing than slow inhalation 
(P<0.001). These results are consistent with the instructions on the use of the Turbuhaler, as 
explained in the device pamphlet, which is to inhale as fast and as deep as possible.  
The results were also consistent with the most desirable inhalation flow for use with the 
Turbuhaler which has been reported to be 60 L min-1 (Borgstrom et al., 1996). Most 
importantly the results are consistent with the in-vitro results in chapter 4 which showed that 
the emitted dose, FPD and FPF are affected by the inhalation flow used. The data shown in 
chapter 4 showed that the increase in the inhalation flow increased the FPD, FPF and the total 
emitted dose. At low flow the decrease in lung deposition is due to the incomplete de-
aggregation of the drug from the device. 
A scintigraphy study by Newman et al (1991) has also showed similar results that support the 
inhalation at fast inhalation flow from a Turbuhaler. In this study the deposition of 500µg 
terbutaline sulphate from the Turbuhaler was measured in 10 asthmatic subjects at two 
inhalation flows (fast, mean 57 L min-1 and slow, mean 28 L min-1). When using a fast 
inhalation flow, a mean (SD) 16.8 (2.6) % of the dose was deposited in the lungs compared 
with 9.1 (1.5) % of the dose for slow inhalation flow (p<0.01). At either flows, the majority of 
the dose was deposited in the oropharynx. This represents a higher relative bioavalaibility than 
found 30 minutes post fast and slow inhalation flows. This might be due to that the gamma 
scintigraphy methodology that includes drug deposited into the lungs which is cleared by 
mucociliary clearance. 
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Radiolabeled budesonide inhaled from a Turbuhaler by 10 healthy volunteers revealed that the 
mean (SD) total lung dose was 14.8% (3.3) of nominal dose when using a slow inhalation flow 
rate (36 L min-1) and 27.7% (9.5) for a fast flow rate (58 L min-1). Hence the inhalation of 
budesonide at the fast flow resulted in a significant increase in lung deposition compared with 
the slower flow which was matched by a decrease in deposition in the oropharynx and 
mouthpiece (Borgstrom et al., 1994).  
A recent study by Meyer et al (2004) had compared the in-vivo and the in-vitro data 
representing the deposition of radiolabeled foradil (Aeroliser) in human lungs. The study 
involved in-vivo results of 10 healthy volunteers and the in-vitro results from the dose 
emission test and aerodynamic characteristics. The results were combined using a 
mathematical model of lung deposition (Meyer et al., 2004). Both in-vitro and in-vivo 
measurements showed a significant increase in the dose delivered as the flow increased 
(Meyer et al., 2004). A study by De Boer et al. (1996) showed that the higher inhalation flow 
result in more FPD. The study also showed that at low flows de-aggregation of drug and 
carrier was incomplete (de Boer et al., 1996). 
8.3 Relative lung and systemic bioavailability of terbutaline inhaled from metered dose 
inhaler with different spacers using urinary drug excretion post inhalation 
8.3.1 Materials and Methods 
8.3.1.1 Equipment and inhalation devices 
Inhaler and spacer devices 
Bricanyl Metered Dose Inhaler: Labelled as a nominal dose of 250μg terbutaline 
sulphate per shot (AstraZeneca, UK) 
AeroChamber MAX spacer: Valved Holding Chambers; Trudell Medical 
International Europe Ltd, UK 
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AeroChamber Plus spacer: Valved Holding Chambers; Trudell Medical 
International Europe Ltd, UK 
Nebuhaler: Valved Holding Chambers; AstraZeneca, UK 
HPLC condition: Previously described in sections 3.2 and 3.3 in this thesis 
8.3.1.2 Procedure 
Twelve non-smoking volunteers (six females), older than 18 years with an average FEV1> 
90% of predicted, gave their informed and written consent to take part in the study. Ethical 
approval has been obtained for the study. On four separate occasions, following a light 
breakfast and no caffeine or alcohol containing drinks for at least 12 hours, each subject 
inhaled two 250 µg terbutaline sulphate doses (500 µg in total) from a MDI (Bricanyl inhaler, 
AstraZeneca, UK) 
(a) With no spacer [MDI]  
(b) With the AeroChamber MAX spacer [AMAX] (Trudell Medical International Europe 
Ltd, UK) 
(c) With the AeroChamber Plus spacer [APLUS] (Trudell Medical International Europe 
Ltd, UK)  
(d) With the Nebuhaler spacer [NH] (AstraZeneca, UK).  
The order of administration was randomized, and there was a seven day washout period 
between the study days. They all received training on how to use a metered dose inhaler 
(MDI) and the MDI was shaken and primed by firing two doses to waste before use (Barry 
and O'Callaghan, 2003). Subjects were trained to shake the MDI, remove the cap, exhale 
slowly as far as comfortable, put the MDI into their mouth and seal their lips round the 
mouthpiece. They were then instructed to start a slow inhalation through their mouth and 
activate the MDI immediately after the start of this slow inhalation. They continued to inhale 
slowly until total lung capacity. After the inhalation they held their breath for 10 seconds and 
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inhaled the second dose 30 seconds later. (Hindle et al., 1993). All subjects were trained how 
to use each spacer according to the manufacturer’s recommended instruction. When using the 
spacer subjects exhaled to residual volume (as much as possible), the dose was discharged into 
the spacer and within 1 second a slow and deep inhalation was taken over a period of 5–10 
seconds using the same inhalation procedure for the MDI alone. This was followed by a 10 
seconds breath hold before the subject breathed out normally and inhaled the second dose 30 
seconds later. 
Subjects emptied their bladder prior to each study dose and urine samples were collected at 30 
minutes post inhalation and cumulatively collected for 24 hours. The volume of each urine 
sample was measured, recorded and an aliquot was stored, at −20°C prior to analysis by a 
previously validated high performance liquid chromatography (HPLC) as explained in section 
3.3 in this thesis. The amount of drug left in the spacer was determined following rinsing by 
HPLC analysis as described in section 3.2. 
Statistical comparisons of the urinary excretion of terbutaline following inhalation from the 
MDI, AMAX, APLUS and nebuhaler in the urine samples collected at 30 minutes and 24 
hours post inhalation and the amount left in the spacers were compared using a two way 
analysis of variance (ANOVA) test using SPSS V15.0 (SPSS Inc., Chicago, USA). The mean 
difference (95% confidence interval) was calculated for each inhaled method.  
8.3.2 Results 
Twelve (six females) healthy non-smoking subjects completed the study. Their mean (SD) 
age, weight and height was 29.2(4.8) years, 66.3(11.8) kg and 170.5(7.4) cm, respectively. 
The FEV1 of all subjects was greater than 90% of predicted value with a mean (SD) of 
96.1(3.7)  % of predicted. Table 8.4 describe the demographic data of the subjects. 
The mean (SD) and individual cumulative urinary excretion of terbutaline post inhalation of 
two doses of 250µg terbutaline sulphate via a MDI with different spacers are shown in Tables 
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8.5 and Figures 8.3 and 8.5. A summary of the mean (SD) amounts of urinary terbutaline 
excretion from the twelve subjects 30 minutes and 24 hours post inhalation of 500 µg 
terbutaline sulphate via MDI, AMAX, APLUS and NH are shown in Table 8.6 and Figures 8.4 
and 8.6. 
A summary of the statistical comparison between amounts of urinary terbutaline excretion for 
the twelve subjects 30 minutes and 24 hours post inhalation of 500 µg terbutaline sulphate via 
MDI, AMAX, APLUS and NH to highlight the differences are presented in Table 8.7 and 8.8, 
respectively. A summary of the statistical comparison between amounts of terbutaline sulphate 
retained in each spacer from the twelve subjects post inhalation of 500 µg terbutaline sulphate 
via AMAX, APLUS and NH is presented in Table 8.9.  
 
Table 8.4 Demographic data of the patients that participated in the study 
Patient code Gender Age Height Weight FEV1 
1 Female 32.0 165.0 54.0 98.0 
2 Female 24.0 172.0 62.0 92.0 
3 Male 25.0 168.0 68.0 95.0 
4 Male 32.0 170.0 80.0 99.0 
5 Male 34.0 180.0 74.0 90.0 
6 Female 36.0 175.0 57.0 97.0 
7 Female 25.0 161.0 50.0 99.0 
8 Female 24.0 160.0 54.0 99.0 
9 Female 25.0 162.0 60.0 89.0 
10 Male 27.0 173.0 72.0 99.0 
11 Male 37.0 180.0 80.0 98.0 
12 Male 29.0 180.0 85.0 98.0 
Mean  29.2 170.5 66.3 96.1 
SD  4.8 7.4 11.8 3.7 
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Table 8.5 Urinary excretion of terbutaline post inhalation of two doses of 250µg terbutaline sulphate and the amount of terbutaline sulphate 
deposited in each spacer expressed in µg, (n=12). 
Method Time 1 2 3 4 5 6 7 8 9 10 11 12 Mean SD 
MDI 0.5 8.5 11.6 3.5 7.3 9.2 10.5 10.1 5.1 9.7 7.8 10.4 13.6 8.9 2.7 
24 224.9 262.5 170.8 187.2 225.3 240.4 241.4 146.2 228.0 192.0 245.5 270.8 219.6 37.8 
AMAX 0.5 32.6 30.1 18.2 12.8 15.7 16.2 14.7 39.0 37.8 28.6 21.5 33.5 25.1 9.6 
Spacer 105.4 108.6 102.4 110.5 108.7 103.6 114.7 153.4 150.7 105.0 104.0 153.9 118.4 21.0 
24 161.1 149.7 110.4 94.2 98.7 93.8 101.2 188.9 181.1 148.3 131.1 167.0 135.5 35.1 
APLUS 0.5 12.4 21.8 10.1 10.0 11.6 12.3 12.6 30.0 32.7 21.6 16.8 31.1 18.6 8.6 
Spacer 135.2 189.3 135.3 163.6 159.8 139.3 163.1 66.2 67.2 181.9 176.0 65.5 136.9 45.9 
24 91.7 103.0 74.8 68.8 72.6 71.4 79.9 142.1 146.5 104.9 90.6 158.2 100.4 31.8 
NH 0.5 11.0 14.8 6.6 12.8 13.3 11.8 14.7 18.3 21.9 16.2 18.0 24.0 15.3 4.8 
Spacer 106.1 93.9 108.6 108.6 93.9 108.0 118.2 116.0 118.2 92.1 99.4 120.1 106.9 10.1 
24 66.3 87.8 55.8 73.0 71.9 63.7 79.3 98.8 103.2 87.8 97.5 105.4 82.5 16.6 
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Table 8.6 Mean (SD) amount of terbutaline (in µg) excreted 30 minutes and 24 hours post-
inhalation of two doses of 250µg terbutaline sulphate and the amount of terbutaline sulphate 
deposited in each spacer. 
Method 
Amount (S.D.) 
0.5 hours Spacer 24 hours 
MDI 8.9 (2.7) -- 219.6 (37.8) 
AMAX 25.1 (9.6) 118.4 (21.0) 135.5 (35.1) 
APLUS 18.6 (8.6) 136.9 (45.9) 100.4 (31.8) 
NH 15.3 (4.8) 106.9 (10.1) 82.5 (16.6) 
 
Table 8.7 Mean difference (95% confidence interval) for the amount of terbutaline excreted 
post 30 minutes using MDI and MDI+Spacers.  
Comparator MDI AMAX APLUS 
Nebuhaler -6.3 (-10.4, -2.3)** 9.8 (5.7, 13.9)** 3.3 (-0.8, 7.4) 
APLUS -9.6 (-13.7, -5.6)** 6.5 (2.4, 10.6)** --- 
AMAX -16.1 (-20.2, -12.0)** --- --- 
* p<0.05, ** <0.001 otherwise no significant difference. 
 
Table 8.8 Mean difference (95% confidence interval) for the amount of terbutaline excreted 
post 24 hours using MDI and MDI+Spacers.  
Comparator MDI AMAX APLUS 
Nebuhaler 137.1 (104.8, 169.3)** 52.8 (20.6, 85.1)** 17.9 (-14.4, 50.1) 
APLUS 119.2 (87.0, 151.5)** 35.0 (2.8, 67.2)* --- 
AMAX 84.2 (52.0, 116.5)** --- --- 
* p<0.05, ** <0.001 otherwise no significant difference. 
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Table 8.9 Mean difference (95% confidence interval) for the amount terbutaline sulphate 
retained in each spacer.  
Comparator APLUS AMAX 
Nebuhaler 30.0 (0.2, 59.8)* 11.5 (-18.3, 41.3) 
AMAX 18.5 (-11.4, 48.3) --- 
* p<0.05, ** <0.001 otherwise no significant difference 
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Figure 8.3 The individual (n=12) amounts of terbutaline excreted 30 minutes post-inhalation 
of 2 doses of 250μg terbutaline sulphate via AMAX, APLUS, Nebuhaler and MDI. 
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Figure 8.4 The mean (SD) [n=12] amounts of terbutaline excreted 30 minutes post-inhalation 
of 2 doses of 250μg terbutaline sulphate via AMAX, APLUS, Nebuhaler and MDI. 
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Figure 8.5 The individual (n=12) amounts of terbutaline excreted 24 hours post-inhalation of 
2 doses of 250μg terbutaline sulphate via AMAX, APLUS, Nebuhaler and MDI. 
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Figure 8.6 The mean (SD) [n=12] amounts of terbutaline excreted 24 hours post-inhalation of 
2 doses of 250μg terbutaline sulphate via AMAX, APLUS, Nebuhaler and MDI. 
 
8.3.3 Discussion 
Add-on devices for MDI improve targeting of drug to the lungs and can correct poor hand-
breath co-ordination (Newman and Newhouse, 1996). 
The amounts of terbutaline excreted 30 minutes and 24 hours post dosing from the MDI and 
MDI+Spacer provide further evidence to the application of the urinary terbutaline 
pharmacokinetic method for inhaled terbutaline. 
The results indicates that the use of the spacer resulted in significantly higher amounts of 
urinary terbutaline excretion after 30 minutes (p<0.001) and lower amounts of urinary 
terbutaline excretion in the first 24 hours (p<0.001) post dosing then the MDI alone for all 
individuals.  
The results were consistent with that of a study by Hindle et al (1994). They found that in 10 
volunteers the amount (SD) of urinary excreted salbutamol 30 minutes post inhalation of four 
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100µg salbutamol doses from the MDI alone (Ventolin, Allen and Hanburys Ltd, UK), MDI 
+Volumatic spacer (Allen and Hanburys Ltd, UK) and MDI + Nebuhaler (Astra 
Pharmaceutical) were 2.83 (0.78), 3.37 (0.69) and 4.34 (1.60)%, respectively. Also the the 
amount (SD) of urinary excreted salbutamol 24 hours post MDI alone , MDI +Volumatic 
spacer and MDI + Nebuhaler, expresses as percentage of nominal dose, were 55.6 (9.74)%, 
26.6 (6.79)% and 27.0 (7.95)%, respectively. They showed that the spacer devices improve 
pulmonary bioavailability of salbutamol and reduce the systemic bioavailability (Hindle et al., 
1994). 
The results were also consistent with that of a study by Silkstone et al (2002). They compared 
the lung and systemic delivery of salbutamol following five 100 µg doses inhaled from a 
metered dose inhaler (MDI) and a MDI attached to a spacer (MDI+SP) using a urinary 
pharmacokinetic method. They found that in twelve (6 females) healthy subjects the mean 
(SD) 30 minutes urinary excretion amounts of salbutamol for MDI and MDI+SP was 12.6 
(3.5) and 27.1 (6.0) µg, respectively. Also they found that the mean (SD) 24 hours urinary 
excretion of salbutamol was 287.0 (46.5) and 198.1 (34.7) µg, respectively. Following 
inhalation a mean of 202.9 (51.5) µg was left in the spacer. When normalised for the amounts 
available for inhalation, the mean amounts of salbutamol excreted in the urine during the first 
30 minutes were 2.86 (0.78) and 9.15 (1.69) % following MDI and MDI+SP, respectively. 
Hence five 100 µg doses inhaled from a MDI attached to a spacer delivered more to the lungs 
and less to the systemic circulation than the same doses from a MDI used alone (Silkstone et 
al., 2002a). 
Also the results were similar to the study by Aswania et al (1999). They have shown in 10 
volunteers that the mean (SD) urinary excretion of sodium cromoglycate in the first 30 
minutes post the inhalation of four 5mg doses from an Intal MDI (Fisons Ltd., UK) and an 
Intal MDI attached to the Fisonair large volume spacer (Fisons Ltd., UK) was 38.1 (27.5) and 
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222.3 (120.3) µg, respectively (Aswania, 1999). These were also similar to the results of 
another study by Aswania et al (2001) for the Cromogen MDI used alone and when attached 
to the Volumatic spacer. The mean (SD) urinary excretion of sodium cromoglycate in the first 
30 minutes post-inhalation was 34.1 (20.2) and 211.7 (123.5) µg following MDI and 
MDI+Volumatic spacer, respectively. This shows that the MDI attached to a large volume 
spacer delivers more sodium cromoglycate to the lungs than MDI alone (Aswania and 
Chrystyn, 2001). 
Although between 21 to 27 % of the nominal dose was retained in the spacers, there was upto 
a three-fold improvement in the relative amounts deposited in the lungs compared to the MDI 
alone. This large difference has been obtained in subjects who have been trained and 
demonstrated an excellent inhalation technique. The in-vitro analysis of the aerodynamic 
characterisation of the emitted dose for a Bricanyl MDI with and without a spacer in chapter 5 
has shown an increase in the FPD and FPF. The FPD and FPF are representatives of the 
respirable amount that reach the lung which account for the amount excreted 30 minutes post 
dosing. However, the magnitude of difference of the in-vitro result is not as large as the in-
vivo results obtained from this study. 
In-vivo results here showed that, there was upto about 2.7-fold decrease in the relative 
amounts that reach the systemic circulation (24 hours results) compared to the MDI alone. The 
in-vitro analysis of the emitted dose for a Bricanyl MDI with and without a spacer in chapter 5 
has shown a similar decrease.  
Measurements of drug delivery from add-on devices by gamma scintigraphy have shown that, 
compared to an MDI, oropharyngeal deposition is always reduced, and that lung deposition is 
generally either increased or unchanged. The total body dose may be reduced by over 80% 
(Newman and Newhouse, 1996). 
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The results were also similar to a study by Richards et al (2001) to assess the deposition and 
pharmacokinetics of a novel formulation of flunisolide (Aerobid, Forest Laboratories) in 
hydrofluoroalkane (HFA) 134a delivered by a MDI. The design was a two-way crossover 
investigation in 12 healthy male subjects comparing HFA-134a flunisolide by MDI versus 
MDI + 50 ml spacer device. Four of these subjects also took part in a two-way crossover 
investigation comparing chlorofluorocarbon (CFC) flunisolide MDI versus MDI + 
AeroChamber holding chamber. The imaging technique of gamma scintigraphy was used to 
quantify total and regional lung deposition of flunisolide. Plasma levels of flunisolide and its 
major metabolite (6β-OH flunisolide) were also determined. The spacer and AeroChamber 
reduced the mean oropharyngeal deposition dramatically from 59.8 to 14.9% (p < 0.01) of 
dose for HFA product and 66.3 to 12.3% (p < 0.01) of dose for CFC product. That was due to 
deposition of part of the dose on the walls of the add-on devices themselves (Richards et al., 
2001). The mean lung deposition was 22.6 and 40.4%, respectively (p < 0.01) of the dose for 
the HFA formulation used with MDI alone and with MDI + spacer. Mean lung deposition of 
the CFC formulation delivered via the AeroChamber (mean 23.4%) was higher than that for 
the CFC MDI alone (mean 17.0%), but this difference was not statistically significant. Plasma 
levels of flunisolide were higher for the MDI + spacer than for the MDI alone, reflecting 
higher lung deposition via the spacer. The plasma levels of the 6β-OH flunisolide metabolite 
were higher for the MDI alone as a consequence of higher oropharyngeal deposition which is 
ingested in the gastrointestinal tract. 
A study by Hirst et al (2001) showed similar results. They assessed the deposition in the lungs 
and oropharynx of triamcinolone acetonide (TAA; Azmacort, Aventis Pharma, Collegeville, 
PA) delivered by a MDI formulated with HFA-134a by gamma scintigraphy. Also they 
measured the pharmacokinetic profile of TAA, to determine the extent to which the Azmacort 
spacer improves targeting of TAA to the lungs. The deposition of TAA, labelled with 99mTc, 
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was assessed by gamma scintigraphy in 10 patients with mild to moderate asthma (mean FEV1 
of 76% of predicted), who received, in randomized order, three delivered doses of 75 μg TAA 
via MDI + Azmacort spacer, and three delivered doses of 230 μg TAA via the MDI, but with 
no spacer. Mean lung deposition, expressed as mass of drug, was similar for each regimen 
(MDI alone 175 μg; MDI+Spacer 188 μg), but when expressed as a percentage of the 
delivered dose, lung deposition was higher for the MDI+Spacer (53.8%) versus the MDI alone 
(26.0%), indicating superior drug targeting for the MDI+Spacer. The spacer reduced 
oropharyngeal deposition. The pharmacokinetic data showed higher plasma levels of drug for 
the MDI alone, resulting from higher oropharyngeal deposition and delivered from the 
gastrointestinal tract (Hirst et al., 2001). 
The results in this part of the thesis showed that the AMAX resulted in significantly higher 
urinary terbutaline excretion 30 minutes post dosing than either the APLUS or the Nebuhaler 
(p<0.001). Also the AMAX resulted in a significantly higher urinary terbutaline excreted post 
24 hours post dosing than either the APLUS or the Nebuhaler (p<0.05 and p<0.001, 
respectively). This might be due to the antistatic property of AMAX. 
The results are consistent with an in-vivo pharmacokinetic study by Anhoj et al (1999). They 
studied the effect of the electrostatic charge in plastic spacers on drug delivery to the lung of 
hydrofluoroalkane (HFA) salbutamol aerosol in children. Salbutamol HFA aerosol was 
delivered on different study days from a non-electrostatic 350 ml Babyhaler (coated with 
benzalkonium chloride) and a new 350 ml Babyhaler (rinsed in water). Plasma salbutamol was 
measured before and 5, 10, 15 and 20 minutes after inhalation of four 100 μg salbutamol 
doses. Cmax was calculated as a reflection of lung dose.  
They found in five children, aged 7–12 years that Cmax for the non-electrostatic Babyhaler was 
4.3 ng ml−1 and New Babyhaler was 1.9 ng ml−1. The non-electrostatic Babyhaler delivered a 
significantly (P<0.05) higher lung dose than the New Babyhaler. Hence, the electrostatic 
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charge in plastic spacers reduces lung dose in children by more than two-fold (Anhoj et al., 
1999).  
The in-vitro analysis of the aerodynamic characterisation of the emitted dose for a Bricanyl 
MDI with and without a spacer in chapter 5 of this thesis has shown AMAX has a 
significantly higher total emitted dose when compared to the APLUS and the Nebuhaler 
(p<0.01) which account for the higher amounts excreted post 24 hours. The APLUS has a 
significantly high FPF and smaller MMAD when compared to the AMAX and Nebuhaler 
(p<0.001). However the AMAX has a relatively high FPD. The combination of the high total 
emitted dose together with the relatively high FPD of the AMAX could account for the 
significantly higher urinary terbutaline excreted 30 minutes post AMAX dosing. Since the 
urinary terbutaline excreted 30 minutes post dosing accounts for the relative amounts 
deposited in the lungs, it can be considered that the total emitted dose and the FPD together 
are more important for the lung deposition than the FPF and MMAD togather. 
The mean amount of terbutaline excreted 30 minutes and 24 hours post APLUS was higher 
than that post Nebuhaler, but these differences were not statistically significant. However, the 
in-vitro results in chapter 5 showed that the FPF of the APLUS was significantly higher than 
that of the Nebuhaler (p<0.001) and the MMAD was significantly lower. The comparison 
between the in-vitro and the in-vivo results of the spacer could further raise doubts about the 
clinical meaning of FPF together with the MMAD when compared to the combination of the 
emitted dose and the FPD. 
8.4 Relative lung and systemic bioavailability of terbutaline inhaled from two different 
nebulisers using urinary drug excretion post inhalation 
8.4.1 Methods 
8.4.1.1 Equipment and inhalation devices 
Inhalation devices and HPLC system 
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Aeroneb Professional Nebuliser: Vibrational mesh Nebuliser System; Aerogen Inc, USA  
Sidestream Jet nebuliser: Intersurgical Ltd, UK; attached to a Porta Neb compressor.  
Bricanyl Respules: Labelled as a nominal dose of 5.0 mg in 2 ml (2.5 mg/ml) 
terbutaline sulphate (AstraZeneca, UK) 
Porta Neb compressor: Respironics, UK 
HPLC condition: Previously described in sections 3.2 and 3.3 in this thesis 
8.4.1.2 Procedure 
Ethical approval was obtained from the University of Bradford and all volunteers gave signed 
informed consent. Twelve non-smoking volunteers (six females), older than 18 years with an 
average (SD) FEV1>90% of predicted, agreed to inhale nebulised aerosol of Bricanyl 
respiratory solution (Bricanyl Respules, labelled 5.0 mg/2ml terbutaline sulphate, 
AstraZeneca, UK) through two different nebulisers using normal tidal breathing. They were 
first trained on how to inhale through the nebulisers. Subjects were trained to place the 
mouthpiece between1their lips and breathe in and out gently through their mouth. Each subject 
randomly inhaled one whole Bricanyl Respules dose from two different nebulisers (Aeroneb 
Pro and Sidestream jet nebuliser). The dose was loaded in the nebuliser for the subject before 
use according to the patient information leaflet. 
On each of the two occasions, following a light breakfast and no caffeine or alcohol containing 
drinks for at least 12 hours, each subject inhaled their doses from the nebuliser. Immediately 
before each study dose subjects voided their urine and then provided a urine sample 30 
minutes after the start of inhaling the dose and cumulatively collected their urine for 24 hours. 
The volume was measured and the urinary terbutaline was assayed using the previously 
validated HPLC method described in section 3.3. The nebulisers and connections were rinsed 
with water and terbutaline sulphate was assayed using the previously validated HPLC method 
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described in section 3.2. The urine samples were compared using a two way analysis of 
variance (ANOVA) test using SPSS V15.0 (SPSS Inc., Chicago, USA).  
8.4.2 Results 
Twelve (six females) with a mean (SD) age, weight and height of 29.7(4.7) years, 65.8(12.8) 
kg and 167.3(6.2) cm, respectively completed the study. The FEV1 of all subjects was greater 
than 90% of predicted value with a mean (SD) of 95.4(4.0) % of predicted. Table 8.10 
describe the demographic data of the subjects. The mean (SD) and individual cumulative 
urinary excretion of terbutaline post inhalation are shown in Tables 8.11 and Figure 8.7 and 
8.8. 
The mean (SD) terbutaline excreted after inhalation from the Sidestream jet nebuliser and 
Aeroneb Pro nebuliser during the 30 minutes post start of the inhalation was 11.6 (5.7) and 
31.2 (7.2) µg, respectively as shown in Figure 8.7 and the mean (SD) 24 hours was 164.5 
(44.0) and 440.4 (101.4) µg, respectively as shown in Figure 8.8. The mean (SD) amounts of 
terbutaline sulphate left in the nebulisation champers and the mouthpiece after inhalation from 
the Sidestream jet nebuliser and Aeroneb Pro nebuliser were 2797.4(181.0) and 1546.2(183.2) 
µg, respectively as shown in Tables 8.11.  
A summary of the statistical comparison between Aeroneb Pro and the Sidestream jet 
nebuliser is shown in Table 8.12.  
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Table 8.10 Demographic data of the patients that participated in the study 
Patient code Gender Age Height Weight FEV1 Sequence of nebulisers* 
1 Female 32.0 165.0 54.0 98.0 A1 
2 Female 24.0 172.0 62.0 92.0 A1 
3 Male 25.0 168.0 68.0 95.0 A1 
4 Male 32.0 170.0 80.0 99.0 A2 
5 Male 34.0 180.0 74.0 90.0 A1 
6 Female 36.0 175.0 57.0 97.0 A2 
7 Female 25.0 161.0 50.0 99.0 A1 
8 Female 24.0 160.0 54.0 99.0 A2 
9 Female 25.0 162.0 60.0 89.0 A2 
10 Male 32.0 169.0 70.0 99.0 A1 
11 Male 36.0 163.0 65.0 90.0 A2 
12 Male 31.0 163.0 95.0 98.0 A2 
Mean  29.7 167.3 65.8 95.4  
SD  4.7 6.2 12.8 4.0  
A1 is Aeroneb Pro first and A2 is Sidestream first  
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Table 8.11 Mean (SD) and individual urinary excretion of terbutaline and the amount of terbutaline sulphate left in the nebulisers post 
inhalation of one dose of 5.0mg via two different nebuliser expressed in µg, (n=12). 
Nebuliser Time 
(Hours) 
1 2 3 4 5 6 7 8 9 10 11 12 Mean SD 
Aeroneb 
Pro 
0.5 42.2 28.5 38.1 41.7 26.2 25.9 28.8 25.1 24.7 27.4 40.7 25.1 31.2 7.2 
24 595.7 401.7 537.8 588.9 369.5 365.7 406.2 354.1 349.1 386.9 575.3 354.2 440.4 101.4 
Remaining 1755.4 1512.6 1771.6 1768.6 1360.0 1725.4 1519.4 1269.3 1356.7 1509.5 1642.2 1363.6 1546.2 183.2 
Sidestream 
jet 
nebuliser 
0.5 12.6 10.9 13.9 17.0 1.5 16.7 8.8 3.4 21.6 13.1 8.0 12.4 11.6 5.7 
24 178.4 153.9 161.3 204.5 111.2 205.7 123.9 117.9 254.4 175.1 112.7 175.0 164.5 44.0 
Remaining 2632.1 2732.5 2649.5 2684.4 3106.9 2638.0 2785.3 2922.6 3039.7 2641.7 2689.2 3047.1 2797.4 181.0 
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Table 8.12 Mean difference (95% confidence interval) of Aeroneb Pro vs the Sidestream jet 
nebuliser.  
Comparator Aeroneb Pro vs Sidestream jet 
nebuliser 
Amount excreted 30 minutes post dose 19.5 (14.1, 25.0, p<0.001) 
Amount excreted 24 hours post dose 105.6 (76.2, 135.0, p<0.001) 
Amount remaining in the nebuliser 
chamber 
-1251.2 (-1473.4, -1029.1, p<0.001) 
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Figure 8.7 Mean (n=12) and the individual amounts of urinary terbutaline excreted 30 minutes 
post 5.0 mg nebulised terbutaline sulphate dosing. 
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Figure 8.8 Mean (n=12) and the individual amounts of urinary terbutaline excreted in the first 
24 hours post 5.0 mg nebulised terbutaline sulphate dosing. 
 
8.4.3 Discussion 
The amount left in the nebulisation chamber and the T-mouthpiece of the Sidestream jet 
nebuliser [55.95 (3.62) % of nominal dose] is significantly higher than that of the Aeroneb pro 
nebuliser [30.92 (3.66) % of nominal dose] (p<0.001). Also, the Aeroneb Pro had a 
significantly higher amount of systemically absorbed terbutaline than the Sidestream jet 
nebuliser, as found from the 24 hours urinary terbutaline (p<0.001) and the relative lung 
bioavailability (p<0.001) as found from the 30 minutes urinary terbutaline. These represents 
an approximate three-fold improvement in the relative amounts deposited in the lungs from 
the Aeroneb pro compared to the Sidestream jet nebuliser, and a 2.7-fold increase of the 
relative amount delivered to the body (systemic bioavailability). This difference has been 
obtained in subjects who have been trained and demonstrated an excellent inhalation 
technique. It has been shown previously using in-vitro analysis that the Aeroneb Pro has a 
three to five fold higher efficiency for delivering drug to the lungs than conventional jet or 
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ultrasonic nebulisers (Fink et al., 2001; Fink and Schmidt, 2002; Kristin et al., 2003). This is 
consistent with our in-vivo results. 
The in-vivo results here are also consistent with a study by Fink et al (2003) who determined 
how Aeroneb Go nebuliser performed compared to a range of commercially available 
pneumatic jet nebulisers. They compared the inhaled mass and performance characteristics of 
three compressor-driven pneumatic jet nebulisers (Omron CompAir Elite, DeVilbiss Model 
800 and Pari LC Plus) to a prototype nebuliser (Aerogen Aeroneb Go). Each nebuliser was 
filled with 2.5 mg (3 ml of 0.083%) salbutamol sulphate. Drug was collected on filters placed 
between the nebuliser and a breath simulator modeling an adult breathing pattern (tidal 
volume 500 ml, rate 15 cycle per minute). The amount of drug deposited on the filter (Inhaled 
Mass) was determined for each device (n=3). The Aeroneb Go had the lowest residual drug 
volumes (<0.3 ml) and delivered more inhaled mass than the other nebulisers tested. Hence, 
the Aerogen Aeroneb Go prototype nebuliser performed better than the pneumatic jet 
nebulisers tested (Fink et al., 2003). 
Moreover the results are consistent with the in-vitro results in chapter 6 as the vibrational 
mesh nebulisers emit higher amounts of the nebulisation solution (emitted dose) and a higher 
respirable amount (the fine particle dose) than the Sidestream jet nebuliser (p<0.001). That 
may be in part due to the small residual volume of the Aeroneb Pro which is less than 0.3ml 
(Fink et al., 2001) and the Sidestream jet nebuliser have a big residual volume. However, the 
magnitude of the in-vitro results in chapter 6 is not as large as the in-vivo results obtained 
from this study. 
The result are similar to that reported by Silkstone et al. (2002) to correlate the in-vivo 
salbutamol pharmacokinetic method and in-vitro CEN method results using eight nebuliser 
systems. They found a significant correlation (p=0.02) between the in-vitro respirable dose 
and the amount of salbutamol excreted in the urine 30 minutes post the start of nebulisation 
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[relative bioavailability of salbutamol to the lung]. Also, there was a significant (p<0.001) 
correlation between the in-vitro dose available for inhalation and the total amount of 
salbutamol cumulatively excreted over the 24 hours post the start of nebulisation [relative 
bioavailability of salbutamol to the body] (Silkstone et al., 2002b). 
8.5 Conclusions 
The results of this chapter demonstrate that the urinary pharmacokinetic method that has 
previously been reported for terbutaline in chapter 7 is a potential tool to compare different 
inhalation technique, methods and products. The results were consistent with the previously 
published literature and the in-vitro results in this thesis. Although this measurement (the 30 
minutes post-inhalation urinary excretion) does not differentiate between depositions into 
different zones of the lungs, it is an index of total lung bioavailability and thus is useful for 
comparing different devices, techniques, methods etc. Also the 24 hours urinary terbutaline 
has showed that it can be used as an index of systemic bioavailability.  
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9.1 Introduction 
Non-invasive positive pressure ventilation (NPPV) is being increasingly employed for the 
treatment of patients with acute and chronic respiratory failure (Carlucci et al., 2001). 
Successful application of NPPV with a nasal or face mask can often prevent the need for 
endotracheal intubation and improve mortality (Brochard et al., 1995; Plant and Elliott, 1998). 
NPPV may be employed as a first line mode of mechanical ventilation in about 50% of 
patients with hypercapnic respiratory failure (Carlucci et al., 2001). Such patients with acute 
or chronic hypercapnic respiratory failure who are receiving NPPV often require inhaled 
bronchodilators for the relief of their airway obstruction. This can be provided to them during 
NPPV by the use of a nebuliser or MDI with spacer in the circuit (Dhand and Tobin, 1997; 
Parkes and Bersten, 1997). The optimal techniques for aerosol delivery in patients receiving 
NPPV have been investigated using in-vitro models (Chatmongkolchart et al., 2002). Aerosol 
delivery can vary as much as five fold during NPPV, depending on the inspiratory and 
expiratory pressures employed and position of the nebuliser (Chatmongkolchart et al., 2002). 
Although the optimum settings required for maximum drug delivery during NPPV have not 
been well established, significant bronchodilator responses occur after salbutamol 
administration with a jet nebuliser or a MDI with spacer (Dolovich et al., 1977; Nava et al., 
2001). 
Traditionally, nebulisers have been used to deliver bronchodilators, antibiotics, and surfactant 
to mechanically ventilated patients, whereas MDIs have been used to deliver β2-adrenergic 
and anticholinergic bronchodilators (Dhand and Tobin, 1997). A new generation of nebulisers 
that are based on vibrating mesh technology have been designed to deliver aerosol in a 
mechanical ventilation circuit. It have been demonstrated that a version of this new generation 
is approximately 3 times more efficient than a Sidestream jet nebuliser at delivering drug to 
the lungs of non-ventilated patients (Ismail and Chrystyn, 2004).  
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In-vivo deposition studies to determine aerosol deposition in the lower respiratory tract can be 
estimated by radionuclide studies (Fok et al., 1996; Harvey et al., 1997) but the radioactivity 
effects on the patient limit the use of these studies to estimate the aerosol deposition. Also the 
set-up procedure and specialized equipment limit the use of this methodology for patients that 
are mechanically ventilated. Furthermore the incorporation of a radionuclide alters the 
formulation of the product and thus its product license. 
The 30 minute urinary salbutamol pharmacokinetic method has previously been used in 
patient with nebuliser studies (Ismail and Chrystyn, 2004) but this has involved switching 
patients onto terbutaline from salbutamol for their routine management and using salbutamol 
as the study drug. When investigating nebulised dosing it is the inhalation method rather than 
the bronchodilator solution that determines the lung and systemic delivery. Hence the urinary 
terbutaline pharmacokinetic method previously validated in chapter 7 can be used with 
patients without switching their salbutamol therapy. Terbutaline sulphate respiratory solution 
can be therefore used as the test. This involves administering a study dose of terbutaline 
sulphate in place of their prescribed salbutamol medication. 
Ex-vivo methods have been described to identify the total emitted dose that a patient would 
have received (Fink and Simmons, 2004; O'Doherty et al., 1992; O'Riordan et al., 1994; 
O'Riordan et al., 1992). This is achieved by placing a filter between the patient’s mouth and 
the mouthpiece of the inhalation method. The filter used has no resistance so does not affect 
the breathing pattern of the patient and does not allow any drug to pass through it. This 
method has been previously used to determine the amount of drug that mechanically ventilated 
patients would receive from a nebulised dose (Palmer et al., 1998; Smaldone, 2004; Smaldone 
and Palmer, 2000; Diot et al., 1997; Fink et al., 1999). The estimation of the amount of drug 
entrained on the filter, left in the nebuliser’s chamber, the tubing and the mouthpiece provides 
a mass balance fate of the nebulised dose. However this method does not differentiate between 
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the amounts of drug that would be deposited into the lungs or swallowed. Nevertheless if 
linked with pharmacokinetic studies would provide valuable data on the lung deposition 
efficiency of an inhalation method. 
The aim of this study was to compare the in-vivo (linked to ex-vivo) fate of nebulised 
terbutaline sulphate from the Aeroneb Pro nebuliser (a vibrating mesh nebuliser) to that of the 
routinely used Sidestream jet nebuliser in hospitalized patients requiring non-invasive 
mechanically ventilation. 
9.2. Methods 
Local hospital research ethics committee approval was obtained for this study. Patients 
prescribed non-invasive positive pressure mechanical ventilation mostly for 72 hours post 
admission were eligible for the study. Due to the necessary washout period of at least 36 hours 
to allow for the body to excrete the entire drug delivered from each study dose it was only 
possible for each subject to inhale two study doses and provide urine samples. This study was 
designed to compare the Sidestream and Aeroneb Pro nebulisers. 
Patients were given their first study dose within the first 12 hours of admission. It was 
anticipated that to obtain consent within this period of time was not ethical or practical. The 
study dose that they received was part of their medication because the only difference was that 
the terbutaline sulphate replaced a prescribed salbutamol dose. The only extra procedure 
compared to routine management was that they were asked to provide a urine sample 30 
minute post study dosing and to collect all their urine into a container over the next 24 hours. 
The volume of the 30 minute and pooled urine samples were measured and aliquots were 
retained for terbutaline analysis using the previously validated HPLC assay method described 
in section 3.3 of this thesis. All urine samples were labelled with a code and no other 
information. Analysis of samples was carried out at the University of Bradford. 
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The bi-level ventilator was set in spontaneous mode at an inspiratory pressure of 20 cmH2O 
and expiratory pressure of 5 cmH2O. The patient’s lung internal pressure triggered the bi-level 
ventilator. The ventilator pressures are the typical levels mostly used for COPD patients when 
bi-level ventilation is initiated during acute exacerbations.  
The attending physician made a decision whether or not a patient would be suitable for the 
study and that substitution of two of their prescribed salbutamol doses by the two terbutaline 
sulphate study doses was acceptable.  
9.2.1 Equipment and inhalation devices 
The Aeroneb Professional Nebuliser: Vibrational mesh Nebuliser System; 
Aerogen,Inc,USA  
Sidestream jet nebuliser: Intersurgical Ltd, UK; attached to a Porta Neb compressor  
Porta Neb compressor: Respironics, UK 
Ventilator: Nippy2 (B&D Electromedical, UK) 
NIV breathing circuit: A 180 cm length of autoclavable corrugated tubing, 
diameter of 22 mm and a fixed leak exhalation valve 
(B&D Electromedical, UK) 
Electrostatic filter: An electrostatic filter enclosed in a filter holder (Filta 
Guard breathing filter, Intersurgical Ltd, UK) 
Normal saline: Sodium chloride 0.9% respiratory solution, Teva, UK 
Inhalation solution: Terbutaline sulphate Respules labelled as a nominal dose of 
5mg terbutaline sulphate in 2 ml (2.5mg/ml, Breath Limited, 
UK) 
HPLC conditions: Previously described in sections 3.2 and 3.3 in this thesis 
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9.2.2 Consent Procedure 
This study involved patients who were seriously ill and thus would not have the capacity to 
consent at enrolment. This study therefore used a two stage consent procedure. In the first 
instance patients were assessed to determine their capacity to consent on the day of admission 
(defined and assessed by the attending physician according to Mental Capacity Act 2005). The 
study investigators who obtained the consent underwent formal training in this prior to the 
start of the study. In those with capacity, consent was obtained from the patient. Where 
capacity did not exist, the patient was enrolled into the study only with the agreement from a 
close relative. If a patient recovered his capacity within 72 hours of admission, his consent 
was sought in retrospect. If a patient declined to give this consent after regaining capacity then 
the samples that had been collected were destroyed. Where capacity was not regained the 
patient’s data remained in the study. 
On day 2 the study procedure was described and the patient was invited to the study. Hence 
delayed written informed consent procedures had been applied. If a patient decided not to be 
part of the study then they were withdrawn together with all their data and their samples were 
disposed. 
9.2.3 Patients 
Inclusion criteria 
• Patients with an acute exacerbation of COPD requiring non-invasive mechanical 
ventilation for respiratory acidosis [as per NICE Guidelines (2004)] 
• Under the care of a consultant chest physician 
• Receiving nebulised bronchodilators 
Exclusion Criteria 
• Previous enrolment in the study 
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• Known hypersensitivity to terbutaline or salbutamol. 
• Systolic blood pressure of <100 mmHg. 
• Moderate or severe renal impairment defined as a Creatinine Clearance or eGFR of 
<20 ml min-1. 
9.2.4 Procedure 
Patients were randomised to the terbutaline study dose on days 1 and 3 nebulised using either 
the Aeroneb Pro or the Sidestream nebuliser. The patients received their terbutaline sulphate 
study doses in place of their afternoon salbutamol dose. 
The study doses were as follows: 
• 2mg (0.8ml) of terbutaline sulphate respiratory solution (Terbutaline sulphate 
Respules, Breath Limited, UK) were nebulised from the Aeroneb Professional Nebuliser 
System (Aerogen, USA). 
• 5mg (2ml) of terbutaline sulphate respiratory solution (Terbutaline sulphate Respules, 
Breath Limited, UK) with 2ml normal saline (sodium chloride 0.9% respiratory solutions, 
Teva, UK) were nebulised from a Sidestream jet nebuliser (Intersurgical limited, UK). 
Patients voided their urine 15 minutes before the study dose. The nebuliser was placed in the 
ventilatory circuit as shown in Figure 9.1. The patients provided a urine sample 30 minute 
after the start of the study dose. Their urine was then pooled for the next 24 hours. The volume 
of the 30 minute and 24 hours collection samples were measured and assayed for the 
terbutaline concentration using an HPLC method previously described in section 3.3 in this 
thesis. All parts of the non-invasive ventilation tubing and the nebuliser were rinsed with 
water. The rinsing solutions were also assayed to determine their terbutaline sulphate amount 
using an HPLC method previously described in section 3.2 of this thesis. 
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On day 2 subjects received both the study doses for the ex-vivo part of the study. On this 
occasion a filter (Filta Guard breathing filter, Intersurgical limited, UK) was placed between 
the inhalation method and the patient’s mask, as shown in Figure 9.1, hence the patients would 
receive no drug. This procedure on day 2 was carried out between two of each patient’s 
routine bronchodilator doses and was extra to the routine management of the patient. These 
procedures only took about 5-10 minutes each and thus any disruption or inconvenience was 
minimal. 
 
Figure 9.1 Schematic design of the nebuliser positions within the non-invasive circuit bi-level 
ventilator. The inspiratory filter was placed as shown in the circuit in the ex-vivo part of the 
study only. 
 
Drug entrained on the filter was desorbed and the amount of terbutaline sulphate was 
determined. This represents the emitted dose the patient would have normally received. After 
each study dose the inhalation method was rinsed with water to collect the residual dose. The 
rinsing solutions were assayed for their terbutaline sulphate concentration using an HPLC 
method previously described in section 3.2 of this thesis.  
 238 
The Sidestream jet nebulisers were one patient use according to standard ward practice and the 
ward washing procedures for the nebulisers applied. The Aeroneb Pro nebulisers were 
sterilised between use according to standard ward practice and the manufacturer’s procedure 
for re-use. 
9.2.5 Data analysis 
The primary outcome measures were  
• The relative bioavailability of terbutaline to the lungs following each inhalation 
method (30 minute urinary excretion). 
• The relative bioavailability of terbutaline to the body following each inhalation 
method (24 hours urinary excretion). 
• The fraction of the nominal dose that the patient would have received – (day 2). 
The urine samples from the Aeroneb Pro and the Sidestream jet nebuliser were compared 
using a two way analysis of variance (ANOVA) test using SPSS V15.0 (SPSS Inc., Chicago, 
USA). Also a comparison between day 1 and day 3 treatments regardless of the inhalation 
method used (30 minute and 24 hours urinary excretion) were done using a two way analysis 
of variance (ANOVA) test using SPSS V15.0 (SPSS Inc., Chicago, USA). The ex-vivo results 
from the Aeroneb Pro and the Sidestream jet nebuliser were compared using a paired T-Test 
using SPSS V15.0 (SPSS Inc., Chicago, USA). 
9.3 Results 
Twelve (six females) NPPV patients with a mean (SD) age, weight and height of 74.8 (8.2) 
years, 61.0 (10.7) kg and 169.8 (12.4) cm, completed this study. FEV1 is not measured in these 
patients due to the severity of their lungs and was anticipated to be <30 % predicted. Table 9.1 
describe the demographic data of the patients. The mean (SD) and individual urinary excretion 
of terbutaline post inhalation of one dose of 5.0 mg terbutaline sulphate via Sidestream jet 
 239 
nebuliser and 2 mg terbutaline sulphate via Aeroneb Pro are shown in Tables 9.2 and 9.3 and 
summarized in Figures 9.2-9.5. The mean (SD) and individual urinary excretion of terbutaline 
post inhalation of day 1 and day 3 (irrespective of inhalation method) are shown in Tables 9.4 
and 9.5 and summarized in Figures 9.6 and 9.7. Tables 9.6 and 9.7 and Figures 9.8 and 9.9 
show the mean (SD) and individual amount of terbutaline sulphate from the filter, T-piece and 
nebulisation chamber used in the ex-vivo part of the study post inhalation of one dose of 2 mg 
terbutaline sulphate via Aeroneb Pro and 5.0 mg terbutaline sulphate via Sidestream jet 
nebuliser expressed in µg, (n=12). The corrugated tubing and the filter next to the ventilator 
did not contain any terbutaline sulphate. 
The mean (SD) terbutaline excreted in 30 minute period after the start inhalation of the study 
dose from the Sidestream jet nebuliser and Aeroneb Pro nebuliser were 10.4 (4.1) and 9.4 
(3.7) µg, respectively as shown in Figure 9.2 and the mean (SD) 24 hours urinary excretion 
were 205.3 (58.0) and 192.3 (52.5) µg, respectively as shown in Figure 9.3. These values are 
equivalent to 0.25 (0.10), 0.57 (0.23), 5.00 (1.41) and 11.71 (3.19) %, respectively when 
calculated as a percentage of the nominal dose. The mean (SD) terbutaline excreted in day 1 
and day 3 during the 30 minute post start of the inhalation irrespective of the nebulisation 
method was 9.6 (4.1) and 9.5 (3.8) µg, respectively as shown in Figure 9.6 and the mean (SD) 
24 hours was 197.8 (65.0) and 198.9 (44.0) µg, respectively as shown in Figure 9.7. These 
values are equivalent to 0.40 (0.20), 0.40 (0.27), 8.41 (3.94) and 8.41 (4.61) %, respectively 
when calculated as a percentage of the nominal dose. The mean (SD) amounts of terbutaline 
sulphate entrained on the filter from the ex-vivo study arm after inhalation from the 
Sidestream jet nebuliser and Aeroneb Pro nebuliser were 1140.6 (186.7) and 771.7 (42.7) µg, 
respectively as shown in Tables 9.6 and 9.7. These values are equivalent to 22.8 (4.0) and 38.6 
(2.3) %, respectively when calculated as a percentage of the nominal dose. 
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A summary of the statistical comparison between Aeroneb Pro and the Sidestream jet 
nebuliser is shown in Table 9.8 and between day 1 and day 3 (irrespective of inhalation 
method) in Table 9.9.  
 
 
 
Table 9.1 Demographic data of the patients that participated in the study 
Patient code Gender Age Height Weight Sequence of nebulisers* 
1 male 70.0 180.0 65.0 A1 
2 female 83.0 150.0 40.0 A1 
3 male 82.0 182.0 65.0 A3 
4 female 63.0 162.0 61.0 A3 
5 male 64.0 188.0 76.0 A3 
6 female 81.0 160.0 61.0 A1 
7 female 85.0 165.0 71.0 A1 
8 female 83.0 156.0 43.0 A3 
9 male 76.0 176.0 60.0 A1 
10 female 64.0 160.0 55.0 A3 
11 male 74.0 177.0 65.0 A1 
12 male 72.0 182.0 70.0 A3 
Mean  74.8 169.8 61.0  
SD  8.2 12.4 10.7  
*A1 Aeroneb Pro was used on day 1 and Sidestream on Day 3 and A3 Aeroneb Pro was used 
on day 3 and Sidestream on Day 1. 
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Table 9.2 Mean (SD) and individual urinary excretion of terbutaline and the amount of terbutaline sulphate left in the nebulisers post 
inhalation of one dose of 5.0 mg terbutaline sulphate via Sidestream jet nebuliser and 2.0 mg terbutaline sulphate via Aeroneb Pro expressed 
in µg, (n=12). 
Nebuliser Time 
(Hour) 1 2 3 4 5 6 7 8 9 10 11 12 Mean SD 
Aeroneb 
Pro 
0.5 5.2 3.9 6.5 14.7 10.2 7.5 15.4 8.2 6.5 11.7 9.5 12.9 9.4 3.7 
24 275.8 198.4 208.4 276.9 164.8 174.3 194.1 186.7 143.7 237.4 102.9 143.8 192.3 52.5 
Remainin
g 950.0 
1190.
0 
1250.
2 
1084.
3 976.4 
1134.
8 
1096.
7 
1204.
9 995.7 
1083.
4 
1108.
3 976.4 
1087.
6 98.0 
Sidestrea
m jet 
nebuliser 
0.5 5.4 4.6 7.9 16.8 11.8 8.7 16.9 8.7 6.7 12.8 10.9 13.7 10.4 4.1 
24 182.7 207.7 175.4 197.8 295.7 143.7 254.8 124.8 176.5 279.5 148.5 276.4 205.3 58.0 
Remainin
g 
2489.
3 
2651.
2 
2479.
3 
2864.
5 
2795.
3 
2821.
5 
2719.
9 
2357.
8 
2265.
8 
2854.
7 
2497.
6 
2594.
3 
2615.
9 
200.
8 
 
Table 9.3 Mean (SD) and individual urinary excretion of terbutaline and the amount of terbutaline sulphate left in the nebulisers post 
inhalation of one dose of 5.0 mg terbutaline sulphate via Sidestream jet nebuliser and 2.0 mg terbutaline sulphate via Aeroneb Pro expressed 
in percentage of nominal dose, (n=12). 
Nebuliser Time 
(Hour) 1 2 3 4 5 6 7 8 9 10 11 12 Mean SD 
Aeroneb Pro 0.5 0.32 0.24 0.40 0.89 0.62 0.46 0.94 0.50 0.40 0.71 0.58 0.79 0.57 0.23 
24 16.79 12.08 12.69 16.86 10.03 10.61 11.82 11.37 8.75 14.45 6.26 8.76 11.71 3.19 
Remaining 47.5 59.5 62.5 54.2 48.8 56.7 54.8 60.2 49.8 54.2 55.4 48.8 54.6 4.6 
Sidestream jet nebuliser 0.5 0.13 0.11 0.19 0.41 0.29 0.21 0.41 0.21 0.16 0.31 0.27 0.33 0.25 0.10 
24 4.45 5.06 4.27 4.82 7.20 3.50 6.21 3.04 4.30 6.81 3.62 6.73 5.00 1.41 
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Remaining 49.8 53.0 49.6 57.3 55.9 56.4 54.4 47.2 45.3 57.1 50.0 51.9 52.5 4.3 
 
Table 9.4 Mean (SD) and individual urinary excretion of terbutaline post inhalation of day 1 and day 3 (irrespective of inhalation method) 
expressed in µg, (n=12). 
Nebuliser Day 1 2 3 4 5 6 7 8 9 10 11 12 Mean SD 
30 minute Day 1 5.2 3.9 7.9 16.8 11.8 7.5 15.4 8.7 6.5 12.8 9.5 13.7 9.6 4.1 
Day 3 5.4 4.6 6.5 14.7 10.2 8.7 16.9 8.2 6.7 11.7 10.9 12.9 9.5 3.8 
24 hours Day 1 275.8 198.4 175.4 197.8 295.7 174.3 194.1 124.8 143.7 279.5 102.9 276.4 197.8 65.0 
Day 3 182.7 207.7 208.4 276.9 164.8 143.7 254.8 186.7 176.5 237.4 148.5 143.8 198.9 44.0 
 
Table 9.5 Mean (SD) and individual urinary excretion of terbutaline post inhalation of day 1 and day 3 (irrespective of inhalation method) 
expressed in percentage of nominal dose, (n=12). 
Nebuliser Day 1 2 3 4 5 6 7 8 9 10 11 12 Mean SD 
30 minute Day 1 0.32 0.24 0.19 0.41 0.29 0.46 0.94 0.21 0.40 0.31 0.58 0.33 0.40 0.20 
Day 3 0.13 0.11 0.40 0.89 0.62 0.21 0.41 0.50 0.16 0.71 0.27 0.79 0.40 0.27 
24 hours Day 1 16.79 12.08 4.27 4.82 7.20 10.61 11.82 3.04 8.75 6.81 6.26 6.73 8.41 3.94 
Day 3 4.45 5.06 12.69 16.86 10.03 3.50 6.21 11.37 4.30 14.45 3.62 8.76 8.41 4.61 
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Table 9.6 Mean (SD) and individual amount of terbutaline sulphate recovered from the 
filter, T-piece and nebuliser’s chamber from the day 2 ex-vivo study dosing of 2.0 mg 
terbutaline sulphate via Aeroneb Pro expressed in µg, (n=12). 
Dose 
Amount in µg Amount deposited on the 
filter in % of nominal dose Filter T-piece nebuliser 
1 800.0 210.0 848.3 40.0 
2 743.4 252.0 933.7 37.2 
3 741.3 248.8 848.9 37.1 
4 751.6 206.2 909.1 37.6 
5 815.1 250.0 717.0 40.8 
6 809.4 231.2 752.0 40.5 
7 850.4 170.2 731.1 42.5 
8 724.0 164.0 885.0 36.2 
9 741.9 179.0 616.8 37.1 
10 714.2 289.2 993.4 35.7 
11 764.8 181.2 968.6 38.2 
12 804.8 189.7 927.1 40.2 
Mean 771.7 214.3 844.3 38.6 
STD 42.7 39.6 115.9 2.3 
RSD 5.5 18.5 13.7 5.9 
 
Table 9.7 Mean (SD) and individual amount of terbutaline sulphate recovered from the 
filter, T-piece and nebuliser’s chamber from the day 2 ex-vivo study dosing of 5.0 mg 
terbutaline sulphate via Sidestream jet nebuliser expressed in µg, (n=12). 
Dose 
Amount in µg Amount deposited on the 
filter in % of nominal dose Filter T-piece nebuliser 
1 1032.6 295.7 2243.7 20.7 
2 1248.5 399.4 2683.8 25.0 
3 1545.0 167.5 2468.1 30.9 
4 1289.1 176.5 1381.7 25.8 
5 860.3 500.2 3356.9 17.2 
6 1025.9 283.4 1091.9 20.5 
7 887.5 490.2 3195.4 17.7 
8 1128.9 258.7 1674.9 22.6 
9 1111.2 576.8 3234.3 22.2 
10 1097.6 303.8 2601.9 22.0 
11 1226.7 382.7 2488.3 24.5 
12 1233.6 335.6 3144.1 24.7 
Mean 1140.6 347.5 2463.7 22.8 
STD 186.7 127.4 749.6 4.0 
RSD 16.4 36.7 30.4 17.5 
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Table 9.8 Mean difference (95% confidence interval) of Aeroneb Pro vs the Sidestream jet 
nebuliser.  
Comparator Aeroneb Pro vs 
Sidestream jet nebuliser 
• Amount excreted 30 minute post dose -1.1 (-1.4, -0.7)*** 
• Amount excreted 24 hours post dose -13.0 (-60.8, 34.7) 
• Percent of the amount excreted 30 minute 
post dose 
0.32 (0.24, 0.39)*** 
• Percent of the amount excreted 24 hours 
post dose 
6.7 (4.6, 8.9)*** 
• Amount remaining in the nebuliser chamber 
and the connections in the in-vivo study 
-1528.342 (-1673.0, -1383.7)*** 
• Amount resolved from the inhalation filter 
in the ex-vivo study 
-368.8 (-505.2, -232.5)*** 
• Percent of the amount resolved from the 
inhalation filter in the ex-vivo study 
15.8 (12.4, 19.1)*** 
* p<0.05, ** <0.01 *** <0.001 otherwise no significant difference. 
 
Table 9.9 Mean difference (95% confidence interval) of Day 1 vs Day 3 (irrespective of 
inhalation method).  
Comparator Day 1 vs Day 3 
• Amount excreted 30 minute post dose 0.2 (-0.6, 1.0)  
• Amount excreted 24 hours post dose 8.9(-39.3, 57.1) 
• Percent of the amount excreted 30 minute post dose -0.05 (0.27, 0.18) 
• Percent of the amount excreted 24 hours post dose -0.2 (-5.1, 4.8)  
* p<0.05, ** <0.01 *** <0.001 otherwise no significant difference. 
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Figure 9.2 Mean (n=12) and the individual amounts in µg of urinary terbutaline excreted 
30 minute post 5.0 mg terbutaline sulphate dosing via Sidestream jet nebuliser and 2.0 mg 
terbutaline sulphate via Aeroneb Pro. 
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Figure 9.3 Mean (n=12) and the individual amounts in µg of urinary terbutaline excreted 
in the first 24 hours post 5.0 mg terbutaline sulphate dosing via Sidestream jet nebuliser 
and 2.0 mg terbutaline sulphate via Aeroneb Pro. 
 246 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Aeroneb Pro Sidestream
Ur
in
ar
y 
te
rb
ut
al
in
e 
(µ
g)
 
Figure 9.4 Mean (n=12) and the individual percentage of nominal dose of urinary 
terbutaline excreted 30 minute post 5.0 mg terbutaline sulphate dosing via Sidestream jet 
nebuliser and 2.0 mg terbutaline sulphate via Aeroneb Pro. 
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Figure 9.5 Mean (n=12) and the individual percentage of nominal dose of urinary 
terbutaline excreted in the first 24 hours post 5.0 mg terbutaline sulphate dosing via 
Sidestream jet nebuliser and 2.0 mg terbutaline sulphate via Aeroneb Pro. 
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Figure 9.6 Mean (n=12) and the individual amounts in µg of urinary terbutaline excreted 
30 minute post inhalation of day 1 and day 3 (irrespective of inhalation method) expressed 
in µg. 
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Figure 9.7 Mean (n=12) and the individual amounts in µg of urinary terbutaline excreted 
in the first 24 hours post inhalation of day 1 and day 3 (irrespective of inhalation method) 
expressed in µg. 
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Figure 9.8 Mean (SD) amounts of terbutaline sulphate recovered from the filter from the 
day 2 ex-vivo study. This filter was placed between the mask and the nebuliser post 
inhalation of one dose of 5.0 mg terbutaline sulphate from the Sidestream jet nebuliser and 
one dose of 2.0 mg terbutaline sulphate from the Aeroneb Pro expressed in µg, (n=12). 
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Figure 9.9 Mean (SD) amounts of terbutaline sulphate, expressed in % of nominal dose, 
sulphate recovered from the filter from the day 2 ex-vivo study. This filter was placed 
between the mask and the nebuliser post inhalation of one dose of 5.0 mg terbutaline 
sulphate from the Sidestream jet nebuliser and one dose of 2.0 mg terbutaline sulphate 
from the Aeroneb Pro, (n=12). 
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9.4 Discussion  
Although it was appreciated that there would be a difference between each patient’s 
condition on days 1 and 3 the statistical comparison between the amounts excreted on day 
one and day three for the 30 minute and 24 hours post dosing samples (irrespective of 
inhalation method) showed no significant difference. This was consistent with a study by 
Mazhar et al (2007) which has been recently completed measuring urinary drug excretion 
following study doses from a MDI+Spacer and a Sidestream nebuliser using patients with 
an acute exacerbation of asthma (n=11) and COPD (n=19) on day 2 and 4 following 
hospitalisation (Mazhar et al., 2008). The relative lung deposition between day 2 and 4 
(irrespective of inhalation method) was similar. The latter suggests that lung deposition 
characteristics did not change significantly as the patient’s FEV1 improved and that if there 
were any changes in renal function the difference was not detected. None of these patients 
had moderate or severe renal impairment. The results is also consistent with another 
urinary pharmacokinetic studies post inhalation (Ismail and Chrystyn, 2004).  
The corrugated tubing and the filter next to the ventilator did not contain any Terbutaline 
sulphate. This might be due to the effect of positive pressure which keeps most of the drug 
next to the patient. 
The amount left in the nebulisation chamber and the connections of the Sidestream jet 
nebuliser [2615.9 (200.8) µg] were significantly higher than that left in the nebulisation 
chamber and connections of the Aeroneb pro nebuliser [1087.6 (98.0) µg] (p<0.001). The 
difference is about 2.5 times that of the Aeroneb pro nebuliser and this is due to the low 
residual volume of Aeroneb Pro compared to the Sidestream jet nebuliser. 
As shown in table 9.8 the Sidestream jet nebuliser resulted in a significantly higher relative 
lung deposition than the Aeroneb Pro (p<0.001). That was consistent with the amount 
deposited on the inhalation filter in the ex-vivo results (p<0.001). Also there was no 
significant difference between the relative systemic bioavailability form the Aeroneb Pro 
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and the Sidestream jet nebuliser, however the doses were different. Hence, when the 
amounts were normalised to the percentage of the nominal dose; the relative lung and 
systemic bioavailability from the Aeroneb Pro was significantly greater (p<0.001) than that 
of the Sidestream jet nebuliser. The percentage of terbutaline sulphate deposited on the 
filter after Aeroneb Pro was also greater in the ex-vivo study (p<0.001). The results for the 
Aeroneb Pro may be in part due to the small residual volume of the Aeroneb Pro which is 
less than 0.3ml (Fink et al., 2001) while the Sidestream jet nebuliser had a very high 
residual volume.  
The results are consistent with the in-vitro results in chapter 6 in that the vibrational mesh 
nebulisers emit higher emitted dose and a higher respirable amount (the fine particle dose) 
than the Sidestream jet nebuliser (p<0.001). Also the patient results are consistent with the 
in-vivo results from the healthy volunteers in chapter 8. There was upto about three-fold 
improvement in the relative amounts deposited in the lungs from the Aeroneb pro 
compared to the Sidestream jet nebuliser and a 2.7-fold increase of the relative amount 
delivered to the body (systemic bioavailability). This difference has been obtained in 
subjects who have been trained and demonstrated an excellent inhalation technique. The 
ratio here is lower than in chapter 8 and that might be due to the smaller fill volume (0.8 
ml) of the Aeroneb Pro compared to 2 ml in chapter 8. 
The amount of terbutaline excreted 30 minute post dosing from any of the two nebulisers 
used was close to that from two (250µg terbutaline sulphate) doses from MDI and much 
lower than that from two (250µg terbutaline sulphate) doses from MDI+Spacer to healthy 
volunteers as shown in section 8.3 of this thesis even though the nebulised dose was much 
higher. Although the results from section 8.3 are from health volunteer who were trained to 
use the device properly and with larger lung volumes, the lower lung deposition in this 
chapter show that the nebulisers are a poor method for aerosol delivery compared to 
properly used MDI with spacer. 
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The in-vivo and the ex-vivo results here are also consistent with a study by Fink et al 
(2001) who compared the ability of the Aeroneb Pro and two small volume jet nebulisers, 
MistyNeb (Allegiance) and Vix One (Westmed), to deliver 2.5 mg salbutamol sulphate in 
3 ml to a simulated pediatric patient during mechanical ventilation. The Aeroneb Pro 
delivered significantly higher (p<0.02) amounts of salbutamol [582.0(89.0) µg] than the 
MistyNeb [201.0(87.0) µg] or the Vix One [197.0(50.0) µg] (Fink et al., 2001) with no 
modification of ventilator parameters. The authors also showed that operation of the 
Aeroneb Pro did not alter any of the monitored ventilator parameters. In contrast, the jet 
nebulisers increased the mean airway pressure during operation by >5 cm H2O and 
required adjustment of ventilator flow settings during operation to maintain ventilator 
parameters with initiation and discontinuation of nebulization. They also found that when 
opening the medication reservoir to refill the Aeroneb Pro there was no change in any of 
the ventilator parameters. In contrast, both of the jet nebulisers required interruption of 
ventilation in order to refill. 
A study by Dubus et al (2005) showed similar results to that shown in this chapter. The 
objective of their study was to assess lung delivery of aerosols in an animal model of 
neonatal ventilation using a conventional jet nebuliser and a novel vibrating mesh 
nebuliser. Aerosol deposition studies with 99mTc diethylenetriamine pentaacetate (99mTc-
DTPA) were performed in four macaques (2.6 kg) that were ventilated with neonatal 
settings (peak inspiratory pressure 12-14 mbar (4.8-5.6 cm H2O), positive end-expiratory 
pressure 2 mbar (0.8 cm H2O), Inspiratory / Expiratory ratio 1/2, respiratory flow 40 L 
min-1. They compared the MistyNeb jet-nebuliser (3-ml fill volume), with a vibrating mesh 
nebuliser operating continuously [Aeroneb Professional Nebuliser (APN-C); 0.5-ml fill 
volume] and another synchronized with inspiration [Aeroneb Professional Nebuliser 
Synchronized (APN-S); 0.5-ml fill volume]. The amount of radioactivity deposited into the 
lungs, the connections and remaining in the nebuliser was measured by a gamma counter. 
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Despite similar amounts of 99mTc-DTPA in the respiratory circuit with all nebulisers, both 
the APN-S and the APN-C delivered more drug to the lungs than the MistyNeb [14.0, 12.6, 
and 0.5% in terms of percentage of nebuliser fill volume, respectively; p = 0.006] (Dubus 
et al., 2005). Duration of delivery was shorter with the APN-C than with the two other 
nebulisers (2 versus 6 and 10 min for the APN-S and the MistyNeb, respectively; p < 
0.001).  
Even though the animal model has limited relevance to humans because of differences in 
anatomy, the absence of underlying lung disease and the lower lung deposition in these 
studies, the results of the above study as well as the results of the study in this chapter 
shows that Aeroneb Pro is more efficient than the Sidestream jet nebuliser.  
The design of the vibrating mesh nebulisers is such that the fill volume required to produce 
the aerosol is much lower than with the jet nebuliser (0.5 versus 3 ml). The ability of the 
Aeroneb Pro nebulisers to deliver more aerosols to the lungs than the jet nebuliser may 
have positive implications in the treatment of critically mechanically ventilated patients. 
9.5 Conclusions 
The urinary terbutaline pharmacokinetic method was very sensitive in detecting the 
difference between the Aeroneb Pro and the Sidestream jet nebulisers. 
The relative lung deposition from 5.0 mg terbutaline sulphate nebulised from the 
Sidestream “jet nebuliser” was 1.1 times that from 2.0 mg terbutaline sulphate nebulised 
from an Aeroneb Pro “vibrating mesh nebuliser”. However the dose was 2.5 times higher. 
Thus when comparing the percentage of the nominal dose as the relative lung deposition, 
the Aeroneb Pro results in more than a 2 fold increase than the Sidestream jet nebuliser. 
The small residual volume of the Aeroneb Pro (0.3 ml) allows the maximum use of the 
nebulised solution. The results were consistent with the previously published literatures 
and the ex-vitro results in this chapter. 
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Vibrating mesh nebulisers are more efficient to administer aerosols to the mechanically 
ventilated patient. This level of aerosol delivery may make aerosol delivery during 
mechanical ventilation more practical. 
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10.1 Summary and future work 
Terbutaline sulphate is a potent short acting β2-agonist which is recommended for the 
management of asthma and COPD by the BTS and NICE guideline, respectively, to be 
used as required to relieve symptoms. Terbutaline sulphate is available as the Bricanyl 
Turbuhaler in the form of a dry powder inhaler, a MDI and Respules for nebulisation 
(AstraZeneca).  
The assessment of pulmonary drug absorption and deposition is becoming increasingly 
important in drug development. Several methods are available to investigate pulmonary 
drug absorption and deposition, e.g. simulated in-vitro experiments, in-vivo 
pharmacokinetic and pharmacodynamic and gamma scintigraphy. In combination, these 
methods can indicate the fate of an inhaled drug. 
In-vitro methods are used as a quality assurance procedure to identify the quality of the 
inhaled product such as the total emitted dose, uniformity of dose, and the aerodynamic 
particle size distribution. Further, they are often extrapolated to give an estimation of in-
vivo deposition. 
Pharmacokinetic methods (using plasma or urine samples), can be used to identify the 
relative lung deposition of the drug (the effective lung dose) and total systemic delivery. 
Some studies have used charcoal, taken before and after an inhalation, to overcome the 
problem of oral absorption (Borgstrom and Nilsson, 1990), but the use of charcoal for 
patients with concomitant use of other drugs would not be ethical as it would block their 
therapeutic effect. It was found that the measurements of urine concentration of the drug 
and hence amount excreted in the absorption lag time of the orally swallowed portion (30 
minutes) would account mainly for the drug absorbed from the lung after inhalation 
(Hindle and Chrystyn, 1992) and hence is a useful index of the lung deposition in cross-
over studies.  
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This research work has focused on the identification and the development of this method, 
urinary terbutaline pharmacokinetic method along with identification of in-vitro 
parameters to characterise the aerodynamic properties of the inhalation methods used in the 
in-vivo studies. Hence the objectives were: 
a) To validate HPLC methods for the determination of terbutaline in aqueous and urine 
samples. 
b) To use in-vitro methods to highlight the potential of the Turbuhaler to deliver 
terbutaline sulphate to the lungs, to determine the effect of the spacers with the MDI on the 
dose emitted from the MDI and to compare the emitted dose nebulised from the Aeroneb 
Pro and Sidestream jet nebuliser. 
c) To validate a urinary pharmacokinetic method for the evaluation of the relative lung 
bioavailability of terbutaline to the lungs and the body following inhalation. 
d) To use the validated pharmacokinetic method to determine the effect of inhalation flow 
on the lung deposition from the Turbuhaler and the effect of spacers attached to the MDI. 
Also to compare the lung deposition following Aeroneb Pro and Sidestream jet nebuliser 
using volunteers and patients. 
In Chapter 3 a novel HPLC assay for the estimation of terbutaline sulphate in aqueous 
samples was validated. The samples were separated using a 5µm Spherisorb, ODS1 (4.6 x 
250mm, C-18, Waters Chromatography) column maintained at 30oC. The mobile phase 
consisted of 5mM potassium dihydrogen orthophosphate buffer : acetonitrile (75:25). The 
buffer was adjusted to pH 2.5, with orthophosphoric acid. The mobile phase was filtered 
through a 45mm membrane filter (Millipore, Whatman Ltd, UK) and degassed under 
vacuum in an ultrasonic bath for 10 minutes prior to use. A fluorescence detector set with 
an excitation/emission of 267/313 nm was used. The calibration for terbutaline sulphate 
aqueous samples was linear using bamethane as the internal standard for terbutaline 
sulphate concentrations from 10µg/L to 800µg/L. The method had an accuracy of >95% 
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and intra and inter-day precision CV% of <2.8 and 4.5%, respectively at three (50, 300 and 
700 µg/L corresponding to low, medium, and high) concentrations. The limit of detection 
(LOD) and lower limit of quantitation (LLOQ) for terbutaline sulphate was 10.9μg/L and 
33.1μg/L, respectively.  
A HPLC assay for the estimation of terbutaline in urine samples was also validated. Two 
solid phase extraction (SPE) methods, using Isolute HCX 130mg 10ml XL cartridge (Pre-
hydrolysis) and Oasis HLB 30mg cartridge (Post hydrolysis), were validated to isolate 
terbutaline from a urine matrix followed by HPLC with fluorescence detector. This 
extraction procedure cleaned the final analytes from impurities such that their peaks were 
separated and easily detected. The urine assay was performed in accordance with FDA and 
ICH regulations of bio-analytical samples. The samples were separated on an ODS 5μm, 
(4.6 x 250mm, Zorbax, Phenomenex) C-18 HPLC column with a (4mm X 3 mm, 
Phenomenex); C-18 (ODS) guard column. Both were maintained at 30oC. The mobile 
phase was acetonitrile : methanol : tetrahydrofuran : ethyl acetate : buffer 5:5:5:5:80% v/v. 
The buffer was 40mM phosphate buffer and 27.5mM sodium dodecyl sulphate with pH 
6.75 adjusted using 10mM KOH. Fluorescence detection set with an excitation/emission of 
267/313 nm was used. The extraction recovery of terbutaline from urine samples was 
>95%. The standard calibration for extracted terbutaline urine samples was with 
bamethane (r2=0.9983) and salbutamol (r2=0.9994), respectively as the internal standard 
over terbutaline concentrations from 10µg/L to 1200µg/L. The method had an accuracy of 
>90% and intra and inter-day precision CV% of <7.5 and 13.0%, respectively at three 
(100, 500 and 1000 µg/L corresponding to low, medium, and high) concentrations. The 
limit of detection (LOD) and lower limit of quantitation (LLOQ) for terbutaline was 
24.2μg/L and 73.4μg/L, respectively. 
Some patients with COPD can only inhale at low flows when using DPIs especially if the 
resistance of the inhaler is high. Most DPIs have flow dependent dose emission properties, 
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especially the Turbuhaler. It has been also shown that during its use the Turbuhaler has a 
minimum threshold for the inhalation flow for the emission of a dose with the potential for 
lung deposition. For the in-vitro determination of the aerodynamic characterization of the 
dose emitted from an inhaler the Pharmacopoeias recommend an inhalation volume of 4 L 
through the inhaler with the inhalation flow maintained constant at a flow that produces a 
pressure drop of 4 kPa across the inhaler. For the Turbuhaler this is equal to an inhalation 
flow of approximately 54 L min-1 which is not achievable by many patients. The main 
focus of chapter 4 was an in-vitro evaluation of the dose emitted from the Bricanyl 
Turbuhaler at different inhalation flows (ranging from 10 to 60 L min-1). 4 L was used as 
the inhalation volume. In-vitro flow dependent dose emission was demonstrated for 
terbutaline sulphate emitted from the Turbuhaler. The effect of this was more pronounced 
for the fine particle dose. The higher inhalation flow resulted in a greater emitted dose and 
FPD than at a lower inhalation flow. The flow dependent dose emission results highlight 
the need for the Pharmacopoeias to use a variety of inhalation flows for in-vitro tests rather 
than one that produces a pressure drop of 4 kPa across the inhaler. Also these flows should 
be consistent with the range normally produced by the patients. The clinical relevance of 
the flow dependent and inconsistent dosage characteristics of terbutaline sulphate in the 
Turbuhaler requires further investigation. 
It is claimed that spacers used with the MDI increase the FPD and hence decrease the 
gastrointestinal ingested portion as well as improving the lung deposition. They are 
recommended for use in children under 6 years and older patients that have a co-ordination 
problem. Hence in chapter 5 the in-vitro characteristics of the MDI and MDI plus four 
different spacers was studied in accordance with compendial methodology. The inhalation 
flow used was 28.3 L min-1 with an inhalation volume of 4 L. The MDI alone resulted in 
the highest emitted dose. The spacer removed most of the amount that would deposit in the 
mouth and throat hence the emitted dose from MDI+Spacer was less than the MDI alone. 
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The FPD from the AeroChamber Max was the highest but the AeroChamber Plus resulted 
in the smallest MMAD and the highest FPF. 
The aerodynamic characteristic of the dose emitted from the AeroChamber Max (antistatic 
spacer) was better than the rest of the static spacers (Fisonair and Nebuhaler). The 
aerodynamic characteristic from the Fisonair without washing (antistatic spacer) was better 
than the Fisonair with washing (static spacer). Hence, the dose emitted and the FPD from 
plastic spacer devices will vary according to the electrostatic charge on the spacer walls. 
A new type of nebuliser which use a vibrating mesh to produce aerosol was found to be 
more efficient than a jet nebuliser. In chapter 6 the in-vitro determination of nebulised 
terbutaline sulphate respiratory solution from two different nebulisers was studied using 
the CEN method and the NGI method. The Aeroneb Pro, as a vibrating mesh, produced a 
higher emitted dose and FPD than the Sidestream jet nebuliser but there was no significant 
difference in regard of FPF and MMAD. The higher emitted dose and FPD would suggest 
better lung deposition. Also using two different nebulizing systems it has been shown that 
the use of cooling and operation at an inhalation flow of 15 L min-1 limits evaporation 
effects when using the NGI. The aerodynamic characteristics of the nebulised dose from 
these two nebuliser systems using the CEN method were significantly different from when 
using NGI method. Hence further investigation for both methods is required together with 
the issue of the evaporation effects. Nevertheless the results consolidate the current 
growing consensus that a cooled NGI operated at 15 L min-1 should be the recommended 
methodology in the European pharmacopoeia. 
In each of the in-vivo experiments twelve healthy non-smoking volunteers (6 females) 
completed the study. In chapter 7 validation of the salbutamol urinary pharmacokinetic 
method by Hindle and Chrystyn (1992) for the determination of urinary terbutaline is 
described. On a separate occasion each volunteer received the following doses: 
(a) The oral administration of 500μg terbutaline sulphate in 20 ml water [O]. 
 259 
(b) The oral administration of 500μg terbutaline sulphate in 20 ml water with 20g activated 
charcoal (10g in 50 ml water before and after dosing) [OC]. 
(c) Two 250μg doses inhaled from a terbutaline sulphate metered dose inhaler (Bricanyl 
inhaler, AstraZeneca, UK) [I]. 
(d) Two 250μg doses inhaled from a terbutaline sulphate metered dose inhaler with 20g 
activated charcoal (10g in 50 ml water before and after dosing) [IC].  
Each volunteer voided their urine pre-dosing and provide urine samples 0.5, 1, 2, 4, 6, 12, 
and 24 hours post study doses. No terbutaline was excreted post OC. The amount excreted 
following IC represents the pulmonary absorbed fraction. The use of activated charcoal 
was found to be unnecessary when this method is used to compare between different 
products or techniques. That was due to the lack of a difference between I and IC in the 
first 30 minutes because the majority of drug excreted in this time period is delivered to the 
body via the lungs. This is shown by the amount of terbutaline excreted 30 minutes post I 
and IC which were significantly higher than post O dosing (p<0.001). Also the cumulative 
amount of terbutaline excreted 24 hours post I and O was relatively similar. Hence the 24 
hours excrtion can be used as an index of the relative systemic bioavailability. 
Another group of volunteers inhaled 1, 2, 3 and 4 doses from the Bricanyl MDI 
(AstraZeneca, UK) on separate occasion to study the dose response relationship of the 
terbutaline urinary excretion method. The volunteers voided their urine pre-dosing and 
provide urine samples at 0.5 and cumulatively 24 hours post study dose. The method was 
found to be linear similar to that for the urinary salbutamol method (Tomlinson et al., 
2003). To further validate the method a group of volunteers inhaled two doses on five 
separate occasions from the Bricanyl MDI (AstraZeneca, UK) in separate occasion to 
identify the intra and inter-subject variability of the terbutaline urinary excretion method. 
The volunteers voided their urine pre-dosing and provide urine samples at 0.5 hour post 
 260 
study dose. The method was found to be reproducible similar to that for the urinary 
salbutamol method (Tomlinson et al., 2003).  
 Thus the urinary drug excretion technique, which has already been considered to be the 
basis for a novel clinical equivalence test for inhalation products of salbutamol (Hindle and 
Chrystyn, 1992) and extended to sodium cromoglycate (Aswania et al., 1997; Aswania and 
Chrystyn, 2002), nedocromil (Aswania et al., 1998), gentamicin (Al-Amoud et al., 2005; 
Al-Amoud et al., 2002), tobramycin. (Barber, 2002) and formoterol (Nadarassan et al., 
2007), can also be used for other water-soluble inhaled drugs like terbutaline. 
Chapter 8 provides some applications of the validated urinary terbutaline pharmacokinetic 
method. The urinary terbutaline pharmacokinetic method was used to detect the effect of 
different inhalation techniques when using the Turbuhaler. The volunteers in this study 
inhaled two doses of 500µg terbutaline sulphate from a Bricanyl Turbuhaler (AstraZeneca, 
UK) on separate occasion using slow and fast inhalation flows. They were trained how to 
inhale at a slow inhalation flow (30 L min-1) and at a fast inhalation flow (60 L min-1) with 
their inhalation flow checked by the In-Check Dial. The volunteers voided their urine pre-
dosing and provided urine samples at 0.5 and cumulatively 24 hours post study dose. The 
amount of terbutaline excreted 30 minutes and 24 hours post dosing using a fast flow were 
significantly higher than that using a slow flow (p<0.001). The results are consistent with 
that from the in-vitro study in chapter 4 and some other in-vivo studies which recommend 
the patient to inhale as fast as possible when inhaling a dose from the Turbuhaler. 
The urinary terbutaline pharmacokinetic method was then used to determine the effect of 
different spacers on the lung and the systemic bioavailability of inhaled terbutaline from 
the MDI. On separate occasions the volunteers in this study inhaled two doses of 250µg 
terbutaline sulphate from a Bricanyl MDI (AstraZeneca, UK) either alone or with different 
spacers. Again the volunteers voided their urine pre-dosing and provided urine samples at 
0.5 and cumulatively 24 hours post study dose. It was found that the MDI alone resulted in 
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a significantly higher urinary excretion of terbutaline 24 hours post dose and lower urinary 
excretion of terbutaline 30 minutes post dose than when using the MDI attached to any of 
the spacers (p<0.001). This was consistent with the in-vitro results in chapter 5 and the 
published literature which highlights that spacer removes most of the large particles that 
would normally deposit in the mouth which are than swallowed followed by 
gastrointestinal absorption. The spacer also allows the aerosol to evaporate resulting in 
smaller particles and hence increase lung deposition. The AeroChamber Max resulted in a 
significantly higher urinary excretion of terbutaline 30 minutes and 24 hours post dose than 
any other spacers (p<0.001-0.05). When comparing these results to the in-vitro results in 
chapter 5 it was found that even though the AeroChamber Plus resulted in the best MMAD 
and FPF the AeroChamber Max with its high emitted dose and FPD provided the highest 
lung deposition. 
The last study in this chapter was to check whether the urinary terbutaline pharmacokinetic 
method was able to determine the effect of different nebuliser on the lung and the systemic 
bioavailability of nebulised terbutaline. The volunteers inhaled, on separate occasions, 
5mg/2ml terbutaline sulphate from Bricanyl Respules (AstraZeneca, UK) from Aeroneb 
Pro (vibrating mesh nebuliser) and Sidestream (Jet nebuliser). The volunteers voided their 
urine pre-dosing and provided urine samples at 0.5 and cumulatively 24 hours post study 
dose. Similar to the result of the in-vitro work in chapter 6 the Aeroneb Pro produced 
higher amounts excreted 30 minutes and 24 hours post dosing than the Sidestream jet 
nebuliser (p<0.001).  
The three above mentioned studies in chapter 8 demonstrates that the urinary 
pharmacokinetic method previously reported for terbutaline in chapter 7 is a potential tool 
to compare different inhalation techniques, methods and products. This consolidate that the 
30 minutes post-inhalation urinary excretion is a reliable index of total lung bioavailability 
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and the 24 hours urinary terbutaline measurement can be used as an index of the systemic 
bioavailability. 
An extension of the applications of the urinary terbutaline pharmacokinetic method to 
patients is described in chapter 9. The study in this chapter was to investigate whether the 
urinary terbutaline pharmacokinetic method was able to determine the effect of different 
nebuliser on the lung and the systemic bioavailability of nebulised terbutaline in non-
invasive positive pressure mechanically ventilated patient. The results were compared to an 
ex-vivo experiments performed on the same patients. 
The patients inhaled, on separate occasions, 5mg in 2ml terbutaline sulphate from 
terbutaline sulphate Respules (Breath Limited, UK) from Sidestream (Jet nebuliser) and 
2mg in 0.8ml terbutaline sulphate from terbutaline sulphate Respules (Breath Limited, UK) 
from Aeroneb Pro (vibrating mesh nebuliser). The volunteers voided their urine pre-dosing 
and provided urine samples at 0.5 and cumulatively 24 hours post study dose. The Aeroneb 
Pro nebuliser resulted was found to have better efficacy than the Sidestream nebuliser. 
That was shown from results of the urinary terbutaline pharmacokinetic method to patients 
and the ex-vivo method. 
10.2 Future work 
The in-vitro characterization of the nebulised dose using a cooled NGI operated at low 
flow of 15 L min-1 has consolidate the consensus that this methodology limits evaporation 
and should be the compendial method. Further work in this area is required. First there 
should be some investigation of using the NGI in a cooled environment possibly inside a 
fridge. Another aspect could look into using a relative humidity similar to that in the lungs 
and also using a temperature of 37 oC. The thermal and the metal effect from the metal 
NGI at these conditions would need to be investigated.  In addition to this work in-vivo 
studies are essential. These could use the urinary pharmacokinetic method to compare 
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different systems with simultaneous clinical measurements. Such data could than be 
compared to that of the in-vitro methods to identify which was the most relevant. 
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